bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
arginine is a CHEMICAL	23439479_task0	Sentence: Biosafety and antioxidant effects of a beverage containing silymarin and arginine. A pilot, human intervention cross-over trial. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Biosafety and antioxidant effects of a beverage containing silymarin and arginine. A pilot, human intervention cross-over trial.	[ "Biosafety", "and", "antioxidant", "effects", "of", "a", "beverage", "containing", "silymarin", "and", "arginine", ".", "A", "pilot", ",", "human", "intervention", "cross", "-", "over", "trial", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
arginine is a CHEMICAL	23439479_task1	Sentence: Biosafety and antioxidant effects of a beverage containing silymarin and arginine. A pilot, human intervention cross-over trial. Instructions: please typing these entity words according to sentence: arginine Options: CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Biosafety and antioxidant effects of a beverage containing silymarin and arginine. A pilot, human intervention cross-over trial.	[ "Biosafety", "and", "antioxidant", "effects", "of", "a", "beverage", "containing", "silymarin", "and", "arginine", ".", "A", "pilot", ",", "human", "intervention", "cross", "-", "over", "trial", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
arginine	23439479_task2	Sentence: Biosafety and antioxidant effects of a beverage containing silymarin and arginine. A pilot, human intervention cross-over trial. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Biosafety and antioxidant effects of a beverage containing silymarin and arginine. A pilot, human intervention cross-over trial.	[ "Biosafety", "and", "antioxidant", "effects", "of", "a", "beverage", "containing", "silymarin", "and", "arginine", ".", "A", "pilot", ",", "human", "intervention", "cross", "-", "over", "trial", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
natural killer cell activity is an other_name, HER-2 / neu oncogene is a DNA_domain_or_region, patients is a multi_cell, breast cancer is an other_name	18197_task0	Sentence: Increased natural killer cell activity correlates with low or negative expression of the HER-2/neu oncogene in patients with breast cancer. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region, multi_cell, other_name	[ "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-multi_cell", "O", "B-other_name", "I-other_name", "O" ]	Increased natural killer cell activity correlates with low or negative expression of the HER-2/neu oncogene in patients with breast cancer.	[ "Increased", "natural", "killer", "cell", "activity", "correlates", "with", "low", "or", "negative", "expression", "of", "the", "HER-2", "/", "neu", "oncogene", "in", "patients", "with", "breast", "cancer", "." ]	[ "other_name", "cell_type", "multi_cell", "DNA_domain_or_region", "protein_family_or_group", "protein_molecule", "cell_line", "lipid" ]
natural killer cell activity is an other_name, HER-2 / neu oncogene is a DNA_domain_or_region, patients is a multi_cell, breast cancer is an other_name	18197_task1	Sentence: Increased natural killer cell activity correlates with low or negative expression of the HER-2/neu oncogene in patients with breast cancer. Instructions: please typing these entity words according to sentence: natural killer cell activity, HER-2 / neu oncogene, patients, breast cancer Options: DNA_domain_or_region, multi_cell, other_name	[ "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-multi_cell", "O", "B-other_name", "I-other_name", "O" ]	Increased natural killer cell activity correlates with low or negative expression of the HER-2/neu oncogene in patients with breast cancer.	[ "Increased", "natural", "killer", "cell", "activity", "correlates", "with", "low", "or", "negative", "expression", "of", "the", "HER-2", "/", "neu", "oncogene", "in", "patients", "with", "breast", "cancer", "." ]	[ "other_name", "cell_type", "multi_cell", "DNA_domain_or_region", "protein_family_or_group", "protein_molecule", "cell_line", "lipid" ]
natural killer cell activity, HER-2 / neu oncogene, patients, breast cancer	18197_task2	Sentence: Increased natural killer cell activity correlates with low or negative expression of the HER-2/neu oncogene in patients with breast cancer. Instructions: please extract entity words from the input sentence	[ "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-multi_cell", "O", "B-other_name", "I-other_name", "O" ]	Increased natural killer cell activity correlates with low or negative expression of the HER-2/neu oncogene in patients with breast cancer.	[ "Increased", "natural", "killer", "cell", "activity", "correlates", "with", "low", "or", "negative", "expression", "of", "the", "HER-2", "/", "neu", "oncogene", "in", "patients", "with", "breast", "cancer", "." ]	[ "other_name", "cell_type", "multi_cell", "DNA_domain_or_region", "protein_family_or_group", "protein_molecule", "cell_line", "lipid" ]
treatment is an umlsterm, postoperative is an umlsterm, fistulas is an umlsterm, lymphoceles is an umlsterm, patients is an umlsterm, fistula is an umlsterm, vascular surgery is an umlsterm, therapy is an umlsterm, operation is an umlsterm, wound is an umlsterm, radiotherapy is an umlsterm, treatment is an umlsterm, surgical is an umlsterm, therapy is an umlsterm, patients is an umlsterm, fistulas is an umlsterm, lymphoceles is an umlsterm, radiation therapy is an umlsterm, fistula is an umlsterm, patients is an umlsterm, electrons is an umlsterm, patients is an umlsterm, lymphoceles is an umlsterm, treatment is an umlsterm, photons is an umlsterm, patients is an umlsterm, fractionation is an umlsterm, radiation therapy is an umlsterm, patients is an umlsterm, fistula is an umlsterm, lymphocele is an umlsterm, radiation is an umlsterm, therapy is an umlsterm, patient is an umlsterm, surgery is an umlsterm, wound is an umlsterm, radiotherapy is an umlsterm, fistulas is an umlsterm, lymphoceles is an umlsterm, complications is an umlsterm, Radiation is an umlsterm, therapy is an umlsterm, surgery is an umlsterm	Strahlentherapie+Onkologie.01760009.eng.abstr_task0	Sentence: The treatment of persistent postoperative lymphatic fistulas or lymphoceles is often a problem . Approximately 2% of patients will develop lymphatic fistula after vascular surgery . This can require a long lasting conservative therapy . If spontaneous cure fails , a second operation with wound revision becomes necessary . We studied low-dose percutaneous radiotherapy to be used as an alternative treatment in addition to conservative or surgical therapy . Between 1989 and 1998 29 patients ( 25 with lymphatic fistulas , 4 with lymphoceles ) received radiation therapy . Depending on the depth of the fistula 27 patients were treated with electrons ( 7 to 18 MeV ) . Two other patients suffering of retroperitoneal lymphoceles received a treatment with photons ( 15 MV ) . In all patients the fractionation was 4- to 5 x 1.0 Gy/week and the dose ranged from 3 to 12 Gy depending upon the onset of the radiation therapy effect . In 27 of 28 evaluable patients a complete disappearance of the fistula or lymphocele was achieved by radiation during therapy or shortly afterwards . In 1 case no benefit was observed after a dose of 11 Gy . This patient required further surgery with wound exploration . Low dose percutaneous radiotherapy ( up to 10 to 12 Gy ) is effective to heal lymphatic fistulas and lymphoceles without complications . Individual dosage is required because doses even lower than 10 Gy may be effective . Radiation can be effective even after a failed conservative therapy or instead of surgery . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]	The treatment of persistent postoperative lymphatic fistulas or lymphoceles is often a problem . Approximately 2% of patients will develop lymphatic fistula after vascular surgery . This can require a long lasting conservative therapy . If spontaneous cure fails , a second operation with wound revision becomes necessary . We studied low-dose percutaneous radiotherapy to be used as an alternative treatment in addition to conservative or surgical therapy . Between 1989 and 1998 29 patients ( 25 with lymphatic fistulas , 4 with lymphoceles ) received radiation therapy . Depending on the depth of the fistula 27 patients were treated with electrons ( 7 to 18 MeV ) . Two other patients suffering of retroperitoneal lymphoceles received a treatment with photons ( 15 MV ) . In all patients the fractionation was 4- to 5 x 1.0 Gy/week and the dose ranged from 3 to 12 Gy depending upon the onset of the radiation therapy effect . In 27 of 28 evaluable patients a complete disappearance of the fistula or lymphocele was achieved by radiation during therapy or shortly afterwards . In 1 case no benefit was observed after a dose of 11 Gy . This patient required further surgery with wound exploration . Low dose percutaneous radiotherapy ( up to 10 to 12 Gy ) is effective to heal lymphatic fistulas and lymphoceles without complications . Individual dosage is required because doses even lower than 10 Gy may be effective . Radiation can be effective even after a failed conservative therapy or instead of surgery .	[ "The", "treatment", "of", "persistent", "postoperative", "lymphatic", "fistulas", "or", "lymphoceles", "is", "often", "a", "problem", ".", "Approximately", "2", "%", "of", "patients", "will", "develop", "lymphatic", "fistula", "after", "vascular", "surgery", ".", "This", "can", "require", "a", "long", "lasting", "conservative", "therapy", ".", "If", "spontaneous", "cure", "fails", ",", "a", "second", "operation", "with", "wound", "revision", "becomes", "necessary", ".", "We", "studied", "low", "-", "dose", "percutaneous", "radiotherapy", "to", "be", "used", "as", "an", "alternative", "treatment", "in", "addition", "to", "conservative", "or", "surgical", "therapy", ".", "Between", "1989", "and", "1998", "29", "patients", "(", "25", "with", "lymphatic", "fistulas", ",", "4", "with", "lymphoceles", ")", "received", "radiation", "therapy", ".", "Depending", "on", "the", "depth", "of", "the", "fistula", "27", "patients", "were", "treated", "with", "electrons", "(", "7", "to", "18", "MeV", ")", ".", "Two", "other", "patients", "suffering", "of", "retroperitoneal", "lymphoceles", "received", "a", "treatment", "with", "photons", "(", "15", "MV", ")", ".", "In", "all", "patients", "the", "fractionation", "was", "4-", "to", "5", "x", "1.0", "Gy", "/", "week", "and", "the", "dose", "ranged", "from", "3", "to", "12", "Gy", "depending", "upon", "the", "onset", "of", "the", "radiation", "therapy", "effect", ".", "In", "27", "of", "28", "evaluable", "patients", "a", "complete", "disappearance", "of", "the", "fistula", "or", "lymphocele", "was", "achieved", "by", "radiation", "during", "therapy", "or", "shortly", "afterwards", ".", "In", "1", "case", "no", "benefit", "was", "observed", "after", "a", "dose", "of", "11", "Gy", ".", "This", "patient", "required", "further", "surgery", "with", "wound", "exploration", ".", "Low", "dose", "percutaneous", "radiotherapy", "(", "up", "to", "10", "to", "12", "Gy", ")", "is", "effective", "to", "heal", "lymphatic", "fistulas", "and", "lymphoceles", "without", "complications", ".", "Individual", "dosage", "is", "required", "because", "doses", "even", "lower", "than", "10", "Gy", "may", "be", "effective", ".", "Radiation", "can", "be", "effective", "even", "after", "a", "failed", "conservative", "therapy", "or", "instead", "of", "surgery", "." ]	[ "umlsterm" ]
treatment is an umlsterm, postoperative is an umlsterm, fistulas is an umlsterm, lymphoceles is an umlsterm, patients is an umlsterm, fistula is an umlsterm, vascular surgery is an umlsterm, therapy is an umlsterm, operation is an umlsterm, wound is an umlsterm, radiotherapy is an umlsterm, treatment is an umlsterm, surgical is an umlsterm, therapy is an umlsterm, patients is an umlsterm, fistulas is an umlsterm, lymphoceles is an umlsterm, radiation therapy is an umlsterm, fistula is an umlsterm, patients is an umlsterm, electrons is an umlsterm, patients is an umlsterm, lymphoceles is an umlsterm, treatment is an umlsterm, photons is an umlsterm, patients is an umlsterm, fractionation is an umlsterm, radiation therapy is an umlsterm, patients is an umlsterm, fistula is an umlsterm, lymphocele is an umlsterm, radiation is an umlsterm, therapy is an umlsterm, patient is an umlsterm, surgery is an umlsterm, wound is an umlsterm, radiotherapy is an umlsterm, fistulas is an umlsterm, lymphoceles is an umlsterm, complications is an umlsterm, Radiation is an umlsterm, therapy is an umlsterm, surgery is an umlsterm	Strahlentherapie+Onkologie.01760009.eng.abstr_task1	Sentence: The treatment of persistent postoperative lymphatic fistulas or lymphoceles is often a problem . Approximately 2% of patients will develop lymphatic fistula after vascular surgery . This can require a long lasting conservative therapy . If spontaneous cure fails , a second operation with wound revision becomes necessary . We studied low-dose percutaneous radiotherapy to be used as an alternative treatment in addition to conservative or surgical therapy . Between 1989 and 1998 29 patients ( 25 with lymphatic fistulas , 4 with lymphoceles ) received radiation therapy . Depending on the depth of the fistula 27 patients were treated with electrons ( 7 to 18 MeV ) . Two other patients suffering of retroperitoneal lymphoceles received a treatment with photons ( 15 MV ) . In all patients the fractionation was 4- to 5 x 1.0 Gy/week and the dose ranged from 3 to 12 Gy depending upon the onset of the radiation therapy effect . In 27 of 28 evaluable patients a complete disappearance of the fistula or lymphocele was achieved by radiation during therapy or shortly afterwards . In 1 case no benefit was observed after a dose of 11 Gy . This patient required further surgery with wound exploration . Low dose percutaneous radiotherapy ( up to 10 to 12 Gy ) is effective to heal lymphatic fistulas and lymphoceles without complications . Individual dosage is required because doses even lower than 10 Gy may be effective . Radiation can be effective even after a failed conservative therapy or instead of surgery . Instructions: please typing these entity words according to sentence: treatment, postoperative, fistulas, lymphoceles, patients, fistula, vascular surgery, therapy, operation, wound, radiotherapy, treatment, surgical, therapy, patients, fistulas, lymphoceles, radiation therapy, fistula, patients, electrons, patients, lymphoceles, treatment, photons, patients, fractionation, radiation therapy, patients, fistula, lymphocele, radiation, therapy, patient, surgery, wound, radiotherapy, fistulas, lymphoceles, complications, Radiation, therapy, surgery Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]	The treatment of persistent postoperative lymphatic fistulas or lymphoceles is often a problem . Approximately 2% of patients will develop lymphatic fistula after vascular surgery . This can require a long lasting conservative therapy . If spontaneous cure fails , a second operation with wound revision becomes necessary . We studied low-dose percutaneous radiotherapy to be used as an alternative treatment in addition to conservative or surgical therapy . Between 1989 and 1998 29 patients ( 25 with lymphatic fistulas , 4 with lymphoceles ) received radiation therapy . Depending on the depth of the fistula 27 patients were treated with electrons ( 7 to 18 MeV ) . Two other patients suffering of retroperitoneal lymphoceles received a treatment with photons ( 15 MV ) . In all patients the fractionation was 4- to 5 x 1.0 Gy/week and the dose ranged from 3 to 12 Gy depending upon the onset of the radiation therapy effect . In 27 of 28 evaluable patients a complete disappearance of the fistula or lymphocele was achieved by radiation during therapy or shortly afterwards . In 1 case no benefit was observed after a dose of 11 Gy . This patient required further surgery with wound exploration . Low dose percutaneous radiotherapy ( up to 10 to 12 Gy ) is effective to heal lymphatic fistulas and lymphoceles without complications . Individual dosage is required because doses even lower than 10 Gy may be effective . Radiation can be effective even after a failed conservative therapy or instead of surgery .	[ "The", "treatment", "of", "persistent", "postoperative", "lymphatic", "fistulas", "or", "lymphoceles", "is", "often", "a", "problem", ".", "Approximately", "2", "%", "of", "patients", "will", "develop", "lymphatic", "fistula", "after", "vascular", "surgery", ".", "This", "can", "require", "a", "long", "lasting", "conservative", "therapy", ".", "If", "spontaneous", "cure", "fails", ",", "a", "second", "operation", "with", "wound", "revision", "becomes", "necessary", ".", "We", "studied", "low", "-", "dose", "percutaneous", "radiotherapy", "to", "be", "used", "as", "an", "alternative", "treatment", "in", "addition", "to", "conservative", "or", "surgical", "therapy", ".", "Between", "1989", "and", "1998", "29", "patients", "(", "25", "with", "lymphatic", "fistulas", ",", "4", "with", "lymphoceles", ")", "received", "radiation", "therapy", ".", "Depending", "on", "the", "depth", "of", "the", "fistula", "27", "patients", "were", "treated", "with", "electrons", "(", "7", "to", "18", "MeV", ")", ".", "Two", "other", "patients", "suffering", "of", "retroperitoneal", "lymphoceles", "received", "a", "treatment", "with", "photons", "(", "15", "MV", ")", ".", "In", "all", "patients", "the", "fractionation", "was", "4-", "to", "5", "x", "1.0", "Gy", "/", "week", "and", "the", "dose", "ranged", "from", "3", "to", "12", "Gy", "depending", "upon", "the", "onset", "of", "the", "radiation", "therapy", "effect", ".", "In", "27", "of", "28", "evaluable", "patients", "a", "complete", "disappearance", "of", "the", "fistula", "or", "lymphocele", "was", "achieved", "by", "radiation", "during", "therapy", "or", "shortly", "afterwards", ".", "In", "1", "case", "no", "benefit", "was", "observed", "after", "a", "dose", "of", "11", "Gy", ".", "This", "patient", "required", "further", "surgery", "with", "wound", "exploration", ".", "Low", "dose", "percutaneous", "radiotherapy", "(", "up", "to", "10", "to", "12", "Gy", ")", "is", "effective", "to", "heal", "lymphatic", "fistulas", "and", "lymphoceles", "without", "complications", ".", "Individual", "dosage", "is", "required", "because", "doses", "even", "lower", "than", "10", "Gy", "may", "be", "effective", ".", "Radiation", "can", "be", "effective", "even", "after", "a", "failed", "conservative", "therapy", "or", "instead", "of", "surgery", "." ]	[ "umlsterm" ]
treatment, postoperative, fistulas, lymphoceles, patients, fistula, vascular surgery, therapy, operation, wound, radiotherapy, treatment, surgical, therapy, patients, fistulas, lymphoceles, radiation therapy, fistula, patients, electrons, patients, lymphoceles, treatment, photons, patients, fractionation, radiation therapy, patients, fistula, lymphocele, radiation, therapy, patient, surgery, wound, radiotherapy, fistulas, lymphoceles, complications, Radiation, therapy, surgery	Strahlentherapie+Onkologie.01760009.eng.abstr_task2	Sentence: The treatment of persistent postoperative lymphatic fistulas or lymphoceles is often a problem . Approximately 2% of patients will develop lymphatic fistula after vascular surgery . This can require a long lasting conservative therapy . If spontaneous cure fails , a second operation with wound revision becomes necessary . We studied low-dose percutaneous radiotherapy to be used as an alternative treatment in addition to conservative or surgical therapy . Between 1989 and 1998 29 patients ( 25 with lymphatic fistulas , 4 with lymphoceles ) received radiation therapy . Depending on the depth of the fistula 27 patients were treated with electrons ( 7 to 18 MeV ) . Two other patients suffering of retroperitoneal lymphoceles received a treatment with photons ( 15 MV ) . In all patients the fractionation was 4- to 5 x 1.0 Gy/week and the dose ranged from 3 to 12 Gy depending upon the onset of the radiation therapy effect . In 27 of 28 evaluable patients a complete disappearance of the fistula or lymphocele was achieved by radiation during therapy or shortly afterwards . In 1 case no benefit was observed after a dose of 11 Gy . This patient required further surgery with wound exploration . Low dose percutaneous radiotherapy ( up to 10 to 12 Gy ) is effective to heal lymphatic fistulas and lymphoceles without complications . Individual dosage is required because doses even lower than 10 Gy may be effective . Radiation can be effective even after a failed conservative therapy or instead of surgery . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]	The treatment of persistent postoperative lymphatic fistulas or lymphoceles is often a problem . Approximately 2% of patients will develop lymphatic fistula after vascular surgery . This can require a long lasting conservative therapy . If spontaneous cure fails , a second operation with wound revision becomes necessary . We studied low-dose percutaneous radiotherapy to be used as an alternative treatment in addition to conservative or surgical therapy . Between 1989 and 1998 29 patients ( 25 with lymphatic fistulas , 4 with lymphoceles ) received radiation therapy . Depending on the depth of the fistula 27 patients were treated with electrons ( 7 to 18 MeV ) . Two other patients suffering of retroperitoneal lymphoceles received a treatment with photons ( 15 MV ) . In all patients the fractionation was 4- to 5 x 1.0 Gy/week and the dose ranged from 3 to 12 Gy depending upon the onset of the radiation therapy effect . In 27 of 28 evaluable patients a complete disappearance of the fistula or lymphocele was achieved by radiation during therapy or shortly afterwards . In 1 case no benefit was observed after a dose of 11 Gy . This patient required further surgery with wound exploration . Low dose percutaneous radiotherapy ( up to 10 to 12 Gy ) is effective to heal lymphatic fistulas and lymphoceles without complications . Individual dosage is required because doses even lower than 10 Gy may be effective . Radiation can be effective even after a failed conservative therapy or instead of surgery .	[ "The", "treatment", "of", "persistent", "postoperative", "lymphatic", "fistulas", "or", "lymphoceles", "is", "often", "a", "problem", ".", "Approximately", "2", "%", "of", "patients", "will", "develop", "lymphatic", "fistula", "after", "vascular", "surgery", ".", "This", "can", "require", "a", "long", "lasting", "conservative", "therapy", ".", "If", "spontaneous", "cure", "fails", ",", "a", "second", "operation", "with", "wound", "revision", "becomes", "necessary", ".", "We", "studied", "low", "-", "dose", "percutaneous", "radiotherapy", "to", "be", "used", "as", "an", "alternative", "treatment", "in", "addition", "to", "conservative", "or", "surgical", "therapy", ".", "Between", "1989", "and", "1998", "29", "patients", "(", "25", "with", "lymphatic", "fistulas", ",", "4", "with", "lymphoceles", ")", "received", "radiation", "therapy", ".", "Depending", "on", "the", "depth", "of", "the", "fistula", "27", "patients", "were", "treated", "with", "electrons", "(", "7", "to", "18", "MeV", ")", ".", "Two", "other", "patients", "suffering", "of", "retroperitoneal", "lymphoceles", "received", "a", "treatment", "with", "photons", "(", "15", "MV", ")", ".", "In", "all", "patients", "the", "fractionation", "was", "4-", "to", "5", "x", "1.0", "Gy", "/", "week", "and", "the", "dose", "ranged", "from", "3", "to", "12", "Gy", "depending", "upon", "the", "onset", "of", "the", "radiation", "therapy", "effect", ".", "In", "27", "of", "28", "evaluable", "patients", "a", "complete", "disappearance", "of", "the", "fistula", "or", "lymphocele", "was", "achieved", "by", "radiation", "during", "therapy", "or", "shortly", "afterwards", ".", "In", "1", "case", "no", "benefit", "was", "observed", "after", "a", "dose", "of", "11", "Gy", ".", "This", "patient", "required", "further", "surgery", "with", "wound", "exploration", ".", "Low", "dose", "percutaneous", "radiotherapy", "(", "up", "to", "10", "to", "12", "Gy", ")", "is", "effective", "to", "heal", "lymphatic", "fistulas", "and", "lymphoceles", "without", "complications", ".", "Individual", "dosage", "is", "required", "because", "doses", "even", "lower", "than", "10", "Gy", "may", "be", "effective", ".", "Radiation", "can", "be", "effective", "even", "after", "a", "failed", "conservative", "therapy", "or", "instead", "of", "surgery", "." ]	[ "umlsterm" ]
Abstract is an umlsterm, date is an umlsterm, skin is an umlsterm, symptoms is an umlsterm, CD1 is an umlsterm, frozen sections is an umlsterm, granules is an umlsterm, electron microscopy is an umlsterm, analysis is an umlsterm, antibodies is an umlsterm, ability is an umlsterm, paraffin is an umlsterm, tissue is an umlsterm, retrospective is an umlsterm, evaluation is an umlsterm, classification is an umlsterm, disorders is an umlsterm, antibodies is an umlsterm, peanut agglutinin is an umlsterm, PCNA is an umlsterm, cell is an umlsterm, nuclear antigen is an umlsterm, cells is an umlsterm, Langerhans cell histiocytosis is an umlsterm, cell is an umlsterm, cell is an umlsterm, cell is an umlsterm, populations is an umlsterm, dendritic cells is an umlsterm, distribution is an umlsterm, dendritic cells is an umlsterm, ability is an umlsterm, markers is an umlsterm, paraffin is an umlsterm, tissue is an umlsterm, antibodies is an umlsterm, factor XIIIa is an umlsterm, xanthoma disseminatum is an umlsterm, monoclonal antibody is an umlsterm, juvenile xanthogranuloma is an umlsterm, discrimination is an umlsterm, markers is an umlsterm, macrophages is an umlsterm, juvenile xanthogranuloma is an umlsterm, foam cells is an umlsterm, giant cells is an umlsterm, anti - cathepsin is an umlsterm, markers is an umlsterm, ability is an umlsterm, paraffin is an umlsterm, tissue is an umlsterm, lysozyme is an umlsterm, Leu - M1 is an umlsterm, contrast is an umlsterm, macrophages is an umlsterm	DerHautarzt.50460144.eng.abstr_task0	Sentence: Abstract . To date , the rare primary histiocytoses of the skin are diagnosed definitively on the basis of the clinical symptoms , H&E-stained sections , and demonstration of CD1 positivity in frozen sections and of Birbeck granules on electron microscopy . The improvement and analysis of antibodies with the ability to react in paraffin tissue allow retrospective evaluation and classification of these disorders . The antibodies for S-100-protein, peanut agglutinin ( PNA ) and PCNA ( proliferating cell nuclear antigen ) have been advocated for differentiation of the specific cells of Langerhans cell histiocytosis ( LCH ) from other histiocytic cell systems . To date the non-Langerhans cell histiocytoses ( non-LCH ) have no common ultrastructural and immunohistochemical characteristics . The infiltrate is made up of multiple cell populations , which are of significance for the cellular pathobiology ( subtypes of monocytes/macrophages and dendritic cells ) . The number and distribution of the different monocyte/macrophages and dendritic cells and their ability to react with immunohistochemical markers in paraffin tissue can be completely different in different clinical entities . The antibodies against factor XIIIa ( shown on xanthoma disseminatum ) and the monoclonal antibody Ki-M1P ( shown on juvenile xanthogranuloma ) seem to be valuable in discrimination between LCH and non-LCH . Both markers show a positive staining pattern with the characteristic large macrophages . In juvenile xanthogranuloma , the foam cells and giant cells express Ki-M1P, KP1 and anti-cathepsin B. Other monocyte/macrophage markers with the ability to react in paraffin tissue , such as Mac387 , lysozyme , 1-antitrypsin and Leu-M1 ( Anti-CD 15 ) , in contrast , did not show a typical staining pattern with the characteristic large macrophages dominating the histological picture . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]	Abstract . To date , the rare primary histiocytoses of the skin are diagnosed definitively on the basis of the clinical symptoms , H&E-stained sections , and demonstration of CD1 positivity in frozen sections and of Birbeck granules on electron microscopy . The improvement and analysis of antibodies with the ability to react in paraffin tissue allow retrospective evaluation and classification of these disorders . The antibodies for S-100-protein, peanut agglutinin ( PNA ) and PCNA ( proliferating cell nuclear antigen ) have been advocated for differentiation of the specific cells of Langerhans cell histiocytosis ( LCH ) from other histiocytic cell systems . To date the non-Langerhans cell histiocytoses ( non-LCH ) have no common ultrastructural and immunohistochemical characteristics . The infiltrate is made up of multiple cell populations , which are of significance for the cellular pathobiology ( subtypes of monocytes/macrophages and dendritic cells ) . The number and distribution of the different monocyte/macrophages and dendritic cells and their ability to react with immunohistochemical markers in paraffin tissue can be completely different in different clinical entities . The antibodies against factor XIIIa ( shown on xanthoma disseminatum ) and the monoclonal antibody Ki-M1P ( shown on juvenile xanthogranuloma ) seem to be valuable in discrimination between LCH and non-LCH . Both markers show a positive staining pattern with the characteristic large macrophages . In juvenile xanthogranuloma , the foam cells and giant cells express Ki-M1P, KP1 and anti-cathepsin B. Other monocyte/macrophage markers with the ability to react in paraffin tissue , such as Mac387 , lysozyme , 1-antitrypsin and Leu-M1 ( Anti-CD 15 ) , in contrast , did not show a typical staining pattern with the characteristic large macrophages dominating the histological picture .	[ "Abstract", ".", "To", "date", ",", "the", "rare", "primary", "histiocytoses", "of", "the", "skin", "are", "diagnosed", "definitively", "on", "the", "basis", "of", "the", "clinical", "symptoms", ",", "H&E", "-", "stained", "sections", ",", "and", "demonstration", "of", "CD1", "positivity", "in", "frozen", "sections", "and", "of", "Birbeck", "granules", "on", "electron", "microscopy", ".", "The", "improvement", "and", "analysis", "of", "antibodies", "with", "the", "ability", "to", "react", "in", "paraffin", "tissue", "allow", "retrospective", "evaluation", "and", "classification", "of", "these", "disorders", ".", "The", "antibodies", "for", "S-100-protein", ",", "peanut", "agglutinin", "(", "PNA", ")", "and", "PCNA", "(", "proliferating", "cell", "nuclear", "antigen", ")", "have", "been", "advocated", "for", "differentiation", "of", "the", "specific", "cells", "of", "Langerhans", "cell", "histiocytosis", "(", "LCH", ")", "from", "other", "histiocytic", "cell", "systems", ".", "To", "date", "the", "non", "-", "Langerhans", "cell", "histiocytoses", "(", "non", "-", "LCH", ")", "have", "no", "common", "ultrastructural", "and", "immunohistochemical", "characteristics", ".", "The", "infiltrate", "is", "made", "up", "of", "multiple", "cell", "populations", ",", "which", "are", "of", "significance", "for", "the", "cellular", "pathobiology", "(", "subtypes", "of", "monocytes", "/", "macrophages", "and", "dendritic", "cells", ")", ".", "The", "number", "and", "distribution", "of", "the", "different", "monocyte", "/", "macrophages", "and", "dendritic", "cells", "and", "their", "ability", "to", "react", "with", "immunohistochemical", "markers", "in", "paraffin", "tissue", "can", "be", "completely", "different", "in", "different", "clinical", "entities", ".", "The", "antibodies", "against", "factor", "XIIIa", "(", "shown", "on", "xanthoma", "disseminatum", ")", "and", "the", "monoclonal", "antibody", "Ki", "-", "M1P", "(", "shown", "on", "juvenile", "xanthogranuloma", ")", "seem", "to", "be", "valuable", "in", "discrimination", "between", "LCH", "and", "non", "-", "LCH", ".", "Both", "markers", "show", "a", "positive", "staining", "pattern", "with", "the", "characteristic", "large", "macrophages", ".", "In", "juvenile", "xanthogranuloma", ",", "the", "foam", "cells", "and", "giant", "cells", "express", "Ki", "-", "M1P", ",", "KP1", "and", "anti", "-", "cathepsin", "B.", "Other", "monocyte", "/", "macrophage", "markers", "with", "the", "ability", "to", "react", "in", "paraffin", "tissue", ",", "such", "as", "Mac387", ",", "lysozyme", ",", "1-antitrypsin", "and", "Leu", "-", "M1", "(", "Anti", "-", "CD", "15", ")", ",", "in", "contrast", ",", "did", "not", "show", "a", "typical", "staining", "pattern", "with", "the", "characteristic", "large", "macrophages", "dominating", "the", "histological", "picture", "." ]	[ "umlsterm" ]
Abstract is an umlsterm, date is an umlsterm, skin is an umlsterm, symptoms is an umlsterm, CD1 is an umlsterm, frozen sections is an umlsterm, granules is an umlsterm, electron microscopy is an umlsterm, analysis is an umlsterm, antibodies is an umlsterm, ability is an umlsterm, paraffin is an umlsterm, tissue is an umlsterm, retrospective is an umlsterm, evaluation is an umlsterm, classification is an umlsterm, disorders is an umlsterm, antibodies is an umlsterm, peanut agglutinin is an umlsterm, PCNA is an umlsterm, cell is an umlsterm, nuclear antigen is an umlsterm, cells is an umlsterm, Langerhans cell histiocytosis is an umlsterm, cell is an umlsterm, cell is an umlsterm, cell is an umlsterm, populations is an umlsterm, dendritic cells is an umlsterm, distribution is an umlsterm, dendritic cells is an umlsterm, ability is an umlsterm, markers is an umlsterm, paraffin is an umlsterm, tissue is an umlsterm, antibodies is an umlsterm, factor XIIIa is an umlsterm, xanthoma disseminatum is an umlsterm, monoclonal antibody is an umlsterm, juvenile xanthogranuloma is an umlsterm, discrimination is an umlsterm, markers is an umlsterm, macrophages is an umlsterm, juvenile xanthogranuloma is an umlsterm, foam cells is an umlsterm, giant cells is an umlsterm, anti - cathepsin is an umlsterm, markers is an umlsterm, ability is an umlsterm, paraffin is an umlsterm, tissue is an umlsterm, lysozyme is an umlsterm, Leu - M1 is an umlsterm, contrast is an umlsterm, macrophages is an umlsterm	DerHautarzt.50460144.eng.abstr_task1	Sentence: Abstract . To date , the rare primary histiocytoses of the skin are diagnosed definitively on the basis of the clinical symptoms , H&E-stained sections , and demonstration of CD1 positivity in frozen sections and of Birbeck granules on electron microscopy . The improvement and analysis of antibodies with the ability to react in paraffin tissue allow retrospective evaluation and classification of these disorders . The antibodies for S-100-protein, peanut agglutinin ( PNA ) and PCNA ( proliferating cell nuclear antigen ) have been advocated for differentiation of the specific cells of Langerhans cell histiocytosis ( LCH ) from other histiocytic cell systems . To date the non-Langerhans cell histiocytoses ( non-LCH ) have no common ultrastructural and immunohistochemical characteristics . The infiltrate is made up of multiple cell populations , which are of significance for the cellular pathobiology ( subtypes of monocytes/macrophages and dendritic cells ) . The number and distribution of the different monocyte/macrophages and dendritic cells and their ability to react with immunohistochemical markers in paraffin tissue can be completely different in different clinical entities . The antibodies against factor XIIIa ( shown on xanthoma disseminatum ) and the monoclonal antibody Ki-M1P ( shown on juvenile xanthogranuloma ) seem to be valuable in discrimination between LCH and non-LCH . Both markers show a positive staining pattern with the characteristic large macrophages . In juvenile xanthogranuloma , the foam cells and giant cells express Ki-M1P, KP1 and anti-cathepsin B. Other monocyte/macrophage markers with the ability to react in paraffin tissue , such as Mac387 , lysozyme , 1-antitrypsin and Leu-M1 ( Anti-CD 15 ) , in contrast , did not show a typical staining pattern with the characteristic large macrophages dominating the histological picture . Instructions: please typing these entity words according to sentence: Abstract, date, skin, symptoms, CD1, frozen sections, granules, electron microscopy, analysis, antibodies, ability, paraffin, tissue, retrospective, evaluation, classification, disorders, antibodies, peanut agglutinin, PCNA, cell, nuclear antigen, cells, Langerhans cell histiocytosis, cell, cell, cell, populations, dendritic cells, distribution, dendritic cells, ability, markers, paraffin, tissue, antibodies, factor XIIIa, xanthoma disseminatum, monoclonal antibody, juvenile xanthogranuloma, discrimination, markers, macrophages, juvenile xanthogranuloma, foam cells, giant cells, anti - cathepsin, markers, ability, paraffin, tissue, lysozyme, Leu - M1, contrast, macrophages Options: umlsterm	[ "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]	Abstract . To date , the rare primary histiocytoses of the skin are diagnosed definitively on the basis of the clinical symptoms , H&E-stained sections , and demonstration of CD1 positivity in frozen sections and of Birbeck granules on electron microscopy . The improvement and analysis of antibodies with the ability to react in paraffin tissue allow retrospective evaluation and classification of these disorders . The antibodies for S-100-protein, peanut agglutinin ( PNA ) and PCNA ( proliferating cell nuclear antigen ) have been advocated for differentiation of the specific cells of Langerhans cell histiocytosis ( LCH ) from other histiocytic cell systems . To date the non-Langerhans cell histiocytoses ( non-LCH ) have no common ultrastructural and immunohistochemical characteristics . The infiltrate is made up of multiple cell populations , which are of significance for the cellular pathobiology ( subtypes of monocytes/macrophages and dendritic cells ) . The number and distribution of the different monocyte/macrophages and dendritic cells and their ability to react with immunohistochemical markers in paraffin tissue can be completely different in different clinical entities . The antibodies against factor XIIIa ( shown on xanthoma disseminatum ) and the monoclonal antibody Ki-M1P ( shown on juvenile xanthogranuloma ) seem to be valuable in discrimination between LCH and non-LCH . Both markers show a positive staining pattern with the characteristic large macrophages . In juvenile xanthogranuloma , the foam cells and giant cells express Ki-M1P, KP1 and anti-cathepsin B. Other monocyte/macrophage markers with the ability to react in paraffin tissue , such as Mac387 , lysozyme , 1-antitrypsin and Leu-M1 ( Anti-CD 15 ) , in contrast , did not show a typical staining pattern with the characteristic large macrophages dominating the histological picture .	[ "Abstract", ".", "To", "date", ",", "the", "rare", "primary", "histiocytoses", "of", "the", "skin", "are", "diagnosed", "definitively", "on", "the", "basis", "of", "the", "clinical", "symptoms", ",", "H&E", "-", "stained", "sections", ",", "and", "demonstration", "of", "CD1", "positivity", "in", "frozen", "sections", "and", "of", "Birbeck", "granules", "on", "electron", "microscopy", ".", "The", "improvement", "and", "analysis", "of", "antibodies", "with", "the", "ability", "to", "react", "in", "paraffin", "tissue", "allow", "retrospective", "evaluation", "and", "classification", "of", "these", "disorders", ".", "The", "antibodies", "for", "S-100-protein", ",", "peanut", "agglutinin", "(", "PNA", ")", "and", "PCNA", "(", "proliferating", "cell", "nuclear", "antigen", ")", "have", "been", "advocated", "for", "differentiation", "of", "the", "specific", "cells", "of", "Langerhans", "cell", "histiocytosis", "(", "LCH", ")", "from", "other", "histiocytic", "cell", "systems", ".", "To", "date", "the", "non", "-", "Langerhans", "cell", "histiocytoses", "(", "non", "-", "LCH", ")", "have", "no", "common", "ultrastructural", "and", "immunohistochemical", "characteristics", ".", "The", "infiltrate", "is", "made", "up", "of", "multiple", "cell", "populations", ",", "which", "are", "of", "significance", "for", "the", "cellular", "pathobiology", "(", "subtypes", "of", "monocytes", "/", "macrophages", "and", "dendritic", "cells", ")", ".", "The", "number", "and", "distribution", "of", "the", "different", "monocyte", "/", "macrophages", "and", "dendritic", "cells", "and", "their", "ability", "to", "react", "with", "immunohistochemical", "markers", "in", "paraffin", "tissue", "can", "be", "completely", "different", "in", "different", "clinical", "entities", ".", "The", "antibodies", "against", "factor", "XIIIa", "(", "shown", "on", "xanthoma", "disseminatum", ")", "and", "the", "monoclonal", "antibody", "Ki", "-", "M1P", "(", "shown", "on", "juvenile", "xanthogranuloma", ")", "seem", "to", "be", "valuable", "in", "discrimination", "between", "LCH", "and", "non", "-", "LCH", ".", "Both", "markers", "show", "a", "positive", "staining", "pattern", "with", "the", "characteristic", "large", "macrophages", ".", "In", "juvenile", "xanthogranuloma", ",", "the", "foam", "cells", "and", "giant", "cells", "express", "Ki", "-", "M1P", ",", "KP1", "and", "anti", "-", "cathepsin", "B.", "Other", "monocyte", "/", "macrophage", "markers", "with", "the", "ability", "to", "react", "in", "paraffin", "tissue", ",", "such", "as", "Mac387", ",", "lysozyme", ",", "1-antitrypsin", "and", "Leu", "-", "M1", "(", "Anti", "-", "CD", "15", ")", ",", "in", "contrast", ",", "did", "not", "show", "a", "typical", "staining", "pattern", "with", "the", "characteristic", "large", "macrophages", "dominating", "the", "histological", "picture", "." ]	[ "umlsterm" ]
Abstract, date, skin, symptoms, CD1, frozen sections, granules, electron microscopy, analysis, antibodies, ability, paraffin, tissue, retrospective, evaluation, classification, disorders, antibodies, peanut agglutinin, PCNA, cell, nuclear antigen, cells, Langerhans cell histiocytosis, cell, cell, cell, populations, dendritic cells, distribution, dendritic cells, ability, markers, paraffin, tissue, antibodies, factor XIIIa, xanthoma disseminatum, monoclonal antibody, juvenile xanthogranuloma, discrimination, markers, macrophages, juvenile xanthogranuloma, foam cells, giant cells, anti - cathepsin, markers, ability, paraffin, tissue, lysozyme, Leu - M1, contrast, macrophages	DerHautarzt.50460144.eng.abstr_task2	Sentence: Abstract . To date , the rare primary histiocytoses of the skin are diagnosed definitively on the basis of the clinical symptoms , H&E-stained sections , and demonstration of CD1 positivity in frozen sections and of Birbeck granules on electron microscopy . The improvement and analysis of antibodies with the ability to react in paraffin tissue allow retrospective evaluation and classification of these disorders . The antibodies for S-100-protein, peanut agglutinin ( PNA ) and PCNA ( proliferating cell nuclear antigen ) have been advocated for differentiation of the specific cells of Langerhans cell histiocytosis ( LCH ) from other histiocytic cell systems . To date the non-Langerhans cell histiocytoses ( non-LCH ) have no common ultrastructural and immunohistochemical characteristics . The infiltrate is made up of multiple cell populations , which are of significance for the cellular pathobiology ( subtypes of monocytes/macrophages and dendritic cells ) . The number and distribution of the different monocyte/macrophages and dendritic cells and their ability to react with immunohistochemical markers in paraffin tissue can be completely different in different clinical entities . The antibodies against factor XIIIa ( shown on xanthoma disseminatum ) and the monoclonal antibody Ki-M1P ( shown on juvenile xanthogranuloma ) seem to be valuable in discrimination between LCH and non-LCH . Both markers show a positive staining pattern with the characteristic large macrophages . In juvenile xanthogranuloma , the foam cells and giant cells express Ki-M1P, KP1 and anti-cathepsin B. Other monocyte/macrophage markers with the ability to react in paraffin tissue , such as Mac387 , lysozyme , 1-antitrypsin and Leu-M1 ( Anti-CD 15 ) , in contrast , did not show a typical staining pattern with the characteristic large macrophages dominating the histological picture . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]	Abstract . To date , the rare primary histiocytoses of the skin are diagnosed definitively on the basis of the clinical symptoms , H&E-stained sections , and demonstration of CD1 positivity in frozen sections and of Birbeck granules on electron microscopy . The improvement and analysis of antibodies with the ability to react in paraffin tissue allow retrospective evaluation and classification of these disorders . The antibodies for S-100-protein, peanut agglutinin ( PNA ) and PCNA ( proliferating cell nuclear antigen ) have been advocated for differentiation of the specific cells of Langerhans cell histiocytosis ( LCH ) from other histiocytic cell systems . To date the non-Langerhans cell histiocytoses ( non-LCH ) have no common ultrastructural and immunohistochemical characteristics . The infiltrate is made up of multiple cell populations , which are of significance for the cellular pathobiology ( subtypes of monocytes/macrophages and dendritic cells ) . The number and distribution of the different monocyte/macrophages and dendritic cells and their ability to react with immunohistochemical markers in paraffin tissue can be completely different in different clinical entities . The antibodies against factor XIIIa ( shown on xanthoma disseminatum ) and the monoclonal antibody Ki-M1P ( shown on juvenile xanthogranuloma ) seem to be valuable in discrimination between LCH and non-LCH . Both markers show a positive staining pattern with the characteristic large macrophages . In juvenile xanthogranuloma , the foam cells and giant cells express Ki-M1P, KP1 and anti-cathepsin B. Other monocyte/macrophage markers with the ability to react in paraffin tissue , such as Mac387 , lysozyme , 1-antitrypsin and Leu-M1 ( Anti-CD 15 ) , in contrast , did not show a typical staining pattern with the characteristic large macrophages dominating the histological picture .	[ "Abstract", ".", "To", "date", ",", "the", "rare", "primary", "histiocytoses", "of", "the", "skin", "are", "diagnosed", "definitively", "on", "the", "basis", "of", "the", "clinical", "symptoms", ",", "H&E", "-", "stained", "sections", ",", "and", "demonstration", "of", "CD1", "positivity", "in", "frozen", "sections", "and", "of", "Birbeck", "granules", "on", "electron", "microscopy", ".", "The", "improvement", "and", "analysis", "of", "antibodies", "with", "the", "ability", "to", "react", "in", "paraffin", "tissue", "allow", "retrospective", "evaluation", "and", "classification", "of", "these", "disorders", ".", "The", "antibodies", "for", "S-100-protein", ",", "peanut", "agglutinin", "(", "PNA", ")", "and", "PCNA", "(", "proliferating", "cell", "nuclear", "antigen", ")", "have", "been", "advocated", "for", "differentiation", "of", "the", "specific", "cells", "of", "Langerhans", "cell", "histiocytosis", "(", "LCH", ")", "from", "other", "histiocytic", "cell", "systems", ".", "To", "date", "the", "non", "-", "Langerhans", "cell", "histiocytoses", "(", "non", "-", "LCH", ")", "have", "no", "common", "ultrastructural", "and", "immunohistochemical", "characteristics", ".", "The", "infiltrate", "is", "made", "up", "of", "multiple", "cell", "populations", ",", "which", "are", "of", "significance", "for", "the", "cellular", "pathobiology", "(", "subtypes", "of", "monocytes", "/", "macrophages", "and", "dendritic", "cells", ")", ".", "The", "number", "and", "distribution", "of", "the", "different", "monocyte", "/", "macrophages", "and", "dendritic", "cells", "and", "their", "ability", "to", "react", "with", "immunohistochemical", "markers", "in", "paraffin", "tissue", "can", "be", "completely", "different", "in", "different", "clinical", "entities", ".", "The", "antibodies", "against", "factor", "XIIIa", "(", "shown", "on", "xanthoma", "disseminatum", ")", "and", "the", "monoclonal", "antibody", "Ki", "-", "M1P", "(", "shown", "on", "juvenile", "xanthogranuloma", ")", "seem", "to", "be", "valuable", "in", "discrimination", "between", "LCH", "and", "non", "-", "LCH", ".", "Both", "markers", "show", "a", "positive", "staining", "pattern", "with", "the", "characteristic", "large", "macrophages", ".", "In", "juvenile", "xanthogranuloma", ",", "the", "foam", "cells", "and", "giant", "cells", "express", "Ki", "-", "M1P", ",", "KP1", "and", "anti", "-", "cathepsin", "B.", "Other", "monocyte", "/", "macrophage", "markers", "with", "the", "ability", "to", "react", "in", "paraffin", "tissue", ",", "such", "as", "Mac387", ",", "lysozyme", ",", "1-antitrypsin", "and", "Leu", "-", "M1", "(", "Anti", "-", "CD", "15", ")", ",", "in", "contrast", ",", "did", "not", "show", "a", "typical", "staining", "pattern", "with", "the", "characteristic", "large", "macrophages", "dominating", "the", "histological", "picture", "." ]	[ "umlsterm" ]
Pedro is a NOMBRE_SUJETO_ASISTENCIA, Espinoza Campos is a NOMBRE_SUJETO_ASISTENCIA, 2987562 is a ID_SUJETO_ASISTENCIA, Av Libertador Bernardo O'Higgins 816 is a CALLE, Santiago is a TERRITORIO, 7591538 is a TERRITORIO, 31/05/1972 is a FECHAS, Chile is a PAIS, 44 años is a EDAD_SUJETO_ASISTENCIA, Hombre is a SEXO_SUJETO_ASISTENCIA, 08/12/2016 is a FECHAS, Luis Córdova Jara is a NOMBRE_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 44 años is a EDAD_SUJETO_ASISTENCIA, Luis Córdova Jara is a NOMBRE_PERSONAL_SANITARIO, Facultad de Odontología is a INSTITUCION, Universidad de Chile is a INSTITUCION, Calle Olivos 943 is a CALLE, Independencia is a TERRITORIO, Santiago de Chile is a TERRITORIO, luiscordovajara@vtr.net is a CORREO_ELECTRONICO	335_task0	Sentence: Nombre: Pedro . Apellidos:Espinoza Campos. NHC: 2987562. Domicilio: Av Libertador Bernardo O'Higgins 816. Localidad/ Provincia: Santiago. CP: 7591538. Datos asistenciales. Fecha de nacimiento: 31/05/1972. País: Chile. Edad: 44 años Sexo: Hombre. Fecha de Ingreso: 08/12/2016. Médico: Luis Córdova Jara . Informe Clinico: Varón de 44 años ingresado por trauma facial. El estudio radiográfico reveló una gran lesión radiolúcida y una fractura del ángulo desplazada. Se realizó enucleación de la lesión, extracción de las raíces dentarias causantes y la reducción-osteosíntesis de la fractura con alambre intraóseo y mini placa con tornillos monocorticales. El estudio histológico del material enucleado, reveló un quiste radicular inflamatorio. La consolidación ósea fue observada radiográficamente dos meses después. Remitido por: Dr. Luis Córdova Jara. Facultad de Odontología. Universidad de Chile Calle Olivos 943, Independencia, Santiago de Chile. Email: luiscordovajara@vtr.net Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, INSTITUCION, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "B-CALLE", "I-CALLE", "I-CALLE", "O", "B-TERRITORIO", "O", "B-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Nombre: Pedro . Apellidos:Espinoza Campos. NHC: 2987562. Domicilio: Av Libertador Bernardo O'Higgins 816. Localidad/ Provincia: Santiago. CP: 7591538. Datos asistenciales. Fecha de nacimiento: 31/05/1972. País: Chile. Edad: 44 años Sexo: Hombre. Fecha de Ingreso: 08/12/2016. Médico: Luis Córdova Jara . Informe Clinico: Varón de 44 años ingresado por trauma facial. El estudio radiográfico reveló una gran lesión radiolúcida y una fractura del ángulo desplazada. Se realizó enucleación de la lesión, extracción de las raíces dentarias causantes y la reducción-osteosíntesis de la fractura con alambre intraóseo y mini placa con tornillos monocorticales. El estudio histológico del material enucleado, reveló un quiste radicular inflamatorio. La consolidación ósea fue observada radiográficamente dos meses después. Remitido por: Dr. Luis Córdova Jara. Facultad de Odontología. Universidad de Chile Calle Olivos 943, Independencia, Santiago de Chile. Email: luiscordovajara@vtr.net	[ "Nombre", ":", " ", "Pedro", ".", "\n", "Apellidos", ":", "Espinoza", "Campos", ".", "\n", "NHC", ":", "2987562", ".", "\n", "Domicilio", ":", "Av", "Libertador", "Bernardo", "O'Higgins", "816", ".", "\n", "Localidad/", "Provincia", ":", "Santiago", ".", "\n", "CP", ":", "7591538", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "31/05/1972", ".", "\n", "País", ":", "Chile", ".", "\n", "Edad", ":", "44", " ", "años", "Sexo", ":", "Hombre", ".", "\n", "Fecha", "de", "Ingreso", ":", "08/12/2016", ".", "\n", "Médico", ":", "Luis", "Córdova", "Jara", ".", "\n", "Informe", "Clinico", ":", "Varón", "de", "44", "años", "ingresado", "por", "trauma", "facial", ".", "El", "estudio", "radiográfico", "reveló", "una", "gran", "lesión", "radiolúcida", "y", "una", "fractura", "del", "ángulo", "desplazada", ".", "\n", "Se", "realizó", "enucleación", "de", "la", "lesión", ",", "extracción", "de", "las", "raíces", "dentarias", "causantes", "y", "la", "reducción", "-", "osteosíntesis", "de", "la", "fractura", "con", "alambre", "intraóseo", "y", "mini", "placa", "con", "tornillos", "monocorticales", ".", "\n", "El", "estudio", "histológico", "del", "material", "enucleado", ",", "reveló", "un", "quiste", "radicular", "inflamatorio", ".", "La", "consolidación", "ósea", "fue", "observada", "radiográficamente", "dos", "meses", "después", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Luis", "Córdova", "Jara", ".", "Facultad", "de", "Odontología", ".", "Universidad", "de", "Chile", "Calle", "Olivos", "943", ",", "Independencia", ",", "Santiago", "de", "Chile", ".", "Email", ":", "luiscordovajara@vtr.net", "\n" ]	[ "CALLE", "CORREO_ELECTRONICO", "INSTITUCION", "TERRITORIO", "NOMBRE_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA", "PAIS" ]
Pedro is a NOMBRE_SUJETO_ASISTENCIA, Espinoza Campos is a NOMBRE_SUJETO_ASISTENCIA, 2987562 is a ID_SUJETO_ASISTENCIA, Av Libertador Bernardo O'Higgins 816 is a CALLE, Santiago is a TERRITORIO, 7591538 is a TERRITORIO, 31/05/1972 is a FECHAS, Chile is a PAIS, 44 años is a EDAD_SUJETO_ASISTENCIA, Hombre is a SEXO_SUJETO_ASISTENCIA, 08/12/2016 is a FECHAS, Luis Córdova Jara is a NOMBRE_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 44 años is a EDAD_SUJETO_ASISTENCIA, Luis Córdova Jara is a NOMBRE_PERSONAL_SANITARIO, Facultad de Odontología is a INSTITUCION, Universidad de Chile is a INSTITUCION, Calle Olivos 943 is a CALLE, Independencia is a TERRITORIO, Santiago de Chile is a TERRITORIO, luiscordovajara@vtr.net is a CORREO_ELECTRONICO	335_task1	Sentence: Nombre: Pedro . Apellidos:Espinoza Campos. NHC: 2987562. Domicilio: Av Libertador Bernardo O'Higgins 816. Localidad/ Provincia: Santiago. CP: 7591538. Datos asistenciales. Fecha de nacimiento: 31/05/1972. País: Chile. Edad: 44 años Sexo: Hombre. Fecha de Ingreso: 08/12/2016. Médico: Luis Córdova Jara . Informe Clinico: Varón de 44 años ingresado por trauma facial. El estudio radiográfico reveló una gran lesión radiolúcida y una fractura del ángulo desplazada. Se realizó enucleación de la lesión, extracción de las raíces dentarias causantes y la reducción-osteosíntesis de la fractura con alambre intraóseo y mini placa con tornillos monocorticales. El estudio histológico del material enucleado, reveló un quiste radicular inflamatorio. La consolidación ósea fue observada radiográficamente dos meses después. Remitido por: Dr. Luis Córdova Jara. Facultad de Odontología. Universidad de Chile Calle Olivos 943, Independencia, Santiago de Chile. Email: luiscordovajara@vtr.net Instructions: please typing these entity words according to sentence: Pedro, Espinoza Campos, 2987562, Av Libertador Bernardo O'Higgins 816, Santiago, 7591538, 31/05/1972, Chile, 44 años, Hombre, 08/12/2016, Luis Córdova Jara, Varón, 44 años, Luis Córdova Jara, Facultad de Odontología, Universidad de Chile, Calle Olivos 943, Independencia, Santiago de Chile, luiscordovajara@vtr.net Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, INSTITUCION, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "B-CALLE", "I-CALLE", "I-CALLE", "O", "B-TERRITORIO", "O", "B-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Nombre: Pedro . Apellidos:Espinoza Campos. NHC: 2987562. Domicilio: Av Libertador Bernardo O'Higgins 816. Localidad/ Provincia: Santiago. CP: 7591538. Datos asistenciales. Fecha de nacimiento: 31/05/1972. País: Chile. Edad: 44 años Sexo: Hombre. Fecha de Ingreso: 08/12/2016. Médico: Luis Córdova Jara . Informe Clinico: Varón de 44 años ingresado por trauma facial. El estudio radiográfico reveló una gran lesión radiolúcida y una fractura del ángulo desplazada. Se realizó enucleación de la lesión, extracción de las raíces dentarias causantes y la reducción-osteosíntesis de la fractura con alambre intraóseo y mini placa con tornillos monocorticales. El estudio histológico del material enucleado, reveló un quiste radicular inflamatorio. La consolidación ósea fue observada radiográficamente dos meses después. Remitido por: Dr. Luis Córdova Jara. Facultad de Odontología. Universidad de Chile Calle Olivos 943, Independencia, Santiago de Chile. Email: luiscordovajara@vtr.net	[ "Nombre", ":", " ", "Pedro", ".", "\n", "Apellidos", ":", "Espinoza", "Campos", ".", "\n", "NHC", ":", "2987562", ".", "\n", "Domicilio", ":", "Av", "Libertador", "Bernardo", "O'Higgins", "816", ".", "\n", "Localidad/", "Provincia", ":", "Santiago", ".", "\n", "CP", ":", "7591538", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "31/05/1972", ".", "\n", "País", ":", "Chile", ".", "\n", "Edad", ":", "44", " ", "años", "Sexo", ":", "Hombre", ".", "\n", "Fecha", "de", "Ingreso", ":", "08/12/2016", ".", "\n", "Médico", ":", "Luis", "Córdova", "Jara", ".", "\n", "Informe", "Clinico", ":", "Varón", "de", "44", "años", "ingresado", "por", "trauma", "facial", ".", "El", "estudio", "radiográfico", "reveló", "una", "gran", "lesión", "radiolúcida", "y", "una", "fractura", "del", "ángulo", "desplazada", ".", "\n", "Se", "realizó", "enucleación", "de", "la", "lesión", ",", "extracción", "de", "las", "raíces", "dentarias", "causantes", "y", "la", "reducción", "-", "osteosíntesis", "de", "la", "fractura", "con", "alambre", "intraóseo", "y", "mini", "placa", "con", "tornillos", "monocorticales", ".", "\n", "El", "estudio", "histológico", "del", "material", "enucleado", ",", "reveló", "un", "quiste", "radicular", "inflamatorio", ".", "La", "consolidación", "ósea", "fue", "observada", "radiográficamente", "dos", "meses", "después", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Luis", "Córdova", "Jara", ".", "Facultad", "de", "Odontología", ".", "Universidad", "de", "Chile", "Calle", "Olivos", "943", ",", "Independencia", ",", "Santiago", "de", "Chile", ".", "Email", ":", "luiscordovajara@vtr.net", "\n" ]	[ "CALLE", "CORREO_ELECTRONICO", "INSTITUCION", "TERRITORIO", "NOMBRE_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA", "PAIS" ]
Pedro, Espinoza Campos, 2987562, Av Libertador Bernardo O'Higgins 816, Santiago, 7591538, 31/05/1972, Chile, 44 años, Hombre, 08/12/2016, Luis Córdova Jara, Varón, 44 años, Luis Córdova Jara, Facultad de Odontología, Universidad de Chile, Calle Olivos 943, Independencia, Santiago de Chile, luiscordovajara@vtr.net	335_task2	Sentence: Nombre: Pedro . Apellidos:Espinoza Campos. NHC: 2987562. Domicilio: Av Libertador Bernardo O'Higgins 816. Localidad/ Provincia: Santiago. CP: 7591538. Datos asistenciales. Fecha de nacimiento: 31/05/1972. País: Chile. Edad: 44 años Sexo: Hombre. Fecha de Ingreso: 08/12/2016. Médico: Luis Córdova Jara . Informe Clinico: Varón de 44 años ingresado por trauma facial. El estudio radiográfico reveló una gran lesión radiolúcida y una fractura del ángulo desplazada. Se realizó enucleación de la lesión, extracción de las raíces dentarias causantes y la reducción-osteosíntesis de la fractura con alambre intraóseo y mini placa con tornillos monocorticales. El estudio histológico del material enucleado, reveló un quiste radicular inflamatorio. La consolidación ósea fue observada radiográficamente dos meses después. Remitido por: Dr. Luis Córdova Jara. Facultad de Odontología. Universidad de Chile Calle Olivos 943, Independencia, Santiago de Chile. Email: luiscordovajara@vtr.net Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "B-CALLE", "I-CALLE", "I-CALLE", "O", "B-TERRITORIO", "O", "B-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Nombre: Pedro . Apellidos:Espinoza Campos. NHC: 2987562. Domicilio: Av Libertador Bernardo O'Higgins 816. Localidad/ Provincia: Santiago. CP: 7591538. Datos asistenciales. Fecha de nacimiento: 31/05/1972. País: Chile. Edad: 44 años Sexo: Hombre. Fecha de Ingreso: 08/12/2016. Médico: Luis Córdova Jara . Informe Clinico: Varón de 44 años ingresado por trauma facial. El estudio radiográfico reveló una gran lesión radiolúcida y una fractura del ángulo desplazada. Se realizó enucleación de la lesión, extracción de las raíces dentarias causantes y la reducción-osteosíntesis de la fractura con alambre intraóseo y mini placa con tornillos monocorticales. El estudio histológico del material enucleado, reveló un quiste radicular inflamatorio. La consolidación ósea fue observada radiográficamente dos meses después. Remitido por: Dr. Luis Córdova Jara. Facultad de Odontología. Universidad de Chile Calle Olivos 943, Independencia, Santiago de Chile. Email: luiscordovajara@vtr.net	[ "Nombre", ":", " ", "Pedro", ".", "\n", "Apellidos", ":", "Espinoza", "Campos", ".", "\n", "NHC", ":", "2987562", ".", "\n", "Domicilio", ":", "Av", "Libertador", "Bernardo", "O'Higgins", "816", ".", "\n", "Localidad/", "Provincia", ":", "Santiago", ".", "\n", "CP", ":", "7591538", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "31/05/1972", ".", "\n", "País", ":", "Chile", ".", "\n", "Edad", ":", "44", " ", "años", "Sexo", ":", "Hombre", ".", "\n", "Fecha", "de", "Ingreso", ":", "08/12/2016", ".", "\n", "Médico", ":", "Luis", "Córdova", "Jara", ".", "\n", "Informe", "Clinico", ":", "Varón", "de", "44", "años", "ingresado", "por", "trauma", "facial", ".", "El", "estudio", "radiográfico", "reveló", "una", "gran", "lesión", "radiolúcida", "y", "una", "fractura", "del", "ángulo", "desplazada", ".", "\n", "Se", "realizó", "enucleación", "de", "la", "lesión", ",", "extracción", "de", "las", "raíces", "dentarias", "causantes", "y", "la", "reducción", "-", "osteosíntesis", "de", "la", "fractura", "con", "alambre", "intraóseo", "y", "mini", "placa", "con", "tornillos", "monocorticales", ".", "\n", "El", "estudio", "histológico", "del", "material", "enucleado", ",", "reveló", "un", "quiste", "radicular", "inflamatorio", ".", "La", "consolidación", "ósea", "fue", "observada", "radiográficamente", "dos", "meses", "después", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Luis", "Córdova", "Jara", ".", "Facultad", "de", "Odontología", ".", "Universidad", "de", "Chile", "Calle", "Olivos", "943", ",", "Independencia", ",", "Santiago", "de", "Chile", ".", "Email", ":", "luiscordovajara@vtr.net", "\n" ]	[ "CALLE", "CORREO_ELECTRONICO", "INSTITUCION", "TERRITORIO", "NOMBRE_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA", "PAIS" ]
Herzinfarktregisters is an umlsterm, Trends is an umlsterm, Herzinfarktmorbiditaet is an umlsterm, Herztodesfaelle is an umlsterm, Krankenhausbehandlung is an umlsterm, Patientenverhalten is an umlsterm, Methoden is an umlsterm, Studienbevoelkerung is an umlsterm, Stadt is an umlsterm, Todesbescheinigungen is an umlsterm, Leichenschauaerzte is an umlsterm, Krankenhaeusern is an umlsterm, Interview is an umlsterm, Krankenaktenauswertung is an umlsterm	IntensiveMedizin.90360652.ger.abstr_task0	Sentence: Zusammenfassung Zielstellung : Auf der Grundlage des bevoelkerungsbasierten MONICA-Augsburg Herzinfarktregisters 1985-1995 werden Haeufigkeit und Trends der Herzinfarktmorbiditaet inkl. der ploetzlichen Herztodesfaelle ( PHT ) vorgestellt und im Zusammenhang mit der praehospitalen und Krankenhausbehandlung sowie dem Patientenverhalten diskutiert . Material und Methoden : Studienbevoelkerung sind die 25-74jaehrigen Einwohner der Stadt Augsburg und der Landkreise Augsburg und Aichach-Friedberg . Datenquellen fuer die 5.712 PHT ( innerhalb von 24 Stunden verstorben ) waren die Todesbescheinigungen der 3 regionalen Gesundheitsaemter und die Frageboegen der zuletzt behandelnden und/oder Leichenschauaerzte ; die Daten der 4.976 MI-Patienten aus 17 regionalen Krankenhaeusern basieren auf einem standardisierten Interview und der Krankenaktenauswertung . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	Zusammenfassung Zielstellung : Auf der Grundlage des bevoelkerungsbasierten MONICA-Augsburg Herzinfarktregisters 1985-1995 werden Haeufigkeit und Trends der Herzinfarktmorbiditaet inkl. der ploetzlichen Herztodesfaelle ( PHT ) vorgestellt und im Zusammenhang mit der praehospitalen und Krankenhausbehandlung sowie dem Patientenverhalten diskutiert . Material und Methoden : Studienbevoelkerung sind die 25-74jaehrigen Einwohner der Stadt Augsburg und der Landkreise Augsburg und Aichach-Friedberg . Datenquellen fuer die 5.712 PHT ( innerhalb von 24 Stunden verstorben ) waren die Todesbescheinigungen der 3 regionalen Gesundheitsaemter und die Frageboegen der zuletzt behandelnden und/oder Leichenschauaerzte ; die Daten der 4.976 MI-Patienten aus 17 regionalen Krankenhaeusern basieren auf einem standardisierten Interview und der Krankenaktenauswertung .	[ "Zusammenfassung", "Zielstellung", ":", "Auf", "der", "Grundlage", "des", "bevoelkerungsbasierten", "MONICA", "-", "Augsburg", "Herzinfarktregisters", "1985", "-", "1995", "werden", "Haeufigkeit", "und", "Trends", "der", "Herzinfarktmorbiditaet", "inkl", ".", "der", "ploetzlichen", "Herztodesfaelle", "(", "PHT", ")", "vorgestellt", "und", "im", "Zusammenhang", "mit", "der", "praehospitalen", "und", "Krankenhausbehandlung", "sowie", "dem", "Patientenverhalten", "diskutiert", ".", "Material", "und", "Methoden", ":", "Studienbevoelkerung", "sind", "die", "25", "-", "74jaehrigen", "Einwohner", "der", "Stadt", "Augsburg", "und", "der", "Landkreise", "Augsburg", "und", "Aichach", "-", "Friedberg", ".", "Datenquellen", "fuer", "die", "5.712", "PHT", "(", "innerhalb", "von", "24", "Stunden", "verstorben", ")", "waren", "die", "Todesbescheinigungen", "der", "3", "regionalen", "Gesundheitsaemter", "und", "die", "Frageboegen", "der", "zuletzt", "behandelnden", "und", "/", "oder", "Leichenschauaerzte", ";", "die", "Daten", "der", "4.976", "MI", "-", "Patienten", "aus", "17", "regionalen", "Krankenhaeusern", "basieren", "auf", "einem", "standardisierten", "Interview", "und", "der", "Krankenaktenauswertung", "." ]	[ "umlsterm" ]
Herzinfarktregisters is an umlsterm, Trends is an umlsterm, Herzinfarktmorbiditaet is an umlsterm, Herztodesfaelle is an umlsterm, Krankenhausbehandlung is an umlsterm, Patientenverhalten is an umlsterm, Methoden is an umlsterm, Studienbevoelkerung is an umlsterm, Stadt is an umlsterm, Todesbescheinigungen is an umlsterm, Leichenschauaerzte is an umlsterm, Krankenhaeusern is an umlsterm, Interview is an umlsterm, Krankenaktenauswertung is an umlsterm	IntensiveMedizin.90360652.ger.abstr_task1	Sentence: Zusammenfassung Zielstellung : Auf der Grundlage des bevoelkerungsbasierten MONICA-Augsburg Herzinfarktregisters 1985-1995 werden Haeufigkeit und Trends der Herzinfarktmorbiditaet inkl. der ploetzlichen Herztodesfaelle ( PHT ) vorgestellt und im Zusammenhang mit der praehospitalen und Krankenhausbehandlung sowie dem Patientenverhalten diskutiert . Material und Methoden : Studienbevoelkerung sind die 25-74jaehrigen Einwohner der Stadt Augsburg und der Landkreise Augsburg und Aichach-Friedberg . Datenquellen fuer die 5.712 PHT ( innerhalb von 24 Stunden verstorben ) waren die Todesbescheinigungen der 3 regionalen Gesundheitsaemter und die Frageboegen der zuletzt behandelnden und/oder Leichenschauaerzte ; die Daten der 4.976 MI-Patienten aus 17 regionalen Krankenhaeusern basieren auf einem standardisierten Interview und der Krankenaktenauswertung . Instructions: please typing these entity words according to sentence: Herzinfarktregisters, Trends, Herzinfarktmorbiditaet, Herztodesfaelle, Krankenhausbehandlung, Patientenverhalten, Methoden, Studienbevoelkerung, Stadt, Todesbescheinigungen, Leichenschauaerzte, Krankenhaeusern, Interview, Krankenaktenauswertung Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	Zusammenfassung Zielstellung : Auf der Grundlage des bevoelkerungsbasierten MONICA-Augsburg Herzinfarktregisters 1985-1995 werden Haeufigkeit und Trends der Herzinfarktmorbiditaet inkl. der ploetzlichen Herztodesfaelle ( PHT ) vorgestellt und im Zusammenhang mit der praehospitalen und Krankenhausbehandlung sowie dem Patientenverhalten diskutiert . Material und Methoden : Studienbevoelkerung sind die 25-74jaehrigen Einwohner der Stadt Augsburg und der Landkreise Augsburg und Aichach-Friedberg . Datenquellen fuer die 5.712 PHT ( innerhalb von 24 Stunden verstorben ) waren die Todesbescheinigungen der 3 regionalen Gesundheitsaemter und die Frageboegen der zuletzt behandelnden und/oder Leichenschauaerzte ; die Daten der 4.976 MI-Patienten aus 17 regionalen Krankenhaeusern basieren auf einem standardisierten Interview und der Krankenaktenauswertung .	[ "Zusammenfassung", "Zielstellung", ":", "Auf", "der", "Grundlage", "des", "bevoelkerungsbasierten", "MONICA", "-", "Augsburg", "Herzinfarktregisters", "1985", "-", "1995", "werden", "Haeufigkeit", "und", "Trends", "der", "Herzinfarktmorbiditaet", "inkl", ".", "der", "ploetzlichen", "Herztodesfaelle", "(", "PHT", ")", "vorgestellt", "und", "im", "Zusammenhang", "mit", "der", "praehospitalen", "und", "Krankenhausbehandlung", "sowie", "dem", "Patientenverhalten", "diskutiert", ".", "Material", "und", "Methoden", ":", "Studienbevoelkerung", "sind", "die", "25", "-", "74jaehrigen", "Einwohner", "der", "Stadt", "Augsburg", "und", "der", "Landkreise", "Augsburg", "und", "Aichach", "-", "Friedberg", ".", "Datenquellen", "fuer", "die", "5.712", "PHT", "(", "innerhalb", "von", "24", "Stunden", "verstorben", ")", "waren", "die", "Todesbescheinigungen", "der", "3", "regionalen", "Gesundheitsaemter", "und", "die", "Frageboegen", "der", "zuletzt", "behandelnden", "und", "/", "oder", "Leichenschauaerzte", ";", "die", "Daten", "der", "4.976", "MI", "-", "Patienten", "aus", "17", "regionalen", "Krankenhaeusern", "basieren", "auf", "einem", "standardisierten", "Interview", "und", "der", "Krankenaktenauswertung", "." ]	[ "umlsterm" ]
Herzinfarktregisters, Trends, Herzinfarktmorbiditaet, Herztodesfaelle, Krankenhausbehandlung, Patientenverhalten, Methoden, Studienbevoelkerung, Stadt, Todesbescheinigungen, Leichenschauaerzte, Krankenhaeusern, Interview, Krankenaktenauswertung	IntensiveMedizin.90360652.ger.abstr_task2	Sentence: Zusammenfassung Zielstellung : Auf der Grundlage des bevoelkerungsbasierten MONICA-Augsburg Herzinfarktregisters 1985-1995 werden Haeufigkeit und Trends der Herzinfarktmorbiditaet inkl. der ploetzlichen Herztodesfaelle ( PHT ) vorgestellt und im Zusammenhang mit der praehospitalen und Krankenhausbehandlung sowie dem Patientenverhalten diskutiert . Material und Methoden : Studienbevoelkerung sind die 25-74jaehrigen Einwohner der Stadt Augsburg und der Landkreise Augsburg und Aichach-Friedberg . Datenquellen fuer die 5.712 PHT ( innerhalb von 24 Stunden verstorben ) waren die Todesbescheinigungen der 3 regionalen Gesundheitsaemter und die Frageboegen der zuletzt behandelnden und/oder Leichenschauaerzte ; die Daten der 4.976 MI-Patienten aus 17 regionalen Krankenhaeusern basieren auf einem standardisierten Interview und der Krankenaktenauswertung . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	Zusammenfassung Zielstellung : Auf der Grundlage des bevoelkerungsbasierten MONICA-Augsburg Herzinfarktregisters 1985-1995 werden Haeufigkeit und Trends der Herzinfarktmorbiditaet inkl. der ploetzlichen Herztodesfaelle ( PHT ) vorgestellt und im Zusammenhang mit der praehospitalen und Krankenhausbehandlung sowie dem Patientenverhalten diskutiert . Material und Methoden : Studienbevoelkerung sind die 25-74jaehrigen Einwohner der Stadt Augsburg und der Landkreise Augsburg und Aichach-Friedberg . Datenquellen fuer die 5.712 PHT ( innerhalb von 24 Stunden verstorben ) waren die Todesbescheinigungen der 3 regionalen Gesundheitsaemter und die Frageboegen der zuletzt behandelnden und/oder Leichenschauaerzte ; die Daten der 4.976 MI-Patienten aus 17 regionalen Krankenhaeusern basieren auf einem standardisierten Interview und der Krankenaktenauswertung .	[ "Zusammenfassung", "Zielstellung", ":", "Auf", "der", "Grundlage", "des", "bevoelkerungsbasierten", "MONICA", "-", "Augsburg", "Herzinfarktregisters", "1985", "-", "1995", "werden", "Haeufigkeit", "und", "Trends", "der", "Herzinfarktmorbiditaet", "inkl", ".", "der", "ploetzlichen", "Herztodesfaelle", "(", "PHT", ")", "vorgestellt", "und", "im", "Zusammenhang", "mit", "der", "praehospitalen", "und", "Krankenhausbehandlung", "sowie", "dem", "Patientenverhalten", "diskutiert", ".", "Material", "und", "Methoden", ":", "Studienbevoelkerung", "sind", "die", "25", "-", "74jaehrigen", "Einwohner", "der", "Stadt", "Augsburg", "und", "der", "Landkreise", "Augsburg", "und", "Aichach", "-", "Friedberg", ".", "Datenquellen", "fuer", "die", "5.712", "PHT", "(", "innerhalb", "von", "24", "Stunden", "verstorben", ")", "waren", "die", "Todesbescheinigungen", "der", "3", "regionalen", "Gesundheitsaemter", "und", "die", "Frageboegen", "der", "zuletzt", "behandelnden", "und", "/", "oder", "Leichenschauaerzte", ";", "die", "Daten", "der", "4.976", "MI", "-", "Patienten", "aus", "17", "regionalen", "Krankenhaeusern", "basieren", "auf", "einem", "standardisierten", "Interview", "und", "der", "Krankenaktenauswertung", "." ]	[ "umlsterm" ]
Patienten is an umlsterm	DerOpthalmologe.90960092.ger.abstr_task0	Sentence: Fragestellung : Auch unter Kortikosteroidtherapie koennen persistierende Nummuli nach Keratoconjunctivitis epidemica ( KE ) auftreten . Sie fuehren zu Visusminderung und erhoehter Blendungsempfindlichkeit der Patienten . Durch eine phototherapeutische Keratektomie ( PTK ) versuchten wird , therapierefraktaere Nummuli zu entfernen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fragestellung : Auch unter Kortikosteroidtherapie koennen persistierende Nummuli nach Keratoconjunctivitis epidemica ( KE ) auftreten . Sie fuehren zu Visusminderung und erhoehter Blendungsempfindlichkeit der Patienten . Durch eine phototherapeutische Keratektomie ( PTK ) versuchten wird , therapierefraktaere Nummuli zu entfernen .	[ "Fragestellung", ":", "Auch", "unter", "Kortikosteroidtherapie", "koennen", "persistierende", "Nummuli", "nach", "Keratoconjunctivitis", "epidemica", "(", "KE", ")", "auftreten", ".", "Sie", "fuehren", "zu", "Visusminderung", "und", "erhoehter", "Blendungsempfindlichkeit", "der", "Patienten", ".", "Durch", "eine", "phototherapeutische", "Keratektomie", "(", "PTK", ")", "versuchten", "wird", ",", "therapierefraktaere", "Nummuli", "zu", "entfernen", "." ]	[ "umlsterm" ]
Patienten is an umlsterm	DerOpthalmologe.90960092.ger.abstr_task1	Sentence: Fragestellung : Auch unter Kortikosteroidtherapie koennen persistierende Nummuli nach Keratoconjunctivitis epidemica ( KE ) auftreten . Sie fuehren zu Visusminderung und erhoehter Blendungsempfindlichkeit der Patienten . Durch eine phototherapeutische Keratektomie ( PTK ) versuchten wird , therapierefraktaere Nummuli zu entfernen . Instructions: please typing these entity words according to sentence: Patienten Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fragestellung : Auch unter Kortikosteroidtherapie koennen persistierende Nummuli nach Keratoconjunctivitis epidemica ( KE ) auftreten . Sie fuehren zu Visusminderung und erhoehter Blendungsempfindlichkeit der Patienten . Durch eine phototherapeutische Keratektomie ( PTK ) versuchten wird , therapierefraktaere Nummuli zu entfernen .	[ "Fragestellung", ":", "Auch", "unter", "Kortikosteroidtherapie", "koennen", "persistierende", "Nummuli", "nach", "Keratoconjunctivitis", "epidemica", "(", "KE", ")", "auftreten", ".", "Sie", "fuehren", "zu", "Visusminderung", "und", "erhoehter", "Blendungsempfindlichkeit", "der", "Patienten", ".", "Durch", "eine", "phototherapeutische", "Keratektomie", "(", "PTK", ")", "versuchten", "wird", ",", "therapierefraktaere", "Nummuli", "zu", "entfernen", "." ]	[ "umlsterm" ]
Patienten	DerOpthalmologe.90960092.ger.abstr_task2	Sentence: Fragestellung : Auch unter Kortikosteroidtherapie koennen persistierende Nummuli nach Keratoconjunctivitis epidemica ( KE ) auftreten . Sie fuehren zu Visusminderung und erhoehter Blendungsempfindlichkeit der Patienten . Durch eine phototherapeutische Keratektomie ( PTK ) versuchten wird , therapierefraktaere Nummuli zu entfernen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fragestellung : Auch unter Kortikosteroidtherapie koennen persistierende Nummuli nach Keratoconjunctivitis epidemica ( KE ) auftreten . Sie fuehren zu Visusminderung und erhoehter Blendungsempfindlichkeit der Patienten . Durch eine phototherapeutische Keratektomie ( PTK ) versuchten wird , therapierefraktaere Nummuli zu entfernen .	[ "Fragestellung", ":", "Auch", "unter", "Kortikosteroidtherapie", "koennen", "persistierende", "Nummuli", "nach", "Keratoconjunctivitis", "epidemica", "(", "KE", ")", "auftreten", ".", "Sie", "fuehren", "zu", "Visusminderung", "und", "erhoehter", "Blendungsempfindlichkeit", "der", "Patienten", ".", "Durch", "eine", "phototherapeutische", "Keratektomie", "(", "PTK", ")", "versuchten", "wird", ",", "therapierefraktaere", "Nummuli", "zu", "entfernen", "." ]	[ "umlsterm" ]
diagnosis is an umlsterm, line is an umlsterm, therapy is an umlsterm, chest pain is an umlsterm, general practitioners is an umlsterm, emergency is an umlsterm, physicians is an umlsterm, myocardial infarction is an umlsterm, syndromes is an umlsterm, patients is an umlsterm, chest pain is an umlsterm, line is an umlsterm, therapy is an umlsterm, understanding is an umlsterm, pathophysiology is an umlsterm, myocardial ischemia is an umlsterm, symptoms is an umlsterm, diagnostic is an umlsterm, therapeutic is an umlsterm, Time is an umlsterm, myocardial ischemia is an umlsterm, infarction is an umlsterm, injury is an umlsterm, cells is an umlsterm, myocardial ischemia is an umlsterm, infarction is an umlsterm, patients dying is an umlsterm, ischemia is an umlsterm, effort is an umlsterm, symptom is an umlsterm, reperfusion therapy is an umlsterm, diagnosis is an umlsterm, line is an umlsterm, therapy is an umlsterm, myocardial infarction is an umlsterm, aim is an umlsterm, transport is an umlsterm, time is an umlsterm, hospital is an umlsterm, therapies is an umlsterm, PTCA is an umlsterm	IntensiveMedizin.90360727.eng.abstr_task0	Sentence: Prehospital diagnosis and first line therapy of acute chest pain are among the most frequently encountered challenges for general practitioners and emergency physicians . Acute myocardial infarction or acute coronary syndromes in general are present in about a third of patients complaining of acute chest pain . The basis of first line therapy is the understanding of the pathophysiology of myocardial ischemia , the clinical symptoms , the diagnostic tools and the preclinically available therapeutic options . Time is the most critical factor in myocardial ischemia and subsequent infarction with irreversible injury of subendocardial cells starting within 30-60 minutes of total myocardial ischemia and with transmural infarction becoming complete in 3 to 6 hours . With 30% of patients dying within the first hour of ischemia mostly due to ventricular arrhyhtmias every effort needs to be made to shorten the delay between symptom onset and start of reperfusion therapy . The present overview concentrates on the armamentarium of preclincial diagnosis and the options of first line therapy of myocardial infarction with the aim of a short transport time to the hospital and therefore a short delay to more specific therapies like thrombolysis or PTCA . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]	Prehospital diagnosis and first line therapy of acute chest pain are among the most frequently encountered challenges for general practitioners and emergency physicians . Acute myocardial infarction or acute coronary syndromes in general are present in about a third of patients complaining of acute chest pain . The basis of first line therapy is the understanding of the pathophysiology of myocardial ischemia , the clinical symptoms , the diagnostic tools and the preclinically available therapeutic options . Time is the most critical factor in myocardial ischemia and subsequent infarction with irreversible injury of subendocardial cells starting within 30-60 minutes of total myocardial ischemia and with transmural infarction becoming complete in 3 to 6 hours . With 30% of patients dying within the first hour of ischemia mostly due to ventricular arrhyhtmias every effort needs to be made to shorten the delay between symptom onset and start of reperfusion therapy . The present overview concentrates on the armamentarium of preclincial diagnosis and the options of first line therapy of myocardial infarction with the aim of a short transport time to the hospital and therefore a short delay to more specific therapies like thrombolysis or PTCA .	[ "Prehospital", "diagnosis", "and", "first", "line", "therapy", "of", "acute", "chest", "pain", "are", "among", "the", "most", "frequently", "encountered", "challenges", "for", "general", "practitioners", "and", "emergency", "physicians", ".", "Acute", "myocardial", "infarction", "or", "acute", "coronary", "syndromes", "in", "general", "are", "present", "in", "about", "a", "third", "of", "patients", "complaining", "of", "acute", "chest", "pain", ".", "The", "basis", "of", "first", "line", "therapy", "is", "the", "understanding", "of", "the", "pathophysiology", "of", "myocardial", "ischemia", ",", "the", "clinical", "symptoms", ",", "the", "diagnostic", "tools", "and", "the", "preclinically", "available", "therapeutic", "options", ".", "Time", "is", "the", "most", "critical", "factor", "in", "myocardial", "ischemia", "and", "subsequent", "infarction", "with", "irreversible", "injury", "of", "subendocardial", "cells", "starting", "within", "30", "-", "60", "minutes", "of", "total", "myocardial", "ischemia", "and", "with", "transmural", "infarction", "becoming", "complete", "in", "3", "to", "6", "hours", ".", "With", "30", "%", "of", "patients", "dying", "within", "the", "first", "hour", "of", "ischemia", "mostly", "due", "to", "ventricular", "arrhyhtmias", "every", "effort", "needs", "to", "be", "made", "to", "shorten", "the", "delay", "between", "symptom", "onset", "and", "start", "of", "reperfusion", "therapy", ".", "The", "present", "overview", "concentrates", "on", "the", "armamentarium", "of", "preclincial", "diagnosis", "and", "the", "options", "of", "first", "line", "therapy", "of", "myocardial", "infarction", "with", "the", "aim", "of", "a", "short", "transport", "time", "to", "the", "hospital", "and", "therefore", "a", "short", "delay", "to", "more", "specific", "therapies", "like", "thrombolysis", "or", "PTCA", "." ]	[ "umlsterm" ]
diagnosis is an umlsterm, line is an umlsterm, therapy is an umlsterm, chest pain is an umlsterm, general practitioners is an umlsterm, emergency is an umlsterm, physicians is an umlsterm, myocardial infarction is an umlsterm, syndromes is an umlsterm, patients is an umlsterm, chest pain is an umlsterm, line is an umlsterm, therapy is an umlsterm, understanding is an umlsterm, pathophysiology is an umlsterm, myocardial ischemia is an umlsterm, symptoms is an umlsterm, diagnostic is an umlsterm, therapeutic is an umlsterm, Time is an umlsterm, myocardial ischemia is an umlsterm, infarction is an umlsterm, injury is an umlsterm, cells is an umlsterm, myocardial ischemia is an umlsterm, infarction is an umlsterm, patients dying is an umlsterm, ischemia is an umlsterm, effort is an umlsterm, symptom is an umlsterm, reperfusion therapy is an umlsterm, diagnosis is an umlsterm, line is an umlsterm, therapy is an umlsterm, myocardial infarction is an umlsterm, aim is an umlsterm, transport is an umlsterm, time is an umlsterm, hospital is an umlsterm, therapies is an umlsterm, PTCA is an umlsterm	IntensiveMedizin.90360727.eng.abstr_task1	Sentence: Prehospital diagnosis and first line therapy of acute chest pain are among the most frequently encountered challenges for general practitioners and emergency physicians . Acute myocardial infarction or acute coronary syndromes in general are present in about a third of patients complaining of acute chest pain . The basis of first line therapy is the understanding of the pathophysiology of myocardial ischemia , the clinical symptoms , the diagnostic tools and the preclinically available therapeutic options . Time is the most critical factor in myocardial ischemia and subsequent infarction with irreversible injury of subendocardial cells starting within 30-60 minutes of total myocardial ischemia and with transmural infarction becoming complete in 3 to 6 hours . With 30% of patients dying within the first hour of ischemia mostly due to ventricular arrhyhtmias every effort needs to be made to shorten the delay between symptom onset and start of reperfusion therapy . The present overview concentrates on the armamentarium of preclincial diagnosis and the options of first line therapy of myocardial infarction with the aim of a short transport time to the hospital and therefore a short delay to more specific therapies like thrombolysis or PTCA . Instructions: please typing these entity words according to sentence: diagnosis, line, therapy, chest pain, general practitioners, emergency, physicians, myocardial infarction, syndromes, patients, chest pain, line, therapy, understanding, pathophysiology, myocardial ischemia, symptoms, diagnostic, therapeutic, Time, myocardial ischemia, infarction, injury, cells, myocardial ischemia, infarction, patients dying, ischemia, effort, symptom, reperfusion therapy, diagnosis, line, therapy, myocardial infarction, aim, transport, time, hospital, therapies, PTCA Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]	Prehospital diagnosis and first line therapy of acute chest pain are among the most frequently encountered challenges for general practitioners and emergency physicians . Acute myocardial infarction or acute coronary syndromes in general are present in about a third of patients complaining of acute chest pain . The basis of first line therapy is the understanding of the pathophysiology of myocardial ischemia , the clinical symptoms , the diagnostic tools and the preclinically available therapeutic options . Time is the most critical factor in myocardial ischemia and subsequent infarction with irreversible injury of subendocardial cells starting within 30-60 minutes of total myocardial ischemia and with transmural infarction becoming complete in 3 to 6 hours . With 30% of patients dying within the first hour of ischemia mostly due to ventricular arrhyhtmias every effort needs to be made to shorten the delay between symptom onset and start of reperfusion therapy . The present overview concentrates on the armamentarium of preclincial diagnosis and the options of first line therapy of myocardial infarction with the aim of a short transport time to the hospital and therefore a short delay to more specific therapies like thrombolysis or PTCA .	[ "Prehospital", "diagnosis", "and", "first", "line", "therapy", "of", "acute", "chest", "pain", "are", "among", "the", "most", "frequently", "encountered", "challenges", "for", "general", "practitioners", "and", "emergency", "physicians", ".", "Acute", "myocardial", "infarction", "or", "acute", "coronary", "syndromes", "in", "general", "are", "present", "in", "about", "a", "third", "of", "patients", "complaining", "of", "acute", "chest", "pain", ".", "The", "basis", "of", "first", "line", "therapy", "is", "the", "understanding", "of", "the", "pathophysiology", "of", "myocardial", "ischemia", ",", "the", "clinical", "symptoms", ",", "the", "diagnostic", "tools", "and", "the", "preclinically", "available", "therapeutic", "options", ".", "Time", "is", "the", "most", "critical", "factor", "in", "myocardial", "ischemia", "and", "subsequent", "infarction", "with", "irreversible", "injury", "of", "subendocardial", "cells", "starting", "within", "30", "-", "60", "minutes", "of", "total", "myocardial", "ischemia", "and", "with", "transmural", "infarction", "becoming", "complete", "in", "3", "to", "6", "hours", ".", "With", "30", "%", "of", "patients", "dying", "within", "the", "first", "hour", "of", "ischemia", "mostly", "due", "to", "ventricular", "arrhyhtmias", "every", "effort", "needs", "to", "be", "made", "to", "shorten", "the", "delay", "between", "symptom", "onset", "and", "start", "of", "reperfusion", "therapy", ".", "The", "present", "overview", "concentrates", "on", "the", "armamentarium", "of", "preclincial", "diagnosis", "and", "the", "options", "of", "first", "line", "therapy", "of", "myocardial", "infarction", "with", "the", "aim", "of", "a", "short", "transport", "time", "to", "the", "hospital", "and", "therefore", "a", "short", "delay", "to", "more", "specific", "therapies", "like", "thrombolysis", "or", "PTCA", "." ]	[ "umlsterm" ]
diagnosis, line, therapy, chest pain, general practitioners, emergency, physicians, myocardial infarction, syndromes, patients, chest pain, line, therapy, understanding, pathophysiology, myocardial ischemia, symptoms, diagnostic, therapeutic, Time, myocardial ischemia, infarction, injury, cells, myocardial ischemia, infarction, patients dying, ischemia, effort, symptom, reperfusion therapy, diagnosis, line, therapy, myocardial infarction, aim, transport, time, hospital, therapies, PTCA	IntensiveMedizin.90360727.eng.abstr_task2	Sentence: Prehospital diagnosis and first line therapy of acute chest pain are among the most frequently encountered challenges for general practitioners and emergency physicians . Acute myocardial infarction or acute coronary syndromes in general are present in about a third of patients complaining of acute chest pain . The basis of first line therapy is the understanding of the pathophysiology of myocardial ischemia , the clinical symptoms , the diagnostic tools and the preclinically available therapeutic options . Time is the most critical factor in myocardial ischemia and subsequent infarction with irreversible injury of subendocardial cells starting within 30-60 minutes of total myocardial ischemia and with transmural infarction becoming complete in 3 to 6 hours . With 30% of patients dying within the first hour of ischemia mostly due to ventricular arrhyhtmias every effort needs to be made to shorten the delay between symptom onset and start of reperfusion therapy . The present overview concentrates on the armamentarium of preclincial diagnosis and the options of first line therapy of myocardial infarction with the aim of a short transport time to the hospital and therefore a short delay to more specific therapies like thrombolysis or PTCA . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]	Prehospital diagnosis and first line therapy of acute chest pain are among the most frequently encountered challenges for general practitioners and emergency physicians . Acute myocardial infarction or acute coronary syndromes in general are present in about a third of patients complaining of acute chest pain . The basis of first line therapy is the understanding of the pathophysiology of myocardial ischemia , the clinical symptoms , the diagnostic tools and the preclinically available therapeutic options . Time is the most critical factor in myocardial ischemia and subsequent infarction with irreversible injury of subendocardial cells starting within 30-60 minutes of total myocardial ischemia and with transmural infarction becoming complete in 3 to 6 hours . With 30% of patients dying within the first hour of ischemia mostly due to ventricular arrhyhtmias every effort needs to be made to shorten the delay between symptom onset and start of reperfusion therapy . The present overview concentrates on the armamentarium of preclincial diagnosis and the options of first line therapy of myocardial infarction with the aim of a short transport time to the hospital and therefore a short delay to more specific therapies like thrombolysis or PTCA .	[ "Prehospital", "diagnosis", "and", "first", "line", "therapy", "of", "acute", "chest", "pain", "are", "among", "the", "most", "frequently", "encountered", "challenges", "for", "general", "practitioners", "and", "emergency", "physicians", ".", "Acute", "myocardial", "infarction", "or", "acute", "coronary", "syndromes", "in", "general", "are", "present", "in", "about", "a", "third", "of", "patients", "complaining", "of", "acute", "chest", "pain", ".", "The", "basis", "of", "first", "line", "therapy", "is", "the", "understanding", "of", "the", "pathophysiology", "of", "myocardial", "ischemia", ",", "the", "clinical", "symptoms", ",", "the", "diagnostic", "tools", "and", "the", "preclinically", "available", "therapeutic", "options", ".", "Time", "is", "the", "most", "critical", "factor", "in", "myocardial", "ischemia", "and", "subsequent", "infarction", "with", "irreversible", "injury", "of", "subendocardial", "cells", "starting", "within", "30", "-", "60", "minutes", "of", "total", "myocardial", "ischemia", "and", "with", "transmural", "infarction", "becoming", "complete", "in", "3", "to", "6", "hours", ".", "With", "30", "%", "of", "patients", "dying", "within", "the", "first", "hour", "of", "ischemia", "mostly", "due", "to", "ventricular", "arrhyhtmias", "every", "effort", "needs", "to", "be", "made", "to", "shorten", "the", "delay", "between", "symptom", "onset", "and", "start", "of", "reperfusion", "therapy", ".", "The", "present", "overview", "concentrates", "on", "the", "armamentarium", "of", "preclincial", "diagnosis", "and", "the", "options", "of", "first", "line", "therapy", "of", "myocardial", "infarction", "with", "the", "aim", "of", "a", "short", "transport", "time", "to", "the", "hospital", "and", "therefore", "a", "short", "delay", "to", "more", "specific", "therapies", "like", "thrombolysis", "or", "PTCA", "." ]	[ "umlsterm" ]
Elf-1 is a Protein, retinoblastoma protein is a Protein, retinoblastoma is a Protein, Rb is a Protein, Elf-1 is a Protein, Elf-1 is a Protein, Rb is a Protein, Rb is a Protein, Elf-1 is a Protein, Rb is a Protein, Rb is a Protein, Elf-1 is a Protein, Rb is a Protein, Rb is a Protein, Elf-1 is a Protein, Rb is a Protein, Rb is a Protein	8493578_task0	Sentence: Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein. The retinoblastoma gene product (Rb) is a nuclear phosphoprotein that regulates cell cycle progression. Elf-1 is a lymphoid-specific Ets transcription factor that regulates inducible gene expression during T cell activation. In this report, it is demonstrated that Elf-1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo. Elf-1 binds exclusively to the underphosphorylated form of Rb and fails to bind to Rb mutants derived from patients with retinoblastoma. Co-immunoprecipitation experiments demonstrated an association between Elf-1 and Rb in resting normal human T cells. After T cell activation, the phosphorylation of Rb results in the release of Elf-1, which is correlated temporally with the activation of Elf-1-mediated transcription. Overexpression of a phosphorylation-defective form of Rb inhibited Elf-1-dependent transcription during T cell activation. These results demonstrate that Rb interacts specifically with a lineage-restricted Ets transcription factor. This regulated interaction may be important for the coordination of lineage-specific effector functions such as lymphokine production with cell cycle progression in activated T cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein. The retinoblastoma gene product (Rb) is a nuclear phosphoprotein that regulates cell cycle progression. Elf-1 is a lymphoid-specific Ets transcription factor that regulates inducible gene expression during T cell activation. In this report, it is demonstrated that Elf-1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo. Elf-1 binds exclusively to the underphosphorylated form of Rb and fails to bind to Rb mutants derived from patients with retinoblastoma. Co-immunoprecipitation experiments demonstrated an association between Elf-1 and Rb in resting normal human T cells. After T cell activation, the phosphorylation of Rb results in the release of Elf-1, which is correlated temporally with the activation of Elf-1-mediated transcription. Overexpression of a phosphorylation-defective form of Rb inhibited Elf-1-dependent transcription during T cell activation. These results demonstrate that Rb interacts specifically with a lineage-restricted Ets transcription factor. This regulated interaction may be important for the coordination of lineage-specific effector functions such as lymphokine production with cell cycle progression in activated T cells.	[ "Regulation", "of", "the", "Ets", "-", "related", "transcription", "factor", "Elf-1", "by", "binding", "to", "the", "retinoblastoma", "protein", ".", "\n", "The", "retinoblastoma", "gene", "product", "(", "Rb", ")", "is", "a", "nuclear", "phosphoprotein", "that", "regulates", "cell", "cycle", "progression", ".", "Elf-1", "is", "a", "lymphoid", "-", "specific", "Ets", "transcription", "factor", "that", "regulates", "inducible", "gene", "expression", "during", "T", "cell", "activation", ".", "In", "this", "report", ",", "it", "is", "demonstrated", "that", "Elf-1", "contains", "a", "sequence", "motif", "that", "is", "highly", "related", "to", "the", "Rb", "binding", "sites", "of", "several", "viral", "oncoproteins", "and", "binds", "to", "the", "pocket", "region", "of", "Rb", "both", "in", "vitro", "and", "in", "vivo", ".", "Elf-1", "binds", "exclusively", "to", "the", "underphosphorylated", "form", "of", "Rb", "and", "fails", "to", "bind", "to", "Rb", "mutants", "derived", "from", "patients", "with", "retinoblastoma", ".", "Co", "-", "immunoprecipitation", "experiments", "demonstrated", "an", "association", "between", "Elf-1", "and", "Rb", "in", "resting", "normal", "human", "T", "cells", ".", "After", "T", "cell", "activation", ",", "the", "phosphorylation", "of", "Rb", "results", "in", "the", "release", "of", "Elf-1", ",", "which", "is", "correlated", "temporally", "with", "the", "activation", "of", "Elf-1-mediated", "transcription", ".", "Overexpression", "of", "a", "phosphorylation", "-", "defective", "form", "of", "Rb", "inhibited", "Elf-1-dependent", "transcription", "during", "T", "cell", "activation", ".", "These", "results", "demonstrate", "that", "Rb", "interacts", "specifically", "with", "a", "lineage", "-", "restricted", "Ets", "transcription", "factor", ".", "This", "regulated", "interaction", "may", "be", "important", "for", "the", "coordination", "of", "lineage", "-", "specific", "effector", "functions", "such", "as", "lymphokine", "production", "with", "cell", "cycle", "progression", "in", "activated", "T", "cells", "." ]	[ "Protein" ]
Elf-1 is a Protein, retinoblastoma protein is a Protein, retinoblastoma is a Protein, Rb is a Protein, Elf-1 is a Protein, Elf-1 is a Protein, Rb is a Protein, Rb is a Protein, Elf-1 is a Protein, Rb is a Protein, Rb is a Protein, Elf-1 is a Protein, Rb is a Protein, Rb is a Protein, Elf-1 is a Protein, Rb is a Protein, Rb is a Protein	8493578_task1	Sentence: Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein. The retinoblastoma gene product (Rb) is a nuclear phosphoprotein that regulates cell cycle progression. Elf-1 is a lymphoid-specific Ets transcription factor that regulates inducible gene expression during T cell activation. In this report, it is demonstrated that Elf-1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo. Elf-1 binds exclusively to the underphosphorylated form of Rb and fails to bind to Rb mutants derived from patients with retinoblastoma. Co-immunoprecipitation experiments demonstrated an association between Elf-1 and Rb in resting normal human T cells. After T cell activation, the phosphorylation of Rb results in the release of Elf-1, which is correlated temporally with the activation of Elf-1-mediated transcription. Overexpression of a phosphorylation-defective form of Rb inhibited Elf-1-dependent transcription during T cell activation. These results demonstrate that Rb interacts specifically with a lineage-restricted Ets transcription factor. This regulated interaction may be important for the coordination of lineage-specific effector functions such as lymphokine production with cell cycle progression in activated T cells. Instructions: please typing these entity words according to sentence: Elf-1, retinoblastoma protein, retinoblastoma, Rb, Elf-1, Elf-1, Rb, Rb, Elf-1, Rb, Rb, Elf-1, Rb, Rb, Elf-1, Rb, Rb Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein. The retinoblastoma gene product (Rb) is a nuclear phosphoprotein that regulates cell cycle progression. Elf-1 is a lymphoid-specific Ets transcription factor that regulates inducible gene expression during T cell activation. In this report, it is demonstrated that Elf-1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo. Elf-1 binds exclusively to the underphosphorylated form of Rb and fails to bind to Rb mutants derived from patients with retinoblastoma. Co-immunoprecipitation experiments demonstrated an association between Elf-1 and Rb in resting normal human T cells. After T cell activation, the phosphorylation of Rb results in the release of Elf-1, which is correlated temporally with the activation of Elf-1-mediated transcription. Overexpression of a phosphorylation-defective form of Rb inhibited Elf-1-dependent transcription during T cell activation. These results demonstrate that Rb interacts specifically with a lineage-restricted Ets transcription factor. This regulated interaction may be important for the coordination of lineage-specific effector functions such as lymphokine production with cell cycle progression in activated T cells.	[ "Regulation", "of", "the", "Ets", "-", "related", "transcription", "factor", "Elf-1", "by", "binding", "to", "the", "retinoblastoma", "protein", ".", "\n", "The", "retinoblastoma", "gene", "product", "(", "Rb", ")", "is", "a", "nuclear", "phosphoprotein", "that", "regulates", "cell", "cycle", "progression", ".", "Elf-1", "is", "a", "lymphoid", "-", "specific", "Ets", "transcription", "factor", "that", "regulates", "inducible", "gene", "expression", "during", "T", "cell", "activation", ".", "In", "this", "report", ",", "it", "is", "demonstrated", "that", "Elf-1", "contains", "a", "sequence", "motif", "that", "is", "highly", "related", "to", "the", "Rb", "binding", "sites", "of", "several", "viral", "oncoproteins", "and", "binds", "to", "the", "pocket", "region", "of", "Rb", "both", "in", "vitro", "and", "in", "vivo", ".", "Elf-1", "binds", "exclusively", "to", "the", "underphosphorylated", "form", "of", "Rb", "and", "fails", "to", "bind", "to", "Rb", "mutants", "derived", "from", "patients", "with", "retinoblastoma", ".", "Co", "-", "immunoprecipitation", "experiments", "demonstrated", "an", "association", "between", "Elf-1", "and", "Rb", "in", "resting", "normal", "human", "T", "cells", ".", "After", "T", "cell", "activation", ",", "the", "phosphorylation", "of", "Rb", "results", "in", "the", "release", "of", "Elf-1", ",", "which", "is", "correlated", "temporally", "with", "the", "activation", "of", "Elf-1-mediated", "transcription", ".", "Overexpression", "of", "a", "phosphorylation", "-", "defective", "form", "of", "Rb", "inhibited", "Elf-1-dependent", "transcription", "during", "T", "cell", "activation", ".", "These", "results", "demonstrate", "that", "Rb", "interacts", "specifically", "with", "a", "lineage", "-", "restricted", "Ets", "transcription", "factor", ".", "This", "regulated", "interaction", "may", "be", "important", "for", "the", "coordination", "of", "lineage", "-", "specific", "effector", "functions", "such", "as", "lymphokine", "production", "with", "cell", "cycle", "progression", "in", "activated", "T", "cells", "." ]	[ "Protein" ]
Elf-1, retinoblastoma protein, retinoblastoma, Rb, Elf-1, Elf-1, Rb, Rb, Elf-1, Rb, Rb, Elf-1, Rb, Rb, Elf-1, Rb, Rb	8493578_task2	Sentence: Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein. The retinoblastoma gene product (Rb) is a nuclear phosphoprotein that regulates cell cycle progression. Elf-1 is a lymphoid-specific Ets transcription factor that regulates inducible gene expression during T cell activation. In this report, it is demonstrated that Elf-1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo. Elf-1 binds exclusively to the underphosphorylated form of Rb and fails to bind to Rb mutants derived from patients with retinoblastoma. Co-immunoprecipitation experiments demonstrated an association between Elf-1 and Rb in resting normal human T cells. After T cell activation, the phosphorylation of Rb results in the release of Elf-1, which is correlated temporally with the activation of Elf-1-mediated transcription. Overexpression of a phosphorylation-defective form of Rb inhibited Elf-1-dependent transcription during T cell activation. These results demonstrate that Rb interacts specifically with a lineage-restricted Ets transcription factor. This regulated interaction may be important for the coordination of lineage-specific effector functions such as lymphokine production with cell cycle progression in activated T cells. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein. The retinoblastoma gene product (Rb) is a nuclear phosphoprotein that regulates cell cycle progression. Elf-1 is a lymphoid-specific Ets transcription factor that regulates inducible gene expression during T cell activation. In this report, it is demonstrated that Elf-1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo. Elf-1 binds exclusively to the underphosphorylated form of Rb and fails to bind to Rb mutants derived from patients with retinoblastoma. Co-immunoprecipitation experiments demonstrated an association between Elf-1 and Rb in resting normal human T cells. After T cell activation, the phosphorylation of Rb results in the release of Elf-1, which is correlated temporally with the activation of Elf-1-mediated transcription. Overexpression of a phosphorylation-defective form of Rb inhibited Elf-1-dependent transcription during T cell activation. These results demonstrate that Rb interacts specifically with a lineage-restricted Ets transcription factor. This regulated interaction may be important for the coordination of lineage-specific effector functions such as lymphokine production with cell cycle progression in activated T cells.	[ "Regulation", "of", "the", "Ets", "-", "related", "transcription", "factor", "Elf-1", "by", "binding", "to", "the", "retinoblastoma", "protein", ".", "\n", "The", "retinoblastoma", "gene", "product", "(", "Rb", ")", "is", "a", "nuclear", "phosphoprotein", "that", "regulates", "cell", "cycle", "progression", ".", "Elf-1", "is", "a", "lymphoid", "-", "specific", "Ets", "transcription", "factor", "that", "regulates", "inducible", "gene", "expression", "during", "T", "cell", "activation", ".", "In", "this", "report", ",", "it", "is", "demonstrated", "that", "Elf-1", "contains", "a", "sequence", "motif", "that", "is", "highly", "related", "to", "the", "Rb", "binding", "sites", "of", "several", "viral", "oncoproteins", "and", "binds", "to", "the", "pocket", "region", "of", "Rb", "both", "in", "vitro", "and", "in", "vivo", ".", "Elf-1", "binds", "exclusively", "to", "the", "underphosphorylated", "form", "of", "Rb", "and", "fails", "to", "bind", "to", "Rb", "mutants", "derived", "from", "patients", "with", "retinoblastoma", ".", "Co", "-", "immunoprecipitation", "experiments", "demonstrated", "an", "association", "between", "Elf-1", "and", "Rb", "in", "resting", "normal", "human", "T", "cells", ".", "After", "T", "cell", "activation", ",", "the", "phosphorylation", "of", "Rb", "results", "in", "the", "release", "of", "Elf-1", ",", "which", "is", "correlated", "temporally", "with", "the", "activation", "of", "Elf-1-mediated", "transcription", ".", "Overexpression", "of", "a", "phosphorylation", "-", "defective", "form", "of", "Rb", "inhibited", "Elf-1-dependent", "transcription", "during", "T", "cell", "activation", ".", "These", "results", "demonstrate", "that", "Rb", "interacts", "specifically", "with", "a", "lineage", "-", "restricted", "Ets", "transcription", "factor", ".", "This", "regulated", "interaction", "may", "be", "important", "for", "the", "coordination", "of", "lineage", "-", "specific", "effector", "functions", "such", "as", "lymphokine", "production", "with", "cell", "cycle", "progression", "in", "activated", "T", "cells", "." ]	[ "Protein" ]
human delta - globin gene promoter is a DNA_domain_or_region, primary adult erythroid cells is a cell_type	69735_task0	Sentence: Activation of the human delta-globin gene promoter in primary adult erythroid cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, DNA_domain_or_region	[ "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O" ]	Activation of the human delta-globin gene promoter in primary adult erythroid cells.	[ "Activation", "of", "the", "human", "delta", "-", "globin", "gene", "promoter", "in", "primary", "adult", "erythroid", "cells", "." ]	[ "DNA_domain_or_region", "cell_line", "cell_type", "protein_molecule", "polynucleotide" ]
human delta - globin gene promoter is a DNA_domain_or_region, primary adult erythroid cells is a cell_type	69735_task1	Sentence: Activation of the human delta-globin gene promoter in primary adult erythroid cells. Instructions: please typing these entity words according to sentence: human delta - globin gene promoter, primary adult erythroid cells Options: cell_type, DNA_domain_or_region	[ "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O" ]	Activation of the human delta-globin gene promoter in primary adult erythroid cells.	[ "Activation", "of", "the", "human", "delta", "-", "globin", "gene", "promoter", "in", "primary", "adult", "erythroid", "cells", "." ]	[ "DNA_domain_or_region", "cell_line", "cell_type", "protein_molecule", "polynucleotide" ]
human delta - globin gene promoter, primary adult erythroid cells	69735_task2	Sentence: Activation of the human delta-globin gene promoter in primary adult erythroid cells. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O" ]	Activation of the human delta-globin gene promoter in primary adult erythroid cells.	[ "Activation", "of", "the", "human", "delta", "-", "globin", "gene", "promoter", "in", "primary", "adult", "erythroid", "cells", "." ]	[ "DNA_domain_or_region", "cell_line", "cell_type", "protein_molecule", "polynucleotide" ]
Plattenepithelkarzinome is an umlsterm, Speicheldruesen is an umlsterm, Speicheldruesen is an umlsterm, Metastasen is an umlsterm, Haut is an umlsterm, Kopfhalsregion is an umlsterm, Plattenepithelmetaplasien is an umlsterm, Speicheldruesenkrankheiten is an umlsterm, nekrotisierende Sialometaplasie is an umlsterm, Speicheldruesentumoren is an umlsterm, Warthin - Tumor is an umlsterm, Speicheldruesen is an umlsterm, Speicheldruesen is an umlsterm, adenoide is an umlsterm, Akantholyse is an umlsterm, Karzinom is an umlsterm, Adenokarzinom is an umlsterm, Karzinom is an umlsterm, Karzinom is an umlsterm, Karzinoms is an umlsterm, schleimbildenden is an umlsterm, Becherzellen is an umlsterm, Prognose is an umlsterm, Therapie is an umlsterm	DerPathologe.80190201.ger.abstr_task0	Sentence: Primaere Plattenepithelkarzinome ( PEC ) der Speicheldruesen sind vorwiegend in den grossen Speicheldruesen lokalisiert und muessen von Metastasen extraglandulaerer PEC der Haut besonders der Kopfhalsregion abgegrenzt werden . Plattenepithelmetaplasien in nichttumoroesen Speicheldruesenkrankheiten ( z.B. nekrotisierende Sialometaplasie ) sowie in benignen oder malignen Speicheldruesentumoren ( z.B. metaplastischer Warthin-Tumor ) koennen PEC vortaeuschen . Ein weiteres differentialdiagnostisches Problem stellen Formvarianten des PEC dar , die ueberwiegend in den kleinen Speicheldruesen , dagegen fast nie in den grossen Speicheldruesen entwickelt sind . Hierzu gehoeren das seltene adenoide PEC mit pseudoglandulaeren Strukturen durch Akantholyse , das biphasische adenosquamoese Karzinom mit Differenzierung als PEC und Adenokarzinom , das basaloidsquamoese Karzinom mit biphasischem Aufbau als PEC und solides basaloides Karzinom ( analog dem soliden Typ des adenoid-zystischen Karzinoms ) und das niedrig-differenzierte Mukoepidermoidkarzinom ( Grad III ) mit biphasischem Aufbau aus undifferenzierten epidermoiden und intermediaeren Zellverbaenden sowie Einschluss kleiner Gruppen von schleimbildenden Becherzellen . Die differentialdiagnostischen Merkmale werden im Hinblick auf die Prognose und Therapie analysiert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]	Primaere Plattenepithelkarzinome ( PEC ) der Speicheldruesen sind vorwiegend in den grossen Speicheldruesen lokalisiert und muessen von Metastasen extraglandulaerer PEC der Haut besonders der Kopfhalsregion abgegrenzt werden . Plattenepithelmetaplasien in nichttumoroesen Speicheldruesenkrankheiten ( z.B. nekrotisierende Sialometaplasie ) sowie in benignen oder malignen Speicheldruesentumoren ( z.B. metaplastischer Warthin-Tumor ) koennen PEC vortaeuschen . Ein weiteres differentialdiagnostisches Problem stellen Formvarianten des PEC dar , die ueberwiegend in den kleinen Speicheldruesen , dagegen fast nie in den grossen Speicheldruesen entwickelt sind . Hierzu gehoeren das seltene adenoide PEC mit pseudoglandulaeren Strukturen durch Akantholyse , das biphasische adenosquamoese Karzinom mit Differenzierung als PEC und Adenokarzinom , das basaloidsquamoese Karzinom mit biphasischem Aufbau als PEC und solides basaloides Karzinom ( analog dem soliden Typ des adenoid-zystischen Karzinoms ) und das niedrig-differenzierte Mukoepidermoidkarzinom ( Grad III ) mit biphasischem Aufbau aus undifferenzierten epidermoiden und intermediaeren Zellverbaenden sowie Einschluss kleiner Gruppen von schleimbildenden Becherzellen . Die differentialdiagnostischen Merkmale werden im Hinblick auf die Prognose und Therapie analysiert .	[ "Primaere", "Plattenepithelkarzinome", "(", "PEC", ")", "der", "Speicheldruesen", "sind", "vorwiegend", "in", "den", "grossen", "Speicheldruesen", "lokalisiert", "und", "muessen", "von", "Metastasen", "extraglandulaerer", "PEC", "der", "Haut", "besonders", "der", "Kopfhalsregion", "abgegrenzt", "werden", ".", "Plattenepithelmetaplasien", "in", "nichttumoroesen", "Speicheldruesenkrankheiten", "(", "z.", "B.", "nekrotisierende", "Sialometaplasie", ")", "sowie", "in", "benignen", "oder", "malignen", "Speicheldruesentumoren", "(", "z.", "B.", "metaplastischer", "Warthin", "-", "Tumor", ")", "koennen", "PEC", "vortaeuschen", ".", "Ein", "weiteres", "differentialdiagnostisches", "Problem", "stellen", "Formvarianten", "des", "PEC", "dar", ",", "die", "ueberwiegend", "in", "den", "kleinen", "Speicheldruesen", ",", "dagegen", "fast", "nie", "in", "den", "grossen", "Speicheldruesen", "entwickelt", "sind", ".", "Hierzu", "gehoeren", "das", "seltene", "adenoide", "PEC", "mit", "pseudoglandulaeren", "Strukturen", "durch", "Akantholyse", ",", "das", "biphasische", "adenosquamoese", "Karzinom", "mit", "Differenzierung", "als", "PEC", "und", "Adenokarzinom", ",", "das", "basaloidsquamoese", "Karzinom", "mit", "biphasischem", "Aufbau", "als", "PEC", "und", "solides", "basaloides", "Karzinom", "(", "analog", "dem", "soliden", "Typ", "des", "adenoid", "-", "zystischen", "Karzinoms", ")", "und", "das", "niedrig", "-", "differenzierte", "Mukoepidermoidkarzinom", "(", "Grad", "III", ")", "mit", "biphasischem", "Aufbau", "aus", "undifferenzierten", "epidermoiden", "und", "intermediaeren", "Zellverbaenden", "sowie", "Einschluss", "kleiner", "Gruppen", "von", "schleimbildenden", "Becherzellen", ".", "Die", "differentialdiagnostischen", "Merkmale", "werden", "im", "Hinblick", "auf", "die", "Prognose", "und", "Therapie", "analysiert", "." ]	[ "umlsterm" ]
Plattenepithelkarzinome is an umlsterm, Speicheldruesen is an umlsterm, Speicheldruesen is an umlsterm, Metastasen is an umlsterm, Haut is an umlsterm, Kopfhalsregion is an umlsterm, Plattenepithelmetaplasien is an umlsterm, Speicheldruesenkrankheiten is an umlsterm, nekrotisierende Sialometaplasie is an umlsterm, Speicheldruesentumoren is an umlsterm, Warthin - Tumor is an umlsterm, Speicheldruesen is an umlsterm, Speicheldruesen is an umlsterm, adenoide is an umlsterm, Akantholyse is an umlsterm, Karzinom is an umlsterm, Adenokarzinom is an umlsterm, Karzinom is an umlsterm, Karzinom is an umlsterm, Karzinoms is an umlsterm, schleimbildenden is an umlsterm, Becherzellen is an umlsterm, Prognose is an umlsterm, Therapie is an umlsterm	DerPathologe.80190201.ger.abstr_task1	Sentence: Primaere Plattenepithelkarzinome ( PEC ) der Speicheldruesen sind vorwiegend in den grossen Speicheldruesen lokalisiert und muessen von Metastasen extraglandulaerer PEC der Haut besonders der Kopfhalsregion abgegrenzt werden . Plattenepithelmetaplasien in nichttumoroesen Speicheldruesenkrankheiten ( z.B. nekrotisierende Sialometaplasie ) sowie in benignen oder malignen Speicheldruesentumoren ( z.B. metaplastischer Warthin-Tumor ) koennen PEC vortaeuschen . Ein weiteres differentialdiagnostisches Problem stellen Formvarianten des PEC dar , die ueberwiegend in den kleinen Speicheldruesen , dagegen fast nie in den grossen Speicheldruesen entwickelt sind . Hierzu gehoeren das seltene adenoide PEC mit pseudoglandulaeren Strukturen durch Akantholyse , das biphasische adenosquamoese Karzinom mit Differenzierung als PEC und Adenokarzinom , das basaloidsquamoese Karzinom mit biphasischem Aufbau als PEC und solides basaloides Karzinom ( analog dem soliden Typ des adenoid-zystischen Karzinoms ) und das niedrig-differenzierte Mukoepidermoidkarzinom ( Grad III ) mit biphasischem Aufbau aus undifferenzierten epidermoiden und intermediaeren Zellverbaenden sowie Einschluss kleiner Gruppen von schleimbildenden Becherzellen . Die differentialdiagnostischen Merkmale werden im Hinblick auf die Prognose und Therapie analysiert . Instructions: please typing these entity words according to sentence: Plattenepithelkarzinome, Speicheldruesen, Speicheldruesen, Metastasen, Haut, Kopfhalsregion, Plattenepithelmetaplasien, Speicheldruesenkrankheiten, nekrotisierende Sialometaplasie, Speicheldruesentumoren, Warthin - Tumor, Speicheldruesen, Speicheldruesen, adenoide, Akantholyse, Karzinom, Adenokarzinom, Karzinom, Karzinom, Karzinoms, schleimbildenden, Becherzellen, Prognose, Therapie Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]	Primaere Plattenepithelkarzinome ( PEC ) der Speicheldruesen sind vorwiegend in den grossen Speicheldruesen lokalisiert und muessen von Metastasen extraglandulaerer PEC der Haut besonders der Kopfhalsregion abgegrenzt werden . Plattenepithelmetaplasien in nichttumoroesen Speicheldruesenkrankheiten ( z.B. nekrotisierende Sialometaplasie ) sowie in benignen oder malignen Speicheldruesentumoren ( z.B. metaplastischer Warthin-Tumor ) koennen PEC vortaeuschen . Ein weiteres differentialdiagnostisches Problem stellen Formvarianten des PEC dar , die ueberwiegend in den kleinen Speicheldruesen , dagegen fast nie in den grossen Speicheldruesen entwickelt sind . Hierzu gehoeren das seltene adenoide PEC mit pseudoglandulaeren Strukturen durch Akantholyse , das biphasische adenosquamoese Karzinom mit Differenzierung als PEC und Adenokarzinom , das basaloidsquamoese Karzinom mit biphasischem Aufbau als PEC und solides basaloides Karzinom ( analog dem soliden Typ des adenoid-zystischen Karzinoms ) und das niedrig-differenzierte Mukoepidermoidkarzinom ( Grad III ) mit biphasischem Aufbau aus undifferenzierten epidermoiden und intermediaeren Zellverbaenden sowie Einschluss kleiner Gruppen von schleimbildenden Becherzellen . Die differentialdiagnostischen Merkmale werden im Hinblick auf die Prognose und Therapie analysiert .	[ "Primaere", "Plattenepithelkarzinome", "(", "PEC", ")", "der", "Speicheldruesen", "sind", "vorwiegend", "in", "den", "grossen", "Speicheldruesen", "lokalisiert", "und", "muessen", "von", "Metastasen", "extraglandulaerer", "PEC", "der", "Haut", "besonders", "der", "Kopfhalsregion", "abgegrenzt", "werden", ".", "Plattenepithelmetaplasien", "in", "nichttumoroesen", "Speicheldruesenkrankheiten", "(", "z.", "B.", "nekrotisierende", "Sialometaplasie", ")", "sowie", "in", "benignen", "oder", "malignen", "Speicheldruesentumoren", "(", "z.", "B.", "metaplastischer", "Warthin", "-", "Tumor", ")", "koennen", "PEC", "vortaeuschen", ".", "Ein", "weiteres", "differentialdiagnostisches", "Problem", "stellen", "Formvarianten", "des", "PEC", "dar", ",", "die", "ueberwiegend", "in", "den", "kleinen", "Speicheldruesen", ",", "dagegen", "fast", "nie", "in", "den", "grossen", "Speicheldruesen", "entwickelt", "sind", ".", "Hierzu", "gehoeren", "das", "seltene", "adenoide", "PEC", "mit", "pseudoglandulaeren", "Strukturen", "durch", "Akantholyse", ",", "das", "biphasische", "adenosquamoese", "Karzinom", "mit", "Differenzierung", "als", "PEC", "und", "Adenokarzinom", ",", "das", "basaloidsquamoese", "Karzinom", "mit", "biphasischem", "Aufbau", "als", "PEC", "und", "solides", "basaloides", "Karzinom", "(", "analog", "dem", "soliden", "Typ", "des", "adenoid", "-", "zystischen", "Karzinoms", ")", "und", "das", "niedrig", "-", "differenzierte", "Mukoepidermoidkarzinom", "(", "Grad", "III", ")", "mit", "biphasischem", "Aufbau", "aus", "undifferenzierten", "epidermoiden", "und", "intermediaeren", "Zellverbaenden", "sowie", "Einschluss", "kleiner", "Gruppen", "von", "schleimbildenden", "Becherzellen", ".", "Die", "differentialdiagnostischen", "Merkmale", "werden", "im", "Hinblick", "auf", "die", "Prognose", "und", "Therapie", "analysiert", "." ]	[ "umlsterm" ]
Plattenepithelkarzinome, Speicheldruesen, Speicheldruesen, Metastasen, Haut, Kopfhalsregion, Plattenepithelmetaplasien, Speicheldruesenkrankheiten, nekrotisierende Sialometaplasie, Speicheldruesentumoren, Warthin - Tumor, Speicheldruesen, Speicheldruesen, adenoide, Akantholyse, Karzinom, Adenokarzinom, Karzinom, Karzinom, Karzinoms, schleimbildenden, Becherzellen, Prognose, Therapie	DerPathologe.80190201.ger.abstr_task2	Sentence: Primaere Plattenepithelkarzinome ( PEC ) der Speicheldruesen sind vorwiegend in den grossen Speicheldruesen lokalisiert und muessen von Metastasen extraglandulaerer PEC der Haut besonders der Kopfhalsregion abgegrenzt werden . Plattenepithelmetaplasien in nichttumoroesen Speicheldruesenkrankheiten ( z.B. nekrotisierende Sialometaplasie ) sowie in benignen oder malignen Speicheldruesentumoren ( z.B. metaplastischer Warthin-Tumor ) koennen PEC vortaeuschen . Ein weiteres differentialdiagnostisches Problem stellen Formvarianten des PEC dar , die ueberwiegend in den kleinen Speicheldruesen , dagegen fast nie in den grossen Speicheldruesen entwickelt sind . Hierzu gehoeren das seltene adenoide PEC mit pseudoglandulaeren Strukturen durch Akantholyse , das biphasische adenosquamoese Karzinom mit Differenzierung als PEC und Adenokarzinom , das basaloidsquamoese Karzinom mit biphasischem Aufbau als PEC und solides basaloides Karzinom ( analog dem soliden Typ des adenoid-zystischen Karzinoms ) und das niedrig-differenzierte Mukoepidermoidkarzinom ( Grad III ) mit biphasischem Aufbau aus undifferenzierten epidermoiden und intermediaeren Zellverbaenden sowie Einschluss kleiner Gruppen von schleimbildenden Becherzellen . Die differentialdiagnostischen Merkmale werden im Hinblick auf die Prognose und Therapie analysiert . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]	Primaere Plattenepithelkarzinome ( PEC ) der Speicheldruesen sind vorwiegend in den grossen Speicheldruesen lokalisiert und muessen von Metastasen extraglandulaerer PEC der Haut besonders der Kopfhalsregion abgegrenzt werden . Plattenepithelmetaplasien in nichttumoroesen Speicheldruesenkrankheiten ( z.B. nekrotisierende Sialometaplasie ) sowie in benignen oder malignen Speicheldruesentumoren ( z.B. metaplastischer Warthin-Tumor ) koennen PEC vortaeuschen . Ein weiteres differentialdiagnostisches Problem stellen Formvarianten des PEC dar , die ueberwiegend in den kleinen Speicheldruesen , dagegen fast nie in den grossen Speicheldruesen entwickelt sind . Hierzu gehoeren das seltene adenoide PEC mit pseudoglandulaeren Strukturen durch Akantholyse , das biphasische adenosquamoese Karzinom mit Differenzierung als PEC und Adenokarzinom , das basaloidsquamoese Karzinom mit biphasischem Aufbau als PEC und solides basaloides Karzinom ( analog dem soliden Typ des adenoid-zystischen Karzinoms ) und das niedrig-differenzierte Mukoepidermoidkarzinom ( Grad III ) mit biphasischem Aufbau aus undifferenzierten epidermoiden und intermediaeren Zellverbaenden sowie Einschluss kleiner Gruppen von schleimbildenden Becherzellen . Die differentialdiagnostischen Merkmale werden im Hinblick auf die Prognose und Therapie analysiert .	[ "Primaere", "Plattenepithelkarzinome", "(", "PEC", ")", "der", "Speicheldruesen", "sind", "vorwiegend", "in", "den", "grossen", "Speicheldruesen", "lokalisiert", "und", "muessen", "von", "Metastasen", "extraglandulaerer", "PEC", "der", "Haut", "besonders", "der", "Kopfhalsregion", "abgegrenzt", "werden", ".", "Plattenepithelmetaplasien", "in", "nichttumoroesen", "Speicheldruesenkrankheiten", "(", "z.", "B.", "nekrotisierende", "Sialometaplasie", ")", "sowie", "in", "benignen", "oder", "malignen", "Speicheldruesentumoren", "(", "z.", "B.", "metaplastischer", "Warthin", "-", "Tumor", ")", "koennen", "PEC", "vortaeuschen", ".", "Ein", "weiteres", "differentialdiagnostisches", "Problem", "stellen", "Formvarianten", "des", "PEC", "dar", ",", "die", "ueberwiegend", "in", "den", "kleinen", "Speicheldruesen", ",", "dagegen", "fast", "nie", "in", "den", "grossen", "Speicheldruesen", "entwickelt", "sind", ".", "Hierzu", "gehoeren", "das", "seltene", "adenoide", "PEC", "mit", "pseudoglandulaeren", "Strukturen", "durch", "Akantholyse", ",", "das", "biphasische", "adenosquamoese", "Karzinom", "mit", "Differenzierung", "als", "PEC", "und", "Adenokarzinom", ",", "das", "basaloidsquamoese", "Karzinom", "mit", "biphasischem", "Aufbau", "als", "PEC", "und", "solides", "basaloides", "Karzinom", "(", "analog", "dem", "soliden", "Typ", "des", "adenoid", "-", "zystischen", "Karzinoms", ")", "und", "das", "niedrig", "-", "differenzierte", "Mukoepidermoidkarzinom", "(", "Grad", "III", ")", "mit", "biphasischem", "Aufbau", "aus", "undifferenzierten", "epidermoiden", "und", "intermediaeren", "Zellverbaenden", "sowie", "Einschluss", "kleiner", "Gruppen", "von", "schleimbildenden", "Becherzellen", ".", "Die", "differentialdiagnostischen", "Merkmale", "werden", "im", "Hinblick", "auf", "die", "Prognose", "und", "Therapie", "analysiert", "." ]	[ "umlsterm" ]
PSEN1 is a Gene, PSEN2 is a Gene, BRCA1 is a Gene, BRCA2 is a Gene, DM1 is a Gene, HD is a Gene, EED is a Gene, CTNNA2 is a Gene, CALM1 is a Gene, CDH13 is a Gene, STMN2 is a Gene, CDH13 is a Gene	39_task0	Sentence: Intra- and interindividual epigenetic variation in human germ cells. Epigenetics represents a secondary inheritance system that has been poorly investigated in human biology. The objective of this study was to perform a comprehensive analysis of DNA methylation variation between and within the germlines of normal males. First, methylated cytosines were mapped using bisulphite modification-based sequencing in the promoter regions of the following disease genes: presenilins (PSEN1 and PSEN2), breast cancer (BRCA1 and BRCA2), myotonic dystrophy (DM1), and Huntington disease (HD). Major epigenetic variation was detected within samples, since the majority of sperm cells of the same individual exhibited unique DNA methylation profiles. In the interindividual analysis, 41 of 61 pairwise comparisons revealed distinct DNA methylation profiles (P=.036 to 6.8 x 10(-14)). Second, a microarray-based epigenetic profiling of the same sperm samples was performed using a 12,198-feature CpG island microarray. The microarray analysis has identified numerous DNA methylation-variable positions in the germ cell genome. The largest degree of variation was detected within the promoter CpG islands and pericentromeric satellites among the single-copy DNA fragments and repetitive elements, respectively. A number of genes, such as EED, CTNNA2, CALM1, CDH13, and STMN2, exhibited age-related DNA methylation changes. Finally, allele-specific methylation patterns in CDH13 were detected. This study provides evidence for significant epigenetic variability in human germ cells, which warrants further research to determine whether such epigenetic patterns can be efficiently transmitted across generations and what impact inherited epigenetic individuality may have on phenotypic outcomes in health and disease. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "B-Gene", "O", "B-Gene", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Intra- and interindividual epigenetic variation in human germ cells. Epigenetics represents a secondary inheritance system that has been poorly investigated in human biology. The objective of this study was to perform a comprehensive analysis of DNA methylation variation between and within the germlines of normal males. First, methylated cytosines were mapped using bisulphite modification-based sequencing in the promoter regions of the following disease genes: presenilins (PSEN1 and PSEN2), breast cancer (BRCA1 and BRCA2), myotonic dystrophy (DM1), and Huntington disease (HD). Major epigenetic variation was detected within samples, since the majority of sperm cells of the same individual exhibited unique DNA methylation profiles. In the interindividual analysis, 41 of 61 pairwise comparisons revealed distinct DNA methylation profiles (P=.036 to 6.8 x 10(-14)). Second, a microarray-based epigenetic profiling of the same sperm samples was performed using a 12,198-feature CpG island microarray. The microarray analysis has identified numerous DNA methylation-variable positions in the germ cell genome. The largest degree of variation was detected within the promoter CpG islands and pericentromeric satellites among the single-copy DNA fragments and repetitive elements, respectively. A number of genes, such as EED, CTNNA2, CALM1, CDH13, and STMN2, exhibited age-related DNA methylation changes. Finally, allele-specific methylation patterns in CDH13 were detected. This study provides evidence for significant epigenetic variability in human germ cells, which warrants further research to determine whether such epigenetic patterns can be efficiently transmitted across generations and what impact inherited epigenetic individuality may have on phenotypic outcomes in health and disease.	[ "Intra-", "and", "interindividual", "epigenetic", "variation", "in", "human", "germ", "cells", ".", "Epigenetics", "represents", "a", "secondary", "inheritance", "system", "that", "has", "been", "poorly", "investigated", "in", "human", "biology", ".", "The", "objective", "of", "this", "study", "was", "to", "perform", "a", "comprehensive", "analysis", "of", "DNA", "methylation", "variation", "between", "and", "within", "the", "germlines", "of", "normal", "males", ".", "First", ",", "methylated", "cytosines", "were", "mapped", "using", "bisulphite", "modification", "-", "based", "sequencing", "in", "the", "promoter", "regions", "of", "the", "following", "disease", "genes", ":", "presenilins", "(", "PSEN1", "and", "PSEN2", ")", ",", "breast", "cancer", "(", "BRCA1", "and", "BRCA2", ")", ",", "myotonic", "dystrophy", "(", "DM1", ")", ",", "and", "Huntington", "disease", "(", "HD", ")", ".", "Major", "epigenetic", "variation", "was", "detected", "within", "samples", ",", "since", "the", "majority", "of", "sperm", "cells", "of", "the", "same", "individual", "exhibited", "unique", "DNA", "methylation", "profiles", ".", "In", "the", "interindividual", "analysis", ",", "41", "of", "61", "pairwise", "comparisons", "revealed", "distinct", "DNA", "methylation", "profiles", "(", "P=.036", "to", "6.8", "x", "10(-14", ")", ")", ".", "Second", ",", "a", "microarray", "-", "based", "epigenetic", "profiling", "of", "the", "same", "sperm", "samples", "was", "performed", "using", "a", "12,198-feature", "CpG", "island", "microarray", ".", "The", "microarray", "analysis", "has", "identified", "numerous", "DNA", "methylation", "-", "variable", "positions", "in", "the", "germ", "cell", "genome", ".", "The", "largest", "degree", "of", "variation", "was", "detected", "within", "the", "promoter", "CpG", "islands", "and", "pericentromeric", "satellites", "among", "the", "single", "-", "copy", "DNA", "fragments", "and", "repetitive", "elements", ",", "respectively", ".", "A", "number", "of", "genes", ",", "such", "as", "EED", ",", "CTNNA2", ",", "CALM1", ",", "CDH13", ",", "and", "STMN2", ",", "exhibited", "age", "-", "related", "DNA", "methylation", "changes", ".", "Finally", ",", "allele", "-", "specific", "methylation", "patterns", "in", "CDH13", "were", "detected", ".", "This", "study", "provides", "evidence", "for", "significant", "epigenetic", "variability", "in", "human", "germ", "cells", ",", "which", "warrants", "further", "research", "to", "determine", "whether", "such", "epigenetic", "patterns", "can", "be", "efficiently", "transmitted", "across", "generations", "and", "what", "impact", "inherited", "epigenetic", "individuality", "may", "have", "on", "phenotypic", "outcomes", "in", "health", "and", "disease", ".", "\n" ]	[ "Gene" ]
PSEN1 is a Gene, PSEN2 is a Gene, BRCA1 is a Gene, BRCA2 is a Gene, DM1 is a Gene, HD is a Gene, EED is a Gene, CTNNA2 is a Gene, CALM1 is a Gene, CDH13 is a Gene, STMN2 is a Gene, CDH13 is a Gene	39_task1	Sentence: Intra- and interindividual epigenetic variation in human germ cells. Epigenetics represents a secondary inheritance system that has been poorly investigated in human biology. The objective of this study was to perform a comprehensive analysis of DNA methylation variation between and within the germlines of normal males. First, methylated cytosines were mapped using bisulphite modification-based sequencing in the promoter regions of the following disease genes: presenilins (PSEN1 and PSEN2), breast cancer (BRCA1 and BRCA2), myotonic dystrophy (DM1), and Huntington disease (HD). Major epigenetic variation was detected within samples, since the majority of sperm cells of the same individual exhibited unique DNA methylation profiles. In the interindividual analysis, 41 of 61 pairwise comparisons revealed distinct DNA methylation profiles (P=.036 to 6.8 x 10(-14)). Second, a microarray-based epigenetic profiling of the same sperm samples was performed using a 12,198-feature CpG island microarray. The microarray analysis has identified numerous DNA methylation-variable positions in the germ cell genome. The largest degree of variation was detected within the promoter CpG islands and pericentromeric satellites among the single-copy DNA fragments and repetitive elements, respectively. A number of genes, such as EED, CTNNA2, CALM1, CDH13, and STMN2, exhibited age-related DNA methylation changes. Finally, allele-specific methylation patterns in CDH13 were detected. This study provides evidence for significant epigenetic variability in human germ cells, which warrants further research to determine whether such epigenetic patterns can be efficiently transmitted across generations and what impact inherited epigenetic individuality may have on phenotypic outcomes in health and disease. Instructions: please typing these entity words according to sentence: PSEN1, PSEN2, BRCA1, BRCA2, DM1, HD, EED, CTNNA2, CALM1, CDH13, STMN2, CDH13 Options: Gene	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "B-Gene", "O", "B-Gene", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Intra- and interindividual epigenetic variation in human germ cells. Epigenetics represents a secondary inheritance system that has been poorly investigated in human biology. The objective of this study was to perform a comprehensive analysis of DNA methylation variation between and within the germlines of normal males. First, methylated cytosines were mapped using bisulphite modification-based sequencing in the promoter regions of the following disease genes: presenilins (PSEN1 and PSEN2), breast cancer (BRCA1 and BRCA2), myotonic dystrophy (DM1), and Huntington disease (HD). Major epigenetic variation was detected within samples, since the majority of sperm cells of the same individual exhibited unique DNA methylation profiles. In the interindividual analysis, 41 of 61 pairwise comparisons revealed distinct DNA methylation profiles (P=.036 to 6.8 x 10(-14)). Second, a microarray-based epigenetic profiling of the same sperm samples was performed using a 12,198-feature CpG island microarray. The microarray analysis has identified numerous DNA methylation-variable positions in the germ cell genome. The largest degree of variation was detected within the promoter CpG islands and pericentromeric satellites among the single-copy DNA fragments and repetitive elements, respectively. A number of genes, such as EED, CTNNA2, CALM1, CDH13, and STMN2, exhibited age-related DNA methylation changes. Finally, allele-specific methylation patterns in CDH13 were detected. This study provides evidence for significant epigenetic variability in human germ cells, which warrants further research to determine whether such epigenetic patterns can be efficiently transmitted across generations and what impact inherited epigenetic individuality may have on phenotypic outcomes in health and disease.	[ "Intra-", "and", "interindividual", "epigenetic", "variation", "in", "human", "germ", "cells", ".", "Epigenetics", "represents", "a", "secondary", "inheritance", "system", "that", "has", "been", "poorly", "investigated", "in", "human", "biology", ".", "The", "objective", "of", "this", "study", "was", "to", "perform", "a", "comprehensive", "analysis", "of", "DNA", "methylation", "variation", "between", "and", "within", "the", "germlines", "of", "normal", "males", ".", "First", ",", "methylated", "cytosines", "were", "mapped", "using", "bisulphite", "modification", "-", "based", "sequencing", "in", "the", "promoter", "regions", "of", "the", "following", "disease", "genes", ":", "presenilins", "(", "PSEN1", "and", "PSEN2", ")", ",", "breast", "cancer", "(", "BRCA1", "and", "BRCA2", ")", ",", "myotonic", "dystrophy", "(", "DM1", ")", ",", "and", "Huntington", "disease", "(", "HD", ")", ".", "Major", "epigenetic", "variation", "was", "detected", "within", "samples", ",", "since", "the", "majority", "of", "sperm", "cells", "of", "the", "same", "individual", "exhibited", "unique", "DNA", "methylation", "profiles", ".", "In", "the", "interindividual", "analysis", ",", "41", "of", "61", "pairwise", "comparisons", "revealed", "distinct", "DNA", "methylation", "profiles", "(", "P=.036", "to", "6.8", "x", "10(-14", ")", ")", ".", "Second", ",", "a", "microarray", "-", "based", "epigenetic", "profiling", "of", "the", "same", "sperm", "samples", "was", "performed", "using", "a", "12,198-feature", "CpG", "island", "microarray", ".", "The", "microarray", "analysis", "has", "identified", "numerous", "DNA", "methylation", "-", "variable", "positions", "in", "the", "germ", "cell", "genome", ".", "The", "largest", "degree", "of", "variation", "was", "detected", "within", "the", "promoter", "CpG", "islands", "and", "pericentromeric", "satellites", "among", "the", "single", "-", "copy", "DNA", "fragments", "and", "repetitive", "elements", ",", "respectively", ".", "A", "number", "of", "genes", ",", "such", "as", "EED", ",", "CTNNA2", ",", "CALM1", ",", "CDH13", ",", "and", "STMN2", ",", "exhibited", "age", "-", "related", "DNA", "methylation", "changes", ".", "Finally", ",", "allele", "-", "specific", "methylation", "patterns", "in", "CDH13", "were", "detected", ".", "This", "study", "provides", "evidence", "for", "significant", "epigenetic", "variability", "in", "human", "germ", "cells", ",", "which", "warrants", "further", "research", "to", "determine", "whether", "such", "epigenetic", "patterns", "can", "be", "efficiently", "transmitted", "across", "generations", "and", "what", "impact", "inherited", "epigenetic", "individuality", "may", "have", "on", "phenotypic", "outcomes", "in", "health", "and", "disease", ".", "\n" ]	[ "Gene" ]
PSEN1, PSEN2, BRCA1, BRCA2, DM1, HD, EED, CTNNA2, CALM1, CDH13, STMN2, CDH13	39_task2	Sentence: Intra- and interindividual epigenetic variation in human germ cells. Epigenetics represents a secondary inheritance system that has been poorly investigated in human biology. The objective of this study was to perform a comprehensive analysis of DNA methylation variation between and within the germlines of normal males. First, methylated cytosines were mapped using bisulphite modification-based sequencing in the promoter regions of the following disease genes: presenilins (PSEN1 and PSEN2), breast cancer (BRCA1 and BRCA2), myotonic dystrophy (DM1), and Huntington disease (HD). Major epigenetic variation was detected within samples, since the majority of sperm cells of the same individual exhibited unique DNA methylation profiles. In the interindividual analysis, 41 of 61 pairwise comparisons revealed distinct DNA methylation profiles (P=.036 to 6.8 x 10(-14)). Second, a microarray-based epigenetic profiling of the same sperm samples was performed using a 12,198-feature CpG island microarray. The microarray analysis has identified numerous DNA methylation-variable positions in the germ cell genome. The largest degree of variation was detected within the promoter CpG islands and pericentromeric satellites among the single-copy DNA fragments and repetitive elements, respectively. A number of genes, such as EED, CTNNA2, CALM1, CDH13, and STMN2, exhibited age-related DNA methylation changes. Finally, allele-specific methylation patterns in CDH13 were detected. This study provides evidence for significant epigenetic variability in human germ cells, which warrants further research to determine whether such epigenetic patterns can be efficiently transmitted across generations and what impact inherited epigenetic individuality may have on phenotypic outcomes in health and disease. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "B-Gene", "O", "B-Gene", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Intra- and interindividual epigenetic variation in human germ cells. Epigenetics represents a secondary inheritance system that has been poorly investigated in human biology. The objective of this study was to perform a comprehensive analysis of DNA methylation variation between and within the germlines of normal males. First, methylated cytosines were mapped using bisulphite modification-based sequencing in the promoter regions of the following disease genes: presenilins (PSEN1 and PSEN2), breast cancer (BRCA1 and BRCA2), myotonic dystrophy (DM1), and Huntington disease (HD). Major epigenetic variation was detected within samples, since the majority of sperm cells of the same individual exhibited unique DNA methylation profiles. In the interindividual analysis, 41 of 61 pairwise comparisons revealed distinct DNA methylation profiles (P=.036 to 6.8 x 10(-14)). Second, a microarray-based epigenetic profiling of the same sperm samples was performed using a 12,198-feature CpG island microarray. The microarray analysis has identified numerous DNA methylation-variable positions in the germ cell genome. The largest degree of variation was detected within the promoter CpG islands and pericentromeric satellites among the single-copy DNA fragments and repetitive elements, respectively. A number of genes, such as EED, CTNNA2, CALM1, CDH13, and STMN2, exhibited age-related DNA methylation changes. Finally, allele-specific methylation patterns in CDH13 were detected. This study provides evidence for significant epigenetic variability in human germ cells, which warrants further research to determine whether such epigenetic patterns can be efficiently transmitted across generations and what impact inherited epigenetic individuality may have on phenotypic outcomes in health and disease.	[ "Intra-", "and", "interindividual", "epigenetic", "variation", "in", "human", "germ", "cells", ".", "Epigenetics", "represents", "a", "secondary", "inheritance", "system", "that", "has", "been", "poorly", "investigated", "in", "human", "biology", ".", "The", "objective", "of", "this", "study", "was", "to", "perform", "a", "comprehensive", "analysis", "of", "DNA", "methylation", "variation", "between", "and", "within", "the", "germlines", "of", "normal", "males", ".", "First", ",", "methylated", "cytosines", "were", "mapped", "using", "bisulphite", "modification", "-", "based", "sequencing", "in", "the", "promoter", "regions", "of", "the", "following", "disease", "genes", ":", "presenilins", "(", "PSEN1", "and", "PSEN2", ")", ",", "breast", "cancer", "(", "BRCA1", "and", "BRCA2", ")", ",", "myotonic", "dystrophy", "(", "DM1", ")", ",", "and", "Huntington", "disease", "(", "HD", ")", ".", "Major", "epigenetic", "variation", "was", "detected", "within", "samples", ",", "since", "the", "majority", "of", "sperm", "cells", "of", "the", "same", "individual", "exhibited", "unique", "DNA", "methylation", "profiles", ".", "In", "the", "interindividual", "analysis", ",", "41", "of", "61", "pairwise", "comparisons", "revealed", "distinct", "DNA", "methylation", "profiles", "(", "P=.036", "to", "6.8", "x", "10(-14", ")", ")", ".", "Second", ",", "a", "microarray", "-", "based", "epigenetic", "profiling", "of", "the", "same", "sperm", "samples", "was", "performed", "using", "a", "12,198-feature", "CpG", "island", "microarray", ".", "The", "microarray", "analysis", "has", "identified", "numerous", "DNA", "methylation", "-", "variable", "positions", "in", "the", "germ", "cell", "genome", ".", "The", "largest", "degree", "of", "variation", "was", "detected", "within", "the", "promoter", "CpG", "islands", "and", "pericentromeric", "satellites", "among", "the", "single", "-", "copy", "DNA", "fragments", "and", "repetitive", "elements", ",", "respectively", ".", "A", "number", "of", "genes", ",", "such", "as", "EED", ",", "CTNNA2", ",", "CALM1", ",", "CDH13", ",", "and", "STMN2", ",", "exhibited", "age", "-", "related", "DNA", "methylation", "changes", ".", "Finally", ",", "allele", "-", "specific", "methylation", "patterns", "in", "CDH13", "were", "detected", ".", "This", "study", "provides", "evidence", "for", "significant", "epigenetic", "variability", "in", "human", "germ", "cells", ",", "which", "warrants", "further", "research", "to", "determine", "whether", "such", "epigenetic", "patterns", "can", "be", "efficiently", "transmitted", "across", "generations", "and", "what", "impact", "inherited", "epigenetic", "individuality", "may", "have", "on", "phenotypic", "outcomes", "in", "health", "and", "disease", ".", "\n" ]	[ "Gene" ]
actin is a Gene/protein/RNA, actin is a Gene/protein/RNA, cofilin is a Gene/protein/RNA, actin depolymerizing factor is a Gene/protein/RNA, profilin is a Gene/protein/RNA	284_task0	Sentence: Fluorographic analysis showed that the specific activity of soluble actin was two to three times that of its particulate form and that soluble actin, cofilin, actin depolymerizing factor, and profilin were transported at similar rates in slow component b of axonal flow. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fluorographic analysis showed that the specific activity of soluble actin was two to three times that of its particulate form and that soluble actin, cofilin, actin depolymerizing factor, and profilin were transported at similar rates in slow component b of axonal flow.	[ "Fluorographic", "analysis", "showed", "that", "the", "specific", "activity", "of", "soluble", "actin", "was", "two", "to", "three", "times", "that", "of", "its", "particulate", "form", "and", "that", "soluble", "actin", ",", "cofilin", ",", "actin", "depolymerizing", "factor", ",", "and", "profilin", "were", "transported", "at", "similar", "rates", "in", "slow", "component", "b", "of", "axonal", "flow", "." ]	[ "Gene/protein/RNA" ]
actin is a Gene/protein/RNA, actin is a Gene/protein/RNA, cofilin is a Gene/protein/RNA, actin depolymerizing factor is a Gene/protein/RNA, profilin is a Gene/protein/RNA	284_task1	Sentence: Fluorographic analysis showed that the specific activity of soluble actin was two to three times that of its particulate form and that soluble actin, cofilin, actin depolymerizing factor, and profilin were transported at similar rates in slow component b of axonal flow. Instructions: please typing these entity words according to sentence: actin, actin, cofilin, actin depolymerizing factor, profilin Options: Gene/protein/RNA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fluorographic analysis showed that the specific activity of soluble actin was two to three times that of its particulate form and that soluble actin, cofilin, actin depolymerizing factor, and profilin were transported at similar rates in slow component b of axonal flow.	[ "Fluorographic", "analysis", "showed", "that", "the", "specific", "activity", "of", "soluble", "actin", "was", "two", "to", "three", "times", "that", "of", "its", "particulate", "form", "and", "that", "soluble", "actin", ",", "cofilin", ",", "actin", "depolymerizing", "factor", ",", "and", "profilin", "were", "transported", "at", "similar", "rates", "in", "slow", "component", "b", "of", "axonal", "flow", "." ]	[ "Gene/protein/RNA" ]
actin, actin, cofilin, actin depolymerizing factor, profilin	284_task2	Sentence: Fluorographic analysis showed that the specific activity of soluble actin was two to three times that of its particulate form and that soluble actin, cofilin, actin depolymerizing factor, and profilin were transported at similar rates in slow component b of axonal flow. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fluorographic analysis showed that the specific activity of soluble actin was two to three times that of its particulate form and that soluble actin, cofilin, actin depolymerizing factor, and profilin were transported at similar rates in slow component b of axonal flow.	[ "Fluorographic", "analysis", "showed", "that", "the", "specific", "activity", "of", "soluble", "actin", "was", "two", "to", "three", "times", "that", "of", "its", "particulate", "form", "and", "that", "soluble", "actin", ",", "cofilin", ",", "actin", "depolymerizing", "factor", ",", "and", "profilin", "were", "transported", "at", "similar", "rates", "in", "slow", "component", "b", "of", "axonal", "flow", "." ]	[ "Gene/protein/RNA" ]
Beurteilung is an umlsterm, Therapie is an umlsterm	DerSchmerz.70110254.ger.abstr_task0	Sentence: Fragestellung : Zwei methodische Zugaenge der Veraenderungsmessung werden miteinander verglichen : der Prae-post-Vergleich der Merkmale und die subjektive Beurteilung der Veraenderung nach der Therapie . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Fragestellung : Zwei methodische Zugaenge der Veraenderungsmessung werden miteinander verglichen : der Prae-post-Vergleich der Merkmale und die subjektive Beurteilung der Veraenderung nach der Therapie .	[ "Fragestellung", ":", "Zwei", "methodische", "Zugaenge", "der", "Veraenderungsmessung", "werden", "miteinander", "verglichen", ":", "der", "Prae", "-", "post", "-", "Vergleich", "der", "Merkmale", "und", "die", "subjektive", "Beurteilung", "der", "Veraenderung", "nach", "der", "Therapie", "." ]	[ "umlsterm" ]
Beurteilung is an umlsterm, Therapie is an umlsterm	DerSchmerz.70110254.ger.abstr_task1	Sentence: Fragestellung : Zwei methodische Zugaenge der Veraenderungsmessung werden miteinander verglichen : der Prae-post-Vergleich der Merkmale und die subjektive Beurteilung der Veraenderung nach der Therapie . Instructions: please typing these entity words according to sentence: Beurteilung, Therapie Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Fragestellung : Zwei methodische Zugaenge der Veraenderungsmessung werden miteinander verglichen : der Prae-post-Vergleich der Merkmale und die subjektive Beurteilung der Veraenderung nach der Therapie .	[ "Fragestellung", ":", "Zwei", "methodische", "Zugaenge", "der", "Veraenderungsmessung", "werden", "miteinander", "verglichen", ":", "der", "Prae", "-", "post", "-", "Vergleich", "der", "Merkmale", "und", "die", "subjektive", "Beurteilung", "der", "Veraenderung", "nach", "der", "Therapie", "." ]	[ "umlsterm" ]
Beurteilung, Therapie	DerSchmerz.70110254.ger.abstr_task2	Sentence: Fragestellung : Zwei methodische Zugaenge der Veraenderungsmessung werden miteinander verglichen : der Prae-post-Vergleich der Merkmale und die subjektive Beurteilung der Veraenderung nach der Therapie . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Fragestellung : Zwei methodische Zugaenge der Veraenderungsmessung werden miteinander verglichen : der Prae-post-Vergleich der Merkmale und die subjektive Beurteilung der Veraenderung nach der Therapie .	[ "Fragestellung", ":", "Zwei", "methodische", "Zugaenge", "der", "Veraenderungsmessung", "werden", "miteinander", "verglichen", ":", "der", "Prae", "-", "post", "-", "Vergleich", "der", "Merkmale", "und", "die", "subjektive", "Beurteilung", "der", "Veraenderung", "nach", "der", "Therapie", "." ]	[ "umlsterm" ]
human immunodeficiency virus type 1 enhancer - binding proteins is a protein_family_or_group, human T - cell line is a cell_line, Jurkat is a cell_line	98025_task0	Sentence: Characterization of the human immunodeficiency virus type 1 enhancer-binding proteins from the human T-cell line Jurkat. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_family_or_group, cell_line	[ "O", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "B-cell_line", "O" ]	Characterization of the human immunodeficiency virus type 1 enhancer-binding proteins from the human T-cell line Jurkat.	[ "Characterization", "of", "the", "human", "immunodeficiency", "virus", "type", "1", "enhancer", "-", "binding", "proteins", "from", "the", "human", "T", "-", "cell", "line", "Jurkat", "." ]	[ "protein_family_or_group", "DNA_domain_or_region", "protein_subunit", "virus", "other_name", "protein_molecule", "cell_line", "atom", "polynucleotide" ]
human immunodeficiency virus type 1 enhancer - binding proteins is a protein_family_or_group, human T - cell line is a cell_line, Jurkat is a cell_line	98025_task1	Sentence: Characterization of the human immunodeficiency virus type 1 enhancer-binding proteins from the human T-cell line Jurkat. Instructions: please typing these entity words according to sentence: human immunodeficiency virus type 1 enhancer - binding proteins, human T - cell line, Jurkat Options: protein_family_or_group, cell_line	[ "O", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "B-cell_line", "O" ]	Characterization of the human immunodeficiency virus type 1 enhancer-binding proteins from the human T-cell line Jurkat.	[ "Characterization", "of", "the", "human", "immunodeficiency", "virus", "type", "1", "enhancer", "-", "binding", "proteins", "from", "the", "human", "T", "-", "cell", "line", "Jurkat", "." ]	[ "protein_family_or_group", "DNA_domain_or_region", "protein_subunit", "virus", "other_name", "protein_molecule", "cell_line", "atom", "polynucleotide" ]
human immunodeficiency virus type 1 enhancer - binding proteins, human T - cell line, Jurkat	98025_task2	Sentence: Characterization of the human immunodeficiency virus type 1 enhancer-binding proteins from the human T-cell line Jurkat. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "B-cell_line", "O" ]	Characterization of the human immunodeficiency virus type 1 enhancer-binding proteins from the human T-cell line Jurkat.	[ "Characterization", "of", "the", "human", "immunodeficiency", "virus", "type", "1", "enhancer", "-", "binding", "proteins", "from", "the", "human", "T", "-", "cell", "line", "Jurkat", "." ]	[ "protein_family_or_group", "DNA_domain_or_region", "protein_subunit", "virus", "other_name", "protein_molecule", "cell_line", "atom", "polynucleotide" ]
Speicheldruesen- is an umlsterm, Parotischirurgie is an umlsterm, Speicheldruesenerkrankungen is an umlsterm, Behandlung is an umlsterm, Speicheldruesenerkrankungen is an umlsterm, Referenzpathologie is an umlsterm, Speicheldruesenerkrankungen is an umlsterm, Sonographie is an umlsterm, Computertomogramm is an umlsterm, Kernspintomographie is an umlsterm, Literatur is an umlsterm, Speicheldruesen is an umlsterm, Therapie is an umlsterm, Parotischirurgie is an umlsterm, Tumorentitaeten is an umlsterm	MundKieferGesichtschirurgie.0004s401.ger.abstr_task0	Sentence: Nach einer ueber 26-jaehrigen Taetigkeit in der Speicheldruesen- und insbesondere in der Parotischirurgie sind folgende Aussagen zu erbringen : 1. Die Speicheldruesenerkrankungen sind extrem variabel und verlangen in der Behandlung einen grossen klinischen Erfahrungswert . 2. Die Bewertung der Speicheldruesenerkrankungen setzt eine hochkompetente pathologische Sekundanz und ein einschlaegiges Labor voraus . Die Forderungen nach einer Referenzpathologie muessen wie fuer viele Organe oder Organsysteme auch fuer die Speicheldruesenerkrankungen erneut und uneingeschraenkt erhoben werden . 3. Ein gewisser Wandel ist in den diagnostischen Massnahmen eingetreten . Die moderne Bildgebung zeigt eine wesentliche Verschiebung zugunsten der nichtinvasiven Sonographie und auch dem Computertomogramm mit und ohne Kontrastdarstellung sowie in zunehmendem Mass auch der Kernspintomographie . 4. Die Literatur zu den Erkrankungen der Speicheldruesen und ihrer Therapie ist kaum noch zu ueberblicken und bedauerlicherweise von ganz unterschiedlichen Bewertungsaspekten charakterisiert . Sie laesst in vielen Faellen vergleichende Diskussionen ueber bestimmte klinische und therapeutische Fragestellungen nur schwer zu . 5. Die Parotischirurgie verlangt ein klares Konzept hinsichtlich der verschiedenen Erkrankungen insbesondere der unterschiedlichen Tumorentitaeten . Die Darstellung und Praeparation des N. facialis von peripher und zentral muessen gleichermassen beherrscht werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Nach einer ueber 26-jaehrigen Taetigkeit in der Speicheldruesen- und insbesondere in der Parotischirurgie sind folgende Aussagen zu erbringen : 1. Die Speicheldruesenerkrankungen sind extrem variabel und verlangen in der Behandlung einen grossen klinischen Erfahrungswert . 2. Die Bewertung der Speicheldruesenerkrankungen setzt eine hochkompetente pathologische Sekundanz und ein einschlaegiges Labor voraus . Die Forderungen nach einer Referenzpathologie muessen wie fuer viele Organe oder Organsysteme auch fuer die Speicheldruesenerkrankungen erneut und uneingeschraenkt erhoben werden . 3. Ein gewisser Wandel ist in den diagnostischen Massnahmen eingetreten . Die moderne Bildgebung zeigt eine wesentliche Verschiebung zugunsten der nichtinvasiven Sonographie und auch dem Computertomogramm mit und ohne Kontrastdarstellung sowie in zunehmendem Mass auch der Kernspintomographie . 4. Die Literatur zu den Erkrankungen der Speicheldruesen und ihrer Therapie ist kaum noch zu ueberblicken und bedauerlicherweise von ganz unterschiedlichen Bewertungsaspekten charakterisiert . Sie laesst in vielen Faellen vergleichende Diskussionen ueber bestimmte klinische und therapeutische Fragestellungen nur schwer zu . 5. Die Parotischirurgie verlangt ein klares Konzept hinsichtlich der verschiedenen Erkrankungen insbesondere der unterschiedlichen Tumorentitaeten . Die Darstellung und Praeparation des N. facialis von peripher und zentral muessen gleichermassen beherrscht werden .	[ "Nach", "einer", "ueber", "26-jaehrigen", "Taetigkeit", "in", "der", "Speicheldruesen-", "und", "insbesondere", "in", "der", "Parotischirurgie", "sind", "folgende", "Aussagen", "zu", "erbringen", ":", "1", ".", "Die", "Speicheldruesenerkrankungen", "sind", "extrem", "variabel", "und", "verlangen", "in", "der", "Behandlung", "einen", "grossen", "klinischen", "Erfahrungswert", ".", "2", ".", "Die", "Bewertung", "der", "Speicheldruesenerkrankungen", "setzt", "eine", "hochkompetente", "pathologische", "Sekundanz", "und", "ein", "einschlaegiges", "Labor", "voraus", ".", "Die", "Forderungen", "nach", "einer", "Referenzpathologie", "muessen", "wie", "fuer", "viele", "Organe", "oder", "Organsysteme", "auch", "fuer", "die", "Speicheldruesenerkrankungen", "erneut", "und", "uneingeschraenkt", "erhoben", "werden", ".", "3", ".", "Ein", "gewisser", "Wandel", "ist", "in", "den", "diagnostischen", "Massnahmen", "eingetreten", ".", "Die", "moderne", "Bildgebung", "zeigt", "eine", "wesentliche", "Verschiebung", "zugunsten", "der", "nichtinvasiven", "Sonographie", "und", "auch", "dem", "Computertomogramm", "mit", "und", "ohne", "Kontrastdarstellung", "sowie", "in", "zunehmendem", "Mass", "auch", "der", "Kernspintomographie", ".", "4", ".", "Die", "Literatur", "zu", "den", "Erkrankungen", "der", "Speicheldruesen", "und", "ihrer", "Therapie", "ist", "kaum", "noch", "zu", "ueberblicken", "und", "bedauerlicherweise", "von", "ganz", "unterschiedlichen", "Bewertungsaspekten", "charakterisiert", ".", "Sie", "laesst", "in", "vielen", "Faellen", "vergleichende", "Diskussionen", "ueber", "bestimmte", "klinische", "und", "therapeutische", "Fragestellungen", "nur", "schwer", "zu", ".", "5", ".", "Die", "Parotischirurgie", "verlangt", "ein", "klares", "Konzept", "hinsichtlich", "der", "verschiedenen", "Erkrankungen", "insbesondere", "der", "unterschiedlichen", "Tumorentitaeten", ".", "Die", "Darstellung", "und", "Praeparation", "des", "N.", "facialis", "von", "peripher", "und", "zentral", "muessen", "gleichermassen", "beherrscht", "werden", "." ]	[ "umlsterm" ]
Speicheldruesen- is an umlsterm, Parotischirurgie is an umlsterm, Speicheldruesenerkrankungen is an umlsterm, Behandlung is an umlsterm, Speicheldruesenerkrankungen is an umlsterm, Referenzpathologie is an umlsterm, Speicheldruesenerkrankungen is an umlsterm, Sonographie is an umlsterm, Computertomogramm is an umlsterm, Kernspintomographie is an umlsterm, Literatur is an umlsterm, Speicheldruesen is an umlsterm, Therapie is an umlsterm, Parotischirurgie is an umlsterm, Tumorentitaeten is an umlsterm	MundKieferGesichtschirurgie.0004s401.ger.abstr_task1	Sentence: Nach einer ueber 26-jaehrigen Taetigkeit in der Speicheldruesen- und insbesondere in der Parotischirurgie sind folgende Aussagen zu erbringen : 1. Die Speicheldruesenerkrankungen sind extrem variabel und verlangen in der Behandlung einen grossen klinischen Erfahrungswert . 2. Die Bewertung der Speicheldruesenerkrankungen setzt eine hochkompetente pathologische Sekundanz und ein einschlaegiges Labor voraus . Die Forderungen nach einer Referenzpathologie muessen wie fuer viele Organe oder Organsysteme auch fuer die Speicheldruesenerkrankungen erneut und uneingeschraenkt erhoben werden . 3. Ein gewisser Wandel ist in den diagnostischen Massnahmen eingetreten . Die moderne Bildgebung zeigt eine wesentliche Verschiebung zugunsten der nichtinvasiven Sonographie und auch dem Computertomogramm mit und ohne Kontrastdarstellung sowie in zunehmendem Mass auch der Kernspintomographie . 4. Die Literatur zu den Erkrankungen der Speicheldruesen und ihrer Therapie ist kaum noch zu ueberblicken und bedauerlicherweise von ganz unterschiedlichen Bewertungsaspekten charakterisiert . Sie laesst in vielen Faellen vergleichende Diskussionen ueber bestimmte klinische und therapeutische Fragestellungen nur schwer zu . 5. Die Parotischirurgie verlangt ein klares Konzept hinsichtlich der verschiedenen Erkrankungen insbesondere der unterschiedlichen Tumorentitaeten . Die Darstellung und Praeparation des N. facialis von peripher und zentral muessen gleichermassen beherrscht werden . Instructions: please typing these entity words according to sentence: Speicheldruesen-, Parotischirurgie, Speicheldruesenerkrankungen, Behandlung, Speicheldruesenerkrankungen, Referenzpathologie, Speicheldruesenerkrankungen, Sonographie, Computertomogramm, Kernspintomographie, Literatur, Speicheldruesen, Therapie, Parotischirurgie, Tumorentitaeten Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Nach einer ueber 26-jaehrigen Taetigkeit in der Speicheldruesen- und insbesondere in der Parotischirurgie sind folgende Aussagen zu erbringen : 1. Die Speicheldruesenerkrankungen sind extrem variabel und verlangen in der Behandlung einen grossen klinischen Erfahrungswert . 2. Die Bewertung der Speicheldruesenerkrankungen setzt eine hochkompetente pathologische Sekundanz und ein einschlaegiges Labor voraus . Die Forderungen nach einer Referenzpathologie muessen wie fuer viele Organe oder Organsysteme auch fuer die Speicheldruesenerkrankungen erneut und uneingeschraenkt erhoben werden . 3. Ein gewisser Wandel ist in den diagnostischen Massnahmen eingetreten . Die moderne Bildgebung zeigt eine wesentliche Verschiebung zugunsten der nichtinvasiven Sonographie und auch dem Computertomogramm mit und ohne Kontrastdarstellung sowie in zunehmendem Mass auch der Kernspintomographie . 4. Die Literatur zu den Erkrankungen der Speicheldruesen und ihrer Therapie ist kaum noch zu ueberblicken und bedauerlicherweise von ganz unterschiedlichen Bewertungsaspekten charakterisiert . Sie laesst in vielen Faellen vergleichende Diskussionen ueber bestimmte klinische und therapeutische Fragestellungen nur schwer zu . 5. Die Parotischirurgie verlangt ein klares Konzept hinsichtlich der verschiedenen Erkrankungen insbesondere der unterschiedlichen Tumorentitaeten . Die Darstellung und Praeparation des N. facialis von peripher und zentral muessen gleichermassen beherrscht werden .	[ "Nach", "einer", "ueber", "26-jaehrigen", "Taetigkeit", "in", "der", "Speicheldruesen-", "und", "insbesondere", "in", "der", "Parotischirurgie", "sind", "folgende", "Aussagen", "zu", "erbringen", ":", "1", ".", "Die", "Speicheldruesenerkrankungen", "sind", "extrem", "variabel", "und", "verlangen", "in", "der", "Behandlung", "einen", "grossen", "klinischen", "Erfahrungswert", ".", "2", ".", "Die", "Bewertung", "der", "Speicheldruesenerkrankungen", "setzt", "eine", "hochkompetente", "pathologische", "Sekundanz", "und", "ein", "einschlaegiges", "Labor", "voraus", ".", "Die", "Forderungen", "nach", "einer", "Referenzpathologie", "muessen", "wie", "fuer", "viele", "Organe", "oder", "Organsysteme", "auch", "fuer", "die", "Speicheldruesenerkrankungen", "erneut", "und", "uneingeschraenkt", "erhoben", "werden", ".", "3", ".", "Ein", "gewisser", "Wandel", "ist", "in", "den", "diagnostischen", "Massnahmen", "eingetreten", ".", "Die", "moderne", "Bildgebung", "zeigt", "eine", "wesentliche", "Verschiebung", "zugunsten", "der", "nichtinvasiven", "Sonographie", "und", "auch", "dem", "Computertomogramm", "mit", "und", "ohne", "Kontrastdarstellung", "sowie", "in", "zunehmendem", "Mass", "auch", "der", "Kernspintomographie", ".", "4", ".", "Die", "Literatur", "zu", "den", "Erkrankungen", "der", "Speicheldruesen", "und", "ihrer", "Therapie", "ist", "kaum", "noch", "zu", "ueberblicken", "und", "bedauerlicherweise", "von", "ganz", "unterschiedlichen", "Bewertungsaspekten", "charakterisiert", ".", "Sie", "laesst", "in", "vielen", "Faellen", "vergleichende", "Diskussionen", "ueber", "bestimmte", "klinische", "und", "therapeutische", "Fragestellungen", "nur", "schwer", "zu", ".", "5", ".", "Die", "Parotischirurgie", "verlangt", "ein", "klares", "Konzept", "hinsichtlich", "der", "verschiedenen", "Erkrankungen", "insbesondere", "der", "unterschiedlichen", "Tumorentitaeten", ".", "Die", "Darstellung", "und", "Praeparation", "des", "N.", "facialis", "von", "peripher", "und", "zentral", "muessen", "gleichermassen", "beherrscht", "werden", "." ]	[ "umlsterm" ]
Speicheldruesen-, Parotischirurgie, Speicheldruesenerkrankungen, Behandlung, Speicheldruesenerkrankungen, Referenzpathologie, Speicheldruesenerkrankungen, Sonographie, Computertomogramm, Kernspintomographie, Literatur, Speicheldruesen, Therapie, Parotischirurgie, Tumorentitaeten	MundKieferGesichtschirurgie.0004s401.ger.abstr_task2	Sentence: Nach einer ueber 26-jaehrigen Taetigkeit in der Speicheldruesen- und insbesondere in der Parotischirurgie sind folgende Aussagen zu erbringen : 1. Die Speicheldruesenerkrankungen sind extrem variabel und verlangen in der Behandlung einen grossen klinischen Erfahrungswert . 2. Die Bewertung der Speicheldruesenerkrankungen setzt eine hochkompetente pathologische Sekundanz und ein einschlaegiges Labor voraus . Die Forderungen nach einer Referenzpathologie muessen wie fuer viele Organe oder Organsysteme auch fuer die Speicheldruesenerkrankungen erneut und uneingeschraenkt erhoben werden . 3. Ein gewisser Wandel ist in den diagnostischen Massnahmen eingetreten . Die moderne Bildgebung zeigt eine wesentliche Verschiebung zugunsten der nichtinvasiven Sonographie und auch dem Computertomogramm mit und ohne Kontrastdarstellung sowie in zunehmendem Mass auch der Kernspintomographie . 4. Die Literatur zu den Erkrankungen der Speicheldruesen und ihrer Therapie ist kaum noch zu ueberblicken und bedauerlicherweise von ganz unterschiedlichen Bewertungsaspekten charakterisiert . Sie laesst in vielen Faellen vergleichende Diskussionen ueber bestimmte klinische und therapeutische Fragestellungen nur schwer zu . 5. Die Parotischirurgie verlangt ein klares Konzept hinsichtlich der verschiedenen Erkrankungen insbesondere der unterschiedlichen Tumorentitaeten . Die Darstellung und Praeparation des N. facialis von peripher und zentral muessen gleichermassen beherrscht werden . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Nach einer ueber 26-jaehrigen Taetigkeit in der Speicheldruesen- und insbesondere in der Parotischirurgie sind folgende Aussagen zu erbringen : 1. Die Speicheldruesenerkrankungen sind extrem variabel und verlangen in der Behandlung einen grossen klinischen Erfahrungswert . 2. Die Bewertung der Speicheldruesenerkrankungen setzt eine hochkompetente pathologische Sekundanz und ein einschlaegiges Labor voraus . Die Forderungen nach einer Referenzpathologie muessen wie fuer viele Organe oder Organsysteme auch fuer die Speicheldruesenerkrankungen erneut und uneingeschraenkt erhoben werden . 3. Ein gewisser Wandel ist in den diagnostischen Massnahmen eingetreten . Die moderne Bildgebung zeigt eine wesentliche Verschiebung zugunsten der nichtinvasiven Sonographie und auch dem Computertomogramm mit und ohne Kontrastdarstellung sowie in zunehmendem Mass auch der Kernspintomographie . 4. Die Literatur zu den Erkrankungen der Speicheldruesen und ihrer Therapie ist kaum noch zu ueberblicken und bedauerlicherweise von ganz unterschiedlichen Bewertungsaspekten charakterisiert . Sie laesst in vielen Faellen vergleichende Diskussionen ueber bestimmte klinische und therapeutische Fragestellungen nur schwer zu . 5. Die Parotischirurgie verlangt ein klares Konzept hinsichtlich der verschiedenen Erkrankungen insbesondere der unterschiedlichen Tumorentitaeten . Die Darstellung und Praeparation des N. facialis von peripher und zentral muessen gleichermassen beherrscht werden .	[ "Nach", "einer", "ueber", "26-jaehrigen", "Taetigkeit", "in", "der", "Speicheldruesen-", "und", "insbesondere", "in", "der", "Parotischirurgie", "sind", "folgende", "Aussagen", "zu", "erbringen", ":", "1", ".", "Die", "Speicheldruesenerkrankungen", "sind", "extrem", "variabel", "und", "verlangen", "in", "der", "Behandlung", "einen", "grossen", "klinischen", "Erfahrungswert", ".", "2", ".", "Die", "Bewertung", "der", "Speicheldruesenerkrankungen", "setzt", "eine", "hochkompetente", "pathologische", "Sekundanz", "und", "ein", "einschlaegiges", "Labor", "voraus", ".", "Die", "Forderungen", "nach", "einer", "Referenzpathologie", "muessen", "wie", "fuer", "viele", "Organe", "oder", "Organsysteme", "auch", "fuer", "die", "Speicheldruesenerkrankungen", "erneut", "und", "uneingeschraenkt", "erhoben", "werden", ".", "3", ".", "Ein", "gewisser", "Wandel", "ist", "in", "den", "diagnostischen", "Massnahmen", "eingetreten", ".", "Die", "moderne", "Bildgebung", "zeigt", "eine", "wesentliche", "Verschiebung", "zugunsten", "der", "nichtinvasiven", "Sonographie", "und", "auch", "dem", "Computertomogramm", "mit", "und", "ohne", "Kontrastdarstellung", "sowie", "in", "zunehmendem", "Mass", "auch", "der", "Kernspintomographie", ".", "4", ".", "Die", "Literatur", "zu", "den", "Erkrankungen", "der", "Speicheldruesen", "und", "ihrer", "Therapie", "ist", "kaum", "noch", "zu", "ueberblicken", "und", "bedauerlicherweise", "von", "ganz", "unterschiedlichen", "Bewertungsaspekten", "charakterisiert", ".", "Sie", "laesst", "in", "vielen", "Faellen", "vergleichende", "Diskussionen", "ueber", "bestimmte", "klinische", "und", "therapeutische", "Fragestellungen", "nur", "schwer", "zu", ".", "5", ".", "Die", "Parotischirurgie", "verlangt", "ein", "klares", "Konzept", "hinsichtlich", "der", "verschiedenen", "Erkrankungen", "insbesondere", "der", "unterschiedlichen", "Tumorentitaeten", ".", "Die", "Darstellung", "und", "Praeparation", "des", "N.", "facialis", "von", "peripher", "und", "zentral", "muessen", "gleichermassen", "beherrscht", "werden", "." ]	[ "umlsterm" ]
Karzinoms is an umlsterm, pleomorphen Adenom is an umlsterm, Speicheldruesen is an umlsterm, Mundschleimhaut is an umlsterm, Tumor is an umlsterm, pleomorphes Adenom is an umlsterm, Speicheldruesen is an umlsterm, Karzinoms is an umlsterm, Rezidivtumor is an umlsterm, Tumoren is an umlsterm, Karzinom is an umlsterm, Speicheldruesen is an umlsterm, pleomorphen Adenoms is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Literatur is an umlsterm	HNO.80460066.ger.abstr_task0	Sentence: Es wird der seltene Verlauf der Entstehung eines myoepithelialen Karzinoms in einem pleomorphen Adenom der kleinen Speicheldruesen der Mundschleimhaut vorgestellt . Der im linken Mundwinkel angesiedelte Tumor zeigte primaer ein dominierendes pleomorphes Adenom der kleinen Speicheldruesen mit einem kleinen kapselnahen Areal eines myoepithelialen Karzinoms . Im Verlauf von 2 und 5 Jahren entwickelte sich im Bereich des linken Mundwinkels 2 malig ein erbsengrosser Rezidivtumor . Die Tumoren wurden grosszuegig exzidiert . Die histologische Aufarbeitung zeigte jeweils ein myoepitheliales Karzinom der kleinen Speicheldruesen , Anteile eines pleomorphen Adenoms liessen sich nicht mehr nachweisen . Die Klinik , Diagnostik , Therapie und histologischen Merkmale unter Beruecksichtigung der Literatur werden diskutiert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Es wird der seltene Verlauf der Entstehung eines myoepithelialen Karzinoms in einem pleomorphen Adenom der kleinen Speicheldruesen der Mundschleimhaut vorgestellt . Der im linken Mundwinkel angesiedelte Tumor zeigte primaer ein dominierendes pleomorphes Adenom der kleinen Speicheldruesen mit einem kleinen kapselnahen Areal eines myoepithelialen Karzinoms . Im Verlauf von 2 und 5 Jahren entwickelte sich im Bereich des linken Mundwinkels 2 malig ein erbsengrosser Rezidivtumor . Die Tumoren wurden grosszuegig exzidiert . Die histologische Aufarbeitung zeigte jeweils ein myoepitheliales Karzinom der kleinen Speicheldruesen , Anteile eines pleomorphen Adenoms liessen sich nicht mehr nachweisen . Die Klinik , Diagnostik , Therapie und histologischen Merkmale unter Beruecksichtigung der Literatur werden diskutiert .	[ "Es", "wird", "der", "seltene", "Verlauf", "der", "Entstehung", "eines", "myoepithelialen", "Karzinoms", "in", "einem", "pleomorphen", "Adenom", "der", "kleinen", "Speicheldruesen", "der", "Mundschleimhaut", "vorgestellt", ".", "Der", "im", "linken", "Mundwinkel", "angesiedelte", "Tumor", "zeigte", "primaer", "ein", "dominierendes", "pleomorphes", "Adenom", "der", "kleinen", "Speicheldruesen", "mit", "einem", "kleinen", "kapselnahen", "Areal", "eines", "myoepithelialen", "Karzinoms", ".", "Im", "Verlauf", "von", "2", "und", "5", "Jahren", "entwickelte", "sich", "im", "Bereich", "des", "linken", "Mundwinkels", "2", "malig", "ein", "erbsengrosser", "Rezidivtumor", ".", "Die", "Tumoren", "wurden", "grosszuegig", "exzidiert", ".", "Die", "histologische", "Aufarbeitung", "zeigte", "jeweils", "ein", "myoepitheliales", "Karzinom", "der", "kleinen", "Speicheldruesen", ",", "Anteile", "eines", "pleomorphen", "Adenoms", "liessen", "sich", "nicht", "mehr", "nachweisen", ".", "Die", "Klinik", ",", "Diagnostik", ",", "Therapie", "und", "histologischen", "Merkmale", "unter", "Beruecksichtigung", "der", "Literatur", "werden", "diskutiert", "." ]	[ "umlsterm" ]
Karzinoms is an umlsterm, pleomorphen Adenom is an umlsterm, Speicheldruesen is an umlsterm, Mundschleimhaut is an umlsterm, Tumor is an umlsterm, pleomorphes Adenom is an umlsterm, Speicheldruesen is an umlsterm, Karzinoms is an umlsterm, Rezidivtumor is an umlsterm, Tumoren is an umlsterm, Karzinom is an umlsterm, Speicheldruesen is an umlsterm, pleomorphen Adenoms is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Literatur is an umlsterm	HNO.80460066.ger.abstr_task1	Sentence: Es wird der seltene Verlauf der Entstehung eines myoepithelialen Karzinoms in einem pleomorphen Adenom der kleinen Speicheldruesen der Mundschleimhaut vorgestellt . Der im linken Mundwinkel angesiedelte Tumor zeigte primaer ein dominierendes pleomorphes Adenom der kleinen Speicheldruesen mit einem kleinen kapselnahen Areal eines myoepithelialen Karzinoms . Im Verlauf von 2 und 5 Jahren entwickelte sich im Bereich des linken Mundwinkels 2 malig ein erbsengrosser Rezidivtumor . Die Tumoren wurden grosszuegig exzidiert . Die histologische Aufarbeitung zeigte jeweils ein myoepitheliales Karzinom der kleinen Speicheldruesen , Anteile eines pleomorphen Adenoms liessen sich nicht mehr nachweisen . Die Klinik , Diagnostik , Therapie und histologischen Merkmale unter Beruecksichtigung der Literatur werden diskutiert . Instructions: please typing these entity words according to sentence: Karzinoms, pleomorphen Adenom, Speicheldruesen, Mundschleimhaut, Tumor, pleomorphes Adenom, Speicheldruesen, Karzinoms, Rezidivtumor, Tumoren, Karzinom, Speicheldruesen, pleomorphen Adenoms, Diagnostik, Therapie, Literatur Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Es wird der seltene Verlauf der Entstehung eines myoepithelialen Karzinoms in einem pleomorphen Adenom der kleinen Speicheldruesen der Mundschleimhaut vorgestellt . Der im linken Mundwinkel angesiedelte Tumor zeigte primaer ein dominierendes pleomorphes Adenom der kleinen Speicheldruesen mit einem kleinen kapselnahen Areal eines myoepithelialen Karzinoms . Im Verlauf von 2 und 5 Jahren entwickelte sich im Bereich des linken Mundwinkels 2 malig ein erbsengrosser Rezidivtumor . Die Tumoren wurden grosszuegig exzidiert . Die histologische Aufarbeitung zeigte jeweils ein myoepitheliales Karzinom der kleinen Speicheldruesen , Anteile eines pleomorphen Adenoms liessen sich nicht mehr nachweisen . Die Klinik , Diagnostik , Therapie und histologischen Merkmale unter Beruecksichtigung der Literatur werden diskutiert .	[ "Es", "wird", "der", "seltene", "Verlauf", "der", "Entstehung", "eines", "myoepithelialen", "Karzinoms", "in", "einem", "pleomorphen", "Adenom", "der", "kleinen", "Speicheldruesen", "der", "Mundschleimhaut", "vorgestellt", ".", "Der", "im", "linken", "Mundwinkel", "angesiedelte", "Tumor", "zeigte", "primaer", "ein", "dominierendes", "pleomorphes", "Adenom", "der", "kleinen", "Speicheldruesen", "mit", "einem", "kleinen", "kapselnahen", "Areal", "eines", "myoepithelialen", "Karzinoms", ".", "Im", "Verlauf", "von", "2", "und", "5", "Jahren", "entwickelte", "sich", "im", "Bereich", "des", "linken", "Mundwinkels", "2", "malig", "ein", "erbsengrosser", "Rezidivtumor", ".", "Die", "Tumoren", "wurden", "grosszuegig", "exzidiert", ".", "Die", "histologische", "Aufarbeitung", "zeigte", "jeweils", "ein", "myoepitheliales", "Karzinom", "der", "kleinen", "Speicheldruesen", ",", "Anteile", "eines", "pleomorphen", "Adenoms", "liessen", "sich", "nicht", "mehr", "nachweisen", ".", "Die", "Klinik", ",", "Diagnostik", ",", "Therapie", "und", "histologischen", "Merkmale", "unter", "Beruecksichtigung", "der", "Literatur", "werden", "diskutiert", "." ]	[ "umlsterm" ]
Karzinoms, pleomorphen Adenom, Speicheldruesen, Mundschleimhaut, Tumor, pleomorphes Adenom, Speicheldruesen, Karzinoms, Rezidivtumor, Tumoren, Karzinom, Speicheldruesen, pleomorphen Adenoms, Diagnostik, Therapie, Literatur	HNO.80460066.ger.abstr_task2	Sentence: Es wird der seltene Verlauf der Entstehung eines myoepithelialen Karzinoms in einem pleomorphen Adenom der kleinen Speicheldruesen der Mundschleimhaut vorgestellt . Der im linken Mundwinkel angesiedelte Tumor zeigte primaer ein dominierendes pleomorphes Adenom der kleinen Speicheldruesen mit einem kleinen kapselnahen Areal eines myoepithelialen Karzinoms . Im Verlauf von 2 und 5 Jahren entwickelte sich im Bereich des linken Mundwinkels 2 malig ein erbsengrosser Rezidivtumor . Die Tumoren wurden grosszuegig exzidiert . Die histologische Aufarbeitung zeigte jeweils ein myoepitheliales Karzinom der kleinen Speicheldruesen , Anteile eines pleomorphen Adenoms liessen sich nicht mehr nachweisen . Die Klinik , Diagnostik , Therapie und histologischen Merkmale unter Beruecksichtigung der Literatur werden diskutiert . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Es wird der seltene Verlauf der Entstehung eines myoepithelialen Karzinoms in einem pleomorphen Adenom der kleinen Speicheldruesen der Mundschleimhaut vorgestellt . Der im linken Mundwinkel angesiedelte Tumor zeigte primaer ein dominierendes pleomorphes Adenom der kleinen Speicheldruesen mit einem kleinen kapselnahen Areal eines myoepithelialen Karzinoms . Im Verlauf von 2 und 5 Jahren entwickelte sich im Bereich des linken Mundwinkels 2 malig ein erbsengrosser Rezidivtumor . Die Tumoren wurden grosszuegig exzidiert . Die histologische Aufarbeitung zeigte jeweils ein myoepitheliales Karzinom der kleinen Speicheldruesen , Anteile eines pleomorphen Adenoms liessen sich nicht mehr nachweisen . Die Klinik , Diagnostik , Therapie und histologischen Merkmale unter Beruecksichtigung der Literatur werden diskutiert .	[ "Es", "wird", "der", "seltene", "Verlauf", "der", "Entstehung", "eines", "myoepithelialen", "Karzinoms", "in", "einem", "pleomorphen", "Adenom", "der", "kleinen", "Speicheldruesen", "der", "Mundschleimhaut", "vorgestellt", ".", "Der", "im", "linken", "Mundwinkel", "angesiedelte", "Tumor", "zeigte", "primaer", "ein", "dominierendes", "pleomorphes", "Adenom", "der", "kleinen", "Speicheldruesen", "mit", "einem", "kleinen", "kapselnahen", "Areal", "eines", "myoepithelialen", "Karzinoms", ".", "Im", "Verlauf", "von", "2", "und", "5", "Jahren", "entwickelte", "sich", "im", "Bereich", "des", "linken", "Mundwinkels", "2", "malig", "ein", "erbsengrosser", "Rezidivtumor", ".", "Die", "Tumoren", "wurden", "grosszuegig", "exzidiert", ".", "Die", "histologische", "Aufarbeitung", "zeigte", "jeweils", "ein", "myoepitheliales", "Karzinom", "der", "kleinen", "Speicheldruesen", ",", "Anteile", "eines", "pleomorphen", "Adenoms", "liessen", "sich", "nicht", "mehr", "nachweisen", ".", "Die", "Klinik", ",", "Diagnostik", ",", "Therapie", "und", "histologischen", "Merkmale", "unter", "Beruecksichtigung", "der", "Literatur", "werden", "diskutiert", "." ]	[ "umlsterm" ]
M - CSF is a Gene_or_gene_product, MAPK is a Gene_or_gene_product, ERK is a Gene_or_gene_product, Sp1 is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, mononuclear phagocytes is a Cell, tumors is a Cancer, VEGF is a Gene_or_gene_product, endothelial cell is a Cell, blood vessel is a Multi-tissue_structure, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, human is a Organism, monocytes is a Cell, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, promoter is a DNA_domain_or_region, luciferase is a Gene_or_gene_product, HIF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, promoter is a DNA_domain_or_region, luciferase is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, MAPK is a Gene_or_gene_product, ERK is a Gene_or_gene_product, Sp1 is a Gene_or_gene_product, ERK is a Gene_or_gene_product, Sp1 is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, nuclear is a Cellular_component, Sp1 is a Gene_or_gene_product, ERK is a Gene_or_gene_product, Sp1 is a Gene_or_gene_product, binding sites is a DNA_domain_or_region, VEGF is a Gene_or_gene_product, promoter is a DNA_domain_or_region, ERK is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, promoter is a DNA_domain_or_region, M - CSF is a Gene_or_gene_product, human is a Organism, monocytes is a Cell, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, mononuclear phagocytes is a Cell, VEGF is a Gene_or_gene_product, VEGF antibody is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, blood vessel is a Multi-tissue_structure, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product	30_task0	Sentence: M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. BACKGROUND: M-CSF recruits mononuclear phagocytes which regulate processes such as angiogenesis and metastases in tumors. VEGF is a potent activator of angiogenesis as it promotes endothelial cell proliferation and new blood vessel formation. Previously, we reported that in vitro M-CSF induces the expression of biologically-active VEGF from human monocytes. METHODOLOGY AND RESULTS: In this study, we demonstrate the molecular mechanism of M-CSF-induced VEGF production. Using a construct containing the VEGF promoter linked to a luciferase reporter, we found that a mutation reducing HIF binding to the VEGF promoter had no significant effect on luciferase production induced by M-CSF stimulation. Further analysis revealed that M-CSF induced VEGF through the MAPK/ERK signaling pathway via the transcription factor, Sp1. Thus, inhibition of either ERK or Sp1 suppressed M-CSF-induced VEGF at the mRNA and protein level. M-CSF also induced the nuclear localization of Sp1, which was blocked by ERK inhibition. Finally, mutating the Sp1 binding sites within the VEGF promoter or inhibiting ERK decreased VEGF promoter activity in M-CSF-treated human monocytes. To evaluate the biological significance of M-CSF induced VEGF production, we used an in vivo angiogenesis model to illustrate the ability of M-CSF to recruit mononuclear phagocytes, increase VEGF levels, and enhance angiogenesis. Importantly, the addition of a neutralizing VEGF antibody abolished M-CSF-induced blood vessel formation. CONCLUSION: These data delineate an ERK- and Sp1-dependent mechanism of M-CSF induced VEGF production and demonstrate for the first time the ability of M-CSF to induce angiogenesis via VEGF in vivo. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene_or_gene_product, Cellular_component, Organism, DNA_domain_or_region, Cancer, Multi-tissue_structure, Cell	[ "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Organism", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Cellular_component", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Organism", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O" ]	M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. BACKGROUND: M-CSF recruits mononuclear phagocytes which regulate processes such as angiogenesis and metastases in tumors. VEGF is a potent activator of angiogenesis as it promotes endothelial cell proliferation and new blood vessel formation. Previously, we reported that in vitro M-CSF induces the expression of biologically-active VEGF from human monocytes. METHODOLOGY AND RESULTS: In this study, we demonstrate the molecular mechanism of M-CSF-induced VEGF production. Using a construct containing the VEGF promoter linked to a luciferase reporter, we found that a mutation reducing HIF binding to the VEGF promoter had no significant effect on luciferase production induced by M-CSF stimulation. Further analysis revealed that M-CSF induced VEGF through the MAPK/ERK signaling pathway via the transcription factor, Sp1. Thus, inhibition of either ERK or Sp1 suppressed M-CSF-induced VEGF at the mRNA and protein level. M-CSF also induced the nuclear localization of Sp1, which was blocked by ERK inhibition. Finally, mutating the Sp1 binding sites within the VEGF promoter or inhibiting ERK decreased VEGF promoter activity in M-CSF-treated human monocytes. To evaluate the biological significance of M-CSF induced VEGF production, we used an in vivo angiogenesis model to illustrate the ability of M-CSF to recruit mononuclear phagocytes, increase VEGF levels, and enhance angiogenesis. Importantly, the addition of a neutralizing VEGF antibody abolished M-CSF-induced blood vessel formation. CONCLUSION: These data delineate an ERK- and Sp1-dependent mechanism of M-CSF induced VEGF production and demonstrate for the first time the ability of M-CSF to induce angiogenesis via VEGF in vivo.	[ "M", "-", "CSF", "signals", "through", "the", "MAPK", "/", "ERK", "pathway", "via", "Sp1", "to", "induce", "VEGF", "production", "and", "induces", "angiogenesis", "in", "vivo", ".", "\n", "BACKGROUND", ":", "M", "-", "CSF", "recruits", "mononuclear", "phagocytes", "which", "regulate", "processes", "such", "as", "angiogenesis", "and", "metastases", "in", "tumors", ".", "VEGF", "is", "a", "potent", "activator", "of", "angiogenesis", "as", "it", "promotes", "endothelial", "cell", "proliferation", "and", "new", "blood", "vessel", "formation", ".", "Previously", ",", "we", "reported", "that", "in", "vitro", "M", "-", "CSF", "induces", "the", "expression", "of", "biologically", "-", "active", "VEGF", "from", "human", "monocytes", ".", "METHODOLOGY", "AND", "RESULTS", ":", "In", "this", "study", ",", "we", "demonstrate", "the", "molecular", "mechanism", "of", "M", "-", "CSF", "-", "induced", "VEGF", "production", ".", "Using", "a", "construct", "containing", "the", "VEGF", "promoter", "linked", "to", "a", "luciferase", "reporter", ",", "we", "found", "that", "a", "mutation", "reducing", "HIF", "binding", "to", "the", "VEGF", "promoter", "had", "no", "significant", "effect", "on", "luciferase", "production", "induced", "by", "M", "-", "CSF", "stimulation", ".", "Further", "analysis", "revealed", "that", "M", "-", "CSF", "induced", "VEGF", "through", "the", "MAPK", "/", "ERK", "signaling", "pathway", "via", "the", "transcription", "factor", ",", "Sp1", ".", "Thus", ",", "inhibition", "of", "either", "ERK", "or", "Sp1", "suppressed", "M", "-", "CSF", "-", "induced", "VEGF", "at", "the", "mRNA", "and", "protein", "level", ".", "M", "-", "CSF", "also", "induced", "the", "nuclear", "localization", "of", "Sp1", ",", "which", "was", "blocked", "by", "ERK", "inhibition", ".", "Finally", ",", "mutating", "the", "Sp1", "binding", "sites", "within", "the", "VEGF", "promoter", "or", "inhibiting", "ERK", "decreased", "VEGF", "promoter", "activity", "in", "M", "-", "CSF", "-", "treated", "human", "monocytes", ".", "To", "evaluate", "the", "biological", "significance", "of", "M", "-", "CSF", "induced", "VEGF", "production", ",", "we", "used", "an", "in", "vivo", "angiogenesis", "model", "to", "illustrate", "the", "ability", "of", "M", "-", "CSF", "to", "recruit", "mononuclear", "phagocytes", ",", "increase", "VEGF", "levels", ",", "and", "enhance", "angiogenesis", ".", "Importantly", ",", "the", "addition", "of", "a", "neutralizing", "VEGF", "antibody", "abolished", "M", "-", "CSF", "-", "induced", "blood", "vessel", "formation", ".", "CONCLUSION", ":", "These", "data", "delineate", "an", "ERK-", "and", "Sp1-dependent", "mechanism", "of", "M", "-", "CSF", "induced", "VEGF", "production", "and", "demonstrate", "for", "the", "first", "time", "the", "ability", "of", "M", "-", "CSF", "to", "induce", "angiogenesis", "via", "VEGF", "in", "vivo", ".", "\n" ]	[ "Cell", "Gene_or_gene_product", "DNA_domain_or_region", "Multi-tissue_structure", "Cellular_component", "Cancer", "Organism" ]
M - CSF is a Gene_or_gene_product, MAPK is a Gene_or_gene_product, ERK is a Gene_or_gene_product, Sp1 is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, mononuclear phagocytes is a Cell, tumors is a Cancer, VEGF is a Gene_or_gene_product, endothelial cell is a Cell, blood vessel is a Multi-tissue_structure, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, human is a Organism, monocytes is a Cell, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, promoter is a DNA_domain_or_region, luciferase is a Gene_or_gene_product, HIF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, promoter is a DNA_domain_or_region, luciferase is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, MAPK is a Gene_or_gene_product, ERK is a Gene_or_gene_product, Sp1 is a Gene_or_gene_product, ERK is a Gene_or_gene_product, Sp1 is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, nuclear is a Cellular_component, Sp1 is a Gene_or_gene_product, ERK is a Gene_or_gene_product, Sp1 is a Gene_or_gene_product, binding sites is a DNA_domain_or_region, VEGF is a Gene_or_gene_product, promoter is a DNA_domain_or_region, ERK is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, promoter is a DNA_domain_or_region, M - CSF is a Gene_or_gene_product, human is a Organism, monocytes is a Cell, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, mononuclear phagocytes is a Cell, VEGF is a Gene_or_gene_product, VEGF antibody is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, blood vessel is a Multi-tissue_structure, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product	30_task1	Sentence: M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. BACKGROUND: M-CSF recruits mononuclear phagocytes which regulate processes such as angiogenesis and metastases in tumors. VEGF is a potent activator of angiogenesis as it promotes endothelial cell proliferation and new blood vessel formation. Previously, we reported that in vitro M-CSF induces the expression of biologically-active VEGF from human monocytes. METHODOLOGY AND RESULTS: In this study, we demonstrate the molecular mechanism of M-CSF-induced VEGF production. Using a construct containing the VEGF promoter linked to a luciferase reporter, we found that a mutation reducing HIF binding to the VEGF promoter had no significant effect on luciferase production induced by M-CSF stimulation. Further analysis revealed that M-CSF induced VEGF through the MAPK/ERK signaling pathway via the transcription factor, Sp1. Thus, inhibition of either ERK or Sp1 suppressed M-CSF-induced VEGF at the mRNA and protein level. M-CSF also induced the nuclear localization of Sp1, which was blocked by ERK inhibition. Finally, mutating the Sp1 binding sites within the VEGF promoter or inhibiting ERK decreased VEGF promoter activity in M-CSF-treated human monocytes. To evaluate the biological significance of M-CSF induced VEGF production, we used an in vivo angiogenesis model to illustrate the ability of M-CSF to recruit mononuclear phagocytes, increase VEGF levels, and enhance angiogenesis. Importantly, the addition of a neutralizing VEGF antibody abolished M-CSF-induced blood vessel formation. CONCLUSION: These data delineate an ERK- and Sp1-dependent mechanism of M-CSF induced VEGF production and demonstrate for the first time the ability of M-CSF to induce angiogenesis via VEGF in vivo. Instructions: please typing these entity words according to sentence: M - CSF, MAPK, ERK, Sp1, VEGF, M - CSF, mononuclear phagocytes, tumors, VEGF, endothelial cell, blood vessel, M - CSF, VEGF, human, monocytes, M - CSF, VEGF, VEGF, promoter, luciferase, HIF, VEGF, promoter, luciferase, M - CSF, M - CSF, VEGF, MAPK, ERK, Sp1, ERK, Sp1, M - CSF, VEGF, M - CSF, nuclear, Sp1, ERK, Sp1, binding sites, VEGF, promoter, ERK, VEGF, promoter, M - CSF, human, monocytes, M - CSF, VEGF, M - CSF, mononuclear phagocytes, VEGF, VEGF antibody, M - CSF, blood vessel, M - CSF, VEGF, M - CSF, VEGF Options: Gene_or_gene_product, Cellular_component, Organism, DNA_domain_or_region, Cancer, Multi-tissue_structure, Cell	[ "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Organism", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Cellular_component", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Organism", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O" ]	M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. BACKGROUND: M-CSF recruits mononuclear phagocytes which regulate processes such as angiogenesis and metastases in tumors. VEGF is a potent activator of angiogenesis as it promotes endothelial cell proliferation and new blood vessel formation. Previously, we reported that in vitro M-CSF induces the expression of biologically-active VEGF from human monocytes. METHODOLOGY AND RESULTS: In this study, we demonstrate the molecular mechanism of M-CSF-induced VEGF production. Using a construct containing the VEGF promoter linked to a luciferase reporter, we found that a mutation reducing HIF binding to the VEGF promoter had no significant effect on luciferase production induced by M-CSF stimulation. Further analysis revealed that M-CSF induced VEGF through the MAPK/ERK signaling pathway via the transcription factor, Sp1. Thus, inhibition of either ERK or Sp1 suppressed M-CSF-induced VEGF at the mRNA and protein level. M-CSF also induced the nuclear localization of Sp1, which was blocked by ERK inhibition. Finally, mutating the Sp1 binding sites within the VEGF promoter or inhibiting ERK decreased VEGF promoter activity in M-CSF-treated human monocytes. To evaluate the biological significance of M-CSF induced VEGF production, we used an in vivo angiogenesis model to illustrate the ability of M-CSF to recruit mononuclear phagocytes, increase VEGF levels, and enhance angiogenesis. Importantly, the addition of a neutralizing VEGF antibody abolished M-CSF-induced blood vessel formation. CONCLUSION: These data delineate an ERK- and Sp1-dependent mechanism of M-CSF induced VEGF production and demonstrate for the first time the ability of M-CSF to induce angiogenesis via VEGF in vivo.	[ "M", "-", "CSF", "signals", "through", "the", "MAPK", "/", "ERK", "pathway", "via", "Sp1", "to", "induce", "VEGF", "production", "and", "induces", "angiogenesis", "in", "vivo", ".", "\n", "BACKGROUND", ":", "M", "-", "CSF", "recruits", "mononuclear", "phagocytes", "which", "regulate", "processes", "such", "as", "angiogenesis", "and", "metastases", "in", "tumors", ".", "VEGF", "is", "a", "potent", "activator", "of", "angiogenesis", "as", "it", "promotes", "endothelial", "cell", "proliferation", "and", "new", "blood", "vessel", "formation", ".", "Previously", ",", "we", "reported", "that", "in", "vitro", "M", "-", "CSF", "induces", "the", "expression", "of", "biologically", "-", "active", "VEGF", "from", "human", "monocytes", ".", "METHODOLOGY", "AND", "RESULTS", ":", "In", "this", "study", ",", "we", "demonstrate", "the", "molecular", "mechanism", "of", "M", "-", "CSF", "-", "induced", "VEGF", "production", ".", "Using", "a", "construct", "containing", "the", "VEGF", "promoter", "linked", "to", "a", "luciferase", "reporter", ",", "we", "found", "that", "a", "mutation", "reducing", "HIF", "binding", "to", "the", "VEGF", "promoter", "had", "no", "significant", "effect", "on", "luciferase", "production", "induced", "by", "M", "-", "CSF", "stimulation", ".", "Further", "analysis", "revealed", "that", "M", "-", "CSF", "induced", "VEGF", "through", "the", "MAPK", "/", "ERK", "signaling", "pathway", "via", "the", "transcription", "factor", ",", "Sp1", ".", "Thus", ",", "inhibition", "of", "either", "ERK", "or", "Sp1", "suppressed", "M", "-", "CSF", "-", "induced", "VEGF", "at", "the", "mRNA", "and", "protein", "level", ".", "M", "-", "CSF", "also", "induced", "the", "nuclear", "localization", "of", "Sp1", ",", "which", "was", "blocked", "by", "ERK", "inhibition", ".", "Finally", ",", "mutating", "the", "Sp1", "binding", "sites", "within", "the", "VEGF", "promoter", "or", "inhibiting", "ERK", "decreased", "VEGF", "promoter", "activity", "in", "M", "-", "CSF", "-", "treated", "human", "monocytes", ".", "To", "evaluate", "the", "biological", "significance", "of", "M", "-", "CSF", "induced", "VEGF", "production", ",", "we", "used", "an", "in", "vivo", "angiogenesis", "model", "to", "illustrate", "the", "ability", "of", "M", "-", "CSF", "to", "recruit", "mononuclear", "phagocytes", ",", "increase", "VEGF", "levels", ",", "and", "enhance", "angiogenesis", ".", "Importantly", ",", "the", "addition", "of", "a", "neutralizing", "VEGF", "antibody", "abolished", "M", "-", "CSF", "-", "induced", "blood", "vessel", "formation", ".", "CONCLUSION", ":", "These", "data", "delineate", "an", "ERK-", "and", "Sp1-dependent", "mechanism", "of", "M", "-", "CSF", "induced", "VEGF", "production", "and", "demonstrate", "for", "the", "first", "time", "the", "ability", "of", "M", "-", "CSF", "to", "induce", "angiogenesis", "via", "VEGF", "in", "vivo", ".", "\n" ]	[ "Cell", "Gene_or_gene_product", "DNA_domain_or_region", "Multi-tissue_structure", "Cellular_component", "Cancer", "Organism" ]
M - CSF, MAPK, ERK, Sp1, VEGF, M - CSF, mononuclear phagocytes, tumors, VEGF, endothelial cell, blood vessel, M - CSF, VEGF, human, monocytes, M - CSF, VEGF, VEGF, promoter, luciferase, HIF, VEGF, promoter, luciferase, M - CSF, M - CSF, VEGF, MAPK, ERK, Sp1, ERK, Sp1, M - CSF, VEGF, M - CSF, nuclear, Sp1, ERK, Sp1, binding sites, VEGF, promoter, ERK, VEGF, promoter, M - CSF, human, monocytes, M - CSF, VEGF, M - CSF, mononuclear phagocytes, VEGF, VEGF antibody, M - CSF, blood vessel, M - CSF, VEGF, M - CSF, VEGF	30_task2	Sentence: M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. BACKGROUND: M-CSF recruits mononuclear phagocytes which regulate processes such as angiogenesis and metastases in tumors. VEGF is a potent activator of angiogenesis as it promotes endothelial cell proliferation and new blood vessel formation. Previously, we reported that in vitro M-CSF induces the expression of biologically-active VEGF from human monocytes. METHODOLOGY AND RESULTS: In this study, we demonstrate the molecular mechanism of M-CSF-induced VEGF production. Using a construct containing the VEGF promoter linked to a luciferase reporter, we found that a mutation reducing HIF binding to the VEGF promoter had no significant effect on luciferase production induced by M-CSF stimulation. Further analysis revealed that M-CSF induced VEGF through the MAPK/ERK signaling pathway via the transcription factor, Sp1. Thus, inhibition of either ERK or Sp1 suppressed M-CSF-induced VEGF at the mRNA and protein level. M-CSF also induced the nuclear localization of Sp1, which was blocked by ERK inhibition. Finally, mutating the Sp1 binding sites within the VEGF promoter or inhibiting ERK decreased VEGF promoter activity in M-CSF-treated human monocytes. To evaluate the biological significance of M-CSF induced VEGF production, we used an in vivo angiogenesis model to illustrate the ability of M-CSF to recruit mononuclear phagocytes, increase VEGF levels, and enhance angiogenesis. Importantly, the addition of a neutralizing VEGF antibody abolished M-CSF-induced blood vessel formation. CONCLUSION: These data delineate an ERK- and Sp1-dependent mechanism of M-CSF induced VEGF production and demonstrate for the first time the ability of M-CSF to induce angiogenesis via VEGF in vivo. Instructions: please extract entity words from the input sentence	[ "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Organism", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Cellular_component", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Organism", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O" ]	M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. BACKGROUND: M-CSF recruits mononuclear phagocytes which regulate processes such as angiogenesis and metastases in tumors. VEGF is a potent activator of angiogenesis as it promotes endothelial cell proliferation and new blood vessel formation. Previously, we reported that in vitro M-CSF induces the expression of biologically-active VEGF from human monocytes. METHODOLOGY AND RESULTS: In this study, we demonstrate the molecular mechanism of M-CSF-induced VEGF production. Using a construct containing the VEGF promoter linked to a luciferase reporter, we found that a mutation reducing HIF binding to the VEGF promoter had no significant effect on luciferase production induced by M-CSF stimulation. Further analysis revealed that M-CSF induced VEGF through the MAPK/ERK signaling pathway via the transcription factor, Sp1. Thus, inhibition of either ERK or Sp1 suppressed M-CSF-induced VEGF at the mRNA and protein level. M-CSF also induced the nuclear localization of Sp1, which was blocked by ERK inhibition. Finally, mutating the Sp1 binding sites within the VEGF promoter or inhibiting ERK decreased VEGF promoter activity in M-CSF-treated human monocytes. To evaluate the biological significance of M-CSF induced VEGF production, we used an in vivo angiogenesis model to illustrate the ability of M-CSF to recruit mononuclear phagocytes, increase VEGF levels, and enhance angiogenesis. Importantly, the addition of a neutralizing VEGF antibody abolished M-CSF-induced blood vessel formation. CONCLUSION: These data delineate an ERK- and Sp1-dependent mechanism of M-CSF induced VEGF production and demonstrate for the first time the ability of M-CSF to induce angiogenesis via VEGF in vivo.	[ "M", "-", "CSF", "signals", "through", "the", "MAPK", "/", "ERK", "pathway", "via", "Sp1", "to", "induce", "VEGF", "production", "and", "induces", "angiogenesis", "in", "vivo", ".", "\n", "BACKGROUND", ":", "M", "-", "CSF", "recruits", "mononuclear", "phagocytes", "which", "regulate", "processes", "such", "as", "angiogenesis", "and", "metastases", "in", "tumors", ".", "VEGF", "is", "a", "potent", "activator", "of", "angiogenesis", "as", "it", "promotes", "endothelial", "cell", "proliferation", "and", "new", "blood", "vessel", "formation", ".", "Previously", ",", "we", "reported", "that", "in", "vitro", "M", "-", "CSF", "induces", "the", "expression", "of", "biologically", "-", "active", "VEGF", "from", "human", "monocytes", ".", "METHODOLOGY", "AND", "RESULTS", ":", "In", "this", "study", ",", "we", "demonstrate", "the", "molecular", "mechanism", "of", "M", "-", "CSF", "-", "induced", "VEGF", "production", ".", "Using", "a", "construct", "containing", "the", "VEGF", "promoter", "linked", "to", "a", "luciferase", "reporter", ",", "we", "found", "that", "a", "mutation", "reducing", "HIF", "binding", "to", "the", "VEGF", "promoter", "had", "no", "significant", "effect", "on", "luciferase", "production", "induced", "by", "M", "-", "CSF", "stimulation", ".", "Further", "analysis", "revealed", "that", "M", "-", "CSF", "induced", "VEGF", "through", "the", "MAPK", "/", "ERK", "signaling", "pathway", "via", "the", "transcription", "factor", ",", "Sp1", ".", "Thus", ",", "inhibition", "of", "either", "ERK", "or", "Sp1", "suppressed", "M", "-", "CSF", "-", "induced", "VEGF", "at", "the", "mRNA", "and", "protein", "level", ".", "M", "-", "CSF", "also", "induced", "the", "nuclear", "localization", "of", "Sp1", ",", "which", "was", "blocked", "by", "ERK", "inhibition", ".", "Finally", ",", "mutating", "the", "Sp1", "binding", "sites", "within", "the", "VEGF", "promoter", "or", "inhibiting", "ERK", "decreased", "VEGF", "promoter", "activity", "in", "M", "-", "CSF", "-", "treated", "human", "monocytes", ".", "To", "evaluate", "the", "biological", "significance", "of", "M", "-", "CSF", "induced", "VEGF", "production", ",", "we", "used", "an", "in", "vivo", "angiogenesis", "model", "to", "illustrate", "the", "ability", "of", "M", "-", "CSF", "to", "recruit", "mononuclear", "phagocytes", ",", "increase", "VEGF", "levels", ",", "and", "enhance", "angiogenesis", ".", "Importantly", ",", "the", "addition", "of", "a", "neutralizing", "VEGF", "antibody", "abolished", "M", "-", "CSF", "-", "induced", "blood", "vessel", "formation", ".", "CONCLUSION", ":", "These", "data", "delineate", "an", "ERK-", "and", "Sp1-dependent", "mechanism", "of", "M", "-", "CSF", "induced", "VEGF", "production", "and", "demonstrate", "for", "the", "first", "time", "the", "ability", "of", "M", "-", "CSF", "to", "induce", "angiogenesis", "via", "VEGF", "in", "vivo", ".", "\n" ]	[ "Cell", "Gene_or_gene_product", "DNA_domain_or_region", "Multi-tissue_structure", "Cellular_component", "Cancer", "Organism" ]
LMP1 is a Protein, LMP1 is a Protein, IL4 is a Protein, LMP1 is a Protein, LMP1 is a Protein, CD19 is a Protein, LMP1 is a Protein, IL4 is a Protein, LMP1 is a Protein, IL4 is a Protein, LMP1 is a Protein	60_task0	Sentence: LMP1 Promotes B Cell Survival and Proliferation In Vitro (A) MTS assay of splenocytes from WT and LMP1 transgenic mice. Splenocytes were cultured in the presence (grey bars) or absence (black bars) of IL4 for 3 d. The results are the mean +/- SEM of triplicate samples averaged from multiple mice where "n" the number of mice analyzed is as follows: n = 2 for WT lymphocytes and WT lymphomas, n = 11 for LMP1 transgenic lymphocytes, and n = 13 for LMP1 transgenic lymphomas. (B) EMA exclusion of CD19+ gated splenocytes from WT and LMP1 transgenic mice showing percentage of viable B cells cultured with (white bars) or without (black bars) IL4 for 2 d. (C) Flow cytometry analysis for incorporated BrdU in WT and LMP1 transgenic lymphoma cells cultured with or without IL4 for 2 d. Shown are the results from WT lymphoma 1 and LMP1 transgenic lymphoma 2. Percentages of cells in each quadrant are shown. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	LMP1 Promotes B Cell Survival and Proliferation In Vitro (A) MTS assay of splenocytes from WT and LMP1 transgenic mice. Splenocytes were cultured in the presence (grey bars) or absence (black bars) of IL4 for 3 d. The results are the mean +/- SEM of triplicate samples averaged from multiple mice where "n" the number of mice analyzed is as follows: n = 2 for WT lymphocytes and WT lymphomas, n = 11 for LMP1 transgenic lymphocytes, and n = 13 for LMP1 transgenic lymphomas. (B) EMA exclusion of CD19+ gated splenocytes from WT and LMP1 transgenic mice showing percentage of viable B cells cultured with (white bars) or without (black bars) IL4 for 2 d. (C) Flow cytometry analysis for incorporated BrdU in WT and LMP1 transgenic lymphoma cells cultured with or without IL4 for 2 d. Shown are the results from WT lymphoma 1 and LMP1 transgenic lymphoma 2. Percentages of cells in each quadrant are shown.	[ "LMP1", "Promotes", "B", "Cell", "Survival", "and", "Proliferation", "In", "Vitro", "\n", "(", "A", ")", "MTS", "assay", "of", "splenocytes", "from", "WT", "and", "LMP1", "transgenic", "mice", ".", "Splenocytes", "were", "cultured", "in", "the", "presence", "(", "grey", "bars", ")", "or", "absence", "(", "black", "bars", ")", "of", "IL4", "for", "3", "d.", "The", "results", "are", "the", "mean", "+", "/-", "SEM", "of", "triplicate", "samples", "averaged", "from", "multiple", "mice", "where", "\"", "n", "\"", "the", "number", "of", "mice", "analyzed", "is", "as", "follows", ":", "n", "=", "2", "for", "WT", "lymphocytes", "and", "WT", "lymphomas", ",", "n", "=", "11", "for", "LMP1", "transgenic", "lymphocytes", ",", "and", "n", "=", "13", "for", "LMP1", "transgenic", "lymphomas", ".", "\n", "(", "B", ")", "EMA", "exclusion", "of", "CD19", "+", "gated", "splenocytes", "from", "WT", "and", "LMP1", "transgenic", "mice", "showing", "percentage", "of", "viable", "B", "cells", "cultured", "with", "(", "white", "bars", ")", "or", "without", "(", "black", "bars", ")", "IL4", "for", "2", "d.", "\n", "(", "C", ")", "Flow", "cytometry", "analysis", "for", "incorporated", "BrdU", "in", "WT", "and", "LMP1", "transgenic", "lymphoma", "cells", "cultured", "with", "or", "without", "IL4", "for", "2", "d.", "Shown", "are", "the", "results", "from", "WT", "lymphoma", "1", "and", "LMP1", "transgenic", "lymphoma", "2", ".", "Percentages", "of", "cells", "in", "each", "quadrant", "are", "shown", ".", "\n" ]	[ "Protein" ]
LMP1 is a Protein, LMP1 is a Protein, IL4 is a Protein, LMP1 is a Protein, LMP1 is a Protein, CD19 is a Protein, LMP1 is a Protein, IL4 is a Protein, LMP1 is a Protein, IL4 is a Protein, LMP1 is a Protein	60_task1	Sentence: LMP1 Promotes B Cell Survival and Proliferation In Vitro (A) MTS assay of splenocytes from WT and LMP1 transgenic mice. Splenocytes were cultured in the presence (grey bars) or absence (black bars) of IL4 for 3 d. The results are the mean +/- SEM of triplicate samples averaged from multiple mice where "n" the number of mice analyzed is as follows: n = 2 for WT lymphocytes and WT lymphomas, n = 11 for LMP1 transgenic lymphocytes, and n = 13 for LMP1 transgenic lymphomas. (B) EMA exclusion of CD19+ gated splenocytes from WT and LMP1 transgenic mice showing percentage of viable B cells cultured with (white bars) or without (black bars) IL4 for 2 d. (C) Flow cytometry analysis for incorporated BrdU in WT and LMP1 transgenic lymphoma cells cultured with or without IL4 for 2 d. Shown are the results from WT lymphoma 1 and LMP1 transgenic lymphoma 2. Percentages of cells in each quadrant are shown. Instructions: please typing these entity words according to sentence: LMP1, LMP1, IL4, LMP1, LMP1, CD19, LMP1, IL4, LMP1, IL4, LMP1 Options: Protein	[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	LMP1 Promotes B Cell Survival and Proliferation In Vitro (A) MTS assay of splenocytes from WT and LMP1 transgenic mice. Splenocytes were cultured in the presence (grey bars) or absence (black bars) of IL4 for 3 d. The results are the mean +/- SEM of triplicate samples averaged from multiple mice where "n" the number of mice analyzed is as follows: n = 2 for WT lymphocytes and WT lymphomas, n = 11 for LMP1 transgenic lymphocytes, and n = 13 for LMP1 transgenic lymphomas. (B) EMA exclusion of CD19+ gated splenocytes from WT and LMP1 transgenic mice showing percentage of viable B cells cultured with (white bars) or without (black bars) IL4 for 2 d. (C) Flow cytometry analysis for incorporated BrdU in WT and LMP1 transgenic lymphoma cells cultured with or without IL4 for 2 d. Shown are the results from WT lymphoma 1 and LMP1 transgenic lymphoma 2. Percentages of cells in each quadrant are shown.	[ "LMP1", "Promotes", "B", "Cell", "Survival", "and", "Proliferation", "In", "Vitro", "\n", "(", "A", ")", "MTS", "assay", "of", "splenocytes", "from", "WT", "and", "LMP1", "transgenic", "mice", ".", "Splenocytes", "were", "cultured", "in", "the", "presence", "(", "grey", "bars", ")", "or", "absence", "(", "black", "bars", ")", "of", "IL4", "for", "3", "d.", "The", "results", "are", "the", "mean", "+", "/-", "SEM", "of", "triplicate", "samples", "averaged", "from", "multiple", "mice", "where", "\"", "n", "\"", "the", "number", "of", "mice", "analyzed", "is", "as", "follows", ":", "n", "=", "2", "for", "WT", "lymphocytes", "and", "WT", "lymphomas", ",", "n", "=", "11", "for", "LMP1", "transgenic", "lymphocytes", ",", "and", "n", "=", "13", "for", "LMP1", "transgenic", "lymphomas", ".", "\n", "(", "B", ")", "EMA", "exclusion", "of", "CD19", "+", "gated", "splenocytes", "from", "WT", "and", "LMP1", "transgenic", "mice", "showing", "percentage", "of", "viable", "B", "cells", "cultured", "with", "(", "white", "bars", ")", "or", "without", "(", "black", "bars", ")", "IL4", "for", "2", "d.", "\n", "(", "C", ")", "Flow", "cytometry", "analysis", "for", "incorporated", "BrdU", "in", "WT", "and", "LMP1", "transgenic", "lymphoma", "cells", "cultured", "with", "or", "without", "IL4", "for", "2", "d.", "Shown", "are", "the", "results", "from", "WT", "lymphoma", "1", "and", "LMP1", "transgenic", "lymphoma", "2", ".", "Percentages", "of", "cells", "in", "each", "quadrant", "are", "shown", ".", "\n" ]	[ "Protein" ]
LMP1, LMP1, IL4, LMP1, LMP1, CD19, LMP1, IL4, LMP1, IL4, LMP1	60_task2	Sentence: LMP1 Promotes B Cell Survival and Proliferation In Vitro (A) MTS assay of splenocytes from WT and LMP1 transgenic mice. Splenocytes were cultured in the presence (grey bars) or absence (black bars) of IL4 for 3 d. The results are the mean +/- SEM of triplicate samples averaged from multiple mice where "n" the number of mice analyzed is as follows: n = 2 for WT lymphocytes and WT lymphomas, n = 11 for LMP1 transgenic lymphocytes, and n = 13 for LMP1 transgenic lymphomas. (B) EMA exclusion of CD19+ gated splenocytes from WT and LMP1 transgenic mice showing percentage of viable B cells cultured with (white bars) or without (black bars) IL4 for 2 d. (C) Flow cytometry analysis for incorporated BrdU in WT and LMP1 transgenic lymphoma cells cultured with or without IL4 for 2 d. Shown are the results from WT lymphoma 1 and LMP1 transgenic lymphoma 2. Percentages of cells in each quadrant are shown. Instructions: please extract entity words from the input sentence	[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	LMP1 Promotes B Cell Survival and Proliferation In Vitro (A) MTS assay of splenocytes from WT and LMP1 transgenic mice. Splenocytes were cultured in the presence (grey bars) or absence (black bars) of IL4 for 3 d. The results are the mean +/- SEM of triplicate samples averaged from multiple mice where "n" the number of mice analyzed is as follows: n = 2 for WT lymphocytes and WT lymphomas, n = 11 for LMP1 transgenic lymphocytes, and n = 13 for LMP1 transgenic lymphomas. (B) EMA exclusion of CD19+ gated splenocytes from WT and LMP1 transgenic mice showing percentage of viable B cells cultured with (white bars) or without (black bars) IL4 for 2 d. (C) Flow cytometry analysis for incorporated BrdU in WT and LMP1 transgenic lymphoma cells cultured with or without IL4 for 2 d. Shown are the results from WT lymphoma 1 and LMP1 transgenic lymphoma 2. Percentages of cells in each quadrant are shown.	[ "LMP1", "Promotes", "B", "Cell", "Survival", "and", "Proliferation", "In", "Vitro", "\n", "(", "A", ")", "MTS", "assay", "of", "splenocytes", "from", "WT", "and", "LMP1", "transgenic", "mice", ".", "Splenocytes", "were", "cultured", "in", "the", "presence", "(", "grey", "bars", ")", "or", "absence", "(", "black", "bars", ")", "of", "IL4", "for", "3", "d.", "The", "results", "are", "the", "mean", "+", "/-", "SEM", "of", "triplicate", "samples", "averaged", "from", "multiple", "mice", "where", "\"", "n", "\"", "the", "number", "of", "mice", "analyzed", "is", "as", "follows", ":", "n", "=", "2", "for", "WT", "lymphocytes", "and", "WT", "lymphomas", ",", "n", "=", "11", "for", "LMP1", "transgenic", "lymphocytes", ",", "and", "n", "=", "13", "for", "LMP1", "transgenic", "lymphomas", ".", "\n", "(", "B", ")", "EMA", "exclusion", "of", "CD19", "+", "gated", "splenocytes", "from", "WT", "and", "LMP1", "transgenic", "mice", "showing", "percentage", "of", "viable", "B", "cells", "cultured", "with", "(", "white", "bars", ")", "or", "without", "(", "black", "bars", ")", "IL4", "for", "2", "d.", "\n", "(", "C", ")", "Flow", "cytometry", "analysis", "for", "incorporated", "BrdU", "in", "WT", "and", "LMP1", "transgenic", "lymphoma", "cells", "cultured", "with", "or", "without", "IL4", "for", "2", "d.", "Shown", "are", "the", "results", "from", "WT", "lymphoma", "1", "and", "LMP1", "transgenic", "lymphoma", "2", ".", "Percentages", "of", "cells", "in", "each", "quadrant", "are", "shown", ".", "\n" ]	[ "Protein" ]
polyethylene glycol is a compound, Na2SO4 is a compound, pectinase is a protein, pectinase is a protein	DS.d535_task0	Sentence: Concentrations of polyethylene glycol 1000 and Na2SO4 were selected as independent variables to evaluate their impact on parameters of partitioning in aqueous two-phase system--the partition coefficient of pectinase, purification factor and pectinase yield. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "B-compound", "I-compound", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein", "O", "O" ]	Concentrations of polyethylene glycol 1000 and Na2SO4 were selected as independent variables to evaluate their impact on parameters of partitioning in aqueous two-phase system--the partition coefficient of pectinase, purification factor and pectinase yield.	[ "Concentrations", "of", "polyethylene", "glycol", "1000", "and", "Na2SO4", "were", "selected", "as", "independent", "variables", "to", "evaluate", "their", "impact", "on", "parameters", "of", "partitioning", "in", "aqueous", "two", "-", "phase", "system", "--", "the", "partition", "coefficient", "of", "pectinase", ",", "purification", "factor", "and", "pectinase", "yield", "." ]	[ "compound", "protein" ]
polyethylene glycol is a compound, Na2SO4 is a compound, pectinase is a protein, pectinase is a protein	DS.d535_task1	Sentence: Concentrations of polyethylene glycol 1000 and Na2SO4 were selected as independent variables to evaluate their impact on parameters of partitioning in aqueous two-phase system--the partition coefficient of pectinase, purification factor and pectinase yield. Instructions: please typing these entity words according to sentence: polyethylene glycol, Na2SO4, pectinase, pectinase Options: compound, protein	[ "O", "O", "B-compound", "I-compound", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein", "O", "O" ]	Concentrations of polyethylene glycol 1000 and Na2SO4 were selected as independent variables to evaluate their impact on parameters of partitioning in aqueous two-phase system--the partition coefficient of pectinase, purification factor and pectinase yield.	[ "Concentrations", "of", "polyethylene", "glycol", "1000", "and", "Na2SO4", "were", "selected", "as", "independent", "variables", "to", "evaluate", "their", "impact", "on", "parameters", "of", "partitioning", "in", "aqueous", "two", "-", "phase", "system", "--", "the", "partition", "coefficient", "of", "pectinase", ",", "purification", "factor", "and", "pectinase", "yield", "." ]	[ "compound", "protein" ]
polyethylene glycol, Na2SO4, pectinase, pectinase	DS.d535_task2	Sentence: Concentrations of polyethylene glycol 1000 and Na2SO4 were selected as independent variables to evaluate their impact on parameters of partitioning in aqueous two-phase system--the partition coefficient of pectinase, purification factor and pectinase yield. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-compound", "I-compound", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein", "O", "O" ]	Concentrations of polyethylene glycol 1000 and Na2SO4 were selected as independent variables to evaluate their impact on parameters of partitioning in aqueous two-phase system--the partition coefficient of pectinase, purification factor and pectinase yield.	[ "Concentrations", "of", "polyethylene", "glycol", "1000", "and", "Na2SO4", "were", "selected", "as", "independent", "variables", "to", "evaluate", "their", "impact", "on", "parameters", "of", "partitioning", "in", "aqueous", "two", "-", "phase", "system", "--", "the", "partition", "coefficient", "of", "pectinase", ",", "purification", "factor", "and", "pectinase", "yield", "." ]	[ "compound", "protein" ]
vasopressin is a CHEMICAL, oxytocin is a CHEMICAL, V1a is a GENE-Y, V1b is a GENE-Y, V2 is a GENE-Y, OT receptors is a GENE-Y	18655903_task0	Sentence: Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O" ]	Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.	[ "Peptide", "and", "non", "-", "peptide", "agonists", "and", "antagonists", "for", "the", "vasopressin", "and", "oxytocin", "V1a", ",", "V1b", ",", "V2", "and", "OT", "receptors", ":", "research", "tools", "and", "potential", "therapeutic", "agents", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
vasopressin is a CHEMICAL, oxytocin is a CHEMICAL, V1a is a GENE-Y, V1b is a GENE-Y, V2 is a GENE-Y, OT receptors is a GENE-Y	18655903_task1	Sentence: Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Instructions: please typing these entity words according to sentence: vasopressin, oxytocin, V1a, V1b, V2, OT receptors Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O" ]	Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.	[ "Peptide", "and", "non", "-", "peptide", "agonists", "and", "antagonists", "for", "the", "vasopressin", "and", "oxytocin", "V1a", ",", "V1b", ",", "V2", "and", "OT", "receptors", ":", "research", "tools", "and", "potential", "therapeutic", "agents", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
vasopressin, oxytocin, V1a, V1b, V2, OT receptors	18655903_task2	Sentence: Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O" ]	Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.	[ "Peptide", "and", "non", "-", "peptide", "agonists", "and", "antagonists", "for", "the", "vasopressin", "and", "oxytocin", "V1a", ",", "V1b", ",", "V2", "and", "OT", "receptors", ":", "research", "tools", "and", "potential", "therapeutic", "agents", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
huGATA-3 transcription is an other_name, GATA regulatory elements is a DNA_domain_or_region, HIV-1 long terminal repeat is a DNA_domain_or_region, surface plasmon resonance is an other_name	54173_task0	Sentence: Analysis of interactions between huGATA-3 transcription factor and three GATA regulatory elements of HIV-1 long terminal repeat, by surface plasmon resonance. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region, other_name	[ "O", "O", "O", "O", "B-other_name", "I-other_name", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]	Analysis of interactions between huGATA-3 transcription factor and three GATA regulatory elements of HIV-1 long terminal repeat, by surface plasmon resonance.	[ "Analysis", "of", "interactions", "between", "huGATA-3", "transcription", "factor", "and", "three", "GATA", "regulatory", "elements", "of", "HIV-1", "long", "terminal", "repeat", ",", "by", "surface", "plasmon", "resonance", "." ]	[ "DNA_domain_or_region", "other_name", "protein_molecule", "protein_family_or_group", "(AND DNA_domain_or_region DNA_domain_or_region DNA_domain_or_region)", "cell_component", "virus", "" ]
huGATA-3 transcription is an other_name, GATA regulatory elements is a DNA_domain_or_region, HIV-1 long terminal repeat is a DNA_domain_or_region, surface plasmon resonance is an other_name	54173_task1	Sentence: Analysis of interactions between huGATA-3 transcription factor and three GATA regulatory elements of HIV-1 long terminal repeat, by surface plasmon resonance. Instructions: please typing these entity words according to sentence: huGATA-3 transcription, GATA regulatory elements, HIV-1 long terminal repeat, surface plasmon resonance Options: DNA_domain_or_region, other_name	[ "O", "O", "O", "O", "B-other_name", "I-other_name", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]	Analysis of interactions between huGATA-3 transcription factor and three GATA regulatory elements of HIV-1 long terminal repeat, by surface plasmon resonance.	[ "Analysis", "of", "interactions", "between", "huGATA-3", "transcription", "factor", "and", "three", "GATA", "regulatory", "elements", "of", "HIV-1", "long", "terminal", "repeat", ",", "by", "surface", "plasmon", "resonance", "." ]	[ "DNA_domain_or_region", "other_name", "protein_molecule", "protein_family_or_group", "(AND DNA_domain_or_region DNA_domain_or_region DNA_domain_or_region)", "cell_component", "virus", "" ]
huGATA-3 transcription, GATA regulatory elements, HIV-1 long terminal repeat, surface plasmon resonance	54173_task2	Sentence: Analysis of interactions between huGATA-3 transcription factor and three GATA regulatory elements of HIV-1 long terminal repeat, by surface plasmon resonance. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-other_name", "I-other_name", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]	Analysis of interactions between huGATA-3 transcription factor and three GATA regulatory elements of HIV-1 long terminal repeat, by surface plasmon resonance.	[ "Analysis", "of", "interactions", "between", "huGATA-3", "transcription", "factor", "and", "three", "GATA", "regulatory", "elements", "of", "HIV-1", "long", "terminal", "repeat", ",", "by", "surface", "plasmon", "resonance", "." ]	[ "DNA_domain_or_region", "other_name", "protein_molecule", "protein_family_or_group", "(AND DNA_domain_or_region DNA_domain_or_region DNA_domain_or_region)", "cell_component", "virus", "" ]
interleukin-2 receptor alpha chain expression is an other_name, nuclear factor.kappa B activation is an other_name, protein kinase C is a protein_molecule, T lymphocytes is a cell_type, tumor necrosis factor alpha is a protein_molecule	11994_task0	Sentence: Regulation of interleukin-2 receptor alpha chain expression and nuclear factor.kappa B activation by protein kinase C in T lymphocytes. Autocrine role of tumor necrosis factor alpha. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, protein_molecule, other_name	[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_type", "I-cell_type", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]	Regulation of interleukin-2 receptor alpha chain expression and nuclear factor.kappa B activation by protein kinase C in T lymphocytes. Autocrine role of tumor necrosis factor alpha.	[ "Regulation", "of", "interleukin-2", "receptor", "alpha", "chain", "expression", "and", "nuclear", "factor.kappa", "B", "activation", "by", "protein", "kinase", "C", "in", "T", "lymphocytes", ".", "Autocrine", "role", "of", "tumor", "necrosis", "factor", "alpha", "." ]	[ "other_name", "protein_molecule", "protein_subunit", "DNA_domain_or_region", "cell_component", "cell_type", "protein_family_or_group", "other_organic_compound", "protein_complex" ]
interleukin-2 receptor alpha chain expression is an other_name, nuclear factor.kappa B activation is an other_name, protein kinase C is a protein_molecule, T lymphocytes is a cell_type, tumor necrosis factor alpha is a protein_molecule	11994_task1	Sentence: Regulation of interleukin-2 receptor alpha chain expression and nuclear factor.kappa B activation by protein kinase C in T lymphocytes. Autocrine role of tumor necrosis factor alpha. Instructions: please typing these entity words according to sentence: interleukin-2 receptor alpha chain expression, nuclear factor.kappa B activation, protein kinase C, T lymphocytes, tumor necrosis factor alpha Options: cell_type, protein_molecule, other_name	[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_type", "I-cell_type", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]	Regulation of interleukin-2 receptor alpha chain expression and nuclear factor.kappa B activation by protein kinase C in T lymphocytes. Autocrine role of tumor necrosis factor alpha.	[ "Regulation", "of", "interleukin-2", "receptor", "alpha", "chain", "expression", "and", "nuclear", "factor.kappa", "B", "activation", "by", "protein", "kinase", "C", "in", "T", "lymphocytes", ".", "Autocrine", "role", "of", "tumor", "necrosis", "factor", "alpha", "." ]	[ "other_name", "protein_molecule", "protein_subunit", "DNA_domain_or_region", "cell_component", "cell_type", "protein_family_or_group", "other_organic_compound", "protein_complex" ]
interleukin-2 receptor alpha chain expression, nuclear factor.kappa B activation, protein kinase C, T lymphocytes, tumor necrosis factor alpha	11994_task2	Sentence: Regulation of interleukin-2 receptor alpha chain expression and nuclear factor.kappa B activation by protein kinase C in T lymphocytes. Autocrine role of tumor necrosis factor alpha. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_type", "I-cell_type", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]	Regulation of interleukin-2 receptor alpha chain expression and nuclear factor.kappa B activation by protein kinase C in T lymphocytes. Autocrine role of tumor necrosis factor alpha.	[ "Regulation", "of", "interleukin-2", "receptor", "alpha", "chain", "expression", "and", "nuclear", "factor.kappa", "B", "activation", "by", "protein", "kinase", "C", "in", "T", "lymphocytes", ".", "Autocrine", "role", "of", "tumor", "necrosis", "factor", "alpha", "." ]	[ "other_name", "protein_molecule", "protein_subunit", "DNA_domain_or_region", "cell_component", "cell_type", "protein_family_or_group", "other_organic_compound", "protein_complex" ]
Sicherheit is an umlsterm, Sumatriptan is an umlsterm, Akuttherapie is an umlsterm, Clusterkopfschmerzen is an umlsterm, Patienten is an umlsterm, Clusterkopfschmerz is an umlsterm, Patienten is an umlsterm, Sumatriptan is an umlsterm, Dokumentation is an umlsterm, Patienten is an umlsterm, Schmerzkalenders is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Injektion is an umlsterm, Schmerzfreiheit is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Sumatriptan is an umlsterm, Akuttherapie is an umlsterm, Kontraindikationen is an umlsterm	DerNervenarzt.80690320.ger.abstr_task0	Sentence: Die Wirksamkeit , Sicherheit und Vertraeglichkeit von Sumatriptan s.c. in der Akuttherapie von Clusterkopfschmerzen wurde in einer offenen multizentrischen Studie in einem Untersuchungszeitraum von bis zu einem Jahr ueberprueft . Hieran nahmen von Dezember 1992 bis Oktober 1993 52 Patienten mit episodischem ( 71% und chronischem ( 29% ) Clusterkopfschmerz ) teil . Die Patienten konnten waehrend der Studie Clusterattacken selbstaendig und ausserhalb der Klinik mit 6 mg Sumatriptan behandeln . Die Dokumentation der entsprechenden Zielparameter wurde von den Patienten mit Hilfe eines Schmerzkalenders durchgefuehrt . Insgesamt wurden 2031 Attacken ausgewertet . Eine erfolgreiche Therapie trat bei 88% aller Attacken ein , 57% der Patienten waren innerhalb 15 min nach der Injektion komplett schmerzfrei . Schmerzfreiheit innerhalb von 15 min in ueber 90% aller behandelten Attacken wurde von 42% der Patienten erreicht . Ein Nachlassen der Therapierfolgsrate im Behandlungszeitraum trat nicht ein . Wegen mangelnder Wirksamkeit oder unerwuenschter Ereignisse wurde die Studie von 10% der Patienten abgebrochen . Ueber unerwuenschte Ereignisse berichteten 62% der Patienten , davon wurden 3,8% als schwerwiegend eingestuft . Sumatriptan s.c. stellt in der Akuttherapie des Clusterkopschmerzes ein zuverlaessiges , schnell wirksames und bei Beachtung von Kontraindikationen sicheres und gut vertraegliches Therapeutikum dar . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Die Wirksamkeit , Sicherheit und Vertraeglichkeit von Sumatriptan s.c. in der Akuttherapie von Clusterkopfschmerzen wurde in einer offenen multizentrischen Studie in einem Untersuchungszeitraum von bis zu einem Jahr ueberprueft . Hieran nahmen von Dezember 1992 bis Oktober 1993 52 Patienten mit episodischem ( 71% und chronischem ( 29% ) Clusterkopfschmerz ) teil . Die Patienten konnten waehrend der Studie Clusterattacken selbstaendig und ausserhalb der Klinik mit 6 mg Sumatriptan behandeln . Die Dokumentation der entsprechenden Zielparameter wurde von den Patienten mit Hilfe eines Schmerzkalenders durchgefuehrt . Insgesamt wurden 2031 Attacken ausgewertet . Eine erfolgreiche Therapie trat bei 88% aller Attacken ein , 57% der Patienten waren innerhalb 15 min nach der Injektion komplett schmerzfrei . Schmerzfreiheit innerhalb von 15 min in ueber 90% aller behandelten Attacken wurde von 42% der Patienten erreicht . Ein Nachlassen der Therapierfolgsrate im Behandlungszeitraum trat nicht ein . Wegen mangelnder Wirksamkeit oder unerwuenschter Ereignisse wurde die Studie von 10% der Patienten abgebrochen . Ueber unerwuenschte Ereignisse berichteten 62% der Patienten , davon wurden 3,8% als schwerwiegend eingestuft . Sumatriptan s.c. stellt in der Akuttherapie des Clusterkopschmerzes ein zuverlaessiges , schnell wirksames und bei Beachtung von Kontraindikationen sicheres und gut vertraegliches Therapeutikum dar .	[ "Die", "Wirksamkeit", ",", "Sicherheit", "und", "Vertraeglichkeit", "von", "Sumatriptan", "s.c", ".", "in", "der", "Akuttherapie", "von", "Clusterkopfschmerzen", "wurde", "in", "einer", "offenen", "multizentrischen", "Studie", "in", "einem", "Untersuchungszeitraum", "von", "bis", "zu", "einem", "Jahr", "ueberprueft", ".", "Hieran", "nahmen", "von", "Dezember", "1992", "bis", "Oktober", "1993", "52", "Patienten", "mit", "episodischem", "(", "71", "%", "und", "chronischem", "(", "29", "%", ")", "Clusterkopfschmerz", ")", "teil", ".", "Die", "Patienten", "konnten", "waehrend", "der", "Studie", "Clusterattacken", "selbstaendig", "und", "ausserhalb", "der", "Klinik", "mit", "6", "mg", "Sumatriptan", "behandeln", ".", "Die", "Dokumentation", "der", "entsprechenden", "Zielparameter", "wurde", "von", "den", "Patienten", "mit", "Hilfe", "eines", "Schmerzkalenders", "durchgefuehrt", ".", "Insgesamt", "wurden", "2031", "Attacken", "ausgewertet", ".", "Eine", "erfolgreiche", "Therapie", "trat", "bei", "88", "%", "aller", "Attacken", "ein", ",", "57", "%", "der", "Patienten", "waren", "innerhalb", "15", "min", "nach", "der", "Injektion", "komplett", "schmerzfrei", ".", "Schmerzfreiheit", "innerhalb", "von", "15", "min", "in", "ueber", "90", "%", "aller", "behandelten", "Attacken", "wurde", "von", "42", "%", "der", "Patienten", "erreicht", ".", "Ein", "Nachlassen", "der", "Therapierfolgsrate", "im", "Behandlungszeitraum", "trat", "nicht", "ein", ".", "Wegen", "mangelnder", "Wirksamkeit", "oder", "unerwuenschter", "Ereignisse", "wurde", "die", "Studie", "von", "10", "%", "der", "Patienten", "abgebrochen", ".", "Ueber", "unerwuenschte", "Ereignisse", "berichteten", "62", "%", "der", "Patienten", ",", "davon", "wurden", "3,8", "%", "als", "schwerwiegend", "eingestuft", ".", "Sumatriptan", "s.c", ".", "stellt", "in", "der", "Akuttherapie", "des", "Clusterkopschmerzes", "ein", "zuverlaessiges", ",", "schnell", "wirksames", "und", "bei", "Beachtung", "von", "Kontraindikationen", "sicheres", "und", "gut", "vertraegliches", "Therapeutikum", "dar", "." ]	[ "umlsterm" ]
Sicherheit is an umlsterm, Sumatriptan is an umlsterm, Akuttherapie is an umlsterm, Clusterkopfschmerzen is an umlsterm, Patienten is an umlsterm, Clusterkopfschmerz is an umlsterm, Patienten is an umlsterm, Sumatriptan is an umlsterm, Dokumentation is an umlsterm, Patienten is an umlsterm, Schmerzkalenders is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Injektion is an umlsterm, Schmerzfreiheit is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Sumatriptan is an umlsterm, Akuttherapie is an umlsterm, Kontraindikationen is an umlsterm	DerNervenarzt.80690320.ger.abstr_task1	Sentence: Die Wirksamkeit , Sicherheit und Vertraeglichkeit von Sumatriptan s.c. in der Akuttherapie von Clusterkopfschmerzen wurde in einer offenen multizentrischen Studie in einem Untersuchungszeitraum von bis zu einem Jahr ueberprueft . Hieran nahmen von Dezember 1992 bis Oktober 1993 52 Patienten mit episodischem ( 71% und chronischem ( 29% ) Clusterkopfschmerz ) teil . Die Patienten konnten waehrend der Studie Clusterattacken selbstaendig und ausserhalb der Klinik mit 6 mg Sumatriptan behandeln . Die Dokumentation der entsprechenden Zielparameter wurde von den Patienten mit Hilfe eines Schmerzkalenders durchgefuehrt . Insgesamt wurden 2031 Attacken ausgewertet . Eine erfolgreiche Therapie trat bei 88% aller Attacken ein , 57% der Patienten waren innerhalb 15 min nach der Injektion komplett schmerzfrei . Schmerzfreiheit innerhalb von 15 min in ueber 90% aller behandelten Attacken wurde von 42% der Patienten erreicht . Ein Nachlassen der Therapierfolgsrate im Behandlungszeitraum trat nicht ein . Wegen mangelnder Wirksamkeit oder unerwuenschter Ereignisse wurde die Studie von 10% der Patienten abgebrochen . Ueber unerwuenschte Ereignisse berichteten 62% der Patienten , davon wurden 3,8% als schwerwiegend eingestuft . Sumatriptan s.c. stellt in der Akuttherapie des Clusterkopschmerzes ein zuverlaessiges , schnell wirksames und bei Beachtung von Kontraindikationen sicheres und gut vertraegliches Therapeutikum dar . Instructions: please typing these entity words according to sentence: Sicherheit, Sumatriptan, Akuttherapie, Clusterkopfschmerzen, Patienten, Clusterkopfschmerz, Patienten, Sumatriptan, Dokumentation, Patienten, Schmerzkalenders, Therapie, Patienten, Injektion, Schmerzfreiheit, Patienten, Patienten, Patienten, Sumatriptan, Akuttherapie, Kontraindikationen Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Die Wirksamkeit , Sicherheit und Vertraeglichkeit von Sumatriptan s.c. in der Akuttherapie von Clusterkopfschmerzen wurde in einer offenen multizentrischen Studie in einem Untersuchungszeitraum von bis zu einem Jahr ueberprueft . Hieran nahmen von Dezember 1992 bis Oktober 1993 52 Patienten mit episodischem ( 71% und chronischem ( 29% ) Clusterkopfschmerz ) teil . Die Patienten konnten waehrend der Studie Clusterattacken selbstaendig und ausserhalb der Klinik mit 6 mg Sumatriptan behandeln . Die Dokumentation der entsprechenden Zielparameter wurde von den Patienten mit Hilfe eines Schmerzkalenders durchgefuehrt . Insgesamt wurden 2031 Attacken ausgewertet . Eine erfolgreiche Therapie trat bei 88% aller Attacken ein , 57% der Patienten waren innerhalb 15 min nach der Injektion komplett schmerzfrei . Schmerzfreiheit innerhalb von 15 min in ueber 90% aller behandelten Attacken wurde von 42% der Patienten erreicht . Ein Nachlassen der Therapierfolgsrate im Behandlungszeitraum trat nicht ein . Wegen mangelnder Wirksamkeit oder unerwuenschter Ereignisse wurde die Studie von 10% der Patienten abgebrochen . Ueber unerwuenschte Ereignisse berichteten 62% der Patienten , davon wurden 3,8% als schwerwiegend eingestuft . Sumatriptan s.c. stellt in der Akuttherapie des Clusterkopschmerzes ein zuverlaessiges , schnell wirksames und bei Beachtung von Kontraindikationen sicheres und gut vertraegliches Therapeutikum dar .	[ "Die", "Wirksamkeit", ",", "Sicherheit", "und", "Vertraeglichkeit", "von", "Sumatriptan", "s.c", ".", "in", "der", "Akuttherapie", "von", "Clusterkopfschmerzen", "wurde", "in", "einer", "offenen", "multizentrischen", "Studie", "in", "einem", "Untersuchungszeitraum", "von", "bis", "zu", "einem", "Jahr", "ueberprueft", ".", "Hieran", "nahmen", "von", "Dezember", "1992", "bis", "Oktober", "1993", "52", "Patienten", "mit", "episodischem", "(", "71", "%", "und", "chronischem", "(", "29", "%", ")", "Clusterkopfschmerz", ")", "teil", ".", "Die", "Patienten", "konnten", "waehrend", "der", "Studie", "Clusterattacken", "selbstaendig", "und", "ausserhalb", "der", "Klinik", "mit", "6", "mg", "Sumatriptan", "behandeln", ".", "Die", "Dokumentation", "der", "entsprechenden", "Zielparameter", "wurde", "von", "den", "Patienten", "mit", "Hilfe", "eines", "Schmerzkalenders", "durchgefuehrt", ".", "Insgesamt", "wurden", "2031", "Attacken", "ausgewertet", ".", "Eine", "erfolgreiche", "Therapie", "trat", "bei", "88", "%", "aller", "Attacken", "ein", ",", "57", "%", "der", "Patienten", "waren", "innerhalb", "15", "min", "nach", "der", "Injektion", "komplett", "schmerzfrei", ".", "Schmerzfreiheit", "innerhalb", "von", "15", "min", "in", "ueber", "90", "%", "aller", "behandelten", "Attacken", "wurde", "von", "42", "%", "der", "Patienten", "erreicht", ".", "Ein", "Nachlassen", "der", "Therapierfolgsrate", "im", "Behandlungszeitraum", "trat", "nicht", "ein", ".", "Wegen", "mangelnder", "Wirksamkeit", "oder", "unerwuenschter", "Ereignisse", "wurde", "die", "Studie", "von", "10", "%", "der", "Patienten", "abgebrochen", ".", "Ueber", "unerwuenschte", "Ereignisse", "berichteten", "62", "%", "der", "Patienten", ",", "davon", "wurden", "3,8", "%", "als", "schwerwiegend", "eingestuft", ".", "Sumatriptan", "s.c", ".", "stellt", "in", "der", "Akuttherapie", "des", "Clusterkopschmerzes", "ein", "zuverlaessiges", ",", "schnell", "wirksames", "und", "bei", "Beachtung", "von", "Kontraindikationen", "sicheres", "und", "gut", "vertraegliches", "Therapeutikum", "dar", "." ]	[ "umlsterm" ]
Sicherheit, Sumatriptan, Akuttherapie, Clusterkopfschmerzen, Patienten, Clusterkopfschmerz, Patienten, Sumatriptan, Dokumentation, Patienten, Schmerzkalenders, Therapie, Patienten, Injektion, Schmerzfreiheit, Patienten, Patienten, Patienten, Sumatriptan, Akuttherapie, Kontraindikationen	DerNervenarzt.80690320.ger.abstr_task2	Sentence: Die Wirksamkeit , Sicherheit und Vertraeglichkeit von Sumatriptan s.c. in der Akuttherapie von Clusterkopfschmerzen wurde in einer offenen multizentrischen Studie in einem Untersuchungszeitraum von bis zu einem Jahr ueberprueft . Hieran nahmen von Dezember 1992 bis Oktober 1993 52 Patienten mit episodischem ( 71% und chronischem ( 29% ) Clusterkopfschmerz ) teil . Die Patienten konnten waehrend der Studie Clusterattacken selbstaendig und ausserhalb der Klinik mit 6 mg Sumatriptan behandeln . Die Dokumentation der entsprechenden Zielparameter wurde von den Patienten mit Hilfe eines Schmerzkalenders durchgefuehrt . Insgesamt wurden 2031 Attacken ausgewertet . Eine erfolgreiche Therapie trat bei 88% aller Attacken ein , 57% der Patienten waren innerhalb 15 min nach der Injektion komplett schmerzfrei . Schmerzfreiheit innerhalb von 15 min in ueber 90% aller behandelten Attacken wurde von 42% der Patienten erreicht . Ein Nachlassen der Therapierfolgsrate im Behandlungszeitraum trat nicht ein . Wegen mangelnder Wirksamkeit oder unerwuenschter Ereignisse wurde die Studie von 10% der Patienten abgebrochen . Ueber unerwuenschte Ereignisse berichteten 62% der Patienten , davon wurden 3,8% als schwerwiegend eingestuft . Sumatriptan s.c. stellt in der Akuttherapie des Clusterkopschmerzes ein zuverlaessiges , schnell wirksames und bei Beachtung von Kontraindikationen sicheres und gut vertraegliches Therapeutikum dar . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Die Wirksamkeit , Sicherheit und Vertraeglichkeit von Sumatriptan s.c. in der Akuttherapie von Clusterkopfschmerzen wurde in einer offenen multizentrischen Studie in einem Untersuchungszeitraum von bis zu einem Jahr ueberprueft . Hieran nahmen von Dezember 1992 bis Oktober 1993 52 Patienten mit episodischem ( 71% und chronischem ( 29% ) Clusterkopfschmerz ) teil . Die Patienten konnten waehrend der Studie Clusterattacken selbstaendig und ausserhalb der Klinik mit 6 mg Sumatriptan behandeln . Die Dokumentation der entsprechenden Zielparameter wurde von den Patienten mit Hilfe eines Schmerzkalenders durchgefuehrt . Insgesamt wurden 2031 Attacken ausgewertet . Eine erfolgreiche Therapie trat bei 88% aller Attacken ein , 57% der Patienten waren innerhalb 15 min nach der Injektion komplett schmerzfrei . Schmerzfreiheit innerhalb von 15 min in ueber 90% aller behandelten Attacken wurde von 42% der Patienten erreicht . Ein Nachlassen der Therapierfolgsrate im Behandlungszeitraum trat nicht ein . Wegen mangelnder Wirksamkeit oder unerwuenschter Ereignisse wurde die Studie von 10% der Patienten abgebrochen . Ueber unerwuenschte Ereignisse berichteten 62% der Patienten , davon wurden 3,8% als schwerwiegend eingestuft . Sumatriptan s.c. stellt in der Akuttherapie des Clusterkopschmerzes ein zuverlaessiges , schnell wirksames und bei Beachtung von Kontraindikationen sicheres und gut vertraegliches Therapeutikum dar .	[ "Die", "Wirksamkeit", ",", "Sicherheit", "und", "Vertraeglichkeit", "von", "Sumatriptan", "s.c", ".", "in", "der", "Akuttherapie", "von", "Clusterkopfschmerzen", "wurde", "in", "einer", "offenen", "multizentrischen", "Studie", "in", "einem", "Untersuchungszeitraum", "von", "bis", "zu", "einem", "Jahr", "ueberprueft", ".", "Hieran", "nahmen", "von", "Dezember", "1992", "bis", "Oktober", "1993", "52", "Patienten", "mit", "episodischem", "(", "71", "%", "und", "chronischem", "(", "29", "%", ")", "Clusterkopfschmerz", ")", "teil", ".", "Die", "Patienten", "konnten", "waehrend", "der", "Studie", "Clusterattacken", "selbstaendig", "und", "ausserhalb", "der", "Klinik", "mit", "6", "mg", "Sumatriptan", "behandeln", ".", "Die", "Dokumentation", "der", "entsprechenden", "Zielparameter", "wurde", "von", "den", "Patienten", "mit", "Hilfe", "eines", "Schmerzkalenders", "durchgefuehrt", ".", "Insgesamt", "wurden", "2031", "Attacken", "ausgewertet", ".", "Eine", "erfolgreiche", "Therapie", "trat", "bei", "88", "%", "aller", "Attacken", "ein", ",", "57", "%", "der", "Patienten", "waren", "innerhalb", "15", "min", "nach", "der", "Injektion", "komplett", "schmerzfrei", ".", "Schmerzfreiheit", "innerhalb", "von", "15", "min", "in", "ueber", "90", "%", "aller", "behandelten", "Attacken", "wurde", "von", "42", "%", "der", "Patienten", "erreicht", ".", "Ein", "Nachlassen", "der", "Therapierfolgsrate", "im", "Behandlungszeitraum", "trat", "nicht", "ein", ".", "Wegen", "mangelnder", "Wirksamkeit", "oder", "unerwuenschter", "Ereignisse", "wurde", "die", "Studie", "von", "10", "%", "der", "Patienten", "abgebrochen", ".", "Ueber", "unerwuenschte", "Ereignisse", "berichteten", "62", "%", "der", "Patienten", ",", "davon", "wurden", "3,8", "%", "als", "schwerwiegend", "eingestuft", ".", "Sumatriptan", "s.c", ".", "stellt", "in", "der", "Akuttherapie", "des", "Clusterkopschmerzes", "ein", "zuverlaessiges", ",", "schnell", "wirksames", "und", "bei", "Beachtung", "von", "Kontraindikationen", "sicheres", "und", "gut", "vertraegliches", "Therapeutikum", "dar", "." ]	[ "umlsterm" ]
Diagnostik is an umlsterm, Wahrnehmungsstoerungen is an umlsterm, Grundschulkindern is an umlsterm, Kindern is an umlsterm, Arbeit is an umlsterm, Analyse is an umlsterm, Testleistungen is an umlsterm	HNO.80460753.ger.abstr_task0	Sentence: Der dichotische Diskriminationstest nach Uttenweiler leistet einen wertvollen Beitrag in der Diagnostik auditiver Wahrnehmungsstoerungen . Er ist in der Lage , Defizite bei der Kontrastierung und Abgrenzung von beidohrig aufgenommenen Schallsignalen verlaesslich aufzudecken , wie eine eigene Untersuchung an normalhoerigen Grundschulkindern und Kindern mit auditiver Wahrnehmungsstoerung aufzeigte . Bisher war der interindividuelle Vergleich von Testergebnissen nur in begrenztem Umfang moeglich , da die bisherige Testdurchfuehrung ein Anheben des Schallpegels vorsah , wenn die Worte nicht vollstaendig verstanden wurden . Ein weiteres Problem ergab sich daraus , dass unterschiedliche dichotische Hoerfaehigkeiten ein gleiches Testergebnis erbrachten . In dieser Arbeit wird eine alternative Form der Durchfuehrung und Auswertung vorgestellt , welche einen direkten interindividuellen Vergleich der Testergebnisse erlaubt . Es entfaellt die Anhebung der Schallpegels auch wenn die Worte nicht vollstaendig verstanden wurden , da die Ueberpruefung mit einem konstanten mittleren Schallpegel erfolgt . Zusaetzlich wurde ein Punktsystem eingefuehrt , welches eine quantitative Analyse der Testleistungen ermoeglicht . Das neue Bewertungsschema wird an konkreten Beispielen vorgestellt und erlaeutert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Der dichotische Diskriminationstest nach Uttenweiler leistet einen wertvollen Beitrag in der Diagnostik auditiver Wahrnehmungsstoerungen . Er ist in der Lage , Defizite bei der Kontrastierung und Abgrenzung von beidohrig aufgenommenen Schallsignalen verlaesslich aufzudecken , wie eine eigene Untersuchung an normalhoerigen Grundschulkindern und Kindern mit auditiver Wahrnehmungsstoerung aufzeigte . Bisher war der interindividuelle Vergleich von Testergebnissen nur in begrenztem Umfang moeglich , da die bisherige Testdurchfuehrung ein Anheben des Schallpegels vorsah , wenn die Worte nicht vollstaendig verstanden wurden . Ein weiteres Problem ergab sich daraus , dass unterschiedliche dichotische Hoerfaehigkeiten ein gleiches Testergebnis erbrachten . In dieser Arbeit wird eine alternative Form der Durchfuehrung und Auswertung vorgestellt , welche einen direkten interindividuellen Vergleich der Testergebnisse erlaubt . Es entfaellt die Anhebung der Schallpegels auch wenn die Worte nicht vollstaendig verstanden wurden , da die Ueberpruefung mit einem konstanten mittleren Schallpegel erfolgt . Zusaetzlich wurde ein Punktsystem eingefuehrt , welches eine quantitative Analyse der Testleistungen ermoeglicht . Das neue Bewertungsschema wird an konkreten Beispielen vorgestellt und erlaeutert .	[ "Der", "dichotische", "Diskriminationstest", "nach", "Uttenweiler", "leistet", "einen", "wertvollen", "Beitrag", "in", "der", "Diagnostik", "auditiver", "Wahrnehmungsstoerungen", ".", "Er", "ist", "in", "der", "Lage", ",", "Defizite", "bei", "der", "Kontrastierung", "und", "Abgrenzung", "von", "beidohrig", "aufgenommenen", "Schallsignalen", "verlaesslich", "aufzudecken", ",", "wie", "eine", "eigene", "Untersuchung", "an", "normalhoerigen", "Grundschulkindern", "und", "Kindern", "mit", "auditiver", "Wahrnehmungsstoerung", "aufzeigte", ".", "Bisher", "war", "der", "interindividuelle", "Vergleich", "von", "Testergebnissen", "nur", "in", "begrenztem", "Umfang", "moeglich", ",", "da", "die", "bisherige", "Testdurchfuehrung", "ein", "Anheben", "des", "Schallpegels", "vorsah", ",", "wenn", "die", "Worte", "nicht", "vollstaendig", "verstanden", "wurden", ".", "Ein", "weiteres", "Problem", "ergab", "sich", "daraus", ",", "dass", "unterschiedliche", "dichotische", "Hoerfaehigkeiten", "ein", "gleiches", "Testergebnis", "erbrachten", ".", "In", "dieser", "Arbeit", "wird", "eine", "alternative", "Form", "der", "Durchfuehrung", "und", "Auswertung", "vorgestellt", ",", "welche", "einen", "direkten", "interindividuellen", "Vergleich", "der", "Testergebnisse", "erlaubt", ".", "Es", "entfaellt", "die", "Anhebung", "der", "Schallpegels", "auch", "wenn", "die", "Worte", "nicht", "vollstaendig", "verstanden", "wurden", ",", "da", "die", "Ueberpruefung", "mit", "einem", "konstanten", "mittleren", "Schallpegel", "erfolgt", ".", "Zusaetzlich", "wurde", "ein", "Punktsystem", "eingefuehrt", ",", "welches", "eine", "quantitative", "Analyse", "der", "Testleistungen", "ermoeglicht", ".", "Das", "neue", "Bewertungsschema", "wird", "an", "konkreten", "Beispielen", "vorgestellt", "und", "erlaeutert", "." ]	[ "umlsterm" ]
Diagnostik is an umlsterm, Wahrnehmungsstoerungen is an umlsterm, Grundschulkindern is an umlsterm, Kindern is an umlsterm, Arbeit is an umlsterm, Analyse is an umlsterm, Testleistungen is an umlsterm	HNO.80460753.ger.abstr_task1	Sentence: Der dichotische Diskriminationstest nach Uttenweiler leistet einen wertvollen Beitrag in der Diagnostik auditiver Wahrnehmungsstoerungen . Er ist in der Lage , Defizite bei der Kontrastierung und Abgrenzung von beidohrig aufgenommenen Schallsignalen verlaesslich aufzudecken , wie eine eigene Untersuchung an normalhoerigen Grundschulkindern und Kindern mit auditiver Wahrnehmungsstoerung aufzeigte . Bisher war der interindividuelle Vergleich von Testergebnissen nur in begrenztem Umfang moeglich , da die bisherige Testdurchfuehrung ein Anheben des Schallpegels vorsah , wenn die Worte nicht vollstaendig verstanden wurden . Ein weiteres Problem ergab sich daraus , dass unterschiedliche dichotische Hoerfaehigkeiten ein gleiches Testergebnis erbrachten . In dieser Arbeit wird eine alternative Form der Durchfuehrung und Auswertung vorgestellt , welche einen direkten interindividuellen Vergleich der Testergebnisse erlaubt . Es entfaellt die Anhebung der Schallpegels auch wenn die Worte nicht vollstaendig verstanden wurden , da die Ueberpruefung mit einem konstanten mittleren Schallpegel erfolgt . Zusaetzlich wurde ein Punktsystem eingefuehrt , welches eine quantitative Analyse der Testleistungen ermoeglicht . Das neue Bewertungsschema wird an konkreten Beispielen vorgestellt und erlaeutert . Instructions: please typing these entity words according to sentence: Diagnostik, Wahrnehmungsstoerungen, Grundschulkindern, Kindern, Arbeit, Analyse, Testleistungen Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Der dichotische Diskriminationstest nach Uttenweiler leistet einen wertvollen Beitrag in der Diagnostik auditiver Wahrnehmungsstoerungen . Er ist in der Lage , Defizite bei der Kontrastierung und Abgrenzung von beidohrig aufgenommenen Schallsignalen verlaesslich aufzudecken , wie eine eigene Untersuchung an normalhoerigen Grundschulkindern und Kindern mit auditiver Wahrnehmungsstoerung aufzeigte . Bisher war der interindividuelle Vergleich von Testergebnissen nur in begrenztem Umfang moeglich , da die bisherige Testdurchfuehrung ein Anheben des Schallpegels vorsah , wenn die Worte nicht vollstaendig verstanden wurden . Ein weiteres Problem ergab sich daraus , dass unterschiedliche dichotische Hoerfaehigkeiten ein gleiches Testergebnis erbrachten . In dieser Arbeit wird eine alternative Form der Durchfuehrung und Auswertung vorgestellt , welche einen direkten interindividuellen Vergleich der Testergebnisse erlaubt . Es entfaellt die Anhebung der Schallpegels auch wenn die Worte nicht vollstaendig verstanden wurden , da die Ueberpruefung mit einem konstanten mittleren Schallpegel erfolgt . Zusaetzlich wurde ein Punktsystem eingefuehrt , welches eine quantitative Analyse der Testleistungen ermoeglicht . Das neue Bewertungsschema wird an konkreten Beispielen vorgestellt und erlaeutert .	[ "Der", "dichotische", "Diskriminationstest", "nach", "Uttenweiler", "leistet", "einen", "wertvollen", "Beitrag", "in", "der", "Diagnostik", "auditiver", "Wahrnehmungsstoerungen", ".", "Er", "ist", "in", "der", "Lage", ",", "Defizite", "bei", "der", "Kontrastierung", "und", "Abgrenzung", "von", "beidohrig", "aufgenommenen", "Schallsignalen", "verlaesslich", "aufzudecken", ",", "wie", "eine", "eigene", "Untersuchung", "an", "normalhoerigen", "Grundschulkindern", "und", "Kindern", "mit", "auditiver", "Wahrnehmungsstoerung", "aufzeigte", ".", "Bisher", "war", "der", "interindividuelle", "Vergleich", "von", "Testergebnissen", "nur", "in", "begrenztem", "Umfang", "moeglich", ",", "da", "die", "bisherige", "Testdurchfuehrung", "ein", "Anheben", "des", "Schallpegels", "vorsah", ",", "wenn", "die", "Worte", "nicht", "vollstaendig", "verstanden", "wurden", ".", "Ein", "weiteres", "Problem", "ergab", "sich", "daraus", ",", "dass", "unterschiedliche", "dichotische", "Hoerfaehigkeiten", "ein", "gleiches", "Testergebnis", "erbrachten", ".", "In", "dieser", "Arbeit", "wird", "eine", "alternative", "Form", "der", "Durchfuehrung", "und", "Auswertung", "vorgestellt", ",", "welche", "einen", "direkten", "interindividuellen", "Vergleich", "der", "Testergebnisse", "erlaubt", ".", "Es", "entfaellt", "die", "Anhebung", "der", "Schallpegels", "auch", "wenn", "die", "Worte", "nicht", "vollstaendig", "verstanden", "wurden", ",", "da", "die", "Ueberpruefung", "mit", "einem", "konstanten", "mittleren", "Schallpegel", "erfolgt", ".", "Zusaetzlich", "wurde", "ein", "Punktsystem", "eingefuehrt", ",", "welches", "eine", "quantitative", "Analyse", "der", "Testleistungen", "ermoeglicht", ".", "Das", "neue", "Bewertungsschema", "wird", "an", "konkreten", "Beispielen", "vorgestellt", "und", "erlaeutert", "." ]	[ "umlsterm" ]
Diagnostik, Wahrnehmungsstoerungen, Grundschulkindern, Kindern, Arbeit, Analyse, Testleistungen	HNO.80460753.ger.abstr_task2	Sentence: Der dichotische Diskriminationstest nach Uttenweiler leistet einen wertvollen Beitrag in der Diagnostik auditiver Wahrnehmungsstoerungen . Er ist in der Lage , Defizite bei der Kontrastierung und Abgrenzung von beidohrig aufgenommenen Schallsignalen verlaesslich aufzudecken , wie eine eigene Untersuchung an normalhoerigen Grundschulkindern und Kindern mit auditiver Wahrnehmungsstoerung aufzeigte . Bisher war der interindividuelle Vergleich von Testergebnissen nur in begrenztem Umfang moeglich , da die bisherige Testdurchfuehrung ein Anheben des Schallpegels vorsah , wenn die Worte nicht vollstaendig verstanden wurden . Ein weiteres Problem ergab sich daraus , dass unterschiedliche dichotische Hoerfaehigkeiten ein gleiches Testergebnis erbrachten . In dieser Arbeit wird eine alternative Form der Durchfuehrung und Auswertung vorgestellt , welche einen direkten interindividuellen Vergleich der Testergebnisse erlaubt . Es entfaellt die Anhebung der Schallpegels auch wenn die Worte nicht vollstaendig verstanden wurden , da die Ueberpruefung mit einem konstanten mittleren Schallpegel erfolgt . Zusaetzlich wurde ein Punktsystem eingefuehrt , welches eine quantitative Analyse der Testleistungen ermoeglicht . Das neue Bewertungsschema wird an konkreten Beispielen vorgestellt und erlaeutert . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Der dichotische Diskriminationstest nach Uttenweiler leistet einen wertvollen Beitrag in der Diagnostik auditiver Wahrnehmungsstoerungen . Er ist in der Lage , Defizite bei der Kontrastierung und Abgrenzung von beidohrig aufgenommenen Schallsignalen verlaesslich aufzudecken , wie eine eigene Untersuchung an normalhoerigen Grundschulkindern und Kindern mit auditiver Wahrnehmungsstoerung aufzeigte . Bisher war der interindividuelle Vergleich von Testergebnissen nur in begrenztem Umfang moeglich , da die bisherige Testdurchfuehrung ein Anheben des Schallpegels vorsah , wenn die Worte nicht vollstaendig verstanden wurden . Ein weiteres Problem ergab sich daraus , dass unterschiedliche dichotische Hoerfaehigkeiten ein gleiches Testergebnis erbrachten . In dieser Arbeit wird eine alternative Form der Durchfuehrung und Auswertung vorgestellt , welche einen direkten interindividuellen Vergleich der Testergebnisse erlaubt . Es entfaellt die Anhebung der Schallpegels auch wenn die Worte nicht vollstaendig verstanden wurden , da die Ueberpruefung mit einem konstanten mittleren Schallpegel erfolgt . Zusaetzlich wurde ein Punktsystem eingefuehrt , welches eine quantitative Analyse der Testleistungen ermoeglicht . Das neue Bewertungsschema wird an konkreten Beispielen vorgestellt und erlaeutert .	[ "Der", "dichotische", "Diskriminationstest", "nach", "Uttenweiler", "leistet", "einen", "wertvollen", "Beitrag", "in", "der", "Diagnostik", "auditiver", "Wahrnehmungsstoerungen", ".", "Er", "ist", "in", "der", "Lage", ",", "Defizite", "bei", "der", "Kontrastierung", "und", "Abgrenzung", "von", "beidohrig", "aufgenommenen", "Schallsignalen", "verlaesslich", "aufzudecken", ",", "wie", "eine", "eigene", "Untersuchung", "an", "normalhoerigen", "Grundschulkindern", "und", "Kindern", "mit", "auditiver", "Wahrnehmungsstoerung", "aufzeigte", ".", "Bisher", "war", "der", "interindividuelle", "Vergleich", "von", "Testergebnissen", "nur", "in", "begrenztem", "Umfang", "moeglich", ",", "da", "die", "bisherige", "Testdurchfuehrung", "ein", "Anheben", "des", "Schallpegels", "vorsah", ",", "wenn", "die", "Worte", "nicht", "vollstaendig", "verstanden", "wurden", ".", "Ein", "weiteres", "Problem", "ergab", "sich", "daraus", ",", "dass", "unterschiedliche", "dichotische", "Hoerfaehigkeiten", "ein", "gleiches", "Testergebnis", "erbrachten", ".", "In", "dieser", "Arbeit", "wird", "eine", "alternative", "Form", "der", "Durchfuehrung", "und", "Auswertung", "vorgestellt", ",", "welche", "einen", "direkten", "interindividuellen", "Vergleich", "der", "Testergebnisse", "erlaubt", ".", "Es", "entfaellt", "die", "Anhebung", "der", "Schallpegels", "auch", "wenn", "die", "Worte", "nicht", "vollstaendig", "verstanden", "wurden", ",", "da", "die", "Ueberpruefung", "mit", "einem", "konstanten", "mittleren", "Schallpegel", "erfolgt", ".", "Zusaetzlich", "wurde", "ein", "Punktsystem", "eingefuehrt", ",", "welches", "eine", "quantitative", "Analyse", "der", "Testleistungen", "ermoeglicht", ".", "Das", "neue", "Bewertungsschema", "wird", "an", "konkreten", "Beispielen", "vorgestellt", "und", "erlaeutert", "." ]	[ "umlsterm" ]
hormone - refractory prostate cancer is a Cancer, HRPC is a Cancer, Hormone - refractory prostate cancer is a Cancer, HRPC is a Cancer, prostate is a Organ, HRPC is a Cancer, cell is a Cell, HRPC is a Cancer, HRPC is a Cancer	PMID-15723619_task0	Sentence: Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC). Hormone-refractory prostate cancer (HRPC) is an inevitable evolution of prostate carcinogenesis, through which the normal dependence on hormones for growth and survival is bypassed. Although advances in terms of symptoms palliation and quality of life improvement have been addressed with current treatment options, innovative approaches are needed to improve survival rates. A thorough understanding of HRPC-associated molecular pathways and mechanisms of resistance are a prerequisite for novel potential therapeutic interventions. Preclinical and early clinical studies are ongoing to evaluate new therapies that target specific molecular entities. Agents under development include growth factor receptor inhibitors, small molecules targeting signal transduction pathways, apoptosis and cell-cycle regulators, angiogenesis and metastasis inhibitors, differentiation agents, telomerase inactivators, and epigenetic therapeutics. Incorporation of these agents into existing treatment regimens will guide us in the development of a multidisciplinary treatment strategy of HRPC. This article critically reviews published data on new biological agents that are being tested in HRPC clinical trials, highlights ongoing research and considers the future perspectives of this new class of agents. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cancer, Organ, Cell	[ "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC). Hormone-refractory prostate cancer (HRPC) is an inevitable evolution of prostate carcinogenesis, through which the normal dependence on hormones for growth and survival is bypassed. Although advances in terms of symptoms palliation and quality of life improvement have been addressed with current treatment options, innovative approaches are needed to improve survival rates. A thorough understanding of HRPC-associated molecular pathways and mechanisms of resistance are a prerequisite for novel potential therapeutic interventions. Preclinical and early clinical studies are ongoing to evaluate new therapies that target specific molecular entities. Agents under development include growth factor receptor inhibitors, small molecules targeting signal transduction pathways, apoptosis and cell-cycle regulators, angiogenesis and metastasis inhibitors, differentiation agents, telomerase inactivators, and epigenetic therapeutics. Incorporation of these agents into existing treatment regimens will guide us in the development of a multidisciplinary treatment strategy of HRPC. This article critically reviews published data on new biological agents that are being tested in HRPC clinical trials, highlights ongoing research and considers the future perspectives of this new class of agents.	[ "Novel", "biological", "agents", "for", "the", "treatment", "of", "hormone", "-", "refractory", "prostate", "cancer", "(", "HRPC", ")", ".", "\n", "Hormone", "-", "refractory", "prostate", "cancer", "(", "HRPC", ")", "is", "an", "inevitable", "evolution", "of", "prostate", "carcinogenesis", ",", "through", "which", "the", "normal", "dependence", "on", "hormones", "for", "growth", "and", "survival", "is", "bypassed", ".", "Although", "advances", "in", "terms", "of", "symptoms", "palliation", "and", "quality", "of", "life", "improvement", "have", "been", "addressed", "with", "current", "treatment", "options", ",", "innovative", "approaches", "are", "needed", "to", "improve", "survival", "rates", ".", "A", "thorough", "understanding", "of", "HRPC", "-", "associated", "molecular", "pathways", "and", "mechanisms", "of", "resistance", "are", "a", "prerequisite", "for", "novel", "potential", "therapeutic", "interventions", ".", "Preclinical", "and", "early", "clinical", "studies", "are", "ongoing", "to", "evaluate", "new", "therapies", "that", "target", "specific", "molecular", "entities", ".", "Agents", "under", "development", "include", "growth", "factor", "receptor", "inhibitors", ",", "small", "molecules", "targeting", "signal", "transduction", "pathways", ",", "apoptosis", "and", "cell", "-", "cycle", "regulators", ",", "angiogenesis", "and", "metastasis", "inhibitors", ",", "differentiation", "agents", ",", "telomerase", "inactivators", ",", "and", "epigenetic", "therapeutics", ".", "Incorporation", "of", "these", "agents", "into", "existing", "treatment", "regimens", "will", "guide", "us", "in", "the", "development", "of", "a", "multidisciplinary", "treatment", "strategy", "of", "HRPC", ".", "This", "article", "critically", "reviews", "published", "data", "on", "new", "biological", "agents", "that", "are", "being", "tested", "in", "HRPC", "clinical", "trials", ",", "highlights", "ongoing", "research", "and", "considers", "the", "future", "perspectives", "of", "this", "new", "class", "of", "agents", ".", "\n" ]	[ "Cancer", "Organ", "Cell" ]
hormone - refractory prostate cancer is a Cancer, HRPC is a Cancer, Hormone - refractory prostate cancer is a Cancer, HRPC is a Cancer, prostate is a Organ, HRPC is a Cancer, cell is a Cell, HRPC is a Cancer, HRPC is a Cancer	PMID-15723619_task1	Sentence: Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC). Hormone-refractory prostate cancer (HRPC) is an inevitable evolution of prostate carcinogenesis, through which the normal dependence on hormones for growth and survival is bypassed. Although advances in terms of symptoms palliation and quality of life improvement have been addressed with current treatment options, innovative approaches are needed to improve survival rates. A thorough understanding of HRPC-associated molecular pathways and mechanisms of resistance are a prerequisite for novel potential therapeutic interventions. Preclinical and early clinical studies are ongoing to evaluate new therapies that target specific molecular entities. Agents under development include growth factor receptor inhibitors, small molecules targeting signal transduction pathways, apoptosis and cell-cycle regulators, angiogenesis and metastasis inhibitors, differentiation agents, telomerase inactivators, and epigenetic therapeutics. Incorporation of these agents into existing treatment regimens will guide us in the development of a multidisciplinary treatment strategy of HRPC. This article critically reviews published data on new biological agents that are being tested in HRPC clinical trials, highlights ongoing research and considers the future perspectives of this new class of agents. Instructions: please typing these entity words according to sentence: hormone - refractory prostate cancer, HRPC, Hormone - refractory prostate cancer, HRPC, prostate, HRPC, cell, HRPC, HRPC Options: Cancer, Organ, Cell	[ "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC). Hormone-refractory prostate cancer (HRPC) is an inevitable evolution of prostate carcinogenesis, through which the normal dependence on hormones for growth and survival is bypassed. Although advances in terms of symptoms palliation and quality of life improvement have been addressed with current treatment options, innovative approaches are needed to improve survival rates. A thorough understanding of HRPC-associated molecular pathways and mechanisms of resistance are a prerequisite for novel potential therapeutic interventions. Preclinical and early clinical studies are ongoing to evaluate new therapies that target specific molecular entities. Agents under development include growth factor receptor inhibitors, small molecules targeting signal transduction pathways, apoptosis and cell-cycle regulators, angiogenesis and metastasis inhibitors, differentiation agents, telomerase inactivators, and epigenetic therapeutics. Incorporation of these agents into existing treatment regimens will guide us in the development of a multidisciplinary treatment strategy of HRPC. This article critically reviews published data on new biological agents that are being tested in HRPC clinical trials, highlights ongoing research and considers the future perspectives of this new class of agents.	[ "Novel", "biological", "agents", "for", "the", "treatment", "of", "hormone", "-", "refractory", "prostate", "cancer", "(", "HRPC", ")", ".", "\n", "Hormone", "-", "refractory", "prostate", "cancer", "(", "HRPC", ")", "is", "an", "inevitable", "evolution", "of", "prostate", "carcinogenesis", ",", "through", "which", "the", "normal", "dependence", "on", "hormones", "for", "growth", "and", "survival", "is", "bypassed", ".", "Although", "advances", "in", "terms", "of", "symptoms", "palliation", "and", "quality", "of", "life", "improvement", "have", "been", "addressed", "with", "current", "treatment", "options", ",", "innovative", "approaches", "are", "needed", "to", "improve", "survival", "rates", ".", "A", "thorough", "understanding", "of", "HRPC", "-", "associated", "molecular", "pathways", "and", "mechanisms", "of", "resistance", "are", "a", "prerequisite", "for", "novel", "potential", "therapeutic", "interventions", ".", "Preclinical", "and", "early", "clinical", "studies", "are", "ongoing", "to", "evaluate", "new", "therapies", "that", "target", "specific", "molecular", "entities", ".", "Agents", "under", "development", "include", "growth", "factor", "receptor", "inhibitors", ",", "small", "molecules", "targeting", "signal", "transduction", "pathways", ",", "apoptosis", "and", "cell", "-", "cycle", "regulators", ",", "angiogenesis", "and", "metastasis", "inhibitors", ",", "differentiation", "agents", ",", "telomerase", "inactivators", ",", "and", "epigenetic", "therapeutics", ".", "Incorporation", "of", "these", "agents", "into", "existing", "treatment", "regimens", "will", "guide", "us", "in", "the", "development", "of", "a", "multidisciplinary", "treatment", "strategy", "of", "HRPC", ".", "This", "article", "critically", "reviews", "published", "data", "on", "new", "biological", "agents", "that", "are", "being", "tested", "in", "HRPC", "clinical", "trials", ",", "highlights", "ongoing", "research", "and", "considers", "the", "future", "perspectives", "of", "this", "new", "class", "of", "agents", ".", "\n" ]	[ "Cancer", "Organ", "Cell" ]
hormone - refractory prostate cancer, HRPC, Hormone - refractory prostate cancer, HRPC, prostate, HRPC, cell, HRPC, HRPC	PMID-15723619_task2	Sentence: Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC). Hormone-refractory prostate cancer (HRPC) is an inevitable evolution of prostate carcinogenesis, through which the normal dependence on hormones for growth and survival is bypassed. Although advances in terms of symptoms palliation and quality of life improvement have been addressed with current treatment options, innovative approaches are needed to improve survival rates. A thorough understanding of HRPC-associated molecular pathways and mechanisms of resistance are a prerequisite for novel potential therapeutic interventions. Preclinical and early clinical studies are ongoing to evaluate new therapies that target specific molecular entities. Agents under development include growth factor receptor inhibitors, small molecules targeting signal transduction pathways, apoptosis and cell-cycle regulators, angiogenesis and metastasis inhibitors, differentiation agents, telomerase inactivators, and epigenetic therapeutics. Incorporation of these agents into existing treatment regimens will guide us in the development of a multidisciplinary treatment strategy of HRPC. This article critically reviews published data on new biological agents that are being tested in HRPC clinical trials, highlights ongoing research and considers the future perspectives of this new class of agents. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC). Hormone-refractory prostate cancer (HRPC) is an inevitable evolution of prostate carcinogenesis, through which the normal dependence on hormones for growth and survival is bypassed. Although advances in terms of symptoms palliation and quality of life improvement have been addressed with current treatment options, innovative approaches are needed to improve survival rates. A thorough understanding of HRPC-associated molecular pathways and mechanisms of resistance are a prerequisite for novel potential therapeutic interventions. Preclinical and early clinical studies are ongoing to evaluate new therapies that target specific molecular entities. Agents under development include growth factor receptor inhibitors, small molecules targeting signal transduction pathways, apoptosis and cell-cycle regulators, angiogenesis and metastasis inhibitors, differentiation agents, telomerase inactivators, and epigenetic therapeutics. Incorporation of these agents into existing treatment regimens will guide us in the development of a multidisciplinary treatment strategy of HRPC. This article critically reviews published data on new biological agents that are being tested in HRPC clinical trials, highlights ongoing research and considers the future perspectives of this new class of agents.	[ "Novel", "biological", "agents", "for", "the", "treatment", "of", "hormone", "-", "refractory", "prostate", "cancer", "(", "HRPC", ")", ".", "\n", "Hormone", "-", "refractory", "prostate", "cancer", "(", "HRPC", ")", "is", "an", "inevitable", "evolution", "of", "prostate", "carcinogenesis", ",", "through", "which", "the", "normal", "dependence", "on", "hormones", "for", "growth", "and", "survival", "is", "bypassed", ".", "Although", "advances", "in", "terms", "of", "symptoms", "palliation", "and", "quality", "of", "life", "improvement", "have", "been", "addressed", "with", "current", "treatment", "options", ",", "innovative", "approaches", "are", "needed", "to", "improve", "survival", "rates", ".", "A", "thorough", "understanding", "of", "HRPC", "-", "associated", "molecular", "pathways", "and", "mechanisms", "of", "resistance", "are", "a", "prerequisite", "for", "novel", "potential", "therapeutic", "interventions", ".", "Preclinical", "and", "early", "clinical", "studies", "are", "ongoing", "to", "evaluate", "new", "therapies", "that", "target", "specific", "molecular", "entities", ".", "Agents", "under", "development", "include", "growth", "factor", "receptor", "inhibitors", ",", "small", "molecules", "targeting", "signal", "transduction", "pathways", ",", "apoptosis", "and", "cell", "-", "cycle", "regulators", ",", "angiogenesis", "and", "metastasis", "inhibitors", ",", "differentiation", "agents", ",", "telomerase", "inactivators", ",", "and", "epigenetic", "therapeutics", ".", "Incorporation", "of", "these", "agents", "into", "existing", "treatment", "regimens", "will", "guide", "us", "in", "the", "development", "of", "a", "multidisciplinary", "treatment", "strategy", "of", "HRPC", ".", "This", "article", "critically", "reviews", "published", "data", "on", "new", "biological", "agents", "that", "are", "being", "tested", "in", "HRPC", "clinical", "trials", ",", "highlights", "ongoing", "research", "and", "considers", "the", "future", "perspectives", "of", "this", "new", "class", "of", "agents", ".", "\n" ]	[ "Cancer", "Organ", "Cell" ]
carcinoma ductal pobremente diferenciado is a MORFOLOGIA_NEOPLASIA, carcinoma inflamatorio is a MORFOLOGIA_NEOPLASIA, carcinoma inflamatorio is a MORFOLOGIA_NEOPLASIA, fibroadenoma is a MORFOLOGIA_NEOPLASIA, carcinoma intraductal sólido de alto grado is a MORFOLOGIA_NEOPLASIA, tumor phyllodes , histológicamente benigno is a MORFOLOGIA_NEOPLASIA, Carcinoma ductal inflamatorio is a MORFOLOGIA_NEOPLASIA, pT4cN1M0 is a MORFOLOGIA_NEOPLASIA, Tumor phyllodes benigno is a MORFOLOGIA_NEOPLASIA, carcinoma intraductal sólido de alto grado is a MORFOLOGIA_NEOPLASIA, carcinoma ductal inflamatorio is a MORFOLOGIA_NEOPLASIA, pT4cN1M0 is a MORFOLOGIA_NEOPLASIA, carcinoma ductal infiltrante is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, carcinoma intraductal de alto grado is a MORFOLOGIA_NEOPLASIA, tumor phyllodes benigno is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA	991_task0	Sentence: Anamnesis Paciente mujer de 45 años de edad, sin antecedentes médico-quirúrgicos importantes, fumadora de 1 paquete de cigarrillos al día desde los 20 años de edad y sin antecedentes familiares oncológicos, que consultó por dolor en la mama izquierda, asociado a enrojecimiento y edema cutáneo, que inicialmente fue manejado como una mastitis con cloxacilina, sin mejoría clínica. Ante la refractariedad al tratamiento antibiótico, se decidió realizar biopsia cutánea. Exploración física A la exploración destaca una mama izquierda dura y nodular, con engrosamiento cutáneo acompañado de piel de naranja y eritema generalizado; en la axila ipsilateral se palpan adenopatías de unos 2 cm, duras y móviles. En la mama derecha se palpa un nódulo en el cuadrante inferoexterno móvil de 2 cm aproximadamente, sin palparse adenopatías a nivel axilar. Pruebas complementarias » Punch de piel de mama izquierda: cilindros cutáneos con múltiples émbolos linfáticos de carcinoma ductal pobremente diferenciado (carcinoma inflamatorio), con receptores hormonales negativos, Her-2 no amplificado y Ki-67 del 40%. » Resonancia de mamas: captación difusa de mama izquierda con edema y engrosamiento de la piel concordante con el diagnóstico histológico de carcinoma inflamatorio (BRADS6), asociado a adenopatías axilares sospechosas. En la mama derecha lesiones con distorsión del parénquima en el cuadrante superoexterno y probable fibroadenoma en el cuadrante ínfero externo. » BAG de mama derecha: CSE, carcinoma intraductal sólido de alto grado. CIE, tumor phyllodes, histológicamente benigno. » Se realiza estudio de extensión con TC y gammagrafía ósea, que son negativos. Diagnóstico Carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB). Tumor phyllodes benigno de mama derecha, asociado a carcinoma intraductal sólido de alto grado. Tratamiento Con el diagnóstico de carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB), inicia tratamiento de quimioterapia con intención neoadyuvante, con taxol semanal (80 mg/m2) por 12 ciclos, con neurotoxicidad grado 2 como evento adverso importante, seguido de cuatro ciclos de FEC (5-FU 600 mg/m2 + epirrubicina 90 mg/m2 + ciclofosfamida 600 mg/m2). Tras finalizar la neoadyuvancia, es intervenida quirúrgicamente con mastectomía bilateral y linfadenectomía axilar izquierda, con resultados de anatomía patológica de: » Mastectomía izquierda: persistencia postneoadyuvancia de carcinoma ductal infiltrante en toda la mama en forma de agregados dispersos (el mayor de 2,5 mm), con invasión tumoral linfática en el parénquima mamario y en la dermis del huso de piel incluido. Con un grado de regresión tumoral por quimioterapia neoadyuvante de al menos el 50% (categoría R1) y afectación de 3 de los 9 ganglios linfáticos aislados de la linfadenectomía axilar.Estadio tumoral AJCC/UICC, 7ª edición: ypT4d N1a. » Mastectomía derecha: alteraciones estromales compatibles con la administración de quimioterapia neoadyuvante. Estadio tumoral AJCC/UICC, 7ª edición: pT0 Nx. En la pieza de mastectomía derecha no se identifica lecho tumoral ni carcinoma intraductal de alto grado ni infiltrante, aunque sí se observan zonas con patrón fibroadenomatoide que pueden explicar el diagnóstico previo de tumor phyllodes benigno. Comparando la morfología de las lesiones observadas en la pieza de mastectomía con las biopsias iniciales de la BAG se evidencia que las imágenes de la pieza quirúrgica podrían ser compatibles con una extensión tumoral residual a los lobulillos que sería lo que, finalmente, queda del tumor original tras la quimioterapia neoadyuvante. Tras el tratamiento quirúrgico, la paciente recibe tratamiento de radioterapia sobre la pared torácica izquierda y áreas ganglionares supraclaviculares, interpectorales, infraclaviculares y niveles ganglionares axilares I a III con una dosis total de 50 Gy, con sobreimpresión de 10 Gy adicionales sobre el área de la pared torácica izquierda. Evolución Actualmente la paciente se encuentra realizando revisiones periódicas sin incidencias. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Paciente mujer de 45 años de edad, sin antecedentes médico-quirúrgicos importantes, fumadora de 1 paquete de cigarrillos al día desde los 20 años de edad y sin antecedentes familiares oncológicos, que consultó por dolor en la mama izquierda, asociado a enrojecimiento y edema cutáneo, que inicialmente fue manejado como una mastitis con cloxacilina, sin mejoría clínica. Ante la refractariedad al tratamiento antibiótico, se decidió realizar biopsia cutánea. Exploración física A la exploración destaca una mama izquierda dura y nodular, con engrosamiento cutáneo acompañado de piel de naranja y eritema generalizado; en la axila ipsilateral se palpan adenopatías de unos 2 cm, duras y móviles. En la mama derecha se palpa un nódulo en el cuadrante inferoexterno móvil de 2 cm aproximadamente, sin palparse adenopatías a nivel axilar. Pruebas complementarias » Punch de piel de mama izquierda: cilindros cutáneos con múltiples émbolos linfáticos de carcinoma ductal pobremente diferenciado (carcinoma inflamatorio), con receptores hormonales negativos, Her-2 no amplificado y Ki-67 del 40%. » Resonancia de mamas: captación difusa de mama izquierda con edema y engrosamiento de la piel concordante con el diagnóstico histológico de carcinoma inflamatorio (BRADS6), asociado a adenopatías axilares sospechosas. En la mama derecha lesiones con distorsión del parénquima en el cuadrante superoexterno y probable fibroadenoma en el cuadrante ínfero externo. » BAG de mama derecha: CSE, carcinoma intraductal sólido de alto grado. CIE, tumor phyllodes, histológicamente benigno. » Se realiza estudio de extensión con TC y gammagrafía ósea, que son negativos. Diagnóstico Carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB). Tumor phyllodes benigno de mama derecha, asociado a carcinoma intraductal sólido de alto grado. Tratamiento Con el diagnóstico de carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB), inicia tratamiento de quimioterapia con intención neoadyuvante, con taxol semanal (80 mg/m2) por 12 ciclos, con neurotoxicidad grado 2 como evento adverso importante, seguido de cuatro ciclos de FEC (5-FU 600 mg/m2 + epirrubicina 90 mg/m2 + ciclofosfamida 600 mg/m2). Tras finalizar la neoadyuvancia, es intervenida quirúrgicamente con mastectomía bilateral y linfadenectomía axilar izquierda, con resultados de anatomía patológica de: » Mastectomía izquierda: persistencia postneoadyuvancia de carcinoma ductal infiltrante en toda la mama en forma de agregados dispersos (el mayor de 2,5 mm), con invasión tumoral linfática en el parénquima mamario y en la dermis del huso de piel incluido. Con un grado de regresión tumoral por quimioterapia neoadyuvante de al menos el 50% (categoría R1) y afectación de 3 de los 9 ganglios linfáticos aislados de la linfadenectomía axilar.Estadio tumoral AJCC/UICC, 7ª edición: ypT4d N1a. » Mastectomía derecha: alteraciones estromales compatibles con la administración de quimioterapia neoadyuvante. Estadio tumoral AJCC/UICC, 7ª edición: pT0 Nx. En la pieza de mastectomía derecha no se identifica lecho tumoral ni carcinoma intraductal de alto grado ni infiltrante, aunque sí se observan zonas con patrón fibroadenomatoide que pueden explicar el diagnóstico previo de tumor phyllodes benigno. Comparando la morfología de las lesiones observadas en la pieza de mastectomía con las biopsias iniciales de la BAG se evidencia que las imágenes de la pieza quirúrgica podrían ser compatibles con una extensión tumoral residual a los lobulillos que sería lo que, finalmente, queda del tumor original tras la quimioterapia neoadyuvante. Tras el tratamiento quirúrgico, la paciente recibe tratamiento de radioterapia sobre la pared torácica izquierda y áreas ganglionares supraclaviculares, interpectorales, infraclaviculares y niveles ganglionares axilares I a III con una dosis total de 50 Gy, con sobreimpresión de 10 Gy adicionales sobre el área de la pared torácica izquierda. Evolución Actualmente la paciente se encuentra realizando revisiones periódicas sin incidencias.	[ "Anamnesis", "\n", "Paciente", "mujer", "de", "45", "años", "de", "edad", ",", "sin", "antecedentes", "médico", "-", "quirúrgicos", "importantes", ",", "fumadora", "de", "1", "paquete", "de", "cigarrillos", "al", "día", "desde", "los", "20", "años", "de", "edad", "y", "sin", "antecedentes", "familiares", "oncológicos", ",", "que", "consultó", "por", "dolor", "en", "la", "mama", "izquierda", ",", "asociado", "a", "enrojecimiento", "y", "edema", "cutáneo", ",", "que", "inicialmente", "fue", "manejado", "como", "una", "mastitis", "con", "cloxacilina", ",", "sin", "mejoría", "clínica", ".", "Ante", "la", "refractariedad", "al", "tratamiento", "antibiótico", ",", "se", "decidió", "realizar", "biopsia", "cutánea", ".", "\n\n", "Exploración", "física", "\n", "A", "la", "exploración", "destaca", "una", "mama", "izquierda", "dura", "y", "nodular", ",", "con", "engrosamiento", "cutáneo", "acompañado", "de", "piel", "de", "naranja", "y", "eritema", "generalizado", ";", "en", "la", "axila", "ipsilateral", "se", "palpan", "adenopatías", "de", "unos", "2", "cm", ",", "duras", "y", "móviles", ".", "En", "la", "mama", "derecha", "se", "palpa", "un", "nódulo", "en", "el", "cuadrante", "inferoexterno", "móvil", "de", "2", "cm", "aproximadamente", ",", "sin", "palparse", "adenopatías", "a", "nivel", "axilar", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "Punch", "de", "piel", "de", "mama", "izquierda", ":", "cilindros", "cutáneos", "con", "múltiples", "émbolos", "linfáticos", "de", "carcinoma", "ductal", "pobremente", "diferenciado", "(", "carcinoma", "inflamatorio", ")", ",", "con", "receptores", "hormonales", "negativos", ",", "Her-2", "no", "amplificado", "y", "Ki-67", "del", "40", "%", ".", "\n", "»", "Resonancia", "de", "mamas", ":", "captación", "difusa", "de", "mama", "izquierda", "con", "edema", "y", "engrosamiento", "de", "la", "piel", "concordante", "con", "el", "diagnóstico", "histológico", "de", "carcinoma", "inflamatorio", "(", "BRADS6", ")", ",", "asociado", "a", "adenopatías", "axilares", "sospechosas", ".", "En", "la", "mama", "derecha", "lesiones", "con", "distorsión", "del", "parénquima", "en", "el", "cuadrante", "superoexterno", "y", "probable", "fibroadenoma", "en", "el", "cuadrante", "ínfero", "externo", ".", "\n", "»", "BAG", "de", "mama", "derecha", ":", "CSE", ",", "carcinoma", "intraductal", "sólido", "de", "alto", "grado", ".", "CIE", ",", "tumor", "phyllodes", ",", "histológicamente", "benigno", ".", "\n", "»", "Se", "realiza", "estudio", "de", "extensión", "con", "TC", "y", "gammagrafía", "ósea", ",", "que", "son", "negativos", ".", "\n\n", "Diagnóstico", "\n", "Carcinoma", "ductal", "inflamatorio", "de", "mama", "izquierda", "pT4cN1M0", "(", "estadio", "IIIB", ")", ".", "\n\n", "Tumor", "phyllodes", "benigno", "de", "mama", "derecha", ",", "asociado", "a", "carcinoma", "intraductal", "sólido", "de", "alto", "grado", ".", "\n\n", "Tratamiento", "\n", "Con", "el", "diagnóstico", "de", "carcinoma", "ductal", "inflamatorio", "de", "mama", "izquierda", "pT4cN1M0", "(", "estadio", "IIIB", ")", ",", "inicia", "tratamiento", "de", "quimioterapia", "con", "intención", "neoadyuvante", ",", "con", "taxol", "semanal", "(", "80", "mg", "/", "m2", ")", "por", "12", "ciclos", ",", "con", "neurotoxicidad", "grado", "2", "como", "evento", "adverso", "importante", ",", "seguido", "de", "cuatro", "ciclos", "de", "FEC", "(", "5-FU", "600", "mg", "/", "m2", "+", "epirrubicina", "90", "mg", "/", "m2", "+", "ciclofosfamida", "600", "mg", "/", "m2", ")", ".", "\n\n", "Tras", "finalizar", "la", "neoadyuvancia", ",", "es", "intervenida", "quirúrgicamente", "con", "mastectomía", "bilateral", "y", "linfadenectomía", "axilar", "izquierda", ",", "con", "resultados", "de", "anatomía", "patológica", "de", ":", "\n", "»", "Mastectomía", "izquierda", ":", "persistencia", "postneoadyuvancia", "de", "carcinoma", "ductal", "infiltrante", "en", "toda", "la", "mama", "en", "forma", "de", "agregados", "dispersos", "(", "el", "mayor", "de", "2,5", "mm", ")", ",", "con", "invasión", "tumoral", "linfática", "en", "el", "parénquima", "mamario", "y", "en", "la", "dermis", "del", "huso", "de", "piel", "incluido", ".", "Con", "un", "grado", "de", "regresión", "tumoral", "por", "quimioterapia", "neoadyuvante", "de", "al", "menos", "el", "50", "%", "(", "categoría", "R1", ")", "y", "afectación", "de", "3", "de", "los", "9", "ganglios", "linfáticos", "aislados", "de", "la", "linfadenectomía", "axilar", ".", "Estadio", "tumoral", "AJCC", "/", "UICC", ",", "7ª", "edición", ":", "ypT4d", "N1a", ".", "\n", "»", "Mastectomía", "derecha", ":", "alteraciones", "estromales", "compatibles", "con", "la", "administración", "de", "quimioterapia", "neoadyuvante", ".", "Estadio", "tumoral", "AJCC", "/", "UICC", ",", "7ª", "edición", ":", "pT0", "Nx", ".", "En", "la", "pieza", "de", "mastectomía", "derecha", "no", "se", "identifica", "lecho", "tumoral", "ni", "carcinoma", "intraductal", "de", "alto", "grado", "ni", "infiltrante", ",", "aunque", "sí", "se", "observan", "zonas", "con", "patrón", "fibroadenomatoide", "que", "pueden", "explicar", "el", "diagnóstico", "previo", "de", "tumor", "phyllodes", "benigno", ".", "Comparando", "la", "morfología", "de", "las", "lesiones", "observadas", "en", "la", "pieza", "de", "mastectomía", "con", "las", "biopsias", "iniciales", "de", "la", "BAG", "se", "evidencia", "que", "las", "imágenes", "de", "la", "pieza", "quirúrgica", "podrían", "ser", "compatibles", "con", "una", "extensión", "tumoral", "residual", "a", "los", "lobulillos", "que", "sería", "lo", "que", ",", "finalmente", ",", "queda", "del", "tumor", "original", "tras", "la", "quimioterapia", "neoadyuvante", ".", "\n", "Tras", "el", "tratamiento", "quirúrgico", ",", "la", "paciente", "recibe", "tratamiento", "de", "radioterapia", "sobre", "la", "pared", "torácica", "izquierda", "y", "áreas", "ganglionares", "supraclaviculares", ",", "interpectorales", ",", "infraclaviculares", "y", "niveles", "ganglionares", "axilares", "I", "a", "III", "con", "una", "dosis", "total", "de", "50", "Gy", ",", "con", "sobreimpresión", "de", "10", "Gy", "adicionales", "sobre", "el", "área", "de", "la", "pared", "torácica", "izquierda", ".", "\n\n", "Evolución", "\n", "Actualmente", "la", "paciente", "se", "encuentra", "realizando", "revisiones", "periódicas", "sin", "incidencias", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
carcinoma ductal pobremente diferenciado is a MORFOLOGIA_NEOPLASIA, carcinoma inflamatorio is a MORFOLOGIA_NEOPLASIA, carcinoma inflamatorio is a MORFOLOGIA_NEOPLASIA, fibroadenoma is a MORFOLOGIA_NEOPLASIA, carcinoma intraductal sólido de alto grado is a MORFOLOGIA_NEOPLASIA, tumor phyllodes , histológicamente benigno is a MORFOLOGIA_NEOPLASIA, Carcinoma ductal inflamatorio is a MORFOLOGIA_NEOPLASIA, pT4cN1M0 is a MORFOLOGIA_NEOPLASIA, Tumor phyllodes benigno is a MORFOLOGIA_NEOPLASIA, carcinoma intraductal sólido de alto grado is a MORFOLOGIA_NEOPLASIA, carcinoma ductal inflamatorio is a MORFOLOGIA_NEOPLASIA, pT4cN1M0 is a MORFOLOGIA_NEOPLASIA, carcinoma ductal infiltrante is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, carcinoma intraductal de alto grado is a MORFOLOGIA_NEOPLASIA, tumor phyllodes benigno is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA	991_task1	Sentence: Anamnesis Paciente mujer de 45 años de edad, sin antecedentes médico-quirúrgicos importantes, fumadora de 1 paquete de cigarrillos al día desde los 20 años de edad y sin antecedentes familiares oncológicos, que consultó por dolor en la mama izquierda, asociado a enrojecimiento y edema cutáneo, que inicialmente fue manejado como una mastitis con cloxacilina, sin mejoría clínica. Ante la refractariedad al tratamiento antibiótico, se decidió realizar biopsia cutánea. Exploración física A la exploración destaca una mama izquierda dura y nodular, con engrosamiento cutáneo acompañado de piel de naranja y eritema generalizado; en la axila ipsilateral se palpan adenopatías de unos 2 cm, duras y móviles. En la mama derecha se palpa un nódulo en el cuadrante inferoexterno móvil de 2 cm aproximadamente, sin palparse adenopatías a nivel axilar. Pruebas complementarias » Punch de piel de mama izquierda: cilindros cutáneos con múltiples émbolos linfáticos de carcinoma ductal pobremente diferenciado (carcinoma inflamatorio), con receptores hormonales negativos, Her-2 no amplificado y Ki-67 del 40%. » Resonancia de mamas: captación difusa de mama izquierda con edema y engrosamiento de la piel concordante con el diagnóstico histológico de carcinoma inflamatorio (BRADS6), asociado a adenopatías axilares sospechosas. En la mama derecha lesiones con distorsión del parénquima en el cuadrante superoexterno y probable fibroadenoma en el cuadrante ínfero externo. » BAG de mama derecha: CSE, carcinoma intraductal sólido de alto grado. CIE, tumor phyllodes, histológicamente benigno. » Se realiza estudio de extensión con TC y gammagrafía ósea, que son negativos. Diagnóstico Carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB). Tumor phyllodes benigno de mama derecha, asociado a carcinoma intraductal sólido de alto grado. Tratamiento Con el diagnóstico de carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB), inicia tratamiento de quimioterapia con intención neoadyuvante, con taxol semanal (80 mg/m2) por 12 ciclos, con neurotoxicidad grado 2 como evento adverso importante, seguido de cuatro ciclos de FEC (5-FU 600 mg/m2 + epirrubicina 90 mg/m2 + ciclofosfamida 600 mg/m2). Tras finalizar la neoadyuvancia, es intervenida quirúrgicamente con mastectomía bilateral y linfadenectomía axilar izquierda, con resultados de anatomía patológica de: » Mastectomía izquierda: persistencia postneoadyuvancia de carcinoma ductal infiltrante en toda la mama en forma de agregados dispersos (el mayor de 2,5 mm), con invasión tumoral linfática en el parénquima mamario y en la dermis del huso de piel incluido. Con un grado de regresión tumoral por quimioterapia neoadyuvante de al menos el 50% (categoría R1) y afectación de 3 de los 9 ganglios linfáticos aislados de la linfadenectomía axilar.Estadio tumoral AJCC/UICC, 7ª edición: ypT4d N1a. » Mastectomía derecha: alteraciones estromales compatibles con la administración de quimioterapia neoadyuvante. Estadio tumoral AJCC/UICC, 7ª edición: pT0 Nx. En la pieza de mastectomía derecha no se identifica lecho tumoral ni carcinoma intraductal de alto grado ni infiltrante, aunque sí se observan zonas con patrón fibroadenomatoide que pueden explicar el diagnóstico previo de tumor phyllodes benigno. Comparando la morfología de las lesiones observadas en la pieza de mastectomía con las biopsias iniciales de la BAG se evidencia que las imágenes de la pieza quirúrgica podrían ser compatibles con una extensión tumoral residual a los lobulillos que sería lo que, finalmente, queda del tumor original tras la quimioterapia neoadyuvante. Tras el tratamiento quirúrgico, la paciente recibe tratamiento de radioterapia sobre la pared torácica izquierda y áreas ganglionares supraclaviculares, interpectorales, infraclaviculares y niveles ganglionares axilares I a III con una dosis total de 50 Gy, con sobreimpresión de 10 Gy adicionales sobre el área de la pared torácica izquierda. Evolución Actualmente la paciente se encuentra realizando revisiones periódicas sin incidencias. Instructions: please typing these entity words according to sentence: carcinoma ductal pobremente diferenciado, carcinoma inflamatorio, carcinoma inflamatorio, fibroadenoma, carcinoma intraductal sólido de alto grado, tumor phyllodes , histológicamente benigno, Carcinoma ductal inflamatorio, pT4cN1M0, Tumor phyllodes benigno, carcinoma intraductal sólido de alto grado, carcinoma ductal inflamatorio, pT4cN1M0, carcinoma ductal infiltrante, tumoral, tumoral, tumoral, tumoral, tumoral, carcinoma intraductal de alto grado, tumor phyllodes benigno, tumoral, tumor Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Paciente mujer de 45 años de edad, sin antecedentes médico-quirúrgicos importantes, fumadora de 1 paquete de cigarrillos al día desde los 20 años de edad y sin antecedentes familiares oncológicos, que consultó por dolor en la mama izquierda, asociado a enrojecimiento y edema cutáneo, que inicialmente fue manejado como una mastitis con cloxacilina, sin mejoría clínica. Ante la refractariedad al tratamiento antibiótico, se decidió realizar biopsia cutánea. Exploración física A la exploración destaca una mama izquierda dura y nodular, con engrosamiento cutáneo acompañado de piel de naranja y eritema generalizado; en la axila ipsilateral se palpan adenopatías de unos 2 cm, duras y móviles. En la mama derecha se palpa un nódulo en el cuadrante inferoexterno móvil de 2 cm aproximadamente, sin palparse adenopatías a nivel axilar. Pruebas complementarias » Punch de piel de mama izquierda: cilindros cutáneos con múltiples émbolos linfáticos de carcinoma ductal pobremente diferenciado (carcinoma inflamatorio), con receptores hormonales negativos, Her-2 no amplificado y Ki-67 del 40%. » Resonancia de mamas: captación difusa de mama izquierda con edema y engrosamiento de la piel concordante con el diagnóstico histológico de carcinoma inflamatorio (BRADS6), asociado a adenopatías axilares sospechosas. En la mama derecha lesiones con distorsión del parénquima en el cuadrante superoexterno y probable fibroadenoma en el cuadrante ínfero externo. » BAG de mama derecha: CSE, carcinoma intraductal sólido de alto grado. CIE, tumor phyllodes, histológicamente benigno. » Se realiza estudio de extensión con TC y gammagrafía ósea, que son negativos. Diagnóstico Carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB). Tumor phyllodes benigno de mama derecha, asociado a carcinoma intraductal sólido de alto grado. Tratamiento Con el diagnóstico de carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB), inicia tratamiento de quimioterapia con intención neoadyuvante, con taxol semanal (80 mg/m2) por 12 ciclos, con neurotoxicidad grado 2 como evento adverso importante, seguido de cuatro ciclos de FEC (5-FU 600 mg/m2 + epirrubicina 90 mg/m2 + ciclofosfamida 600 mg/m2). Tras finalizar la neoadyuvancia, es intervenida quirúrgicamente con mastectomía bilateral y linfadenectomía axilar izquierda, con resultados de anatomía patológica de: » Mastectomía izquierda: persistencia postneoadyuvancia de carcinoma ductal infiltrante en toda la mama en forma de agregados dispersos (el mayor de 2,5 mm), con invasión tumoral linfática en el parénquima mamario y en la dermis del huso de piel incluido. Con un grado de regresión tumoral por quimioterapia neoadyuvante de al menos el 50% (categoría R1) y afectación de 3 de los 9 ganglios linfáticos aislados de la linfadenectomía axilar.Estadio tumoral AJCC/UICC, 7ª edición: ypT4d N1a. » Mastectomía derecha: alteraciones estromales compatibles con la administración de quimioterapia neoadyuvante. Estadio tumoral AJCC/UICC, 7ª edición: pT0 Nx. En la pieza de mastectomía derecha no se identifica lecho tumoral ni carcinoma intraductal de alto grado ni infiltrante, aunque sí se observan zonas con patrón fibroadenomatoide que pueden explicar el diagnóstico previo de tumor phyllodes benigno. Comparando la morfología de las lesiones observadas en la pieza de mastectomía con las biopsias iniciales de la BAG se evidencia que las imágenes de la pieza quirúrgica podrían ser compatibles con una extensión tumoral residual a los lobulillos que sería lo que, finalmente, queda del tumor original tras la quimioterapia neoadyuvante. Tras el tratamiento quirúrgico, la paciente recibe tratamiento de radioterapia sobre la pared torácica izquierda y áreas ganglionares supraclaviculares, interpectorales, infraclaviculares y niveles ganglionares axilares I a III con una dosis total de 50 Gy, con sobreimpresión de 10 Gy adicionales sobre el área de la pared torácica izquierda. Evolución Actualmente la paciente se encuentra realizando revisiones periódicas sin incidencias.	[ "Anamnesis", "\n", "Paciente", "mujer", "de", "45", "años", "de", "edad", ",", "sin", "antecedentes", "médico", "-", "quirúrgicos", "importantes", ",", "fumadora", "de", "1", "paquete", "de", "cigarrillos", "al", "día", "desde", "los", "20", "años", "de", "edad", "y", "sin", "antecedentes", "familiares", "oncológicos", ",", "que", "consultó", "por", "dolor", "en", "la", "mama", "izquierda", ",", "asociado", "a", "enrojecimiento", "y", "edema", "cutáneo", ",", "que", "inicialmente", "fue", "manejado", "como", "una", "mastitis", "con", "cloxacilina", ",", "sin", "mejoría", "clínica", ".", "Ante", "la", "refractariedad", "al", "tratamiento", "antibiótico", ",", "se", "decidió", "realizar", "biopsia", "cutánea", ".", "\n\n", "Exploración", "física", "\n", "A", "la", "exploración", "destaca", "una", "mama", "izquierda", "dura", "y", "nodular", ",", "con", "engrosamiento", "cutáneo", "acompañado", "de", "piel", "de", "naranja", "y", "eritema", "generalizado", ";", "en", "la", "axila", "ipsilateral", "se", "palpan", "adenopatías", "de", "unos", "2", "cm", ",", "duras", "y", "móviles", ".", "En", "la", "mama", "derecha", "se", "palpa", "un", "nódulo", "en", "el", "cuadrante", "inferoexterno", "móvil", "de", "2", "cm", "aproximadamente", ",", "sin", "palparse", "adenopatías", "a", "nivel", "axilar", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "Punch", "de", "piel", "de", "mama", "izquierda", ":", "cilindros", "cutáneos", "con", "múltiples", "émbolos", "linfáticos", "de", "carcinoma", "ductal", "pobremente", "diferenciado", "(", "carcinoma", "inflamatorio", ")", ",", "con", "receptores", "hormonales", "negativos", ",", "Her-2", "no", "amplificado", "y", "Ki-67", "del", "40", "%", ".", "\n", "»", "Resonancia", "de", "mamas", ":", "captación", "difusa", "de", "mama", "izquierda", "con", "edema", "y", "engrosamiento", "de", "la", "piel", "concordante", "con", "el", "diagnóstico", "histológico", "de", "carcinoma", "inflamatorio", "(", "BRADS6", ")", ",", "asociado", "a", "adenopatías", "axilares", "sospechosas", ".", "En", "la", "mama", "derecha", "lesiones", "con", "distorsión", "del", "parénquima", "en", "el", "cuadrante", "superoexterno", "y", "probable", "fibroadenoma", "en", "el", "cuadrante", "ínfero", "externo", ".", "\n", "»", "BAG", "de", "mama", "derecha", ":", "CSE", ",", "carcinoma", "intraductal", "sólido", "de", "alto", "grado", ".", "CIE", ",", "tumor", "phyllodes", ",", "histológicamente", "benigno", ".", "\n", "»", "Se", "realiza", "estudio", "de", "extensión", "con", "TC", "y", "gammagrafía", "ósea", ",", "que", "son", "negativos", ".", "\n\n", "Diagnóstico", "\n", "Carcinoma", "ductal", "inflamatorio", "de", "mama", "izquierda", "pT4cN1M0", "(", "estadio", "IIIB", ")", ".", "\n\n", "Tumor", "phyllodes", "benigno", "de", "mama", "derecha", ",", "asociado", "a", "carcinoma", "intraductal", "sólido", "de", "alto", "grado", ".", "\n\n", "Tratamiento", "\n", "Con", "el", "diagnóstico", "de", "carcinoma", "ductal", "inflamatorio", "de", "mama", "izquierda", "pT4cN1M0", "(", "estadio", "IIIB", ")", ",", "inicia", "tratamiento", "de", "quimioterapia", "con", "intención", "neoadyuvante", ",", "con", "taxol", "semanal", "(", "80", "mg", "/", "m2", ")", "por", "12", "ciclos", ",", "con", "neurotoxicidad", "grado", "2", "como", "evento", "adverso", "importante", ",", "seguido", "de", "cuatro", "ciclos", "de", "FEC", "(", "5-FU", "600", "mg", "/", "m2", "+", "epirrubicina", "90", "mg", "/", "m2", "+", "ciclofosfamida", "600", "mg", "/", "m2", ")", ".", "\n\n", "Tras", "finalizar", "la", "neoadyuvancia", ",", "es", "intervenida", "quirúrgicamente", "con", "mastectomía", "bilateral", "y", "linfadenectomía", "axilar", "izquierda", ",", "con", "resultados", "de", "anatomía", "patológica", "de", ":", "\n", "»", "Mastectomía", "izquierda", ":", "persistencia", "postneoadyuvancia", "de", "carcinoma", "ductal", "infiltrante", "en", "toda", "la", "mama", "en", "forma", "de", "agregados", "dispersos", "(", "el", "mayor", "de", "2,5", "mm", ")", ",", "con", "invasión", "tumoral", "linfática", "en", "el", "parénquima", "mamario", "y", "en", "la", "dermis", "del", "huso", "de", "piel", "incluido", ".", "Con", "un", "grado", "de", "regresión", "tumoral", "por", "quimioterapia", "neoadyuvante", "de", "al", "menos", "el", "50", "%", "(", "categoría", "R1", ")", "y", "afectación", "de", "3", "de", "los", "9", "ganglios", "linfáticos", "aislados", "de", "la", "linfadenectomía", "axilar", ".", "Estadio", "tumoral", "AJCC", "/", "UICC", ",", "7ª", "edición", ":", "ypT4d", "N1a", ".", "\n", "»", "Mastectomía", "derecha", ":", "alteraciones", "estromales", "compatibles", "con", "la", "administración", "de", "quimioterapia", "neoadyuvante", ".", "Estadio", "tumoral", "AJCC", "/", "UICC", ",", "7ª", "edición", ":", "pT0", "Nx", ".", "En", "la", "pieza", "de", "mastectomía", "derecha", "no", "se", "identifica", "lecho", "tumoral", "ni", "carcinoma", "intraductal", "de", "alto", "grado", "ni", "infiltrante", ",", "aunque", "sí", "se", "observan", "zonas", "con", "patrón", "fibroadenomatoide", "que", "pueden", "explicar", "el", "diagnóstico", "previo", "de", "tumor", "phyllodes", "benigno", ".", "Comparando", "la", "morfología", "de", "las", "lesiones", "observadas", "en", "la", "pieza", "de", "mastectomía", "con", "las", "biopsias", "iniciales", "de", "la", "BAG", "se", "evidencia", "que", "las", "imágenes", "de", "la", "pieza", "quirúrgica", "podrían", "ser", "compatibles", "con", "una", "extensión", "tumoral", "residual", "a", "los", "lobulillos", "que", "sería", "lo", "que", ",", "finalmente", ",", "queda", "del", "tumor", "original", "tras", "la", "quimioterapia", "neoadyuvante", ".", "\n", "Tras", "el", "tratamiento", "quirúrgico", ",", "la", "paciente", "recibe", "tratamiento", "de", "radioterapia", "sobre", "la", "pared", "torácica", "izquierda", "y", "áreas", "ganglionares", "supraclaviculares", ",", "interpectorales", ",", "infraclaviculares", "y", "niveles", "ganglionares", "axilares", "I", "a", "III", "con", "una", "dosis", "total", "de", "50", "Gy", ",", "con", "sobreimpresión", "de", "10", "Gy", "adicionales", "sobre", "el", "área", "de", "la", "pared", "torácica", "izquierda", ".", "\n\n", "Evolución", "\n", "Actualmente", "la", "paciente", "se", "encuentra", "realizando", "revisiones", "periódicas", "sin", "incidencias", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
carcinoma ductal pobremente diferenciado, carcinoma inflamatorio, carcinoma inflamatorio, fibroadenoma, carcinoma intraductal sólido de alto grado, tumor phyllodes , histológicamente benigno, Carcinoma ductal inflamatorio, pT4cN1M0, Tumor phyllodes benigno, carcinoma intraductal sólido de alto grado, carcinoma ductal inflamatorio, pT4cN1M0, carcinoma ductal infiltrante, tumoral, tumoral, tumoral, tumoral, tumoral, carcinoma intraductal de alto grado, tumor phyllodes benigno, tumoral, tumor	991_task2	Sentence: Anamnesis Paciente mujer de 45 años de edad, sin antecedentes médico-quirúrgicos importantes, fumadora de 1 paquete de cigarrillos al día desde los 20 años de edad y sin antecedentes familiares oncológicos, que consultó por dolor en la mama izquierda, asociado a enrojecimiento y edema cutáneo, que inicialmente fue manejado como una mastitis con cloxacilina, sin mejoría clínica. Ante la refractariedad al tratamiento antibiótico, se decidió realizar biopsia cutánea. Exploración física A la exploración destaca una mama izquierda dura y nodular, con engrosamiento cutáneo acompañado de piel de naranja y eritema generalizado; en la axila ipsilateral se palpan adenopatías de unos 2 cm, duras y móviles. En la mama derecha se palpa un nódulo en el cuadrante inferoexterno móvil de 2 cm aproximadamente, sin palparse adenopatías a nivel axilar. Pruebas complementarias » Punch de piel de mama izquierda: cilindros cutáneos con múltiples émbolos linfáticos de carcinoma ductal pobremente diferenciado (carcinoma inflamatorio), con receptores hormonales negativos, Her-2 no amplificado y Ki-67 del 40%. » Resonancia de mamas: captación difusa de mama izquierda con edema y engrosamiento de la piel concordante con el diagnóstico histológico de carcinoma inflamatorio (BRADS6), asociado a adenopatías axilares sospechosas. En la mama derecha lesiones con distorsión del parénquima en el cuadrante superoexterno y probable fibroadenoma en el cuadrante ínfero externo. » BAG de mama derecha: CSE, carcinoma intraductal sólido de alto grado. CIE, tumor phyllodes, histológicamente benigno. » Se realiza estudio de extensión con TC y gammagrafía ósea, que son negativos. Diagnóstico Carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB). Tumor phyllodes benigno de mama derecha, asociado a carcinoma intraductal sólido de alto grado. Tratamiento Con el diagnóstico de carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB), inicia tratamiento de quimioterapia con intención neoadyuvante, con taxol semanal (80 mg/m2) por 12 ciclos, con neurotoxicidad grado 2 como evento adverso importante, seguido de cuatro ciclos de FEC (5-FU 600 mg/m2 + epirrubicina 90 mg/m2 + ciclofosfamida 600 mg/m2). Tras finalizar la neoadyuvancia, es intervenida quirúrgicamente con mastectomía bilateral y linfadenectomía axilar izquierda, con resultados de anatomía patológica de: » Mastectomía izquierda: persistencia postneoadyuvancia de carcinoma ductal infiltrante en toda la mama en forma de agregados dispersos (el mayor de 2,5 mm), con invasión tumoral linfática en el parénquima mamario y en la dermis del huso de piel incluido. Con un grado de regresión tumoral por quimioterapia neoadyuvante de al menos el 50% (categoría R1) y afectación de 3 de los 9 ganglios linfáticos aislados de la linfadenectomía axilar.Estadio tumoral AJCC/UICC, 7ª edición: ypT4d N1a. » Mastectomía derecha: alteraciones estromales compatibles con la administración de quimioterapia neoadyuvante. Estadio tumoral AJCC/UICC, 7ª edición: pT0 Nx. En la pieza de mastectomía derecha no se identifica lecho tumoral ni carcinoma intraductal de alto grado ni infiltrante, aunque sí se observan zonas con patrón fibroadenomatoide que pueden explicar el diagnóstico previo de tumor phyllodes benigno. Comparando la morfología de las lesiones observadas en la pieza de mastectomía con las biopsias iniciales de la BAG se evidencia que las imágenes de la pieza quirúrgica podrían ser compatibles con una extensión tumoral residual a los lobulillos que sería lo que, finalmente, queda del tumor original tras la quimioterapia neoadyuvante. Tras el tratamiento quirúrgico, la paciente recibe tratamiento de radioterapia sobre la pared torácica izquierda y áreas ganglionares supraclaviculares, interpectorales, infraclaviculares y niveles ganglionares axilares I a III con una dosis total de 50 Gy, con sobreimpresión de 10 Gy adicionales sobre el área de la pared torácica izquierda. Evolución Actualmente la paciente se encuentra realizando revisiones periódicas sin incidencias. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Paciente mujer de 45 años de edad, sin antecedentes médico-quirúrgicos importantes, fumadora de 1 paquete de cigarrillos al día desde los 20 años de edad y sin antecedentes familiares oncológicos, que consultó por dolor en la mama izquierda, asociado a enrojecimiento y edema cutáneo, que inicialmente fue manejado como una mastitis con cloxacilina, sin mejoría clínica. Ante la refractariedad al tratamiento antibiótico, se decidió realizar biopsia cutánea. Exploración física A la exploración destaca una mama izquierda dura y nodular, con engrosamiento cutáneo acompañado de piel de naranja y eritema generalizado; en la axila ipsilateral se palpan adenopatías de unos 2 cm, duras y móviles. En la mama derecha se palpa un nódulo en el cuadrante inferoexterno móvil de 2 cm aproximadamente, sin palparse adenopatías a nivel axilar. Pruebas complementarias » Punch de piel de mama izquierda: cilindros cutáneos con múltiples émbolos linfáticos de carcinoma ductal pobremente diferenciado (carcinoma inflamatorio), con receptores hormonales negativos, Her-2 no amplificado y Ki-67 del 40%. » Resonancia de mamas: captación difusa de mama izquierda con edema y engrosamiento de la piel concordante con el diagnóstico histológico de carcinoma inflamatorio (BRADS6), asociado a adenopatías axilares sospechosas. En la mama derecha lesiones con distorsión del parénquima en el cuadrante superoexterno y probable fibroadenoma en el cuadrante ínfero externo. » BAG de mama derecha: CSE, carcinoma intraductal sólido de alto grado. CIE, tumor phyllodes, histológicamente benigno. » Se realiza estudio de extensión con TC y gammagrafía ósea, que son negativos. Diagnóstico Carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB). Tumor phyllodes benigno de mama derecha, asociado a carcinoma intraductal sólido de alto grado. Tratamiento Con el diagnóstico de carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB), inicia tratamiento de quimioterapia con intención neoadyuvante, con taxol semanal (80 mg/m2) por 12 ciclos, con neurotoxicidad grado 2 como evento adverso importante, seguido de cuatro ciclos de FEC (5-FU 600 mg/m2 + epirrubicina 90 mg/m2 + ciclofosfamida 600 mg/m2). Tras finalizar la neoadyuvancia, es intervenida quirúrgicamente con mastectomía bilateral y linfadenectomía axilar izquierda, con resultados de anatomía patológica de: » Mastectomía izquierda: persistencia postneoadyuvancia de carcinoma ductal infiltrante en toda la mama en forma de agregados dispersos (el mayor de 2,5 mm), con invasión tumoral linfática en el parénquima mamario y en la dermis del huso de piel incluido. Con un grado de regresión tumoral por quimioterapia neoadyuvante de al menos el 50% (categoría R1) y afectación de 3 de los 9 ganglios linfáticos aislados de la linfadenectomía axilar.Estadio tumoral AJCC/UICC, 7ª edición: ypT4d N1a. » Mastectomía derecha: alteraciones estromales compatibles con la administración de quimioterapia neoadyuvante. Estadio tumoral AJCC/UICC, 7ª edición: pT0 Nx. En la pieza de mastectomía derecha no se identifica lecho tumoral ni carcinoma intraductal de alto grado ni infiltrante, aunque sí se observan zonas con patrón fibroadenomatoide que pueden explicar el diagnóstico previo de tumor phyllodes benigno. Comparando la morfología de las lesiones observadas en la pieza de mastectomía con las biopsias iniciales de la BAG se evidencia que las imágenes de la pieza quirúrgica podrían ser compatibles con una extensión tumoral residual a los lobulillos que sería lo que, finalmente, queda del tumor original tras la quimioterapia neoadyuvante. Tras el tratamiento quirúrgico, la paciente recibe tratamiento de radioterapia sobre la pared torácica izquierda y áreas ganglionares supraclaviculares, interpectorales, infraclaviculares y niveles ganglionares axilares I a III con una dosis total de 50 Gy, con sobreimpresión de 10 Gy adicionales sobre el área de la pared torácica izquierda. Evolución Actualmente la paciente se encuentra realizando revisiones periódicas sin incidencias.	[ "Anamnesis", "\n", "Paciente", "mujer", "de", "45", "años", "de", "edad", ",", "sin", "antecedentes", "médico", "-", "quirúrgicos", "importantes", ",", "fumadora", "de", "1", "paquete", "de", "cigarrillos", "al", "día", "desde", "los", "20", "años", "de", "edad", "y", "sin", "antecedentes", "familiares", "oncológicos", ",", "que", "consultó", "por", "dolor", "en", "la", "mama", "izquierda", ",", "asociado", "a", "enrojecimiento", "y", "edema", "cutáneo", ",", "que", "inicialmente", "fue", "manejado", "como", "una", "mastitis", "con", "cloxacilina", ",", "sin", "mejoría", "clínica", ".", "Ante", "la", "refractariedad", "al", "tratamiento", "antibiótico", ",", "se", "decidió", "realizar", "biopsia", "cutánea", ".", "\n\n", "Exploración", "física", "\n", "A", "la", "exploración", "destaca", "una", "mama", "izquierda", "dura", "y", "nodular", ",", "con", "engrosamiento", "cutáneo", "acompañado", "de", "piel", "de", "naranja", "y", "eritema", "generalizado", ";", "en", "la", "axila", "ipsilateral", "se", "palpan", "adenopatías", "de", "unos", "2", "cm", ",", "duras", "y", "móviles", ".", "En", "la", "mama", "derecha", "se", "palpa", "un", "nódulo", "en", "el", "cuadrante", "inferoexterno", "móvil", "de", "2", "cm", "aproximadamente", ",", "sin", "palparse", "adenopatías", "a", "nivel", "axilar", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "Punch", "de", "piel", "de", "mama", "izquierda", ":", "cilindros", "cutáneos", "con", "múltiples", "émbolos", "linfáticos", "de", "carcinoma", "ductal", "pobremente", "diferenciado", "(", "carcinoma", "inflamatorio", ")", ",", "con", "receptores", "hormonales", "negativos", ",", "Her-2", "no", "amplificado", "y", "Ki-67", "del", "40", "%", ".", "\n", "»", "Resonancia", "de", "mamas", ":", "captación", "difusa", "de", "mama", "izquierda", "con", "edema", "y", "engrosamiento", "de", "la", "piel", "concordante", "con", "el", "diagnóstico", "histológico", "de", "carcinoma", "inflamatorio", "(", "BRADS6", ")", ",", "asociado", "a", "adenopatías", "axilares", "sospechosas", ".", "En", "la", "mama", "derecha", "lesiones", "con", "distorsión", "del", "parénquima", "en", "el", "cuadrante", "superoexterno", "y", "probable", "fibroadenoma", "en", "el", "cuadrante", "ínfero", "externo", ".", "\n", "»", "BAG", "de", "mama", "derecha", ":", "CSE", ",", "carcinoma", "intraductal", "sólido", "de", "alto", "grado", ".", "CIE", ",", "tumor", "phyllodes", ",", "histológicamente", "benigno", ".", "\n", "»", "Se", "realiza", "estudio", "de", "extensión", "con", "TC", "y", "gammagrafía", "ósea", ",", "que", "son", "negativos", ".", "\n\n", "Diagnóstico", "\n", "Carcinoma", "ductal", "inflamatorio", "de", "mama", "izquierda", "pT4cN1M0", "(", "estadio", "IIIB", ")", ".", "\n\n", "Tumor", "phyllodes", "benigno", "de", "mama", "derecha", ",", "asociado", "a", "carcinoma", "intraductal", "sólido", "de", "alto", "grado", ".", "\n\n", "Tratamiento", "\n", "Con", "el", "diagnóstico", "de", "carcinoma", "ductal", "inflamatorio", "de", "mama", "izquierda", "pT4cN1M0", "(", "estadio", "IIIB", ")", ",", "inicia", "tratamiento", "de", "quimioterapia", "con", "intención", "neoadyuvante", ",", "con", "taxol", "semanal", "(", "80", "mg", "/", "m2", ")", "por", "12", "ciclos", ",", "con", "neurotoxicidad", "grado", "2", "como", "evento", "adverso", "importante", ",", "seguido", "de", "cuatro", "ciclos", "de", "FEC", "(", "5-FU", "600", "mg", "/", "m2", "+", "epirrubicina", "90", "mg", "/", "m2", "+", "ciclofosfamida", "600", "mg", "/", "m2", ")", ".", "\n\n", "Tras", "finalizar", "la", "neoadyuvancia", ",", "es", "intervenida", "quirúrgicamente", "con", "mastectomía", "bilateral", "y", "linfadenectomía", "axilar", "izquierda", ",", "con", "resultados", "de", "anatomía", "patológica", "de", ":", "\n", "»", "Mastectomía", "izquierda", ":", "persistencia", "postneoadyuvancia", "de", "carcinoma", "ductal", "infiltrante", "en", "toda", "la", "mama", "en", "forma", "de", "agregados", "dispersos", "(", "el", "mayor", "de", "2,5", "mm", ")", ",", "con", "invasión", "tumoral", "linfática", "en", "el", "parénquima", "mamario", "y", "en", "la", "dermis", "del", "huso", "de", "piel", "incluido", ".", "Con", "un", "grado", "de", "regresión", "tumoral", "por", "quimioterapia", "neoadyuvante", "de", "al", "menos", "el", "50", "%", "(", "categoría", "R1", ")", "y", "afectación", "de", "3", "de", "los", "9", "ganglios", "linfáticos", "aislados", "de", "la", "linfadenectomía", "axilar", ".", "Estadio", "tumoral", "AJCC", "/", "UICC", ",", "7ª", "edición", ":", "ypT4d", "N1a", ".", "\n", "»", "Mastectomía", "derecha", ":", "alteraciones", "estromales", "compatibles", "con", "la", "administración", "de", "quimioterapia", "neoadyuvante", ".", "Estadio", "tumoral", "AJCC", "/", "UICC", ",", "7ª", "edición", ":", "pT0", "Nx", ".", "En", "la", "pieza", "de", "mastectomía", "derecha", "no", "se", "identifica", "lecho", "tumoral", "ni", "carcinoma", "intraductal", "de", "alto", "grado", "ni", "infiltrante", ",", "aunque", "sí", "se", "observan", "zonas", "con", "patrón", "fibroadenomatoide", "que", "pueden", "explicar", "el", "diagnóstico", "previo", "de", "tumor", "phyllodes", "benigno", ".", "Comparando", "la", "morfología", "de", "las", "lesiones", "observadas", "en", "la", "pieza", "de", "mastectomía", "con", "las", "biopsias", "iniciales", "de", "la", "BAG", "se", "evidencia", "que", "las", "imágenes", "de", "la", "pieza", "quirúrgica", "podrían", "ser", "compatibles", "con", "una", "extensión", "tumoral", "residual", "a", "los", "lobulillos", "que", "sería", "lo", "que", ",", "finalmente", ",", "queda", "del", "tumor", "original", "tras", "la", "quimioterapia", "neoadyuvante", ".", "\n", "Tras", "el", "tratamiento", "quirúrgico", ",", "la", "paciente", "recibe", "tratamiento", "de", "radioterapia", "sobre", "la", "pared", "torácica", "izquierda", "y", "áreas", "ganglionares", "supraclaviculares", ",", "interpectorales", ",", "infraclaviculares", "y", "niveles", "ganglionares", "axilares", "I", "a", "III", "con", "una", "dosis", "total", "de", "50", "Gy", ",", "con", "sobreimpresión", "de", "10", "Gy", "adicionales", "sobre", "el", "área", "de", "la", "pared", "torácica", "izquierda", ".", "\n\n", "Evolución", "\n", "Actualmente", "la", "paciente", "se", "encuentra", "realizando", "revisiones", "periódicas", "sin", "incidencias", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
Lck is a Protein, Lck is a Protein, L - selectin is a Protein, ICAM-3 is a Protein, H - CAM is a Protein	9175835_task0	Sentence: Tap: a novel cellular protein that interacts with tip of herpesvirus saimiri and induces lymphocyte aggregation. Tip of herpesvirus saimiri associates with Lck and down-regulates Lck-mediated activation. We identified a novel cellular Tip-associated protein (Tap) by a yeast two-hybrid screen. Tap associated with Tip following transient expression in COS-1 cells and stable expression in human Jurkat-T cells. Expression of Tip and Tap in Jurkat-T cells induced dramatic cell aggregation. Aggregation was likely caused by the up-regulated surface expression of adhesion molecules including integrin alpha, L-selectin, ICAM-3, and H-CAM. Furthermore, NF-kappaB transcriptional factor of aggregated cells had approximately 40-fold higher activity than that of parental cells. Thus, Tap is likely to be an important cellular mediator of Tip function in T cell transformation by herpesvirus saimiri. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Tap: a novel cellular protein that interacts with tip of herpesvirus saimiri and induces lymphocyte aggregation. Tip of herpesvirus saimiri associates with Lck and down-regulates Lck-mediated activation. We identified a novel cellular Tip-associated protein (Tap) by a yeast two-hybrid screen. Tap associated with Tip following transient expression in COS-1 cells and stable expression in human Jurkat-T cells. Expression of Tip and Tap in Jurkat-T cells induced dramatic cell aggregation. Aggregation was likely caused by the up-regulated surface expression of adhesion molecules including integrin alpha, L-selectin, ICAM-3, and H-CAM. Furthermore, NF-kappaB transcriptional factor of aggregated cells had approximately 40-fold higher activity than that of parental cells. Thus, Tap is likely to be an important cellular mediator of Tip function in T cell transformation by herpesvirus saimiri.	[ "Tap", ":", "a", "novel", "cellular", "protein", "that", "interacts", "with", "tip", "of", "herpesvirus", "saimiri", "and", "induces", "lymphocyte", "aggregation", ".", "\n", "Tip", "of", "herpesvirus", "saimiri", "associates", "with", "Lck", "and", "down", "-", "regulates", "Lck", "-", "mediated", "activation", ".", "We", "identified", "a", "novel", "cellular", "Tip", "-", "associated", "protein", "(", "Tap", ")", "by", "a", "yeast", "two", "-", "hybrid", "screen", ".", "Tap", "associated", "with", "Tip", "following", "transient", "expression", "in", "COS-1", "cells", "and", "stable", "expression", "in", "human", "Jurkat", "-", "T", "cells", ".", "Expression", "of", "Tip", "and", "Tap", "in", "Jurkat", "-", "T", "cells", "induced", "dramatic", "cell", "aggregation", ".", "Aggregation", "was", "likely", "caused", "by", "the", "up", "-", "regulated", "surface", "expression", "of", "adhesion", "molecules", "including", "integrin", "alpha", ",", "L", "-", "selectin", ",", "ICAM-3", ",", "and", "H", "-", "CAM", ".", "Furthermore", ",", "NF", "-", "kappaB", "transcriptional", "factor", "of", "aggregated", "cells", "had", "approximately", "40-fold", "higher", "activity", "than", "that", "of", "parental", "cells", ".", "Thus", ",", "Tap", "is", "likely", "to", "be", "an", "important", "cellular", "mediator", "of", "Tip", "function", "in", "T", "cell", "transformation", "by", "herpesvirus", "saimiri", "." ]	[ "Protein" ]
Lck is a Protein, Lck is a Protein, L - selectin is a Protein, ICAM-3 is a Protein, H - CAM is a Protein	9175835_task1	Sentence: Tap: a novel cellular protein that interacts with tip of herpesvirus saimiri and induces lymphocyte aggregation. Tip of herpesvirus saimiri associates with Lck and down-regulates Lck-mediated activation. We identified a novel cellular Tip-associated protein (Tap) by a yeast two-hybrid screen. Tap associated with Tip following transient expression in COS-1 cells and stable expression in human Jurkat-T cells. Expression of Tip and Tap in Jurkat-T cells induced dramatic cell aggregation. Aggregation was likely caused by the up-regulated surface expression of adhesion molecules including integrin alpha, L-selectin, ICAM-3, and H-CAM. Furthermore, NF-kappaB transcriptional factor of aggregated cells had approximately 40-fold higher activity than that of parental cells. Thus, Tap is likely to be an important cellular mediator of Tip function in T cell transformation by herpesvirus saimiri. Instructions: please typing these entity words according to sentence: Lck, Lck, L - selectin, ICAM-3, H - CAM Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Tap: a novel cellular protein that interacts with tip of herpesvirus saimiri and induces lymphocyte aggregation. Tip of herpesvirus saimiri associates with Lck and down-regulates Lck-mediated activation. We identified a novel cellular Tip-associated protein (Tap) by a yeast two-hybrid screen. Tap associated with Tip following transient expression in COS-1 cells and stable expression in human Jurkat-T cells. Expression of Tip and Tap in Jurkat-T cells induced dramatic cell aggregation. Aggregation was likely caused by the up-regulated surface expression of adhesion molecules including integrin alpha, L-selectin, ICAM-3, and H-CAM. Furthermore, NF-kappaB transcriptional factor of aggregated cells had approximately 40-fold higher activity than that of parental cells. Thus, Tap is likely to be an important cellular mediator of Tip function in T cell transformation by herpesvirus saimiri.	[ "Tap", ":", "a", "novel", "cellular", "protein", "that", "interacts", "with", "tip", "of", "herpesvirus", "saimiri", "and", "induces", "lymphocyte", "aggregation", ".", "\n", "Tip", "of", "herpesvirus", "saimiri", "associates", "with", "Lck", "and", "down", "-", "regulates", "Lck", "-", "mediated", "activation", ".", "We", "identified", "a", "novel", "cellular", "Tip", "-", "associated", "protein", "(", "Tap", ")", "by", "a", "yeast", "two", "-", "hybrid", "screen", ".", "Tap", "associated", "with", "Tip", "following", "transient", "expression", "in", "COS-1", "cells", "and", "stable", "expression", "in", "human", "Jurkat", "-", "T", "cells", ".", "Expression", "of", "Tip", "and", "Tap", "in", "Jurkat", "-", "T", "cells", "induced", "dramatic", "cell", "aggregation", ".", "Aggregation", "was", "likely", "caused", "by", "the", "up", "-", "regulated", "surface", "expression", "of", "adhesion", "molecules", "including", "integrin", "alpha", ",", "L", "-", "selectin", ",", "ICAM-3", ",", "and", "H", "-", "CAM", ".", "Furthermore", ",", "NF", "-", "kappaB", "transcriptional", "factor", "of", "aggregated", "cells", "had", "approximately", "40-fold", "higher", "activity", "than", "that", "of", "parental", "cells", ".", "Thus", ",", "Tap", "is", "likely", "to", "be", "an", "important", "cellular", "mediator", "of", "Tip", "function", "in", "T", "cell", "transformation", "by", "herpesvirus", "saimiri", "." ]	[ "Protein" ]
Lck, Lck, L - selectin, ICAM-3, H - CAM	9175835_task2	Sentence: Tap: a novel cellular protein that interacts with tip of herpesvirus saimiri and induces lymphocyte aggregation. Tip of herpesvirus saimiri associates with Lck and down-regulates Lck-mediated activation. We identified a novel cellular Tip-associated protein (Tap) by a yeast two-hybrid screen. Tap associated with Tip following transient expression in COS-1 cells and stable expression in human Jurkat-T cells. Expression of Tip and Tap in Jurkat-T cells induced dramatic cell aggregation. Aggregation was likely caused by the up-regulated surface expression of adhesion molecules including integrin alpha, L-selectin, ICAM-3, and H-CAM. Furthermore, NF-kappaB transcriptional factor of aggregated cells had approximately 40-fold higher activity than that of parental cells. Thus, Tap is likely to be an important cellular mediator of Tip function in T cell transformation by herpesvirus saimiri. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Tap: a novel cellular protein that interacts with tip of herpesvirus saimiri and induces lymphocyte aggregation. Tip of herpesvirus saimiri associates with Lck and down-regulates Lck-mediated activation. We identified a novel cellular Tip-associated protein (Tap) by a yeast two-hybrid screen. Tap associated with Tip following transient expression in COS-1 cells and stable expression in human Jurkat-T cells. Expression of Tip and Tap in Jurkat-T cells induced dramatic cell aggregation. Aggregation was likely caused by the up-regulated surface expression of adhesion molecules including integrin alpha, L-selectin, ICAM-3, and H-CAM. Furthermore, NF-kappaB transcriptional factor of aggregated cells had approximately 40-fold higher activity than that of parental cells. Thus, Tap is likely to be an important cellular mediator of Tip function in T cell transformation by herpesvirus saimiri.	[ "Tap", ":", "a", "novel", "cellular", "protein", "that", "interacts", "with", "tip", "of", "herpesvirus", "saimiri", "and", "induces", "lymphocyte", "aggregation", ".", "\n", "Tip", "of", "herpesvirus", "saimiri", "associates", "with", "Lck", "and", "down", "-", "regulates", "Lck", "-", "mediated", "activation", ".", "We", "identified", "a", "novel", "cellular", "Tip", "-", "associated", "protein", "(", "Tap", ")", "by", "a", "yeast", "two", "-", "hybrid", "screen", ".", "Tap", "associated", "with", "Tip", "following", "transient", "expression", "in", "COS-1", "cells", "and", "stable", "expression", "in", "human", "Jurkat", "-", "T", "cells", ".", "Expression", "of", "Tip", "and", "Tap", "in", "Jurkat", "-", "T", "cells", "induced", "dramatic", "cell", "aggregation", ".", "Aggregation", "was", "likely", "caused", "by", "the", "up", "-", "regulated", "surface", "expression", "of", "adhesion", "molecules", "including", "integrin", "alpha", ",", "L", "-", "selectin", ",", "ICAM-3", ",", "and", "H", "-", "CAM", ".", "Furthermore", ",", "NF", "-", "kappaB", "transcriptional", "factor", "of", "aggregated", "cells", "had", "approximately", "40-fold", "higher", "activity", "than", "that", "of", "parental", "cells", ".", "Thus", ",", "Tap", "is", "likely", "to", "be", "an", "important", "cellular", "mediator", "of", "Tip", "function", "in", "T", "cell", "transformation", "by", "herpesvirus", "saimiri", "." ]	[ "Protein" ]
beta - catenin is a Individual_protein, beta - catenin is a Gene/protein/RNA, alpha - catenin is a Individual_protein, beta - catenin is a Gene/protein/RNA	184_task0	Sentence: Full-length beta-catenin, beta-catenin mutant proteins with NH2-terminal deletions before (deltaN90) or after (deltaN131, deltaN151) the alpha-catenin binding site, or a mutant beta-catenin with a COOH-terminal deletion (delta C) were expressed in MDCK cells under the control of the tetracycline-repressible transactivator. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA, Individual_protein	[ "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Full-length beta-catenin, beta-catenin mutant proteins with NH2-terminal deletions before (deltaN90) or after (deltaN131, deltaN151) the alpha-catenin binding site, or a mutant beta-catenin with a COOH-terminal deletion (delta C) were expressed in MDCK cells under the control of the tetracycline-repressible transactivator.	[ "Full", "-", "length", "beta", "-", "catenin", ",", "beta", "-", "catenin", "mutant", "proteins", "with", "NH2-terminal", "deletions", "before", "(", "deltaN90", ")", "or", "after", "(", "deltaN131", ",", "deltaN151", ")", "the", "alpha", "-", "catenin", "binding", "site", ",", "or", "a", "mutant", "beta", "-", "catenin", "with", "a", "COOH", "-", "terminal", "deletion", "(", "delta", "C", ")", "were", "expressed", "in", "MDCK", "cells", "under", "the", "control", "of", "the", "tetracycline", "-", "repressible", "transactivator", "." ]	[ "Individual_protein", "Gene/protein/RNA" ]
beta - catenin is a Individual_protein, beta - catenin is a Gene/protein/RNA, alpha - catenin is a Individual_protein, beta - catenin is a Gene/protein/RNA	184_task1	Sentence: Full-length beta-catenin, beta-catenin mutant proteins with NH2-terminal deletions before (deltaN90) or after (deltaN131, deltaN151) the alpha-catenin binding site, or a mutant beta-catenin with a COOH-terminal deletion (delta C) were expressed in MDCK cells under the control of the tetracycline-repressible transactivator. Instructions: please typing these entity words according to sentence: beta - catenin, beta - catenin, alpha - catenin, beta - catenin Options: Gene/protein/RNA, Individual_protein	[ "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Full-length beta-catenin, beta-catenin mutant proteins with NH2-terminal deletions before (deltaN90) or after (deltaN131, deltaN151) the alpha-catenin binding site, or a mutant beta-catenin with a COOH-terminal deletion (delta C) were expressed in MDCK cells under the control of the tetracycline-repressible transactivator.	[ "Full", "-", "length", "beta", "-", "catenin", ",", "beta", "-", "catenin", "mutant", "proteins", "with", "NH2-terminal", "deletions", "before", "(", "deltaN90", ")", "or", "after", "(", "deltaN131", ",", "deltaN151", ")", "the", "alpha", "-", "catenin", "binding", "site", ",", "or", "a", "mutant", "beta", "-", "catenin", "with", "a", "COOH", "-", "terminal", "deletion", "(", "delta", "C", ")", "were", "expressed", "in", "MDCK", "cells", "under", "the", "control", "of", "the", "tetracycline", "-", "repressible", "transactivator", "." ]	[ "Individual_protein", "Gene/protein/RNA" ]
beta - catenin, beta - catenin, alpha - catenin, beta - catenin	184_task2	Sentence: Full-length beta-catenin, beta-catenin mutant proteins with NH2-terminal deletions before (deltaN90) or after (deltaN131, deltaN151) the alpha-catenin binding site, or a mutant beta-catenin with a COOH-terminal deletion (delta C) were expressed in MDCK cells under the control of the tetracycline-repressible transactivator. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Full-length beta-catenin, beta-catenin mutant proteins with NH2-terminal deletions before (deltaN90) or after (deltaN131, deltaN151) the alpha-catenin binding site, or a mutant beta-catenin with a COOH-terminal deletion (delta C) were expressed in MDCK cells under the control of the tetracycline-repressible transactivator.	[ "Full", "-", "length", "beta", "-", "catenin", ",", "beta", "-", "catenin", "mutant", "proteins", "with", "NH2-terminal", "deletions", "before", "(", "deltaN90", ")", "or", "after", "(", "deltaN131", ",", "deltaN151", ")", "the", "alpha", "-", "catenin", "binding", "site", ",", "or", "a", "mutant", "beta", "-", "catenin", "with", "a", "COOH", "-", "terminal", "deletion", "(", "delta", "C", ")", "were", "expressed", "in", "MDCK", "cells", "under", "the", "control", "of", "the", "tetracycline", "-", "repressible", "transactivator", "." ]	[ "Individual_protein", "Gene/protein/RNA" ]
direct is an umlsterm, mammography is an umlsterm, radiography is an umlsterm, clinical study is an umlsterm, direct is an umlsterm, mammograms is an umlsterm, Methods is an umlsterm, survey is an umlsterm, mammograms is an umlsterm, spot is an umlsterm, direct is an umlsterm, mammography is an umlsterm, radiograms is an umlsterm, patients is an umlsterm, diagnostic is an umlsterm, value is an umlsterm, survey is an umlsterm, mammograms is an umlsterm, direct is an umlsterm, technique is an umlsterm, radiograms is an umlsterm, breast is an umlsterm, identification is an umlsterm, Spot is an umlsterm, techniques is an umlsterm, evaluation is an umlsterm, diagnostic is an umlsterm, procedures is an umlsterm, direct is an umlsterm, technique is an umlsterm, radiography is an umlsterm, mammography is an umlsterm, overall is an umlsterm, diagnostic is an umlsterm, value is an umlsterm, direct is an umlsterm, survey is an umlsterm, mammograms is an umlsterm, mammograms is an umlsterm, spot is an umlsterm	DerRadiologe.70370597.eng.abstr_task0	Sentence: Introduction : The combination of direct magnification mammography and computed radiography provides an improvement in spatial resolution of storage phosphor-based digital systems . A clinical study comparing conventional and digital direct magnification mammograms was performed . Methods : 100 survey mammograms in 1.5- or 1.7-fold magnification and 50 4-fold spot magnification views were obtained with a prototype direct magnification mammography system and a storage phosphor-based digital system . An intraindividual comparison of these with previous conventional radiograms of the same patients was carried out . Results : The diagnostic value of digital survey mammograms using the direct magnification technique is comparable to that of conventional radiograms of the breast , especially with regard to the identification of microcalcifications and lesions and the clinical consequences . Spot magnification views performed with this combination of techniques allowed improvement in the evaluation of microcalcifications . In 15 % of cases , diagnostic procedures were adjusted accordingly . Conclusion : The combination of the direct magnification technique with digital storage phosphor radiography systems allows the performance of digital mammography by improving the overall spatial resolution . The diagnostic value of digital direct magnification survey mammograms was comparable to that of conventional mammograms . Digital 4-fold spot magnification views improved visualisation of the morphologic aspects of microcalcifications . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Introduction : The combination of direct magnification mammography and computed radiography provides an improvement in spatial resolution of storage phosphor-based digital systems . A clinical study comparing conventional and digital direct magnification mammograms was performed . Methods : 100 survey mammograms in 1.5- or 1.7-fold magnification and 50 4-fold spot magnification views were obtained with a prototype direct magnification mammography system and a storage phosphor-based digital system . An intraindividual comparison of these with previous conventional radiograms of the same patients was carried out . Results : The diagnostic value of digital survey mammograms using the direct magnification technique is comparable to that of conventional radiograms of the breast , especially with regard to the identification of microcalcifications and lesions and the clinical consequences . Spot magnification views performed with this combination of techniques allowed improvement in the evaluation of microcalcifications . In 15 % of cases , diagnostic procedures were adjusted accordingly . Conclusion : The combination of the direct magnification technique with digital storage phosphor radiography systems allows the performance of digital mammography by improving the overall spatial resolution . The diagnostic value of digital direct magnification survey mammograms was comparable to that of conventional mammograms . Digital 4-fold spot magnification views improved visualisation of the morphologic aspects of microcalcifications .	[ "Introduction", ":", "The", "combination", "of", "direct", "magnification", "mammography", "and", "computed", "radiography", "provides", "an", "improvement", "in", "spatial", "resolution", "of", "storage", "phosphor", "-", "based", "digital", "systems", ".", "A", "clinical", "study", "comparing", "conventional", "and", "digital", "direct", "magnification", "mammograms", "was", "performed", ".", "Methods", ":", "100", "survey", "mammograms", "in", "1.5-", "or", "1.7-fold", "magnification", "and", "50", "4-fold", "spot", "magnification", "views", "were", "obtained", "with", "a", "prototype", "direct", "magnification", "mammography", "system", "and", "a", "storage", "phosphor", "-", "based", "digital", "system", ".", "An", "intraindividual", "comparison", "of", "these", "with", "previous", "conventional", "radiograms", "of", "the", "same", "patients", "was", "carried", "out", ".", "Results", ":", "The", "diagnostic", "value", "of", "digital", "survey", "mammograms", "using", "the", "direct", "magnification", "technique", "is", "comparable", "to", "that", "of", "conventional", "radiograms", "of", "the", "breast", ",", "especially", "with", "regard", "to", "the", "identification", "of", "microcalcifications", "and", "lesions", "and", "the", "clinical", "consequences", ".", "Spot", "magnification", "views", "performed", "with", "this", "combination", "of", "techniques", "allowed", "improvement", "in", "the", "evaluation", "of", "microcalcifications", ".", "In", "15", "%", "of", "cases", ",", "diagnostic", "procedures", "were", "adjusted", "accordingly", ".", "Conclusion", ":", "The", "combination", "of", "the", "direct", "magnification", "technique", "with", "digital", "storage", "phosphor", "radiography", "systems", "allows", "the", "performance", "of", "digital", "mammography", "by", "improving", "the", "overall", "spatial", "resolution", ".", "The", "diagnostic", "value", "of", "digital", "direct", "magnification", "survey", "mammograms", "was", "comparable", "to", "that", "of", "conventional", "mammograms", ".", "Digital", "4-fold", "spot", "magnification", "views", "improved", "visualisation", "of", "the", "morphologic", "aspects", "of", "microcalcifications", "." ]	[ "umlsterm" ]
direct is an umlsterm, mammography is an umlsterm, radiography is an umlsterm, clinical study is an umlsterm, direct is an umlsterm, mammograms is an umlsterm, Methods is an umlsterm, survey is an umlsterm, mammograms is an umlsterm, spot is an umlsterm, direct is an umlsterm, mammography is an umlsterm, radiograms is an umlsterm, patients is an umlsterm, diagnostic is an umlsterm, value is an umlsterm, survey is an umlsterm, mammograms is an umlsterm, direct is an umlsterm, technique is an umlsterm, radiograms is an umlsterm, breast is an umlsterm, identification is an umlsterm, Spot is an umlsterm, techniques is an umlsterm, evaluation is an umlsterm, diagnostic is an umlsterm, procedures is an umlsterm, direct is an umlsterm, technique is an umlsterm, radiography is an umlsterm, mammography is an umlsterm, overall is an umlsterm, diagnostic is an umlsterm, value is an umlsterm, direct is an umlsterm, survey is an umlsterm, mammograms is an umlsterm, mammograms is an umlsterm, spot is an umlsterm	DerRadiologe.70370597.eng.abstr_task1	Sentence: Introduction : The combination of direct magnification mammography and computed radiography provides an improvement in spatial resolution of storage phosphor-based digital systems . A clinical study comparing conventional and digital direct magnification mammograms was performed . Methods : 100 survey mammograms in 1.5- or 1.7-fold magnification and 50 4-fold spot magnification views were obtained with a prototype direct magnification mammography system and a storage phosphor-based digital system . An intraindividual comparison of these with previous conventional radiograms of the same patients was carried out . Results : The diagnostic value of digital survey mammograms using the direct magnification technique is comparable to that of conventional radiograms of the breast , especially with regard to the identification of microcalcifications and lesions and the clinical consequences . Spot magnification views performed with this combination of techniques allowed improvement in the evaluation of microcalcifications . In 15 % of cases , diagnostic procedures were adjusted accordingly . Conclusion : The combination of the direct magnification technique with digital storage phosphor radiography systems allows the performance of digital mammography by improving the overall spatial resolution . The diagnostic value of digital direct magnification survey mammograms was comparable to that of conventional mammograms . Digital 4-fold spot magnification views improved visualisation of the morphologic aspects of microcalcifications . Instructions: please typing these entity words according to sentence: direct, mammography, radiography, clinical study, direct, mammograms, Methods, survey, mammograms, spot, direct, mammography, radiograms, patients, diagnostic, value, survey, mammograms, direct, technique, radiograms, breast, identification, Spot, techniques, evaluation, diagnostic, procedures, direct, technique, radiography, mammography, overall, diagnostic, value, direct, survey, mammograms, mammograms, spot Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Introduction : The combination of direct magnification mammography and computed radiography provides an improvement in spatial resolution of storage phosphor-based digital systems . A clinical study comparing conventional and digital direct magnification mammograms was performed . Methods : 100 survey mammograms in 1.5- or 1.7-fold magnification and 50 4-fold spot magnification views were obtained with a prototype direct magnification mammography system and a storage phosphor-based digital system . An intraindividual comparison of these with previous conventional radiograms of the same patients was carried out . Results : The diagnostic value of digital survey mammograms using the direct magnification technique is comparable to that of conventional radiograms of the breast , especially with regard to the identification of microcalcifications and lesions and the clinical consequences . Spot magnification views performed with this combination of techniques allowed improvement in the evaluation of microcalcifications . In 15 % of cases , diagnostic procedures were adjusted accordingly . Conclusion : The combination of the direct magnification technique with digital storage phosphor radiography systems allows the performance of digital mammography by improving the overall spatial resolution . The diagnostic value of digital direct magnification survey mammograms was comparable to that of conventional mammograms . Digital 4-fold spot magnification views improved visualisation of the morphologic aspects of microcalcifications .	[ "Introduction", ":", "The", "combination", "of", "direct", "magnification", "mammography", "and", "computed", "radiography", "provides", "an", "improvement", "in", "spatial", "resolution", "of", "storage", "phosphor", "-", "based", "digital", "systems", ".", "A", "clinical", "study", "comparing", "conventional", "and", "digital", "direct", "magnification", "mammograms", "was", "performed", ".", "Methods", ":", "100", "survey", "mammograms", "in", "1.5-", "or", "1.7-fold", "magnification", "and", "50", "4-fold", "spot", "magnification", "views", "were", "obtained", "with", "a", "prototype", "direct", "magnification", "mammography", "system", "and", "a", "storage", "phosphor", "-", "based", "digital", "system", ".", "An", "intraindividual", "comparison", "of", "these", "with", "previous", "conventional", "radiograms", "of", "the", "same", "patients", "was", "carried", "out", ".", "Results", ":", "The", "diagnostic", "value", "of", "digital", "survey", "mammograms", "using", "the", "direct", "magnification", "technique", "is", "comparable", "to", "that", "of", "conventional", "radiograms", "of", "the", "breast", ",", "especially", "with", "regard", "to", "the", "identification", "of", "microcalcifications", "and", "lesions", "and", "the", "clinical", "consequences", ".", "Spot", "magnification", "views", "performed", "with", "this", "combination", "of", "techniques", "allowed", "improvement", "in", "the", "evaluation", "of", "microcalcifications", ".", "In", "15", "%", "of", "cases", ",", "diagnostic", "procedures", "were", "adjusted", "accordingly", ".", "Conclusion", ":", "The", "combination", "of", "the", "direct", "magnification", "technique", "with", "digital", "storage", "phosphor", "radiography", "systems", "allows", "the", "performance", "of", "digital", "mammography", "by", "improving", "the", "overall", "spatial", "resolution", ".", "The", "diagnostic", "value", "of", "digital", "direct", "magnification", "survey", "mammograms", "was", "comparable", "to", "that", "of", "conventional", "mammograms", ".", "Digital", "4-fold", "spot", "magnification", "views", "improved", "visualisation", "of", "the", "morphologic", "aspects", "of", "microcalcifications", "." ]	[ "umlsterm" ]
direct, mammography, radiography, clinical study, direct, mammograms, Methods, survey, mammograms, spot, direct, mammography, radiograms, patients, diagnostic, value, survey, mammograms, direct, technique, radiograms, breast, identification, Spot, techniques, evaluation, diagnostic, procedures, direct, technique, radiography, mammography, overall, diagnostic, value, direct, survey, mammograms, mammograms, spot	DerRadiologe.70370597.eng.abstr_task2	Sentence: Introduction : The combination of direct magnification mammography and computed radiography provides an improvement in spatial resolution of storage phosphor-based digital systems . A clinical study comparing conventional and digital direct magnification mammograms was performed . Methods : 100 survey mammograms in 1.5- or 1.7-fold magnification and 50 4-fold spot magnification views were obtained with a prototype direct magnification mammography system and a storage phosphor-based digital system . An intraindividual comparison of these with previous conventional radiograms of the same patients was carried out . Results : The diagnostic value of digital survey mammograms using the direct magnification technique is comparable to that of conventional radiograms of the breast , especially with regard to the identification of microcalcifications and lesions and the clinical consequences . Spot magnification views performed with this combination of techniques allowed improvement in the evaluation of microcalcifications . In 15 % of cases , diagnostic procedures were adjusted accordingly . Conclusion : The combination of the direct magnification technique with digital storage phosphor radiography systems allows the performance of digital mammography by improving the overall spatial resolution . The diagnostic value of digital direct magnification survey mammograms was comparable to that of conventional mammograms . Digital 4-fold spot magnification views improved visualisation of the morphologic aspects of microcalcifications . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Introduction : The combination of direct magnification mammography and computed radiography provides an improvement in spatial resolution of storage phosphor-based digital systems . A clinical study comparing conventional and digital direct magnification mammograms was performed . Methods : 100 survey mammograms in 1.5- or 1.7-fold magnification and 50 4-fold spot magnification views were obtained with a prototype direct magnification mammography system and a storage phosphor-based digital system . An intraindividual comparison of these with previous conventional radiograms of the same patients was carried out . Results : The diagnostic value of digital survey mammograms using the direct magnification technique is comparable to that of conventional radiograms of the breast , especially with regard to the identification of microcalcifications and lesions and the clinical consequences . Spot magnification views performed with this combination of techniques allowed improvement in the evaluation of microcalcifications . In 15 % of cases , diagnostic procedures were adjusted accordingly . Conclusion : The combination of the direct magnification technique with digital storage phosphor radiography systems allows the performance of digital mammography by improving the overall spatial resolution . The diagnostic value of digital direct magnification survey mammograms was comparable to that of conventional mammograms . Digital 4-fold spot magnification views improved visualisation of the morphologic aspects of microcalcifications .	[ "Introduction", ":", "The", "combination", "of", "direct", "magnification", "mammography", "and", "computed", "radiography", "provides", "an", "improvement", "in", "spatial", "resolution", "of", "storage", "phosphor", "-", "based", "digital", "systems", ".", "A", "clinical", "study", "comparing", "conventional", "and", "digital", "direct", "magnification", "mammograms", "was", "performed", ".", "Methods", ":", "100", "survey", "mammograms", "in", "1.5-", "or", "1.7-fold", "magnification", "and", "50", "4-fold", "spot", "magnification", "views", "were", "obtained", "with", "a", "prototype", "direct", "magnification", "mammography", "system", "and", "a", "storage", "phosphor", "-", "based", "digital", "system", ".", "An", "intraindividual", "comparison", "of", "these", "with", "previous", "conventional", "radiograms", "of", "the", "same", "patients", "was", "carried", "out", ".", "Results", ":", "The", "diagnostic", "value", "of", "digital", "survey", "mammograms", "using", "the", "direct", "magnification", "technique", "is", "comparable", "to", "that", "of", "conventional", "radiograms", "of", "the", "breast", ",", "especially", "with", "regard", "to", "the", "identification", "of", "microcalcifications", "and", "lesions", "and", "the", "clinical", "consequences", ".", "Spot", "magnification", "views", "performed", "with", "this", "combination", "of", "techniques", "allowed", "improvement", "in", "the", "evaluation", "of", "microcalcifications", ".", "In", "15", "%", "of", "cases", ",", "diagnostic", "procedures", "were", "adjusted", "accordingly", ".", "Conclusion", ":", "The", "combination", "of", "the", "direct", "magnification", "technique", "with", "digital", "storage", "phosphor", "radiography", "systems", "allows", "the", "performance", "of", "digital", "mammography", "by", "improving", "the", "overall", "spatial", "resolution", ".", "The", "diagnostic", "value", "of", "digital", "direct", "magnification", "survey", "mammograms", "was", "comparable", "to", "that", "of", "conventional", "mammograms", ".", "Digital", "4-fold", "spot", "magnification", "views", "improved", "visualisation", "of", "the", "morphologic", "aspects", "of", "microcalcifications", "." ]	[ "umlsterm" ]
Orexin - A is a GENE-Y, glucose is a CHEMICAL, brain - derived neurotrophic factor is a GENE-Y	23117790_task0	Sentence: Orexin-A suppresses postischemic glucose intolerance and neuronal damage through hypothalamic brain-derived neurotrophic factor. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]	Orexin-A suppresses postischemic glucose intolerance and neuronal damage through hypothalamic brain-derived neurotrophic factor.	[ "Orexin", "-", "A", "suppresses", "postischemic", "glucose", "intolerance", "and", "neuronal", "damage", "through", "hypothalamic", "brain", "-", "derived", "neurotrophic", "factor", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
Orexin - A is a GENE-Y, glucose is a CHEMICAL, brain - derived neurotrophic factor is a GENE-Y	23117790_task1	Sentence: Orexin-A suppresses postischemic glucose intolerance and neuronal damage through hypothalamic brain-derived neurotrophic factor. Instructions: please typing these entity words according to sentence: Orexin - A, glucose, brain - derived neurotrophic factor Options: GENE-Y, CHEMICAL	[ "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]	Orexin-A suppresses postischemic glucose intolerance and neuronal damage through hypothalamic brain-derived neurotrophic factor.	[ "Orexin", "-", "A", "suppresses", "postischemic", "glucose", "intolerance", "and", "neuronal", "damage", "through", "hypothalamic", "brain", "-", "derived", "neurotrophic", "factor", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
Orexin - A, glucose, brain - derived neurotrophic factor	23117790_task2	Sentence: Orexin-A suppresses postischemic glucose intolerance and neuronal damage through hypothalamic brain-derived neurotrophic factor. Instructions: please extract entity words from the input sentence	[ "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]	Orexin-A suppresses postischemic glucose intolerance and neuronal damage through hypothalamic brain-derived neurotrophic factor.	[ "Orexin", "-", "A", "suppresses", "postischemic", "glucose", "intolerance", "and", "neuronal", "damage", "through", "hypothalamic", "brain", "-", "derived", "neurotrophic", "factor", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
fractures is an umlsterm, injuries is an umlsterm, diagnosis is an umlsterm, therapy is an umlsterm, anatomic is an umlsterm, tissues is an umlsterm, treatment is an umlsterm, standard is an umlsterm, Maryland is an umlsterm, operation is an umlsterm, variation is an umlsterm, skin is an umlsterm, fractures is an umlsterm, surgical is an umlsterm, Maryland is an umlsterm, universal is an umlsterm	DerOrthopaede.70260384.eng.abstr_task0	Sentence: Acetabular fractures are severe injuries . Making a diagnosis and deciding on therapy are difficult because of the complexity of the anatomic structure and because of the soft tissues . Choosing the most suitable approach is the most important problem when deciding on the operative treatment . Besides standard approaches ( Kocher/Langenbeck , ilioinguinal and extended iliofemoral ) , the " Maryland approach " has been established in the last few years . Modifying the steps of preparation , it is possible to begin the operation with a Kocher/Langenbeck approach ( with variation on where the skin incision is made ) and to extend the approach step by step to achieve optimal exposure . Here we describe the results of acetabular fractures treated between 1989 and 1994 ( n = 159 ) in our clinic related to the surgical approach . The " modified Maryland approach " as used in our clinic , starts with exposure of the dorsal column , offering the possibility of a universal exposure . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Acetabular fractures are severe injuries . Making a diagnosis and deciding on therapy are difficult because of the complexity of the anatomic structure and because of the soft tissues . Choosing the most suitable approach is the most important problem when deciding on the operative treatment . Besides standard approaches ( Kocher/Langenbeck , ilioinguinal and extended iliofemoral ) , the " Maryland approach " has been established in the last few years . Modifying the steps of preparation , it is possible to begin the operation with a Kocher/Langenbeck approach ( with variation on where the skin incision is made ) and to extend the approach step by step to achieve optimal exposure . Here we describe the results of acetabular fractures treated between 1989 and 1994 ( n = 159 ) in our clinic related to the surgical approach . The " modified Maryland approach " as used in our clinic , starts with exposure of the dorsal column , offering the possibility of a universal exposure .	[ "Acetabular", "fractures", "are", "severe", "injuries", ".", "Making", "a", "diagnosis", "and", "deciding", "on", "therapy", "are", "difficult", "because", "of", "the", "complexity", "of", "the", "anatomic", "structure", "and", "because", "of", "the", "soft", "tissues", ".", "Choosing", "the", "most", "suitable", "approach", "is", "the", "most", "important", "problem", "when", "deciding", "on", "the", "operative", "treatment", ".", "Besides", "standard", "approaches", "(", "Kocher", "/", "Langenbeck", ",", "ilioinguinal", "and", "extended", "iliofemoral", ")", ",", "the", "\"", "Maryland", "approach", "\"", "has", "been", "established", "in", "the", "last", "few", "years", ".", "Modifying", "the", "steps", "of", "preparation", ",", "it", "is", "possible", "to", "begin", "the", "operation", "with", "a", "Kocher", "/", "Langenbeck", "approach", "(", "with", "variation", "on", "where", "the", "skin", "incision", "is", "made", ")", "and", "to", "extend", "the", "approach", "step", "by", "step", "to", "achieve", "optimal", "exposure", ".", "Here", "we", "describe", "the", "results", "of", "acetabular", "fractures", "treated", "between", "1989", "and", "1994", "(", "n", "=", "159", ")", "in", "our", "clinic", "related", "to", "the", "surgical", "approach", ".", "The", "\"", "modified", "Maryland", "approach", "\"", "as", "used", "in", "our", "clinic", ",", "starts", "with", "exposure", "of", "the", "dorsal", "column", ",", "offering", "the", "possibility", "of", "a", "universal", "exposure", "." ]	[ "umlsterm" ]
fractures is an umlsterm, injuries is an umlsterm, diagnosis is an umlsterm, therapy is an umlsterm, anatomic is an umlsterm, tissues is an umlsterm, treatment is an umlsterm, standard is an umlsterm, Maryland is an umlsterm, operation is an umlsterm, variation is an umlsterm, skin is an umlsterm, fractures is an umlsterm, surgical is an umlsterm, Maryland is an umlsterm, universal is an umlsterm	DerOrthopaede.70260384.eng.abstr_task1	Sentence: Acetabular fractures are severe injuries . Making a diagnosis and deciding on therapy are difficult because of the complexity of the anatomic structure and because of the soft tissues . Choosing the most suitable approach is the most important problem when deciding on the operative treatment . Besides standard approaches ( Kocher/Langenbeck , ilioinguinal and extended iliofemoral ) , the " Maryland approach " has been established in the last few years . Modifying the steps of preparation , it is possible to begin the operation with a Kocher/Langenbeck approach ( with variation on where the skin incision is made ) and to extend the approach step by step to achieve optimal exposure . Here we describe the results of acetabular fractures treated between 1989 and 1994 ( n = 159 ) in our clinic related to the surgical approach . The " modified Maryland approach " as used in our clinic , starts with exposure of the dorsal column , offering the possibility of a universal exposure . Instructions: please typing these entity words according to sentence: fractures, injuries, diagnosis, therapy, anatomic, tissues, treatment, standard, Maryland, operation, variation, skin, fractures, surgical, Maryland, universal Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Acetabular fractures are severe injuries . Making a diagnosis and deciding on therapy are difficult because of the complexity of the anatomic structure and because of the soft tissues . Choosing the most suitable approach is the most important problem when deciding on the operative treatment . Besides standard approaches ( Kocher/Langenbeck , ilioinguinal and extended iliofemoral ) , the " Maryland approach " has been established in the last few years . Modifying the steps of preparation , it is possible to begin the operation with a Kocher/Langenbeck approach ( with variation on where the skin incision is made ) and to extend the approach step by step to achieve optimal exposure . Here we describe the results of acetabular fractures treated between 1989 and 1994 ( n = 159 ) in our clinic related to the surgical approach . The " modified Maryland approach " as used in our clinic , starts with exposure of the dorsal column , offering the possibility of a universal exposure .	[ "Acetabular", "fractures", "are", "severe", "injuries", ".", "Making", "a", "diagnosis", "and", "deciding", "on", "therapy", "are", "difficult", "because", "of", "the", "complexity", "of", "the", "anatomic", "structure", "and", "because", "of", "the", "soft", "tissues", ".", "Choosing", "the", "most", "suitable", "approach", "is", "the", "most", "important", "problem", "when", "deciding", "on", "the", "operative", "treatment", ".", "Besides", "standard", "approaches", "(", "Kocher", "/", "Langenbeck", ",", "ilioinguinal", "and", "extended", "iliofemoral", ")", ",", "the", "\"", "Maryland", "approach", "\"", "has", "been", "established", "in", "the", "last", "few", "years", ".", "Modifying", "the", "steps", "of", "preparation", ",", "it", "is", "possible", "to", "begin", "the", "operation", "with", "a", "Kocher", "/", "Langenbeck", "approach", "(", "with", "variation", "on", "where", "the", "skin", "incision", "is", "made", ")", "and", "to", "extend", "the", "approach", "step", "by", "step", "to", "achieve", "optimal", "exposure", ".", "Here", "we", "describe", "the", "results", "of", "acetabular", "fractures", "treated", "between", "1989", "and", "1994", "(", "n", "=", "159", ")", "in", "our", "clinic", "related", "to", "the", "surgical", "approach", ".", "The", "\"", "modified", "Maryland", "approach", "\"", "as", "used", "in", "our", "clinic", ",", "starts", "with", "exposure", "of", "the", "dorsal", "column", ",", "offering", "the", "possibility", "of", "a", "universal", "exposure", "." ]	[ "umlsterm" ]
fractures, injuries, diagnosis, therapy, anatomic, tissues, treatment, standard, Maryland, operation, variation, skin, fractures, surgical, Maryland, universal	DerOrthopaede.70260384.eng.abstr_task2	Sentence: Acetabular fractures are severe injuries . Making a diagnosis and deciding on therapy are difficult because of the complexity of the anatomic structure and because of the soft tissues . Choosing the most suitable approach is the most important problem when deciding on the operative treatment . Besides standard approaches ( Kocher/Langenbeck , ilioinguinal and extended iliofemoral ) , the " Maryland approach " has been established in the last few years . Modifying the steps of preparation , it is possible to begin the operation with a Kocher/Langenbeck approach ( with variation on where the skin incision is made ) and to extend the approach step by step to achieve optimal exposure . Here we describe the results of acetabular fractures treated between 1989 and 1994 ( n = 159 ) in our clinic related to the surgical approach . The " modified Maryland approach " as used in our clinic , starts with exposure of the dorsal column , offering the possibility of a universal exposure . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Acetabular fractures are severe injuries . Making a diagnosis and deciding on therapy are difficult because of the complexity of the anatomic structure and because of the soft tissues . Choosing the most suitable approach is the most important problem when deciding on the operative treatment . Besides standard approaches ( Kocher/Langenbeck , ilioinguinal and extended iliofemoral ) , the " Maryland approach " has been established in the last few years . Modifying the steps of preparation , it is possible to begin the operation with a Kocher/Langenbeck approach ( with variation on where the skin incision is made ) and to extend the approach step by step to achieve optimal exposure . Here we describe the results of acetabular fractures treated between 1989 and 1994 ( n = 159 ) in our clinic related to the surgical approach . The " modified Maryland approach " as used in our clinic , starts with exposure of the dorsal column , offering the possibility of a universal exposure .	[ "Acetabular", "fractures", "are", "severe", "injuries", ".", "Making", "a", "diagnosis", "and", "deciding", "on", "therapy", "are", "difficult", "because", "of", "the", "complexity", "of", "the", "anatomic", "structure", "and", "because", "of", "the", "soft", "tissues", ".", "Choosing", "the", "most", "suitable", "approach", "is", "the", "most", "important", "problem", "when", "deciding", "on", "the", "operative", "treatment", ".", "Besides", "standard", "approaches", "(", "Kocher", "/", "Langenbeck", ",", "ilioinguinal", "and", "extended", "iliofemoral", ")", ",", "the", "\"", "Maryland", "approach", "\"", "has", "been", "established", "in", "the", "last", "few", "years", ".", "Modifying", "the", "steps", "of", "preparation", ",", "it", "is", "possible", "to", "begin", "the", "operation", "with", "a", "Kocher", "/", "Langenbeck", "approach", "(", "with", "variation", "on", "where", "the", "skin", "incision", "is", "made", ")", "and", "to", "extend", "the", "approach", "step", "by", "step", "to", "achieve", "optimal", "exposure", ".", "Here", "we", "describe", "the", "results", "of", "acetabular", "fractures", "treated", "between", "1989", "and", "1994", "(", "n", "=", "159", ")", "in", "our", "clinic", "related", "to", "the", "surgical", "approach", ".", "The", "\"", "modified", "Maryland", "approach", "\"", "as", "used", "in", "our", "clinic", ",", "starts", "with", "exposure", "of", "the", "dorsal", "column", ",", "offering", "the", "possibility", "of", "a", "universal", "exposure", "." ]	[ "umlsterm" ]
CHB is a Condition, NAs is a Drug, more than 12 months . is a Temporal, Hepatitis B e antigen is a Measurement, anti - HBeAg is a Measurement, positive is a Value, Hepatitis B surface antigen is a Measurement, HBsAg is a Measurement, positive is a Value, Hepatitis B virus DNA is a Measurement	NCT02745704_inc_task0	Sentence: CHB patients who had received NAs for more than 12 months. Hepatitis B e antigen (HBeAg)-negative and anti-HBeAg positive. Hepatitis B surface antigen (HBsAg) positive and <1500 IU/mL. Hepatitis B virus DNA not detectable(Roche Cobas). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Value, Measurement, Drug	[ "B-Condition", "O", "O", "O", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Measurement", "O", "B-Value", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "O", "O", "O" ]	CHB patients who had received NAs for more than 12 months. Hepatitis B e antigen (HBeAg)-negative and anti-HBeAg positive. Hepatitis B surface antigen (HBsAg) positive and <1500 IU/mL. Hepatitis B virus DNA not detectable(Roche Cobas).	[ "CHB", "patients", "who", "had", "received", "NAs", "for", "more", "than", "12", "months", ".", "\n", "Hepatitis", "B", "e", "antigen", "(", "HBeAg)-negative", "and", "anti", "-", "HBeAg", "positive", ".", "\n", "Hepatitis", "B", "surface", "antigen", "(", "HBsAg", ")", "positive", "and", "<", "1500", "IU", "/", "mL.", "\n", "Hepatitis", "B", "virus", "DNA", "not", "detectable(Roche", "Cobas", ")", ".", "\n" ]	[ "Measurement", "Temporal", "Value", "Condition", "Drug" ]
CHB is a Condition, NAs is a Drug, more than 12 months . is a Temporal, Hepatitis B e antigen is a Measurement, anti - HBeAg is a Measurement, positive is a Value, Hepatitis B surface antigen is a Measurement, HBsAg is a Measurement, positive is a Value, Hepatitis B virus DNA is a Measurement	NCT02745704_inc_task1	Sentence: CHB patients who had received NAs for more than 12 months. Hepatitis B e antigen (HBeAg)-negative and anti-HBeAg positive. Hepatitis B surface antigen (HBsAg) positive and <1500 IU/mL. Hepatitis B virus DNA not detectable(Roche Cobas). Instructions: please typing these entity words according to sentence: CHB, NAs, more than 12 months ., Hepatitis B e antigen, anti - HBeAg, positive, Hepatitis B surface antigen, HBsAg, positive, Hepatitis B virus DNA Options: Temporal, Condition, Value, Measurement, Drug	[ "B-Condition", "O", "O", "O", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Measurement", "O", "B-Value", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "O", "O", "O" ]	CHB patients who had received NAs for more than 12 months. Hepatitis B e antigen (HBeAg)-negative and anti-HBeAg positive. Hepatitis B surface antigen (HBsAg) positive and <1500 IU/mL. Hepatitis B virus DNA not detectable(Roche Cobas).	[ "CHB", "patients", "who", "had", "received", "NAs", "for", "more", "than", "12", "months", ".", "\n", "Hepatitis", "B", "e", "antigen", "(", "HBeAg)-negative", "and", "anti", "-", "HBeAg", "positive", ".", "\n", "Hepatitis", "B", "surface", "antigen", "(", "HBsAg", ")", "positive", "and", "<", "1500", "IU", "/", "mL.", "\n", "Hepatitis", "B", "virus", "DNA", "not", "detectable(Roche", "Cobas", ")", ".", "\n" ]	[ "Measurement", "Temporal", "Value", "Condition", "Drug" ]
CHB, NAs, more than 12 months ., Hepatitis B e antigen, anti - HBeAg, positive, Hepatitis B surface antigen, HBsAg, positive, Hepatitis B virus DNA	NCT02745704_inc_task2	Sentence: CHB patients who had received NAs for more than 12 months. Hepatitis B e antigen (HBeAg)-negative and anti-HBeAg positive. Hepatitis B surface antigen (HBsAg) positive and <1500 IU/mL. Hepatitis B virus DNA not detectable(Roche Cobas). Instructions: please extract entity words from the input sentence	[ "B-Condition", "O", "O", "O", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Measurement", "O", "B-Value", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "O", "O", "O" ]	CHB patients who had received NAs for more than 12 months. Hepatitis B e antigen (HBeAg)-negative and anti-HBeAg positive. Hepatitis B surface antigen (HBsAg) positive and <1500 IU/mL. Hepatitis B virus DNA not detectable(Roche Cobas).	[ "CHB", "patients", "who", "had", "received", "NAs", "for", "more", "than", "12", "months", ".", "\n", "Hepatitis", "B", "e", "antigen", "(", "HBeAg)-negative", "and", "anti", "-", "HBeAg", "positive", ".", "\n", "Hepatitis", "B", "surface", "antigen", "(", "HBsAg", ")", "positive", "and", "<", "1500", "IU", "/", "mL.", "\n", "Hepatitis", "B", "virus", "DNA", "not", "detectable(Roche", "Cobas", ")", ".", "\n" ]	[ "Measurement", "Temporal", "Value", "Condition", "Drug" ]
FHL1 is a Gene, EMD is a Gene, LMNA is a Gene, FHL1 is a Gene, EMD- is a Gene, LMNA is a Gene, FHL1 is a Gene, FHL1 is a Gene, FHL1 is a Gene, FHL1 is a Gene, FHL1 is a Gene	406_task0	Sentence: Mutations of the FHL1 gene cause Emery-Dreifuss muscular dystrophy. Emery-Dreifuss muscular dystrophy (EDMD) is a rare disorder characterized by early joint contractures, muscular dystrophy, and cardiac involvement with conduction defects and arrhythmias. So far, only 35% of EDMD cases are genetically elucidated and associated with EMD or LMNA gene mutations, suggesting the existence of additional major genes. By whole-genome scan, we identified linkage to the Xq26.3 locus containing the FHL1 gene in three informative families belonging to our EMD- and LMNA-negative cohort. Analysis of the FHL1 gene identified seven mutations, in the distal exons of FHL1 in these families, three additional families, and one isolated case, which differently affect the three FHL1 protein isoforms: two missense mutations affecting highly conserved cysteines, one abolishing the termination codon, and four out-of-frame insertions or deletions. The predominant phenotype was characterized by myopathy with scapulo-peroneal and/or axial distribution, as well as joint contractures, and associated with a peculiar cardiac disease characterized by conduction defects, arrhythmias, and hypertrophic cardiomyopathy in all index cases of the seven families. Heterozygous female carriers were either asymptomatic or had cardiac disease and/or mild myopathy. Interestingly, four of the FHL1-mutated male relatives had isolated cardiac disease, and an overt hypertrophic cardiomyopathy was present in two. Expression and functional studies demonstrated that the FHL1 proteins were severely reduced in all tested patients and that this was associated with a severe delay in myotube formation in the two patients for whom myoblasts were available. In conclusion, FHL1 should be considered as a gene associated with the X-linked EDMD phenotype, as well as with hypertrophic cardiomyopathy. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene	[ "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mutations of the FHL1 gene cause Emery-Dreifuss muscular dystrophy. Emery-Dreifuss muscular dystrophy (EDMD) is a rare disorder characterized by early joint contractures, muscular dystrophy, and cardiac involvement with conduction defects and arrhythmias. So far, only 35% of EDMD cases are genetically elucidated and associated with EMD or LMNA gene mutations, suggesting the existence of additional major genes. By whole-genome scan, we identified linkage to the Xq26.3 locus containing the FHL1 gene in three informative families belonging to our EMD- and LMNA-negative cohort. Analysis of the FHL1 gene identified seven mutations, in the distal exons of FHL1 in these families, three additional families, and one isolated case, which differently affect the three FHL1 protein isoforms: two missense mutations affecting highly conserved cysteines, one abolishing the termination codon, and four out-of-frame insertions or deletions. The predominant phenotype was characterized by myopathy with scapulo-peroneal and/or axial distribution, as well as joint contractures, and associated with a peculiar cardiac disease characterized by conduction defects, arrhythmias, and hypertrophic cardiomyopathy in all index cases of the seven families. Heterozygous female carriers were either asymptomatic or had cardiac disease and/or mild myopathy. Interestingly, four of the FHL1-mutated male relatives had isolated cardiac disease, and an overt hypertrophic cardiomyopathy was present in two. Expression and functional studies demonstrated that the FHL1 proteins were severely reduced in all tested patients and that this was associated with a severe delay in myotube formation in the two patients for whom myoblasts were available. In conclusion, FHL1 should be considered as a gene associated with the X-linked EDMD phenotype, as well as with hypertrophic cardiomyopathy.	[ "Mutations", "of", "the", "FHL1", "gene", "cause", "Emery", "-", "Dreifuss", "muscular", "dystrophy", ".", "Emery", "-", "Dreifuss", "muscular", "dystrophy", "(", "EDMD", ")", "is", "a", "rare", "disorder", "characterized", "by", "early", "joint", "contractures", ",", "muscular", "dystrophy", ",", "and", "cardiac", "involvement", "with", "conduction", "defects", "and", "arrhythmias", ".", "So", "far", ",", "only", "35", "%", "of", "EDMD", "cases", "are", "genetically", "elucidated", "and", "associated", "with", "EMD", "or", "LMNA", "gene", "mutations", ",", "suggesting", "the", "existence", "of", "additional", "major", "genes", ".", "By", "whole", "-", "genome", "scan", ",", "we", "identified", "linkage", "to", "the", "Xq26.3", "locus", "containing", "the", "FHL1", "gene", "in", "three", "informative", "families", "belonging", "to", "our", "EMD-", "and", "LMNA", "-", "negative", "cohort", ".", "Analysis", "of", "the", "FHL1", "gene", "identified", "seven", "mutations", ",", "in", "the", "distal", "exons", "of", "FHL1", "in", "these", "families", ",", "three", "additional", "families", ",", "and", "one", "isolated", "case", ",", "which", "differently", "affect", "the", "three", "FHL1", "protein", "isoforms", ":", "two", "missense", "mutations", "affecting", "highly", "conserved", "cysteines", ",", "one", "abolishing", "the", "termination", "codon", ",", "and", "four", "out", "-", "of", "-", "frame", "insertions", "or", "deletions", ".", "The", "predominant", "phenotype", "was", "characterized", "by", "myopathy", "with", "scapulo", "-", "peroneal", "and", "/", "or", "axial", "distribution", ",", "as", "well", "as", "joint", "contractures", ",", "and", "associated", "with", "a", "peculiar", "cardiac", "disease", "characterized", "by", "conduction", "defects", ",", "arrhythmias", ",", "and", "hypertrophic", "cardiomyopathy", "in", "all", "index", "cases", "of", "the", "seven", "families", ".", "Heterozygous", "female", "carriers", "were", "either", "asymptomatic", "or", "had", "cardiac", "disease", "and", "/", "or", "mild", "myopathy", ".", "Interestingly", ",", "four", "of", "the", "FHL1-mutated", "male", "relatives", "had", "isolated", "cardiac", "disease", ",", "and", "an", "overt", "hypertrophic", "cardiomyopathy", "was", "present", "in", "two", ".", "Expression", "and", "functional", "studies", "demonstrated", "that", "the", "FHL1", "proteins", "were", "severely", "reduced", "in", "all", "tested", "patients", "and", "that", "this", "was", "associated", "with", "a", "severe", "delay", "in", "myotube", "formation", "in", "the", "two", "patients", "for", "whom", "myoblasts", "were", "available", ".", "In", "conclusion", ",", "FHL1", "should", "be", "considered", "as", "a", "gene", "associated", "with", "the", "X", "-", "linked", "EDMD", "phenotype", ",", "as", "well", "as", "with", "hypertrophic", "cardiomyopathy", ".", "\n" ]	[ "Gene" ]

arginine is a CHEMICAL

23439479_task0

Sentence: Biosafety and antioxidant effects of a beverage containing silymarin and arginine. A pilot, human intervention cross-over trial. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Biosafety and antioxidant effects of a beverage containing silymarin and arginine. A pilot, human intervention cross-over trial.

[ "Biosafety", "and", "antioxidant", "effects", "of", "a", "beverage", "containing", "silymarin", "and", "arginine", ".", "A", "pilot", ",", "human", "intervention", "cross", "-", "over", "trial", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

arginine is a CHEMICAL

23439479_task1

Sentence: Biosafety and antioxidant effects of a beverage containing silymarin and arginine. A pilot, human intervention cross-over trial. Instructions: please typing these entity words according to sentence: arginine Options: CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Biosafety and antioxidant effects of a beverage containing silymarin and arginine. A pilot, human intervention cross-over trial.

[ "Biosafety", "and", "antioxidant", "effects", "of", "a", "beverage", "containing", "silymarin", "and", "arginine", ".", "A", "pilot", ",", "human", "intervention", "cross", "-", "over", "trial", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

arginine

23439479_task2

Sentence: Biosafety and antioxidant effects of a beverage containing silymarin and arginine. A pilot, human intervention cross-over trial. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Biosafety and antioxidant effects of a beverage containing silymarin and arginine. A pilot, human intervention cross-over trial.

[ "Biosafety", "and", "antioxidant", "effects", "of", "a", "beverage", "containing", "silymarin", "and", "arginine", ".", "A", "pilot", ",", "human", "intervention", "cross", "-", "over", "trial", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

natural killer cell activity is an other_name, HER-2 / neu oncogene is a DNA_domain_or_region, patients is a multi_cell, breast cancer is an other_name

18197_task0

Sentence: Increased natural killer cell activity correlates with low or negative expression of the HER-2/neu oncogene in patients with breast cancer. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region, multi_cell, other_name

[ "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-multi_cell", "O", "B-other_name", "I-other_name", "O" ]

Increased natural killer cell activity correlates with low or negative expression of the HER-2/neu oncogene in patients with breast cancer.

[ "Increased", "natural", "killer", "cell", "activity", "correlates", "with", "low", "or", "negative", "expression", "of", "the", "HER-2", "/", "neu", "oncogene", "in", "patients", "with", "breast", "cancer", "." ]

[ "other_name", "cell_type", "multi_cell", "DNA_domain_or_region", "protein_family_or_group", "protein_molecule", "cell_line", "lipid" ]

natural killer cell activity is an other_name, HER-2 / neu oncogene is a DNA_domain_or_region, patients is a multi_cell, breast cancer is an other_name

18197_task1

Sentence: Increased natural killer cell activity correlates with low or negative expression of the HER-2/neu oncogene in patients with breast cancer. Instructions: please typing these entity words according to sentence: natural killer cell activity, HER-2 / neu oncogene, patients, breast cancer Options: DNA_domain_or_region, multi_cell, other_name

[ "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-multi_cell", "O", "B-other_name", "I-other_name", "O" ]

Increased natural killer cell activity correlates with low or negative expression of the HER-2/neu oncogene in patients with breast cancer.

[ "Increased", "natural", "killer", "cell", "activity", "correlates", "with", "low", "or", "negative", "expression", "of", "the", "HER-2", "/", "neu", "oncogene", "in", "patients", "with", "breast", "cancer", "." ]

[ "other_name", "cell_type", "multi_cell", "DNA_domain_or_region", "protein_family_or_group", "protein_molecule", "cell_line", "lipid" ]

natural killer cell activity, HER-2 / neu oncogene, patients, breast cancer

18197_task2

Sentence: Increased natural killer cell activity correlates with low or negative expression of the HER-2/neu oncogene in patients with breast cancer. Instructions: please extract entity words from the input sentence

[ "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-multi_cell", "O", "B-other_name", "I-other_name", "O" ]

Increased natural killer cell activity correlates with low or negative expression of the HER-2/neu oncogene in patients with breast cancer.

[ "Increased", "natural", "killer", "cell", "activity", "correlates", "with", "low", "or", "negative", "expression", "of", "the", "HER-2", "/", "neu", "oncogene", "in", "patients", "with", "breast", "cancer", "." ]

[ "other_name", "cell_type", "multi_cell", "DNA_domain_or_region", "protein_family_or_group", "protein_molecule", "cell_line", "lipid" ]

treatment is an umlsterm, postoperative is an umlsterm, fistulas is an umlsterm, lymphoceles is an umlsterm, patients is an umlsterm, fistula is an umlsterm, vascular surgery is an umlsterm, therapy is an umlsterm, operation is an umlsterm, wound is an umlsterm, radiotherapy is an umlsterm, treatment is an umlsterm, surgical is an umlsterm, therapy is an umlsterm, patients is an umlsterm, fistulas is an umlsterm, lymphoceles is an umlsterm, radiation therapy is an umlsterm, fistula is an umlsterm, patients is an umlsterm, electrons is an umlsterm, patients is an umlsterm, lymphoceles is an umlsterm, treatment is an umlsterm, photons is an umlsterm, patients is an umlsterm, fractionation is an umlsterm, radiation therapy is an umlsterm, patients is an umlsterm, fistula is an umlsterm, lymphocele is an umlsterm, radiation is an umlsterm, therapy is an umlsterm, patient is an umlsterm, surgery is an umlsterm, wound is an umlsterm, radiotherapy is an umlsterm, fistulas is an umlsterm, lymphoceles is an umlsterm, complications is an umlsterm, Radiation is an umlsterm, therapy is an umlsterm, surgery is an umlsterm

Strahlentherapie+Onkologie.01760009.eng.abstr_task0

Sentence: The treatment of persistent postoperative lymphatic fistulas or lymphoceles is often a problem . Approximately 2% of patients will develop lymphatic fistula after vascular surgery . This can require a long lasting conservative therapy . If spontaneous cure fails , a second operation with wound revision becomes necessary . We studied low-dose percutaneous radiotherapy to be used as an alternative treatment in addition to conservative or surgical therapy . Between 1989 and 1998 29 patients ( 25 with lymphatic fistulas , 4 with lymphoceles ) received radiation therapy . Depending on the depth of the fistula 27 patients were treated with electrons ( 7 to 18 MeV ) . Two other patients suffering of retroperitoneal lymphoceles received a treatment with photons ( 15 MV ) . In all patients the fractionation was 4- to 5 x 1.0 Gy/week and the dose ranged from 3 to 12 Gy depending upon the onset of the radiation therapy effect . In 27 of 28 evaluable patients a complete disappearance of the fistula or lymphocele was achieved by radiation during therapy or shortly afterwards . In 1 case no benefit was observed after a dose of 11 Gy . This patient required further surgery with wound exploration . Low dose percutaneous radiotherapy ( up to 10 to 12 Gy ) is effective to heal lymphatic fistulas and lymphoceles without complications . Individual dosage is required because doses even lower than 10 Gy may be effective . Radiation can be effective even after a failed conservative therapy or instead of surgery . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]

The treatment of persistent postoperative lymphatic fistulas or lymphoceles is often a problem . Approximately 2% of patients will develop lymphatic fistula after vascular surgery . This can require a long lasting conservative therapy . If spontaneous cure fails , a second operation with wound revision becomes necessary . We studied low-dose percutaneous radiotherapy to be used as an alternative treatment in addition to conservative or surgical therapy . Between 1989 and 1998 29 patients ( 25 with lymphatic fistulas , 4 with lymphoceles ) received radiation therapy . Depending on the depth of the fistula 27 patients were treated with electrons ( 7 to 18 MeV ) . Two other patients suffering of retroperitoneal lymphoceles received a treatment with photons ( 15 MV ) . In all patients the fractionation was 4- to 5 x 1.0 Gy/week and the dose ranged from 3 to 12 Gy depending upon the onset of the radiation therapy effect . In 27 of 28 evaluable patients a complete disappearance of the fistula or lymphocele was achieved by radiation during therapy or shortly afterwards . In 1 case no benefit was observed after a dose of 11 Gy . This patient required further surgery with wound exploration . Low dose percutaneous radiotherapy ( up to 10 to 12 Gy ) is effective to heal lymphatic fistulas and lymphoceles without complications . Individual dosage is required because doses even lower than 10 Gy may be effective . Radiation can be effective even after a failed conservative therapy or instead of surgery .

[ "The", "treatment", "of", "persistent", "postoperative", "lymphatic", "fistulas", "or", "lymphoceles", "is", "often", "a", "problem", ".", "Approximately", "2", "%", "of", "patients", "will", "develop", "lymphatic", "fistula", "after", "vascular", "surgery", ".", "This", "can", "require", "a", "long", "lasting", "conservative", "therapy", ".", "If", "spontaneous", "cure", "fails", ",", "a", "second", "operation", "with", "wound", "revision", "becomes", "necessary", ".", "We", "studied", "low", "-", "dose", "percutaneous", "radiotherapy", "to", "be", "used", "as", "an", "alternative", "treatment", "in", "addition", "to", "conservative", "or", "surgical", "therapy", ".", "Between", "1989", "and", "1998", "29", "patients", "(", "25", "with", "lymphatic", "fistulas", ",", "4", "with", "lymphoceles", ")", "received", "radiation", "therapy", ".", "Depending", "on", "the", "depth", "of", "the", "fistula", "27", "patients", "were", "treated", "with", "electrons", "(", "7", "to", "18", "MeV", ")", ".", "Two", "other", "patients", "suffering", "of", "retroperitoneal", "lymphoceles", "received", "a", "treatment", "with", "photons", "(", "15", "MV", ")", ".", "In", "all", "patients", "the", "fractionation", "was", "4-", "to", "5", "x", "1.0", "Gy", "/", "week", "and", "the", "dose", "ranged", "from", "3", "to", "12", "Gy", "depending", "upon", "the", "onset", "of", "the", "radiation", "therapy", "effect", ".", "In", "27", "of", "28", "evaluable", "patients", "a", "complete", "disappearance", "of", "the", "fistula", "or", "lymphocele", "was", "achieved", "by", "radiation", "during", "therapy", "or", "shortly", "afterwards", ".", "In", "1", "case", "no", "benefit", "was", "observed", "after", "a", "dose", "of", "11", "Gy", ".", "This", "patient", "required", "further", "surgery", "with", "wound", "exploration", ".", "Low", "dose", "percutaneous", "radiotherapy", "(", "up", "to", "10", "to", "12", "Gy", ")", "is", "effective", "to", "heal", "lymphatic", "fistulas", "and", "lymphoceles", "without", "complications", ".", "Individual", "dosage", "is", "required", "because", "doses", "even", "lower", "than", "10", "Gy", "may", "be", "effective", ".", "Radiation", "can", "be", "effective", "even", "after", "a", "failed", "conservative", "therapy", "or", "instead", "of", "surgery", "." ]

[ "umlsterm" ]

treatment is an umlsterm, postoperative is an umlsterm, fistulas is an umlsterm, lymphoceles is an umlsterm, patients is an umlsterm, fistula is an umlsterm, vascular surgery is an umlsterm, therapy is an umlsterm, operation is an umlsterm, wound is an umlsterm, radiotherapy is an umlsterm, treatment is an umlsterm, surgical is an umlsterm, therapy is an umlsterm, patients is an umlsterm, fistulas is an umlsterm, lymphoceles is an umlsterm, radiation therapy is an umlsterm, fistula is an umlsterm, patients is an umlsterm, electrons is an umlsterm, patients is an umlsterm, lymphoceles is an umlsterm, treatment is an umlsterm, photons is an umlsterm, patients is an umlsterm, fractionation is an umlsterm, radiation therapy is an umlsterm, patients is an umlsterm, fistula is an umlsterm, lymphocele is an umlsterm, radiation is an umlsterm, therapy is an umlsterm, patient is an umlsterm, surgery is an umlsterm, wound is an umlsterm, radiotherapy is an umlsterm, fistulas is an umlsterm, lymphoceles is an umlsterm, complications is an umlsterm, Radiation is an umlsterm, therapy is an umlsterm, surgery is an umlsterm

Strahlentherapie+Onkologie.01760009.eng.abstr_task1

Sentence: The treatment of persistent postoperative lymphatic fistulas or lymphoceles is often a problem . Approximately 2% of patients will develop lymphatic fistula after vascular surgery . This can require a long lasting conservative therapy . If spontaneous cure fails , a second operation with wound revision becomes necessary . We studied low-dose percutaneous radiotherapy to be used as an alternative treatment in addition to conservative or surgical therapy . Between 1989 and 1998 29 patients ( 25 with lymphatic fistulas , 4 with lymphoceles ) received radiation therapy . Depending on the depth of the fistula 27 patients were treated with electrons ( 7 to 18 MeV ) . Two other patients suffering of retroperitoneal lymphoceles received a treatment with photons ( 15 MV ) . In all patients the fractionation was 4- to 5 x 1.0 Gy/week and the dose ranged from 3 to 12 Gy depending upon the onset of the radiation therapy effect . In 27 of 28 evaluable patients a complete disappearance of the fistula or lymphocele was achieved by radiation during therapy or shortly afterwards . In 1 case no benefit was observed after a dose of 11 Gy . This patient required further surgery with wound exploration . Low dose percutaneous radiotherapy ( up to 10 to 12 Gy ) is effective to heal lymphatic fistulas and lymphoceles without complications . Individual dosage is required because doses even lower than 10 Gy may be effective . Radiation can be effective even after a failed conservative therapy or instead of surgery . Instructions: please typing these entity words according to sentence: treatment, postoperative, fistulas, lymphoceles, patients, fistula, vascular surgery, therapy, operation, wound, radiotherapy, treatment, surgical, therapy, patients, fistulas, lymphoceles, radiation therapy, fistula, patients, electrons, patients, lymphoceles, treatment, photons, patients, fractionation, radiation therapy, patients, fistula, lymphocele, radiation, therapy, patient, surgery, wound, radiotherapy, fistulas, lymphoceles, complications, Radiation, therapy, surgery Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]

The treatment of persistent postoperative lymphatic fistulas or lymphoceles is often a problem . Approximately 2% of patients will develop lymphatic fistula after vascular surgery . This can require a long lasting conservative therapy . If spontaneous cure fails , a second operation with wound revision becomes necessary . We studied low-dose percutaneous radiotherapy to be used as an alternative treatment in addition to conservative or surgical therapy . Between 1989 and 1998 29 patients ( 25 with lymphatic fistulas , 4 with lymphoceles ) received radiation therapy . Depending on the depth of the fistula 27 patients were treated with electrons ( 7 to 18 MeV ) . Two other patients suffering of retroperitoneal lymphoceles received a treatment with photons ( 15 MV ) . In all patients the fractionation was 4- to 5 x 1.0 Gy/week and the dose ranged from 3 to 12 Gy depending upon the onset of the radiation therapy effect . In 27 of 28 evaluable patients a complete disappearance of the fistula or lymphocele was achieved by radiation during therapy or shortly afterwards . In 1 case no benefit was observed after a dose of 11 Gy . This patient required further surgery with wound exploration . Low dose percutaneous radiotherapy ( up to 10 to 12 Gy ) is effective to heal lymphatic fistulas and lymphoceles without complications . Individual dosage is required because doses even lower than 10 Gy may be effective . Radiation can be effective even after a failed conservative therapy or instead of surgery .

[ "The", "treatment", "of", "persistent", "postoperative", "lymphatic", "fistulas", "or", "lymphoceles", "is", "often", "a", "problem", ".", "Approximately", "2", "%", "of", "patients", "will", "develop", "lymphatic", "fistula", "after", "vascular", "surgery", ".", "This", "can", "require", "a", "long", "lasting", "conservative", "therapy", ".", "If", "spontaneous", "cure", "fails", ",", "a", "second", "operation", "with", "wound", "revision", "becomes", "necessary", ".", "We", "studied", "low", "-", "dose", "percutaneous", "radiotherapy", "to", "be", "used", "as", "an", "alternative", "treatment", "in", "addition", "to", "conservative", "or", "surgical", "therapy", ".", "Between", "1989", "and", "1998", "29", "patients", "(", "25", "with", "lymphatic", "fistulas", ",", "4", "with", "lymphoceles", ")", "received", "radiation", "therapy", ".", "Depending", "on", "the", "depth", "of", "the", "fistula", "27", "patients", "were", "treated", "with", "electrons", "(", "7", "to", "18", "MeV", ")", ".", "Two", "other", "patients", "suffering", "of", "retroperitoneal", "lymphoceles", "received", "a", "treatment", "with", "photons", "(", "15", "MV", ")", ".", "In", "all", "patients", "the", "fractionation", "was", "4-", "to", "5", "x", "1.0", "Gy", "/", "week", "and", "the", "dose", "ranged", "from", "3", "to", "12", "Gy", "depending", "upon", "the", "onset", "of", "the", "radiation", "therapy", "effect", ".", "In", "27", "of", "28", "evaluable", "patients", "a", "complete", "disappearance", "of", "the", "fistula", "or", "lymphocele", "was", "achieved", "by", "radiation", "during", "therapy", "or", "shortly", "afterwards", ".", "In", "1", "case", "no", "benefit", "was", "observed", "after", "a", "dose", "of", "11", "Gy", ".", "This", "patient", "required", "further", "surgery", "with", "wound", "exploration", ".", "Low", "dose", "percutaneous", "radiotherapy", "(", "up", "to", "10", "to", "12", "Gy", ")", "is", "effective", "to", "heal", "lymphatic", "fistulas", "and", "lymphoceles", "without", "complications", ".", "Individual", "dosage", "is", "required", "because", "doses", "even", "lower", "than", "10", "Gy", "may", "be", "effective", ".", "Radiation", "can", "be", "effective", "even", "after", "a", "failed", "conservative", "therapy", "or", "instead", "of", "surgery", "." ]

[ "umlsterm" ]

treatment, postoperative, fistulas, lymphoceles, patients, fistula, vascular surgery, therapy, operation, wound, radiotherapy, treatment, surgical, therapy, patients, fistulas, lymphoceles, radiation therapy, fistula, patients, electrons, patients, lymphoceles, treatment, photons, patients, fractionation, radiation therapy, patients, fistula, lymphocele, radiation, therapy, patient, surgery, wound, radiotherapy, fistulas, lymphoceles, complications, Radiation, therapy, surgery

Strahlentherapie+Onkologie.01760009.eng.abstr_task2

Sentence: The treatment of persistent postoperative lymphatic fistulas or lymphoceles is often a problem . Approximately 2% of patients will develop lymphatic fistula after vascular surgery . This can require a long lasting conservative therapy . If spontaneous cure fails , a second operation with wound revision becomes necessary . We studied low-dose percutaneous radiotherapy to be used as an alternative treatment in addition to conservative or surgical therapy . Between 1989 and 1998 29 patients ( 25 with lymphatic fistulas , 4 with lymphoceles ) received radiation therapy . Depending on the depth of the fistula 27 patients were treated with electrons ( 7 to 18 MeV ) . Two other patients suffering of retroperitoneal lymphoceles received a treatment with photons ( 15 MV ) . In all patients the fractionation was 4- to 5 x 1.0 Gy/week and the dose ranged from 3 to 12 Gy depending upon the onset of the radiation therapy effect . In 27 of 28 evaluable patients a complete disappearance of the fistula or lymphocele was achieved by radiation during therapy or shortly afterwards . In 1 case no benefit was observed after a dose of 11 Gy . This patient required further surgery with wound exploration . Low dose percutaneous radiotherapy ( up to 10 to 12 Gy ) is effective to heal lymphatic fistulas and lymphoceles without complications . Individual dosage is required because doses even lower than 10 Gy may be effective . Radiation can be effective even after a failed conservative therapy or instead of surgery . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]

The treatment of persistent postoperative lymphatic fistulas or lymphoceles is often a problem . Approximately 2% of patients will develop lymphatic fistula after vascular surgery . This can require a long lasting conservative therapy . If spontaneous cure fails , a second operation with wound revision becomes necessary . We studied low-dose percutaneous radiotherapy to be used as an alternative treatment in addition to conservative or surgical therapy . Between 1989 and 1998 29 patients ( 25 with lymphatic fistulas , 4 with lymphoceles ) received radiation therapy . Depending on the depth of the fistula 27 patients were treated with electrons ( 7 to 18 MeV ) . Two other patients suffering of retroperitoneal lymphoceles received a treatment with photons ( 15 MV ) . In all patients the fractionation was 4- to 5 x 1.0 Gy/week and the dose ranged from 3 to 12 Gy depending upon the onset of the radiation therapy effect . In 27 of 28 evaluable patients a complete disappearance of the fistula or lymphocele was achieved by radiation during therapy or shortly afterwards . In 1 case no benefit was observed after a dose of 11 Gy . This patient required further surgery with wound exploration . Low dose percutaneous radiotherapy ( up to 10 to 12 Gy ) is effective to heal lymphatic fistulas and lymphoceles without complications . Individual dosage is required because doses even lower than 10 Gy may be effective . Radiation can be effective even after a failed conservative therapy or instead of surgery .

[ "The", "treatment", "of", "persistent", "postoperative", "lymphatic", "fistulas", "or", "lymphoceles", "is", "often", "a", "problem", ".", "Approximately", "2", "%", "of", "patients", "will", "develop", "lymphatic", "fistula", "after", "vascular", "surgery", ".", "This", "can", "require", "a", "long", "lasting", "conservative", "therapy", ".", "If", "spontaneous", "cure", "fails", ",", "a", "second", "operation", "with", "wound", "revision", "becomes", "necessary", ".", "We", "studied", "low", "-", "dose", "percutaneous", "radiotherapy", "to", "be", "used", "as", "an", "alternative", "treatment", "in", "addition", "to", "conservative", "or", "surgical", "therapy", ".", "Between", "1989", "and", "1998", "29", "patients", "(", "25", "with", "lymphatic", "fistulas", ",", "4", "with", "lymphoceles", ")", "received", "radiation", "therapy", ".", "Depending", "on", "the", "depth", "of", "the", "fistula", "27", "patients", "were", "treated", "with", "electrons", "(", "7", "to", "18", "MeV", ")", ".", "Two", "other", "patients", "suffering", "of", "retroperitoneal", "lymphoceles", "received", "a", "treatment", "with", "photons", "(", "15", "MV", ")", ".", "In", "all", "patients", "the", "fractionation", "was", "4-", "to", "5", "x", "1.0", "Gy", "/", "week", "and", "the", "dose", "ranged", "from", "3", "to", "12", "Gy", "depending", "upon", "the", "onset", "of", "the", "radiation", "therapy", "effect", ".", "In", "27", "of", "28", "evaluable", "patients", "a", "complete", "disappearance", "of", "the", "fistula", "or", "lymphocele", "was", "achieved", "by", "radiation", "during", "therapy", "or", "shortly", "afterwards", ".", "In", "1", "case", "no", "benefit", "was", "observed", "after", "a", "dose", "of", "11", "Gy", ".", "This", "patient", "required", "further", "surgery", "with", "wound", "exploration", ".", "Low", "dose", "percutaneous", "radiotherapy", "(", "up", "to", "10", "to", "12", "Gy", ")", "is", "effective", "to", "heal", "lymphatic", "fistulas", "and", "lymphoceles", "without", "complications", ".", "Individual", "dosage", "is", "required", "because", "doses", "even", "lower", "than", "10", "Gy", "may", "be", "effective", ".", "Radiation", "can", "be", "effective", "even", "after", "a", "failed", "conservative", "therapy", "or", "instead", "of", "surgery", "." ]

[ "umlsterm" ]

Abstract is an umlsterm, date is an umlsterm, skin is an umlsterm, symptoms is an umlsterm, CD1 is an umlsterm, frozen sections is an umlsterm, granules is an umlsterm, electron microscopy is an umlsterm, analysis is an umlsterm, antibodies is an umlsterm, ability is an umlsterm, paraffin is an umlsterm, tissue is an umlsterm, retrospective is an umlsterm, evaluation is an umlsterm, classification is an umlsterm, disorders is an umlsterm, antibodies is an umlsterm, peanut agglutinin is an umlsterm, PCNA is an umlsterm, cell is an umlsterm, nuclear antigen is an umlsterm, cells is an umlsterm, Langerhans cell histiocytosis is an umlsterm, cell is an umlsterm, cell is an umlsterm, cell is an umlsterm, populations is an umlsterm, dendritic cells is an umlsterm, distribution is an umlsterm, dendritic cells is an umlsterm, ability is an umlsterm, markers is an umlsterm, paraffin is an umlsterm, tissue is an umlsterm, antibodies is an umlsterm, factor XIIIa is an umlsterm, xanthoma disseminatum is an umlsterm, monoclonal antibody is an umlsterm, juvenile xanthogranuloma is an umlsterm, discrimination is an umlsterm, markers is an umlsterm, macrophages is an umlsterm, juvenile xanthogranuloma is an umlsterm, foam cells is an umlsterm, giant cells is an umlsterm, anti - cathepsin is an umlsterm, markers is an umlsterm, ability is an umlsterm, paraffin is an umlsterm, tissue is an umlsterm, lysozyme is an umlsterm, Leu - M1 is an umlsterm, contrast is an umlsterm, macrophages is an umlsterm

DerHautarzt.50460144.eng.abstr_task0

Sentence: Abstract . To date , the rare primary histiocytoses of the skin are diagnosed definitively on the basis of the clinical symptoms , H&E-stained sections , and demonstration of CD1 positivity in frozen sections and of Birbeck granules on electron microscopy . The improvement and analysis of antibodies with the ability to react in paraffin tissue allow retrospective evaluation and classification of these disorders . The antibodies for S-100-protein, peanut agglutinin ( PNA ) and PCNA ( proliferating cell nuclear antigen ) have been advocated for differentiation of the specific cells of Langerhans cell histiocytosis ( LCH ) from other histiocytic cell systems . To date the non-Langerhans cell histiocytoses ( non-LCH ) have no common ultrastructural and immunohistochemical characteristics . The infiltrate is made up of multiple cell populations , which are of significance for the cellular pathobiology ( subtypes of monocytes/macrophages and dendritic cells ) . The number and distribution of the different monocyte/macrophages and dendritic cells and their ability to react with immunohistochemical markers in paraffin tissue can be completely different in different clinical entities . The antibodies against factor XIIIa ( shown on xanthoma disseminatum ) and the monoclonal antibody Ki-M1P ( shown on juvenile xanthogranuloma ) seem to be valuable in discrimination between LCH and non-LCH . Both markers show a positive staining pattern with the characteristic large macrophages . In juvenile xanthogranuloma , the foam cells and giant cells express Ki-M1P, KP1 and anti-cathepsin B. Other monocyte/macrophage markers with the ability to react in paraffin tissue , such as Mac387 , lysozyme , 1-antitrypsin and Leu-M1 ( Anti-CD 15 ) , in contrast , did not show a typical staining pattern with the characteristic large macrophages dominating the histological picture . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]

Abstract . To date , the rare primary histiocytoses of the skin are diagnosed definitively on the basis of the clinical symptoms , H&E-stained sections , and demonstration of CD1 positivity in frozen sections and of Birbeck granules on electron microscopy . The improvement and analysis of antibodies with the ability to react in paraffin tissue allow retrospective evaluation and classification of these disorders . The antibodies for S-100-protein, peanut agglutinin ( PNA ) and PCNA ( proliferating cell nuclear antigen ) have been advocated for differentiation of the specific cells of Langerhans cell histiocytosis ( LCH ) from other histiocytic cell systems . To date the non-Langerhans cell histiocytoses ( non-LCH ) have no common ultrastructural and immunohistochemical characteristics . The infiltrate is made up of multiple cell populations , which are of significance for the cellular pathobiology ( subtypes of monocytes/macrophages and dendritic cells ) . The number and distribution of the different monocyte/macrophages and dendritic cells and their ability to react with immunohistochemical markers in paraffin tissue can be completely different in different clinical entities . The antibodies against factor XIIIa ( shown on xanthoma disseminatum ) and the monoclonal antibody Ki-M1P ( shown on juvenile xanthogranuloma ) seem to be valuable in discrimination between LCH and non-LCH . Both markers show a positive staining pattern with the characteristic large macrophages . In juvenile xanthogranuloma , the foam cells and giant cells express Ki-M1P, KP1 and anti-cathepsin B. Other monocyte/macrophage markers with the ability to react in paraffin tissue , such as Mac387 , lysozyme , 1-antitrypsin and Leu-M1 ( Anti-CD 15 ) , in contrast , did not show a typical staining pattern with the characteristic large macrophages dominating the histological picture .

[ "Abstract", ".", "To", "date", ",", "the", "rare", "primary", "histiocytoses", "of", "the", "skin", "are", "diagnosed", "definitively", "on", "the", "basis", "of", "the", "clinical", "symptoms", ",", "H&E", "-", "stained", "sections", ",", "and", "demonstration", "of", "CD1", "positivity", "in", "frozen", "sections", "and", "of", "Birbeck", "granules", "on", "electron", "microscopy", ".", "The", "improvement", "and", "analysis", "of", "antibodies", "with", "the", "ability", "to", "react", "in", "paraffin", "tissue", "allow", "retrospective", "evaluation", "and", "classification", "of", "these", "disorders", ".", "The", "antibodies", "for", "S-100-protein", ",", "peanut", "agglutinin", "(", "PNA", ")", "and", "PCNA", "(", "proliferating", "cell", "nuclear", "antigen", ")", "have", "been", "advocated", "for", "differentiation", "of", "the", "specific", "cells", "of", "Langerhans", "cell", "histiocytosis", "(", "LCH", ")", "from", "other", "histiocytic", "cell", "systems", ".", "To", "date", "the", "non", "-", "Langerhans", "cell", "histiocytoses", "(", "non", "-", "LCH", ")", "have", "no", "common", "ultrastructural", "and", "immunohistochemical", "characteristics", ".", "The", "infiltrate", "is", "made", "up", "of", "multiple", "cell", "populations", ",", "which", "are", "of", "significance", "for", "the", "cellular", "pathobiology", "(", "subtypes", "of", "monocytes", "/", "macrophages", "and", "dendritic", "cells", ")", ".", "The", "number", "and", "distribution", "of", "the", "different", "monocyte", "/", "macrophages", "and", "dendritic", "cells", "and", "their", "ability", "to", "react", "with", "immunohistochemical", "markers", "in", "paraffin", "tissue", "can", "be", "completely", "different", "in", "different", "clinical", "entities", ".", "The", "antibodies", "against", "factor", "XIIIa", "(", "shown", "on", "xanthoma", "disseminatum", ")", "and", "the", "monoclonal", "antibody", "Ki", "-", "M1P", "(", "shown", "on", "juvenile", "xanthogranuloma", ")", "seem", "to", "be", "valuable", "in", "discrimination", "between", "LCH", "and", "non", "-", "LCH", ".", "Both", "markers", "show", "a", "positive", "staining", "pattern", "with", "the", "characteristic", "large", "macrophages", ".", "In", "juvenile", "xanthogranuloma", ",", "the", "foam", "cells", "and", "giant", "cells", "express", "Ki", "-", "M1P", ",", "KP1", "and", "anti", "-", "cathepsin", "B.", "Other", "monocyte", "/", "macrophage", "markers", "with", "the", "ability", "to", "react", "in", "paraffin", "tissue", ",", "such", "as", "Mac387", ",", "lysozyme", ",", "1-antitrypsin", "and", "Leu", "-", "M1", "(", "Anti", "-", "CD", "15", ")", ",", "in", "contrast", ",", "did", "not", "show", "a", "typical", "staining", "pattern", "with", "the", "characteristic", "large", "macrophages", "dominating", "the", "histological", "picture", "." ]

[ "umlsterm" ]

Abstract is an umlsterm, date is an umlsterm, skin is an umlsterm, symptoms is an umlsterm, CD1 is an umlsterm, frozen sections is an umlsterm, granules is an umlsterm, electron microscopy is an umlsterm, analysis is an umlsterm, antibodies is an umlsterm, ability is an umlsterm, paraffin is an umlsterm, tissue is an umlsterm, retrospective is an umlsterm, evaluation is an umlsterm, classification is an umlsterm, disorders is an umlsterm, antibodies is an umlsterm, peanut agglutinin is an umlsterm, PCNA is an umlsterm, cell is an umlsterm, nuclear antigen is an umlsterm, cells is an umlsterm, Langerhans cell histiocytosis is an umlsterm, cell is an umlsterm, cell is an umlsterm, cell is an umlsterm, populations is an umlsterm, dendritic cells is an umlsterm, distribution is an umlsterm, dendritic cells is an umlsterm, ability is an umlsterm, markers is an umlsterm, paraffin is an umlsterm, tissue is an umlsterm, antibodies is an umlsterm, factor XIIIa is an umlsterm, xanthoma disseminatum is an umlsterm, monoclonal antibody is an umlsterm, juvenile xanthogranuloma is an umlsterm, discrimination is an umlsterm, markers is an umlsterm, macrophages is an umlsterm, juvenile xanthogranuloma is an umlsterm, foam cells is an umlsterm, giant cells is an umlsterm, anti - cathepsin is an umlsterm, markers is an umlsterm, ability is an umlsterm, paraffin is an umlsterm, tissue is an umlsterm, lysozyme is an umlsterm, Leu - M1 is an umlsterm, contrast is an umlsterm, macrophages is an umlsterm

DerHautarzt.50460144.eng.abstr_task1

Sentence: Abstract . To date , the rare primary histiocytoses of the skin are diagnosed definitively on the basis of the clinical symptoms , H&E-stained sections , and demonstration of CD1 positivity in frozen sections and of Birbeck granules on electron microscopy . The improvement and analysis of antibodies with the ability to react in paraffin tissue allow retrospective evaluation and classification of these disorders . The antibodies for S-100-protein, peanut agglutinin ( PNA ) and PCNA ( proliferating cell nuclear antigen ) have been advocated for differentiation of the specific cells of Langerhans cell histiocytosis ( LCH ) from other histiocytic cell systems . To date the non-Langerhans cell histiocytoses ( non-LCH ) have no common ultrastructural and immunohistochemical characteristics . The infiltrate is made up of multiple cell populations , which are of significance for the cellular pathobiology ( subtypes of monocytes/macrophages and dendritic cells ) . The number and distribution of the different monocyte/macrophages and dendritic cells and their ability to react with immunohistochemical markers in paraffin tissue can be completely different in different clinical entities . The antibodies against factor XIIIa ( shown on xanthoma disseminatum ) and the monoclonal antibody Ki-M1P ( shown on juvenile xanthogranuloma ) seem to be valuable in discrimination between LCH and non-LCH . Both markers show a positive staining pattern with the characteristic large macrophages . In juvenile xanthogranuloma , the foam cells and giant cells express Ki-M1P, KP1 and anti-cathepsin B. Other monocyte/macrophage markers with the ability to react in paraffin tissue , such as Mac387 , lysozyme , 1-antitrypsin and Leu-M1 ( Anti-CD 15 ) , in contrast , did not show a typical staining pattern with the characteristic large macrophages dominating the histological picture . Instructions: please typing these entity words according to sentence: Abstract, date, skin, symptoms, CD1, frozen sections, granules, electron microscopy, analysis, antibodies, ability, paraffin, tissue, retrospective, evaluation, classification, disorders, antibodies, peanut agglutinin, PCNA, cell, nuclear antigen, cells, Langerhans cell histiocytosis, cell, cell, cell, populations, dendritic cells, distribution, dendritic cells, ability, markers, paraffin, tissue, antibodies, factor XIIIa, xanthoma disseminatum, monoclonal antibody, juvenile xanthogranuloma, discrimination, markers, macrophages, juvenile xanthogranuloma, foam cells, giant cells, anti - cathepsin, markers, ability, paraffin, tissue, lysozyme, Leu - M1, contrast, macrophages Options: umlsterm

[ "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]

Abstract . To date , the rare primary histiocytoses of the skin are diagnosed definitively on the basis of the clinical symptoms , H&E-stained sections , and demonstration of CD1 positivity in frozen sections and of Birbeck granules on electron microscopy . The improvement and analysis of antibodies with the ability to react in paraffin tissue allow retrospective evaluation and classification of these disorders . The antibodies for S-100-protein, peanut agglutinin ( PNA ) and PCNA ( proliferating cell nuclear antigen ) have been advocated for differentiation of the specific cells of Langerhans cell histiocytosis ( LCH ) from other histiocytic cell systems . To date the non-Langerhans cell histiocytoses ( non-LCH ) have no common ultrastructural and immunohistochemical characteristics . The infiltrate is made up of multiple cell populations , which are of significance for the cellular pathobiology ( subtypes of monocytes/macrophages and dendritic cells ) . The number and distribution of the different monocyte/macrophages and dendritic cells and their ability to react with immunohistochemical markers in paraffin tissue can be completely different in different clinical entities . The antibodies against factor XIIIa ( shown on xanthoma disseminatum ) and the monoclonal antibody Ki-M1P ( shown on juvenile xanthogranuloma ) seem to be valuable in discrimination between LCH and non-LCH . Both markers show a positive staining pattern with the characteristic large macrophages . In juvenile xanthogranuloma , the foam cells and giant cells express Ki-M1P, KP1 and anti-cathepsin B. Other monocyte/macrophage markers with the ability to react in paraffin tissue , such as Mac387 , lysozyme , 1-antitrypsin and Leu-M1 ( Anti-CD 15 ) , in contrast , did not show a typical staining pattern with the characteristic large macrophages dominating the histological picture .

[ "Abstract", ".", "To", "date", ",", "the", "rare", "primary", "histiocytoses", "of", "the", "skin", "are", "diagnosed", "definitively", "on", "the", "basis", "of", "the", "clinical", "symptoms", ",", "H&E", "-", "stained", "sections", ",", "and", "demonstration", "of", "CD1", "positivity", "in", "frozen", "sections", "and", "of", "Birbeck", "granules", "on", "electron", "microscopy", ".", "The", "improvement", "and", "analysis", "of", "antibodies", "with", "the", "ability", "to", "react", "in", "paraffin", "tissue", "allow", "retrospective", "evaluation", "and", "classification", "of", "these", "disorders", ".", "The", "antibodies", "for", "S-100-protein", ",", "peanut", "agglutinin", "(", "PNA", ")", "and", "PCNA", "(", "proliferating", "cell", "nuclear", "antigen", ")", "have", "been", "advocated", "for", "differentiation", "of", "the", "specific", "cells", "of", "Langerhans", "cell", "histiocytosis", "(", "LCH", ")", "from", "other", "histiocytic", "cell", "systems", ".", "To", "date", "the", "non", "-", "Langerhans", "cell", "histiocytoses", "(", "non", "-", "LCH", ")", "have", "no", "common", "ultrastructural", "and", "immunohistochemical", "characteristics", ".", "The", "infiltrate", "is", "made", "up", "of", "multiple", "cell", "populations", ",", "which", "are", "of", "significance", "for", "the", "cellular", "pathobiology", "(", "subtypes", "of", "monocytes", "/", "macrophages", "and", "dendritic", "cells", ")", ".", "The", "number", "and", "distribution", "of", "the", "different", "monocyte", "/", "macrophages", "and", "dendritic", "cells", "and", "their", "ability", "to", "react", "with", "immunohistochemical", "markers", "in", "paraffin", "tissue", "can", "be", "completely", "different", "in", "different", "clinical", "entities", ".", "The", "antibodies", "against", "factor", "XIIIa", "(", "shown", "on", "xanthoma", "disseminatum", ")", "and", "the", "monoclonal", "antibody", "Ki", "-", "M1P", "(", "shown", "on", "juvenile", "xanthogranuloma", ")", "seem", "to", "be", "valuable", "in", "discrimination", "between", "LCH", "and", "non", "-", "LCH", ".", "Both", "markers", "show", "a", "positive", "staining", "pattern", "with", "the", "characteristic", "large", "macrophages", ".", "In", "juvenile", "xanthogranuloma", ",", "the", "foam", "cells", "and", "giant", "cells", "express", "Ki", "-", "M1P", ",", "KP1", "and", "anti", "-", "cathepsin", "B.", "Other", "monocyte", "/", "macrophage", "markers", "with", "the", "ability", "to", "react", "in", "paraffin", "tissue", ",", "such", "as", "Mac387", ",", "lysozyme", ",", "1-antitrypsin", "and", "Leu", "-", "M1", "(", "Anti", "-", "CD", "15", ")", ",", "in", "contrast", ",", "did", "not", "show", "a", "typical", "staining", "pattern", "with", "the", "characteristic", "large", "macrophages", "dominating", "the", "histological", "picture", "." ]

[ "umlsterm" ]

Abstract, date, skin, symptoms, CD1, frozen sections, granules, electron microscopy, analysis, antibodies, ability, paraffin, tissue, retrospective, evaluation, classification, disorders, antibodies, peanut agglutinin, PCNA, cell, nuclear antigen, cells, Langerhans cell histiocytosis, cell, cell, cell, populations, dendritic cells, distribution, dendritic cells, ability, markers, paraffin, tissue, antibodies, factor XIIIa, xanthoma disseminatum, monoclonal antibody, juvenile xanthogranuloma, discrimination, markers, macrophages, juvenile xanthogranuloma, foam cells, giant cells, anti - cathepsin, markers, ability, paraffin, tissue, lysozyme, Leu - M1, contrast, macrophages

DerHautarzt.50460144.eng.abstr_task2

Sentence: Abstract . To date , the rare primary histiocytoses of the skin are diagnosed definitively on the basis of the clinical symptoms , H&E-stained sections , and demonstration of CD1 positivity in frozen sections and of Birbeck granules on electron microscopy . The improvement and analysis of antibodies with the ability to react in paraffin tissue allow retrospective evaluation and classification of these disorders . The antibodies for S-100-protein, peanut agglutinin ( PNA ) and PCNA ( proliferating cell nuclear antigen ) have been advocated for differentiation of the specific cells of Langerhans cell histiocytosis ( LCH ) from other histiocytic cell systems . To date the non-Langerhans cell histiocytoses ( non-LCH ) have no common ultrastructural and immunohistochemical characteristics . The infiltrate is made up of multiple cell populations , which are of significance for the cellular pathobiology ( subtypes of monocytes/macrophages and dendritic cells ) . The number and distribution of the different monocyte/macrophages and dendritic cells and their ability to react with immunohistochemical markers in paraffin tissue can be completely different in different clinical entities . The antibodies against factor XIIIa ( shown on xanthoma disseminatum ) and the monoclonal antibody Ki-M1P ( shown on juvenile xanthogranuloma ) seem to be valuable in discrimination between LCH and non-LCH . Both markers show a positive staining pattern with the characteristic large macrophages . In juvenile xanthogranuloma , the foam cells and giant cells express Ki-M1P, KP1 and anti-cathepsin B. Other monocyte/macrophage markers with the ability to react in paraffin tissue , such as Mac387 , lysozyme , 1-antitrypsin and Leu-M1 ( Anti-CD 15 ) , in contrast , did not show a typical staining pattern with the characteristic large macrophages dominating the histological picture . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]

Abstract . To date , the rare primary histiocytoses of the skin are diagnosed definitively on the basis of the clinical symptoms , H&E-stained sections , and demonstration of CD1 positivity in frozen sections and of Birbeck granules on electron microscopy . The improvement and analysis of antibodies with the ability to react in paraffin tissue allow retrospective evaluation and classification of these disorders . The antibodies for S-100-protein, peanut agglutinin ( PNA ) and PCNA ( proliferating cell nuclear antigen ) have been advocated for differentiation of the specific cells of Langerhans cell histiocytosis ( LCH ) from other histiocytic cell systems . To date the non-Langerhans cell histiocytoses ( non-LCH ) have no common ultrastructural and immunohistochemical characteristics . The infiltrate is made up of multiple cell populations , which are of significance for the cellular pathobiology ( subtypes of monocytes/macrophages and dendritic cells ) . The number and distribution of the different monocyte/macrophages and dendritic cells and their ability to react with immunohistochemical markers in paraffin tissue can be completely different in different clinical entities . The antibodies against factor XIIIa ( shown on xanthoma disseminatum ) and the monoclonal antibody Ki-M1P ( shown on juvenile xanthogranuloma ) seem to be valuable in discrimination between LCH and non-LCH . Both markers show a positive staining pattern with the characteristic large macrophages . In juvenile xanthogranuloma , the foam cells and giant cells express Ki-M1P, KP1 and anti-cathepsin B. Other monocyte/macrophage markers with the ability to react in paraffin tissue , such as Mac387 , lysozyme , 1-antitrypsin and Leu-M1 ( Anti-CD 15 ) , in contrast , did not show a typical staining pattern with the characteristic large macrophages dominating the histological picture .

[ "Abstract", ".", "To", "date", ",", "the", "rare", "primary", "histiocytoses", "of", "the", "skin", "are", "diagnosed", "definitively", "on", "the", "basis", "of", "the", "clinical", "symptoms", ",", "H&E", "-", "stained", "sections", ",", "and", "demonstration", "of", "CD1", "positivity", "in", "frozen", "sections", "and", "of", "Birbeck", "granules", "on", "electron", "microscopy", ".", "The", "improvement", "and", "analysis", "of", "antibodies", "with", "the", "ability", "to", "react", "in", "paraffin", "tissue", "allow", "retrospective", "evaluation", "and", "classification", "of", "these", "disorders", ".", "The", "antibodies", "for", "S-100-protein", ",", "peanut", "agglutinin", "(", "PNA", ")", "and", "PCNA", "(", "proliferating", "cell", "nuclear", "antigen", ")", "have", "been", "advocated", "for", "differentiation", "of", "the", "specific", "cells", "of", "Langerhans", "cell", "histiocytosis", "(", "LCH", ")", "from", "other", "histiocytic", "cell", "systems", ".", "To", "date", "the", "non", "-", "Langerhans", "cell", "histiocytoses", "(", "non", "-", "LCH", ")", "have", "no", "common", "ultrastructural", "and", "immunohistochemical", "characteristics", ".", "The", "infiltrate", "is", "made", "up", "of", "multiple", "cell", "populations", ",", "which", "are", "of", "significance", "for", "the", "cellular", "pathobiology", "(", "subtypes", "of", "monocytes", "/", "macrophages", "and", "dendritic", "cells", ")", ".", "The", "number", "and", "distribution", "of", "the", "different", "monocyte", "/", "macrophages", "and", "dendritic", "cells", "and", "their", "ability", "to", "react", "with", "immunohistochemical", "markers", "in", "paraffin", "tissue", "can", "be", "completely", "different", "in", "different", "clinical", "entities", ".", "The", "antibodies", "against", "factor", "XIIIa", "(", "shown", "on", "xanthoma", "disseminatum", ")", "and", "the", "monoclonal", "antibody", "Ki", "-", "M1P", "(", "shown", "on", "juvenile", "xanthogranuloma", ")", "seem", "to", "be", "valuable", "in", "discrimination", "between", "LCH", "and", "non", "-", "LCH", ".", "Both", "markers", "show", "a", "positive", "staining", "pattern", "with", "the", "characteristic", "large", "macrophages", ".", "In", "juvenile", "xanthogranuloma", ",", "the", "foam", "cells", "and", "giant", "cells", "express", "Ki", "-", "M1P", ",", "KP1", "and", "anti", "-", "cathepsin", "B.", "Other", "monocyte", "/", "macrophage", "markers", "with", "the", "ability", "to", "react", "in", "paraffin", "tissue", ",", "such", "as", "Mac387", ",", "lysozyme", ",", "1-antitrypsin", "and", "Leu", "-", "M1", "(", "Anti", "-", "CD", "15", ")", ",", "in", "contrast", ",", "did", "not", "show", "a", "typical", "staining", "pattern", "with", "the", "characteristic", "large", "macrophages", "dominating", "the", "histological", "picture", "." ]

[ "umlsterm" ]

Pedro is a NOMBRE_SUJETO_ASISTENCIA, Espinoza Campos is a NOMBRE_SUJETO_ASISTENCIA, 2987562 is a ID_SUJETO_ASISTENCIA, Av Libertador Bernardo O'Higgins 816 is a CALLE, Santiago is a TERRITORIO, 7591538 is a TERRITORIO, 31/05/1972 is a FECHAS, Chile is a PAIS, 44 años is a EDAD_SUJETO_ASISTENCIA, Hombre is a SEXO_SUJETO_ASISTENCIA, 08/12/2016 is a FECHAS, Luis Córdova Jara is a NOMBRE_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 44 años is a EDAD_SUJETO_ASISTENCIA, Luis Córdova Jara is a NOMBRE_PERSONAL_SANITARIO, Facultad de Odontología is a INSTITUCION, Universidad de Chile is a INSTITUCION, Calle Olivos 943 is a CALLE, Independencia is a TERRITORIO, Santiago de Chile is a TERRITORIO, luiscordovajara@vtr.net is a CORREO_ELECTRONICO

335_task0

Sentence: Nombre: Pedro . Apellidos:Espinoza Campos. NHC: 2987562. Domicilio: Av Libertador Bernardo O'Higgins 816. Localidad/ Provincia: Santiago. CP: 7591538. Datos asistenciales. Fecha de nacimiento: 31/05/1972. País: Chile. Edad: 44 años Sexo: Hombre. Fecha de Ingreso: 08/12/2016. Médico: Luis Córdova Jara . Informe Clinico: Varón de 44 años ingresado por trauma facial. El estudio radiográfico reveló una gran lesión radiolúcida y una fractura del ángulo desplazada. Se realizó enucleación de la lesión, extracción de las raíces dentarias causantes y la reducción-osteosíntesis de la fractura con alambre intraóseo y mini placa con tornillos monocorticales. El estudio histológico del material enucleado, reveló un quiste radicular inflamatorio. La consolidación ósea fue observada radiográficamente dos meses después. Remitido por: Dr. Luis Córdova Jara. Facultad de Odontología. Universidad de Chile Calle Olivos 943, Independencia, Santiago de Chile. Email: luiscordovajara@vtr.net Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, INSTITUCION, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "B-CALLE", "I-CALLE", "I-CALLE", "O", "B-TERRITORIO", "O", "B-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Nombre: Pedro . Apellidos:Espinoza Campos. NHC: 2987562. Domicilio: Av Libertador Bernardo O'Higgins 816. Localidad/ Provincia: Santiago. CP: 7591538. Datos asistenciales. Fecha de nacimiento: 31/05/1972. País: Chile. Edad: 44 años Sexo: Hombre. Fecha de Ingreso: 08/12/2016. Médico: Luis Córdova Jara . Informe Clinico: Varón de 44 años ingresado por trauma facial. El estudio radiográfico reveló una gran lesión radiolúcida y una fractura del ángulo desplazada. Se realizó enucleación de la lesión, extracción de las raíces dentarias causantes y la reducción-osteosíntesis de la fractura con alambre intraóseo y mini placa con tornillos monocorticales. El estudio histológico del material enucleado, reveló un quiste radicular inflamatorio. La consolidación ósea fue observada radiográficamente dos meses después. Remitido por: Dr. Luis Córdova Jara. Facultad de Odontología. Universidad de Chile Calle Olivos 943, Independencia, Santiago de Chile. Email: luiscordovajara@vtr.net

[ "Nombre", ":", " ", "Pedro", ".", "\n", "Apellidos", ":", "Espinoza", "Campos", ".", "\n", "NHC", ":", "2987562", ".", "\n", "Domicilio", ":", "Av", "Libertador", "Bernardo", "O'Higgins", "816", ".", "\n", "Localidad/", "Provincia", ":", "Santiago", ".", "\n", "CP", ":", "7591538", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "31/05/1972", ".", "\n", "País", ":", "Chile", ".", "\n", "Edad", ":", "44", " ", "años", "Sexo", ":", "Hombre", ".", "\n", "Fecha", "de", "Ingreso", ":", "08/12/2016", ".", "\n", "Médico", ":", "Luis", "Córdova", "Jara", ".", "\n", "Informe", "Clinico", ":", "Varón", "de", "44", "años", "ingresado", "por", "trauma", "facial", ".", "El", "estudio", "radiográfico", "reveló", "una", "gran", "lesión", "radiolúcida", "y", "una", "fractura", "del", "ángulo", "desplazada", ".", "\n", "Se", "realizó", "enucleación", "de", "la", "lesión", ",", "extracción", "de", "las", "raíces", "dentarias", "causantes", "y", "la", "reducción", "-", "osteosíntesis", "de", "la", "fractura", "con", "alambre", "intraóseo", "y", "mini", "placa", "con", "tornillos", "monocorticales", ".", "\n", "El", "estudio", "histológico", "del", "material", "enucleado", ",", "reveló", "un", "quiste", "radicular", "inflamatorio", ".", "La", "consolidación", "ósea", "fue", "observada", "radiográficamente", "dos", "meses", "después", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Luis", "Córdova", "Jara", ".", "Facultad", "de", "Odontología", ".", "Universidad", "de", "Chile", "Calle", "Olivos", "943", ",", "Independencia", ",", "Santiago", "de", "Chile", ".", "Email", ":", "luiscordovajara@vtr.net", "\n" ]

[ "CALLE", "CORREO_ELECTRONICO", "INSTITUCION", "TERRITORIO", "NOMBRE_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA", "PAIS" ]

Pedro is a NOMBRE_SUJETO_ASISTENCIA, Espinoza Campos is a NOMBRE_SUJETO_ASISTENCIA, 2987562 is a ID_SUJETO_ASISTENCIA, Av Libertador Bernardo O'Higgins 816 is a CALLE, Santiago is a TERRITORIO, 7591538 is a TERRITORIO, 31/05/1972 is a FECHAS, Chile is a PAIS, 44 años is a EDAD_SUJETO_ASISTENCIA, Hombre is a SEXO_SUJETO_ASISTENCIA, 08/12/2016 is a FECHAS, Luis Córdova Jara is a NOMBRE_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 44 años is a EDAD_SUJETO_ASISTENCIA, Luis Córdova Jara is a NOMBRE_PERSONAL_SANITARIO, Facultad de Odontología is a INSTITUCION, Universidad de Chile is a INSTITUCION, Calle Olivos 943 is a CALLE, Independencia is a TERRITORIO, Santiago de Chile is a TERRITORIO, luiscordovajara@vtr.net is a CORREO_ELECTRONICO

335_task1

Sentence: Nombre: Pedro . Apellidos:Espinoza Campos. NHC: 2987562. Domicilio: Av Libertador Bernardo O'Higgins 816. Localidad/ Provincia: Santiago. CP: 7591538. Datos asistenciales. Fecha de nacimiento: 31/05/1972. País: Chile. Edad: 44 años Sexo: Hombre. Fecha de Ingreso: 08/12/2016. Médico: Luis Córdova Jara . Informe Clinico: Varón de 44 años ingresado por trauma facial. El estudio radiográfico reveló una gran lesión radiolúcida y una fractura del ángulo desplazada. Se realizó enucleación de la lesión, extracción de las raíces dentarias causantes y la reducción-osteosíntesis de la fractura con alambre intraóseo y mini placa con tornillos monocorticales. El estudio histológico del material enucleado, reveló un quiste radicular inflamatorio. La consolidación ósea fue observada radiográficamente dos meses después. Remitido por: Dr. Luis Córdova Jara. Facultad de Odontología. Universidad de Chile Calle Olivos 943, Independencia, Santiago de Chile. Email: luiscordovajara@vtr.net Instructions: please typing these entity words according to sentence: Pedro, Espinoza Campos, 2987562, Av Libertador Bernardo O'Higgins 816, Santiago, 7591538, 31/05/1972, Chile, 44 años, Hombre, 08/12/2016, Luis Córdova Jara, Varón, 44 años, Luis Córdova Jara, Facultad de Odontología, Universidad de Chile, Calle Olivos 943, Independencia, Santiago de Chile, luiscordovajara@vtr.net Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, INSTITUCION, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "B-CALLE", "I-CALLE", "I-CALLE", "O", "B-TERRITORIO", "O", "B-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Nombre: Pedro . Apellidos:Espinoza Campos. NHC: 2987562. Domicilio: Av Libertador Bernardo O'Higgins 816. Localidad/ Provincia: Santiago. CP: 7591538. Datos asistenciales. Fecha de nacimiento: 31/05/1972. País: Chile. Edad: 44 años Sexo: Hombre. Fecha de Ingreso: 08/12/2016. Médico: Luis Córdova Jara . Informe Clinico: Varón de 44 años ingresado por trauma facial. El estudio radiográfico reveló una gran lesión radiolúcida y una fractura del ángulo desplazada. Se realizó enucleación de la lesión, extracción de las raíces dentarias causantes y la reducción-osteosíntesis de la fractura con alambre intraóseo y mini placa con tornillos monocorticales. El estudio histológico del material enucleado, reveló un quiste radicular inflamatorio. La consolidación ósea fue observada radiográficamente dos meses después. Remitido por: Dr. Luis Córdova Jara. Facultad de Odontología. Universidad de Chile Calle Olivos 943, Independencia, Santiago de Chile. Email: luiscordovajara@vtr.net

[ "Nombre", ":", " ", "Pedro", ".", "\n", "Apellidos", ":", "Espinoza", "Campos", ".", "\n", "NHC", ":", "2987562", ".", "\n", "Domicilio", ":", "Av", "Libertador", "Bernardo", "O'Higgins", "816", ".", "\n", "Localidad/", "Provincia", ":", "Santiago", ".", "\n", "CP", ":", "7591538", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "31/05/1972", ".", "\n", "País", ":", "Chile", ".", "\n", "Edad", ":", "44", " ", "años", "Sexo", ":", "Hombre", ".", "\n", "Fecha", "de", "Ingreso", ":", "08/12/2016", ".", "\n", "Médico", ":", "Luis", "Córdova", "Jara", ".", "\n", "Informe", "Clinico", ":", "Varón", "de", "44", "años", "ingresado", "por", "trauma", "facial", ".", "El", "estudio", "radiográfico", "reveló", "una", "gran", "lesión", "radiolúcida", "y", "una", "fractura", "del", "ángulo", "desplazada", ".", "\n", "Se", "realizó", "enucleación", "de", "la", "lesión", ",", "extracción", "de", "las", "raíces", "dentarias", "causantes", "y", "la", "reducción", "-", "osteosíntesis", "de", "la", "fractura", "con", "alambre", "intraóseo", "y", "mini", "placa", "con", "tornillos", "monocorticales", ".", "\n", "El", "estudio", "histológico", "del", "material", "enucleado", ",", "reveló", "un", "quiste", "radicular", "inflamatorio", ".", "La", "consolidación", "ósea", "fue", "observada", "radiográficamente", "dos", "meses", "después", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Luis", "Córdova", "Jara", ".", "Facultad", "de", "Odontología", ".", "Universidad", "de", "Chile", "Calle", "Olivos", "943", ",", "Independencia", ",", "Santiago", "de", "Chile", ".", "Email", ":", "luiscordovajara@vtr.net", "\n" ]

[ "CALLE", "CORREO_ELECTRONICO", "INSTITUCION", "TERRITORIO", "NOMBRE_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA", "PAIS" ]

Pedro, Espinoza Campos, 2987562, Av Libertador Bernardo O'Higgins 816, Santiago, 7591538, 31/05/1972, Chile, 44 años, Hombre, 08/12/2016, Luis Córdova Jara, Varón, 44 años, Luis Córdova Jara, Facultad de Odontología, Universidad de Chile, Calle Olivos 943, Independencia, Santiago de Chile, luiscordovajara@vtr.net

335_task2

Sentence: Nombre: Pedro . Apellidos:Espinoza Campos. NHC: 2987562. Domicilio: Av Libertador Bernardo O'Higgins 816. Localidad/ Provincia: Santiago. CP: 7591538. Datos asistenciales. Fecha de nacimiento: 31/05/1972. País: Chile. Edad: 44 años Sexo: Hombre. Fecha de Ingreso: 08/12/2016. Médico: Luis Córdova Jara . Informe Clinico: Varón de 44 años ingresado por trauma facial. El estudio radiográfico reveló una gran lesión radiolúcida y una fractura del ángulo desplazada. Se realizó enucleación de la lesión, extracción de las raíces dentarias causantes y la reducción-osteosíntesis de la fractura con alambre intraóseo y mini placa con tornillos monocorticales. El estudio histológico del material enucleado, reveló un quiste radicular inflamatorio. La consolidación ósea fue observada radiográficamente dos meses después. Remitido por: Dr. Luis Córdova Jara. Facultad de Odontología. Universidad de Chile Calle Olivos 943, Independencia, Santiago de Chile. Email: luiscordovajara@vtr.net Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "B-CALLE", "I-CALLE", "I-CALLE", "O", "B-TERRITORIO", "O", "B-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Nombre: Pedro . Apellidos:Espinoza Campos. NHC: 2987562. Domicilio: Av Libertador Bernardo O'Higgins 816. Localidad/ Provincia: Santiago. CP: 7591538. Datos asistenciales. Fecha de nacimiento: 31/05/1972. País: Chile. Edad: 44 años Sexo: Hombre. Fecha de Ingreso: 08/12/2016. Médico: Luis Córdova Jara . Informe Clinico: Varón de 44 años ingresado por trauma facial. El estudio radiográfico reveló una gran lesión radiolúcida y una fractura del ángulo desplazada. Se realizó enucleación de la lesión, extracción de las raíces dentarias causantes y la reducción-osteosíntesis de la fractura con alambre intraóseo y mini placa con tornillos monocorticales. El estudio histológico del material enucleado, reveló un quiste radicular inflamatorio. La consolidación ósea fue observada radiográficamente dos meses después. Remitido por: Dr. Luis Córdova Jara. Facultad de Odontología. Universidad de Chile Calle Olivos 943, Independencia, Santiago de Chile. Email: luiscordovajara@vtr.net

[ "Nombre", ":", " ", "Pedro", ".", "\n", "Apellidos", ":", "Espinoza", "Campos", ".", "\n", "NHC", ":", "2987562", ".", "\n", "Domicilio", ":", "Av", "Libertador", "Bernardo", "O'Higgins", "816", ".", "\n", "Localidad/", "Provincia", ":", "Santiago", ".", "\n", "CP", ":", "7591538", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "31/05/1972", ".", "\n", "País", ":", "Chile", ".", "\n", "Edad", ":", "44", " ", "años", "Sexo", ":", "Hombre", ".", "\n", "Fecha", "de", "Ingreso", ":", "08/12/2016", ".", "\n", "Médico", ":", "Luis", "Córdova", "Jara", ".", "\n", "Informe", "Clinico", ":", "Varón", "de", "44", "años", "ingresado", "por", "trauma", "facial", ".", "El", "estudio", "radiográfico", "reveló", "una", "gran", "lesión", "radiolúcida", "y", "una", "fractura", "del", "ángulo", "desplazada", ".", "\n", "Se", "realizó", "enucleación", "de", "la", "lesión", ",", "extracción", "de", "las", "raíces", "dentarias", "causantes", "y", "la", "reducción", "-", "osteosíntesis", "de", "la", "fractura", "con", "alambre", "intraóseo", "y", "mini", "placa", "con", "tornillos", "monocorticales", ".", "\n", "El", "estudio", "histológico", "del", "material", "enucleado", ",", "reveló", "un", "quiste", "radicular", "inflamatorio", ".", "La", "consolidación", "ósea", "fue", "observada", "radiográficamente", "dos", "meses", "después", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Luis", "Córdova", "Jara", ".", "Facultad", "de", "Odontología", ".", "Universidad", "de", "Chile", "Calle", "Olivos", "943", ",", "Independencia", ",", "Santiago", "de", "Chile", ".", "Email", ":", "luiscordovajara@vtr.net", "\n" ]

[ "CALLE", "CORREO_ELECTRONICO", "INSTITUCION", "TERRITORIO", "NOMBRE_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA", "PAIS" ]

Herzinfarktregisters is an umlsterm, Trends is an umlsterm, Herzinfarktmorbiditaet is an umlsterm, Herztodesfaelle is an umlsterm, Krankenhausbehandlung is an umlsterm, Patientenverhalten is an umlsterm, Methoden is an umlsterm, Studienbevoelkerung is an umlsterm, Stadt is an umlsterm, Todesbescheinigungen is an umlsterm, Leichenschauaerzte is an umlsterm, Krankenhaeusern is an umlsterm, Interview is an umlsterm, Krankenaktenauswertung is an umlsterm

IntensiveMedizin.90360652.ger.abstr_task0

Sentence: Zusammenfassung Zielstellung : Auf der Grundlage des bevoelkerungsbasierten MONICA-Augsburg Herzinfarktregisters 1985-1995 werden Haeufigkeit und Trends der Herzinfarktmorbiditaet inkl. der ploetzlichen Herztodesfaelle ( PHT ) vorgestellt und im Zusammenhang mit der praehospitalen und Krankenhausbehandlung sowie dem Patientenverhalten diskutiert . Material und Methoden : Studienbevoelkerung sind die 25-74jaehrigen Einwohner der Stadt Augsburg und der Landkreise Augsburg und Aichach-Friedberg . Datenquellen fuer die 5.712 PHT ( innerhalb von 24 Stunden verstorben ) waren die Todesbescheinigungen der 3 regionalen Gesundheitsaemter und die Frageboegen der zuletzt behandelnden und/oder Leichenschauaerzte ; die Daten der 4.976 MI-Patienten aus 17 regionalen Krankenhaeusern basieren auf einem standardisierten Interview und der Krankenaktenauswertung . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

Zusammenfassung Zielstellung : Auf der Grundlage des bevoelkerungsbasierten MONICA-Augsburg Herzinfarktregisters 1985-1995 werden Haeufigkeit und Trends der Herzinfarktmorbiditaet inkl. der ploetzlichen Herztodesfaelle ( PHT ) vorgestellt und im Zusammenhang mit der praehospitalen und Krankenhausbehandlung sowie dem Patientenverhalten diskutiert . Material und Methoden : Studienbevoelkerung sind die 25-74jaehrigen Einwohner der Stadt Augsburg und der Landkreise Augsburg und Aichach-Friedberg . Datenquellen fuer die 5.712 PHT ( innerhalb von 24 Stunden verstorben ) waren die Todesbescheinigungen der 3 regionalen Gesundheitsaemter und die Frageboegen der zuletzt behandelnden und/oder Leichenschauaerzte ; die Daten der 4.976 MI-Patienten aus 17 regionalen Krankenhaeusern basieren auf einem standardisierten Interview und der Krankenaktenauswertung .

[ "Zusammenfassung", "Zielstellung", ":", "Auf", "der", "Grundlage", "des", "bevoelkerungsbasierten", "MONICA", "-", "Augsburg", "Herzinfarktregisters", "1985", "-", "1995", "werden", "Haeufigkeit", "und", "Trends", "der", "Herzinfarktmorbiditaet", "inkl", ".", "der", "ploetzlichen", "Herztodesfaelle", "(", "PHT", ")", "vorgestellt", "und", "im", "Zusammenhang", "mit", "der", "praehospitalen", "und", "Krankenhausbehandlung", "sowie", "dem", "Patientenverhalten", "diskutiert", ".", "Material", "und", "Methoden", ":", "Studienbevoelkerung", "sind", "die", "25", "-", "74jaehrigen", "Einwohner", "der", "Stadt", "Augsburg", "und", "der", "Landkreise", "Augsburg", "und", "Aichach", "-", "Friedberg", ".", "Datenquellen", "fuer", "die", "5.712", "PHT", "(", "innerhalb", "von", "24", "Stunden", "verstorben", ")", "waren", "die", "Todesbescheinigungen", "der", "3", "regionalen", "Gesundheitsaemter", "und", "die", "Frageboegen", "der", "zuletzt", "behandelnden", "und", "/", "oder", "Leichenschauaerzte", ";", "die", "Daten", "der", "4.976", "MI", "-", "Patienten", "aus", "17", "regionalen", "Krankenhaeusern", "basieren", "auf", "einem", "standardisierten", "Interview", "und", "der", "Krankenaktenauswertung", "." ]

[ "umlsterm" ]

Herzinfarktregisters is an umlsterm, Trends is an umlsterm, Herzinfarktmorbiditaet is an umlsterm, Herztodesfaelle is an umlsterm, Krankenhausbehandlung is an umlsterm, Patientenverhalten is an umlsterm, Methoden is an umlsterm, Studienbevoelkerung is an umlsterm, Stadt is an umlsterm, Todesbescheinigungen is an umlsterm, Leichenschauaerzte is an umlsterm, Krankenhaeusern is an umlsterm, Interview is an umlsterm, Krankenaktenauswertung is an umlsterm

IntensiveMedizin.90360652.ger.abstr_task1

Sentence: Zusammenfassung Zielstellung : Auf der Grundlage des bevoelkerungsbasierten MONICA-Augsburg Herzinfarktregisters 1985-1995 werden Haeufigkeit und Trends der Herzinfarktmorbiditaet inkl. der ploetzlichen Herztodesfaelle ( PHT ) vorgestellt und im Zusammenhang mit der praehospitalen und Krankenhausbehandlung sowie dem Patientenverhalten diskutiert . Material und Methoden : Studienbevoelkerung sind die 25-74jaehrigen Einwohner der Stadt Augsburg und der Landkreise Augsburg und Aichach-Friedberg . Datenquellen fuer die 5.712 PHT ( innerhalb von 24 Stunden verstorben ) waren die Todesbescheinigungen der 3 regionalen Gesundheitsaemter und die Frageboegen der zuletzt behandelnden und/oder Leichenschauaerzte ; die Daten der 4.976 MI-Patienten aus 17 regionalen Krankenhaeusern basieren auf einem standardisierten Interview und der Krankenaktenauswertung . Instructions: please typing these entity words according to sentence: Herzinfarktregisters, Trends, Herzinfarktmorbiditaet, Herztodesfaelle, Krankenhausbehandlung, Patientenverhalten, Methoden, Studienbevoelkerung, Stadt, Todesbescheinigungen, Leichenschauaerzte, Krankenhaeusern, Interview, Krankenaktenauswertung Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

Zusammenfassung Zielstellung : Auf der Grundlage des bevoelkerungsbasierten MONICA-Augsburg Herzinfarktregisters 1985-1995 werden Haeufigkeit und Trends der Herzinfarktmorbiditaet inkl. der ploetzlichen Herztodesfaelle ( PHT ) vorgestellt und im Zusammenhang mit der praehospitalen und Krankenhausbehandlung sowie dem Patientenverhalten diskutiert . Material und Methoden : Studienbevoelkerung sind die 25-74jaehrigen Einwohner der Stadt Augsburg und der Landkreise Augsburg und Aichach-Friedberg . Datenquellen fuer die 5.712 PHT ( innerhalb von 24 Stunden verstorben ) waren die Todesbescheinigungen der 3 regionalen Gesundheitsaemter und die Frageboegen der zuletzt behandelnden und/oder Leichenschauaerzte ; die Daten der 4.976 MI-Patienten aus 17 regionalen Krankenhaeusern basieren auf einem standardisierten Interview und der Krankenaktenauswertung .

[ "Zusammenfassung", "Zielstellung", ":", "Auf", "der", "Grundlage", "des", "bevoelkerungsbasierten", "MONICA", "-", "Augsburg", "Herzinfarktregisters", "1985", "-", "1995", "werden", "Haeufigkeit", "und", "Trends", "der", "Herzinfarktmorbiditaet", "inkl", ".", "der", "ploetzlichen", "Herztodesfaelle", "(", "PHT", ")", "vorgestellt", "und", "im", "Zusammenhang", "mit", "der", "praehospitalen", "und", "Krankenhausbehandlung", "sowie", "dem", "Patientenverhalten", "diskutiert", ".", "Material", "und", "Methoden", ":", "Studienbevoelkerung", "sind", "die", "25", "-", "74jaehrigen", "Einwohner", "der", "Stadt", "Augsburg", "und", "der", "Landkreise", "Augsburg", "und", "Aichach", "-", "Friedberg", ".", "Datenquellen", "fuer", "die", "5.712", "PHT", "(", "innerhalb", "von", "24", "Stunden", "verstorben", ")", "waren", "die", "Todesbescheinigungen", "der", "3", "regionalen", "Gesundheitsaemter", "und", "die", "Frageboegen", "der", "zuletzt", "behandelnden", "und", "/", "oder", "Leichenschauaerzte", ";", "die", "Daten", "der", "4.976", "MI", "-", "Patienten", "aus", "17", "regionalen", "Krankenhaeusern", "basieren", "auf", "einem", "standardisierten", "Interview", "und", "der", "Krankenaktenauswertung", "." ]

[ "umlsterm" ]

Herzinfarktregisters, Trends, Herzinfarktmorbiditaet, Herztodesfaelle, Krankenhausbehandlung, Patientenverhalten, Methoden, Studienbevoelkerung, Stadt, Todesbescheinigungen, Leichenschauaerzte, Krankenhaeusern, Interview, Krankenaktenauswertung

IntensiveMedizin.90360652.ger.abstr_task2

Sentence: Zusammenfassung Zielstellung : Auf der Grundlage des bevoelkerungsbasierten MONICA-Augsburg Herzinfarktregisters 1985-1995 werden Haeufigkeit und Trends der Herzinfarktmorbiditaet inkl. der ploetzlichen Herztodesfaelle ( PHT ) vorgestellt und im Zusammenhang mit der praehospitalen und Krankenhausbehandlung sowie dem Patientenverhalten diskutiert . Material und Methoden : Studienbevoelkerung sind die 25-74jaehrigen Einwohner der Stadt Augsburg und der Landkreise Augsburg und Aichach-Friedberg . Datenquellen fuer die 5.712 PHT ( innerhalb von 24 Stunden verstorben ) waren die Todesbescheinigungen der 3 regionalen Gesundheitsaemter und die Frageboegen der zuletzt behandelnden und/oder Leichenschauaerzte ; die Daten der 4.976 MI-Patienten aus 17 regionalen Krankenhaeusern basieren auf einem standardisierten Interview und der Krankenaktenauswertung . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

Zusammenfassung Zielstellung : Auf der Grundlage des bevoelkerungsbasierten MONICA-Augsburg Herzinfarktregisters 1985-1995 werden Haeufigkeit und Trends der Herzinfarktmorbiditaet inkl. der ploetzlichen Herztodesfaelle ( PHT ) vorgestellt und im Zusammenhang mit der praehospitalen und Krankenhausbehandlung sowie dem Patientenverhalten diskutiert . Material und Methoden : Studienbevoelkerung sind die 25-74jaehrigen Einwohner der Stadt Augsburg und der Landkreise Augsburg und Aichach-Friedberg . Datenquellen fuer die 5.712 PHT ( innerhalb von 24 Stunden verstorben ) waren die Todesbescheinigungen der 3 regionalen Gesundheitsaemter und die Frageboegen der zuletzt behandelnden und/oder Leichenschauaerzte ; die Daten der 4.976 MI-Patienten aus 17 regionalen Krankenhaeusern basieren auf einem standardisierten Interview und der Krankenaktenauswertung .

[ "Zusammenfassung", "Zielstellung", ":", "Auf", "der", "Grundlage", "des", "bevoelkerungsbasierten", "MONICA", "-", "Augsburg", "Herzinfarktregisters", "1985", "-", "1995", "werden", "Haeufigkeit", "und", "Trends", "der", "Herzinfarktmorbiditaet", "inkl", ".", "der", "ploetzlichen", "Herztodesfaelle", "(", "PHT", ")", "vorgestellt", "und", "im", "Zusammenhang", "mit", "der", "praehospitalen", "und", "Krankenhausbehandlung", "sowie", "dem", "Patientenverhalten", "diskutiert", ".", "Material", "und", "Methoden", ":", "Studienbevoelkerung", "sind", "die", "25", "-", "74jaehrigen", "Einwohner", "der", "Stadt", "Augsburg", "und", "der", "Landkreise", "Augsburg", "und", "Aichach", "-", "Friedberg", ".", "Datenquellen", "fuer", "die", "5.712", "PHT", "(", "innerhalb", "von", "24", "Stunden", "verstorben", ")", "waren", "die", "Todesbescheinigungen", "der", "3", "regionalen", "Gesundheitsaemter", "und", "die", "Frageboegen", "der", "zuletzt", "behandelnden", "und", "/", "oder", "Leichenschauaerzte", ";", "die", "Daten", "der", "4.976", "MI", "-", "Patienten", "aus", "17", "regionalen", "Krankenhaeusern", "basieren", "auf", "einem", "standardisierten", "Interview", "und", "der", "Krankenaktenauswertung", "." ]

[ "umlsterm" ]

Patienten is an umlsterm

DerOpthalmologe.90960092.ger.abstr_task0

Sentence: Fragestellung : Auch unter Kortikosteroidtherapie koennen persistierende Nummuli nach Keratoconjunctivitis epidemica ( KE ) auftreten . Sie fuehren zu Visusminderung und erhoehter Blendungsempfindlichkeit der Patienten . Durch eine phototherapeutische Keratektomie ( PTK ) versuchten wird , therapierefraktaere Nummuli zu entfernen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fragestellung : Auch unter Kortikosteroidtherapie koennen persistierende Nummuli nach Keratoconjunctivitis epidemica ( KE ) auftreten . Sie fuehren zu Visusminderung und erhoehter Blendungsempfindlichkeit der Patienten . Durch eine phototherapeutische Keratektomie ( PTK ) versuchten wird , therapierefraktaere Nummuli zu entfernen .

[ "Fragestellung", ":", "Auch", "unter", "Kortikosteroidtherapie", "koennen", "persistierende", "Nummuli", "nach", "Keratoconjunctivitis", "epidemica", "(", "KE", ")", "auftreten", ".", "Sie", "fuehren", "zu", "Visusminderung", "und", "erhoehter", "Blendungsempfindlichkeit", "der", "Patienten", ".", "Durch", "eine", "phototherapeutische", "Keratektomie", "(", "PTK", ")", "versuchten", "wird", ",", "therapierefraktaere", "Nummuli", "zu", "entfernen", "." ]

[ "umlsterm" ]

Patienten is an umlsterm

DerOpthalmologe.90960092.ger.abstr_task1

Sentence: Fragestellung : Auch unter Kortikosteroidtherapie koennen persistierende Nummuli nach Keratoconjunctivitis epidemica ( KE ) auftreten . Sie fuehren zu Visusminderung und erhoehter Blendungsempfindlichkeit der Patienten . Durch eine phototherapeutische Keratektomie ( PTK ) versuchten wird , therapierefraktaere Nummuli zu entfernen . Instructions: please typing these entity words according to sentence: Patienten Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fragestellung : Auch unter Kortikosteroidtherapie koennen persistierende Nummuli nach Keratoconjunctivitis epidemica ( KE ) auftreten . Sie fuehren zu Visusminderung und erhoehter Blendungsempfindlichkeit der Patienten . Durch eine phototherapeutische Keratektomie ( PTK ) versuchten wird , therapierefraktaere Nummuli zu entfernen .

[ "Fragestellung", ":", "Auch", "unter", "Kortikosteroidtherapie", "koennen", "persistierende", "Nummuli", "nach", "Keratoconjunctivitis", "epidemica", "(", "KE", ")", "auftreten", ".", "Sie", "fuehren", "zu", "Visusminderung", "und", "erhoehter", "Blendungsempfindlichkeit", "der", "Patienten", ".", "Durch", "eine", "phototherapeutische", "Keratektomie", "(", "PTK", ")", "versuchten", "wird", ",", "therapierefraktaere", "Nummuli", "zu", "entfernen", "." ]

[ "umlsterm" ]

Patienten

DerOpthalmologe.90960092.ger.abstr_task2

Sentence: Fragestellung : Auch unter Kortikosteroidtherapie koennen persistierende Nummuli nach Keratoconjunctivitis epidemica ( KE ) auftreten . Sie fuehren zu Visusminderung und erhoehter Blendungsempfindlichkeit der Patienten . Durch eine phototherapeutische Keratektomie ( PTK ) versuchten wird , therapierefraktaere Nummuli zu entfernen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fragestellung : Auch unter Kortikosteroidtherapie koennen persistierende Nummuli nach Keratoconjunctivitis epidemica ( KE ) auftreten . Sie fuehren zu Visusminderung und erhoehter Blendungsempfindlichkeit der Patienten . Durch eine phototherapeutische Keratektomie ( PTK ) versuchten wird , therapierefraktaere Nummuli zu entfernen .

[ "Fragestellung", ":", "Auch", "unter", "Kortikosteroidtherapie", "koennen", "persistierende", "Nummuli", "nach", "Keratoconjunctivitis", "epidemica", "(", "KE", ")", "auftreten", ".", "Sie", "fuehren", "zu", "Visusminderung", "und", "erhoehter", "Blendungsempfindlichkeit", "der", "Patienten", ".", "Durch", "eine", "phototherapeutische", "Keratektomie", "(", "PTK", ")", "versuchten", "wird", ",", "therapierefraktaere", "Nummuli", "zu", "entfernen", "." ]

[ "umlsterm" ]

diagnosis is an umlsterm, line is an umlsterm, therapy is an umlsterm, chest pain is an umlsterm, general practitioners is an umlsterm, emergency is an umlsterm, physicians is an umlsterm, myocardial infarction is an umlsterm, syndromes is an umlsterm, patients is an umlsterm, chest pain is an umlsterm, line is an umlsterm, therapy is an umlsterm, understanding is an umlsterm, pathophysiology is an umlsterm, myocardial ischemia is an umlsterm, symptoms is an umlsterm, diagnostic is an umlsterm, therapeutic is an umlsterm, Time is an umlsterm, myocardial ischemia is an umlsterm, infarction is an umlsterm, injury is an umlsterm, cells is an umlsterm, myocardial ischemia is an umlsterm, infarction is an umlsterm, patients dying is an umlsterm, ischemia is an umlsterm, effort is an umlsterm, symptom is an umlsterm, reperfusion therapy is an umlsterm, diagnosis is an umlsterm, line is an umlsterm, therapy is an umlsterm, myocardial infarction is an umlsterm, aim is an umlsterm, transport is an umlsterm, time is an umlsterm, hospital is an umlsterm, therapies is an umlsterm, PTCA is an umlsterm

IntensiveMedizin.90360727.eng.abstr_task0

Sentence: Prehospital diagnosis and first line therapy of acute chest pain are among the most frequently encountered challenges for general practitioners and emergency physicians . Acute myocardial infarction or acute coronary syndromes in general are present in about a third of patients complaining of acute chest pain . The basis of first line therapy is the understanding of the pathophysiology of myocardial ischemia , the clinical symptoms , the diagnostic tools and the preclinically available therapeutic options . Time is the most critical factor in myocardial ischemia and subsequent infarction with irreversible injury of subendocardial cells starting within 30-60 minutes of total myocardial ischemia and with transmural infarction becoming complete in 3 to 6 hours . With 30% of patients dying within the first hour of ischemia mostly due to ventricular arrhyhtmias every effort needs to be made to shorten the delay between symptom onset and start of reperfusion therapy . The present overview concentrates on the armamentarium of preclincial diagnosis and the options of first line therapy of myocardial infarction with the aim of a short transport time to the hospital and therefore a short delay to more specific therapies like thrombolysis or PTCA . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]

Prehospital diagnosis and first line therapy of acute chest pain are among the most frequently encountered challenges for general practitioners and emergency physicians . Acute myocardial infarction or acute coronary syndromes in general are present in about a third of patients complaining of acute chest pain . The basis of first line therapy is the understanding of the pathophysiology of myocardial ischemia , the clinical symptoms , the diagnostic tools and the preclinically available therapeutic options . Time is the most critical factor in myocardial ischemia and subsequent infarction with irreversible injury of subendocardial cells starting within 30-60 minutes of total myocardial ischemia and with transmural infarction becoming complete in 3 to 6 hours . With 30% of patients dying within the first hour of ischemia mostly due to ventricular arrhyhtmias every effort needs to be made to shorten the delay between symptom onset and start of reperfusion therapy . The present overview concentrates on the armamentarium of preclincial diagnosis and the options of first line therapy of myocardial infarction with the aim of a short transport time to the hospital and therefore a short delay to more specific therapies like thrombolysis or PTCA .

[ "Prehospital", "diagnosis", "and", "first", "line", "therapy", "of", "acute", "chest", "pain", "are", "among", "the", "most", "frequently", "encountered", "challenges", "for", "general", "practitioners", "and", "emergency", "physicians", ".", "Acute", "myocardial", "infarction", "or", "acute", "coronary", "syndromes", "in", "general", "are", "present", "in", "about", "a", "third", "of", "patients", "complaining", "of", "acute", "chest", "pain", ".", "The", "basis", "of", "first", "line", "therapy", "is", "the", "understanding", "of", "the", "pathophysiology", "of", "myocardial", "ischemia", ",", "the", "clinical", "symptoms", ",", "the", "diagnostic", "tools", "and", "the", "preclinically", "available", "therapeutic", "options", ".", "Time", "is", "the", "most", "critical", "factor", "in", "myocardial", "ischemia", "and", "subsequent", "infarction", "with", "irreversible", "injury", "of", "subendocardial", "cells", "starting", "within", "30", "-", "60", "minutes", "of", "total", "myocardial", "ischemia", "and", "with", "transmural", "infarction", "becoming", "complete", "in", "3", "to", "6", "hours", ".", "With", "30", "%", "of", "patients", "dying", "within", "the", "first", "hour", "of", "ischemia", "mostly", "due", "to", "ventricular", "arrhyhtmias", "every", "effort", "needs", "to", "be", "made", "to", "shorten", "the", "delay", "between", "symptom", "onset", "and", "start", "of", "reperfusion", "therapy", ".", "The", "present", "overview", "concentrates", "on", "the", "armamentarium", "of", "preclincial", "diagnosis", "and", "the", "options", "of", "first", "line", "therapy", "of", "myocardial", "infarction", "with", "the", "aim", "of", "a", "short", "transport", "time", "to", "the", "hospital", "and", "therefore", "a", "short", "delay", "to", "more", "specific", "therapies", "like", "thrombolysis", "or", "PTCA", "." ]

[ "umlsterm" ]

diagnosis is an umlsterm, line is an umlsterm, therapy is an umlsterm, chest pain is an umlsterm, general practitioners is an umlsterm, emergency is an umlsterm, physicians is an umlsterm, myocardial infarction is an umlsterm, syndromes is an umlsterm, patients is an umlsterm, chest pain is an umlsterm, line is an umlsterm, therapy is an umlsterm, understanding is an umlsterm, pathophysiology is an umlsterm, myocardial ischemia is an umlsterm, symptoms is an umlsterm, diagnostic is an umlsterm, therapeutic is an umlsterm, Time is an umlsterm, myocardial ischemia is an umlsterm, infarction is an umlsterm, injury is an umlsterm, cells is an umlsterm, myocardial ischemia is an umlsterm, infarction is an umlsterm, patients dying is an umlsterm, ischemia is an umlsterm, effort is an umlsterm, symptom is an umlsterm, reperfusion therapy is an umlsterm, diagnosis is an umlsterm, line is an umlsterm, therapy is an umlsterm, myocardial infarction is an umlsterm, aim is an umlsterm, transport is an umlsterm, time is an umlsterm, hospital is an umlsterm, therapies is an umlsterm, PTCA is an umlsterm

IntensiveMedizin.90360727.eng.abstr_task1

Sentence: Prehospital diagnosis and first line therapy of acute chest pain are among the most frequently encountered challenges for general practitioners and emergency physicians . Acute myocardial infarction or acute coronary syndromes in general are present in about a third of patients complaining of acute chest pain . The basis of first line therapy is the understanding of the pathophysiology of myocardial ischemia , the clinical symptoms , the diagnostic tools and the preclinically available therapeutic options . Time is the most critical factor in myocardial ischemia and subsequent infarction with irreversible injury of subendocardial cells starting within 30-60 minutes of total myocardial ischemia and with transmural infarction becoming complete in 3 to 6 hours . With 30% of patients dying within the first hour of ischemia mostly due to ventricular arrhyhtmias every effort needs to be made to shorten the delay between symptom onset and start of reperfusion therapy . The present overview concentrates on the armamentarium of preclincial diagnosis and the options of first line therapy of myocardial infarction with the aim of a short transport time to the hospital and therefore a short delay to more specific therapies like thrombolysis or PTCA . Instructions: please typing these entity words according to sentence: diagnosis, line, therapy, chest pain, general practitioners, emergency, physicians, myocardial infarction, syndromes, patients, chest pain, line, therapy, understanding, pathophysiology, myocardial ischemia, symptoms, diagnostic, therapeutic, Time, myocardial ischemia, infarction, injury, cells, myocardial ischemia, infarction, patients dying, ischemia, effort, symptom, reperfusion therapy, diagnosis, line, therapy, myocardial infarction, aim, transport, time, hospital, therapies, PTCA Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]

Prehospital diagnosis and first line therapy of acute chest pain are among the most frequently encountered challenges for general practitioners and emergency physicians . Acute myocardial infarction or acute coronary syndromes in general are present in about a third of patients complaining of acute chest pain . The basis of first line therapy is the understanding of the pathophysiology of myocardial ischemia , the clinical symptoms , the diagnostic tools and the preclinically available therapeutic options . Time is the most critical factor in myocardial ischemia and subsequent infarction with irreversible injury of subendocardial cells starting within 30-60 minutes of total myocardial ischemia and with transmural infarction becoming complete in 3 to 6 hours . With 30% of patients dying within the first hour of ischemia mostly due to ventricular arrhyhtmias every effort needs to be made to shorten the delay between symptom onset and start of reperfusion therapy . The present overview concentrates on the armamentarium of preclincial diagnosis and the options of first line therapy of myocardial infarction with the aim of a short transport time to the hospital and therefore a short delay to more specific therapies like thrombolysis or PTCA .

[ "Prehospital", "diagnosis", "and", "first", "line", "therapy", "of", "acute", "chest", "pain", "are", "among", "the", "most", "frequently", "encountered", "challenges", "for", "general", "practitioners", "and", "emergency", "physicians", ".", "Acute", "myocardial", "infarction", "or", "acute", "coronary", "syndromes", "in", "general", "are", "present", "in", "about", "a", "third", "of", "patients", "complaining", "of", "acute", "chest", "pain", ".", "The", "basis", "of", "first", "line", "therapy", "is", "the", "understanding", "of", "the", "pathophysiology", "of", "myocardial", "ischemia", ",", "the", "clinical", "symptoms", ",", "the", "diagnostic", "tools", "and", "the", "preclinically", "available", "therapeutic", "options", ".", "Time", "is", "the", "most", "critical", "factor", "in", "myocardial", "ischemia", "and", "subsequent", "infarction", "with", "irreversible", "injury", "of", "subendocardial", "cells", "starting", "within", "30", "-", "60", "minutes", "of", "total", "myocardial", "ischemia", "and", "with", "transmural", "infarction", "becoming", "complete", "in", "3", "to", "6", "hours", ".", "With", "30", "%", "of", "patients", "dying", "within", "the", "first", "hour", "of", "ischemia", "mostly", "due", "to", "ventricular", "arrhyhtmias", "every", "effort", "needs", "to", "be", "made", "to", "shorten", "the", "delay", "between", "symptom", "onset", "and", "start", "of", "reperfusion", "therapy", ".", "The", "present", "overview", "concentrates", "on", "the", "armamentarium", "of", "preclincial", "diagnosis", "and", "the", "options", "of", "first", "line", "therapy", "of", "myocardial", "infarction", "with", "the", "aim", "of", "a", "short", "transport", "time", "to", "the", "hospital", "and", "therefore", "a", "short", "delay", "to", "more", "specific", "therapies", "like", "thrombolysis", "or", "PTCA", "." ]

[ "umlsterm" ]

diagnosis, line, therapy, chest pain, general practitioners, emergency, physicians, myocardial infarction, syndromes, patients, chest pain, line, therapy, understanding, pathophysiology, myocardial ischemia, symptoms, diagnostic, therapeutic, Time, myocardial ischemia, infarction, injury, cells, myocardial ischemia, infarction, patients dying, ischemia, effort, symptom, reperfusion therapy, diagnosis, line, therapy, myocardial infarction, aim, transport, time, hospital, therapies, PTCA

IntensiveMedizin.90360727.eng.abstr_task2

Sentence: Prehospital diagnosis and first line therapy of acute chest pain are among the most frequently encountered challenges for general practitioners and emergency physicians . Acute myocardial infarction or acute coronary syndromes in general are present in about a third of patients complaining of acute chest pain . The basis of first line therapy is the understanding of the pathophysiology of myocardial ischemia , the clinical symptoms , the diagnostic tools and the preclinically available therapeutic options . Time is the most critical factor in myocardial ischemia and subsequent infarction with irreversible injury of subendocardial cells starting within 30-60 minutes of total myocardial ischemia and with transmural infarction becoming complete in 3 to 6 hours . With 30% of patients dying within the first hour of ischemia mostly due to ventricular arrhyhtmias every effort needs to be made to shorten the delay between symptom onset and start of reperfusion therapy . The present overview concentrates on the armamentarium of preclincial diagnosis and the options of first line therapy of myocardial infarction with the aim of a short transport time to the hospital and therefore a short delay to more specific therapies like thrombolysis or PTCA . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]

Prehospital diagnosis and first line therapy of acute chest pain are among the most frequently encountered challenges for general practitioners and emergency physicians . Acute myocardial infarction or acute coronary syndromes in general are present in about a third of patients complaining of acute chest pain . The basis of first line therapy is the understanding of the pathophysiology of myocardial ischemia , the clinical symptoms , the diagnostic tools and the preclinically available therapeutic options . Time is the most critical factor in myocardial ischemia and subsequent infarction with irreversible injury of subendocardial cells starting within 30-60 minutes of total myocardial ischemia and with transmural infarction becoming complete in 3 to 6 hours . With 30% of patients dying within the first hour of ischemia mostly due to ventricular arrhyhtmias every effort needs to be made to shorten the delay between symptom onset and start of reperfusion therapy . The present overview concentrates on the armamentarium of preclincial diagnosis and the options of first line therapy of myocardial infarction with the aim of a short transport time to the hospital and therefore a short delay to more specific therapies like thrombolysis or PTCA .

[ "Prehospital", "diagnosis", "and", "first", "line", "therapy", "of", "acute", "chest", "pain", "are", "among", "the", "most", "frequently", "encountered", "challenges", "for", "general", "practitioners", "and", "emergency", "physicians", ".", "Acute", "myocardial", "infarction", "or", "acute", "coronary", "syndromes", "in", "general", "are", "present", "in", "about", "a", "third", "of", "patients", "complaining", "of", "acute", "chest", "pain", ".", "The", "basis", "of", "first", "line", "therapy", "is", "the", "understanding", "of", "the", "pathophysiology", "of", "myocardial", "ischemia", ",", "the", "clinical", "symptoms", ",", "the", "diagnostic", "tools", "and", "the", "preclinically", "available", "therapeutic", "options", ".", "Time", "is", "the", "most", "critical", "factor", "in", "myocardial", "ischemia", "and", "subsequent", "infarction", "with", "irreversible", "injury", "of", "subendocardial", "cells", "starting", "within", "30", "-", "60", "minutes", "of", "total", "myocardial", "ischemia", "and", "with", "transmural", "infarction", "becoming", "complete", "in", "3", "to", "6", "hours", ".", "With", "30", "%", "of", "patients", "dying", "within", "the", "first", "hour", "of", "ischemia", "mostly", "due", "to", "ventricular", "arrhyhtmias", "every", "effort", "needs", "to", "be", "made", "to", "shorten", "the", "delay", "between", "symptom", "onset", "and", "start", "of", "reperfusion", "therapy", ".", "The", "present", "overview", "concentrates", "on", "the", "armamentarium", "of", "preclincial", "diagnosis", "and", "the", "options", "of", "first", "line", "therapy", "of", "myocardial", "infarction", "with", "the", "aim", "of", "a", "short", "transport", "time", "to", "the", "hospital", "and", "therefore", "a", "short", "delay", "to", "more", "specific", "therapies", "like", "thrombolysis", "or", "PTCA", "." ]

[ "umlsterm" ]

Elf-1 is a Protein, retinoblastoma protein is a Protein, retinoblastoma is a Protein, Rb is a Protein, Elf-1 is a Protein, Elf-1 is a Protein, Rb is a Protein, Rb is a Protein, Elf-1 is a Protein, Rb is a Protein, Rb is a Protein, Elf-1 is a Protein, Rb is a Protein, Rb is a Protein, Elf-1 is a Protein, Rb is a Protein, Rb is a Protein

8493578_task0

Sentence: Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein. The retinoblastoma gene product (Rb) is a nuclear phosphoprotein that regulates cell cycle progression. Elf-1 is a lymphoid-specific Ets transcription factor that regulates inducible gene expression during T cell activation. In this report, it is demonstrated that Elf-1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo. Elf-1 binds exclusively to the underphosphorylated form of Rb and fails to bind to Rb mutants derived from patients with retinoblastoma. Co-immunoprecipitation experiments demonstrated an association between Elf-1 and Rb in resting normal human T cells. After T cell activation, the phosphorylation of Rb results in the release of Elf-1, which is correlated temporally with the activation of Elf-1-mediated transcription. Overexpression of a phosphorylation-defective form of Rb inhibited Elf-1-dependent transcription during T cell activation. These results demonstrate that Rb interacts specifically with a lineage-restricted Ets transcription factor. This regulated interaction may be important for the coordination of lineage-specific effector functions such as lymphokine production with cell cycle progression in activated T cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein. The retinoblastoma gene product (Rb) is a nuclear phosphoprotein that regulates cell cycle progression. Elf-1 is a lymphoid-specific Ets transcription factor that regulates inducible gene expression during T cell activation. In this report, it is demonstrated that Elf-1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo. Elf-1 binds exclusively to the underphosphorylated form of Rb and fails to bind to Rb mutants derived from patients with retinoblastoma. Co-immunoprecipitation experiments demonstrated an association between Elf-1 and Rb in resting normal human T cells. After T cell activation, the phosphorylation of Rb results in the release of Elf-1, which is correlated temporally with the activation of Elf-1-mediated transcription. Overexpression of a phosphorylation-defective form of Rb inhibited Elf-1-dependent transcription during T cell activation. These results demonstrate that Rb interacts specifically with a lineage-restricted Ets transcription factor. This regulated interaction may be important for the coordination of lineage-specific effector functions such as lymphokine production with cell cycle progression in activated T cells.

[ "Regulation", "of", "the", "Ets", "-", "related", "transcription", "factor", "Elf-1", "by", "binding", "to", "the", "retinoblastoma", "protein", ".", "\n", "The", "retinoblastoma", "gene", "product", "(", "Rb", ")", "is", "a", "nuclear", "phosphoprotein", "that", "regulates", "cell", "cycle", "progression", ".", "Elf-1", "is", "a", "lymphoid", "-", "specific", "Ets", "transcription", "factor", "that", "regulates", "inducible", "gene", "expression", "during", "T", "cell", "activation", ".", "In", "this", "report", ",", "it", "is", "demonstrated", "that", "Elf-1", "contains", "a", "sequence", "motif", "that", "is", "highly", "related", "to", "the", "Rb", "binding", "sites", "of", "several", "viral", "oncoproteins", "and", "binds", "to", "the", "pocket", "region", "of", "Rb", "both", "in", "vitro", "and", "in", "vivo", ".", "Elf-1", "binds", "exclusively", "to", "the", "underphosphorylated", "form", "of", "Rb", "and", "fails", "to", "bind", "to", "Rb", "mutants", "derived", "from", "patients", "with", "retinoblastoma", ".", "Co", "-", "immunoprecipitation", "experiments", "demonstrated", "an", "association", "between", "Elf-1", "and", "Rb", "in", "resting", "normal", "human", "T", "cells", ".", "After", "T", "cell", "activation", ",", "the", "phosphorylation", "of", "Rb", "results", "in", "the", "release", "of", "Elf-1", ",", "which", "is", "correlated", "temporally", "with", "the", "activation", "of", "Elf-1-mediated", "transcription", ".", "Overexpression", "of", "a", "phosphorylation", "-", "defective", "form", "of", "Rb", "inhibited", "Elf-1-dependent", "transcription", "during", "T", "cell", "activation", ".", "These", "results", "demonstrate", "that", "Rb", "interacts", "specifically", "with", "a", "lineage", "-", "restricted", "Ets", "transcription", "factor", ".", "This", "regulated", "interaction", "may", "be", "important", "for", "the", "coordination", "of", "lineage", "-", "specific", "effector", "functions", "such", "as", "lymphokine", "production", "with", "cell", "cycle", "progression", "in", "activated", "T", "cells", "." ]

[ "Protein" ]

Elf-1 is a Protein, retinoblastoma protein is a Protein, retinoblastoma is a Protein, Rb is a Protein, Elf-1 is a Protein, Elf-1 is a Protein, Rb is a Protein, Rb is a Protein, Elf-1 is a Protein, Rb is a Protein, Rb is a Protein, Elf-1 is a Protein, Rb is a Protein, Rb is a Protein, Elf-1 is a Protein, Rb is a Protein, Rb is a Protein

8493578_task1

Sentence: Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein. The retinoblastoma gene product (Rb) is a nuclear phosphoprotein that regulates cell cycle progression. Elf-1 is a lymphoid-specific Ets transcription factor that regulates inducible gene expression during T cell activation. In this report, it is demonstrated that Elf-1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo. Elf-1 binds exclusively to the underphosphorylated form of Rb and fails to bind to Rb mutants derived from patients with retinoblastoma. Co-immunoprecipitation experiments demonstrated an association between Elf-1 and Rb in resting normal human T cells. After T cell activation, the phosphorylation of Rb results in the release of Elf-1, which is correlated temporally with the activation of Elf-1-mediated transcription. Overexpression of a phosphorylation-defective form of Rb inhibited Elf-1-dependent transcription during T cell activation. These results demonstrate that Rb interacts specifically with a lineage-restricted Ets transcription factor. This regulated interaction may be important for the coordination of lineage-specific effector functions such as lymphokine production with cell cycle progression in activated T cells. Instructions: please typing these entity words according to sentence: Elf-1, retinoblastoma protein, retinoblastoma, Rb, Elf-1, Elf-1, Rb, Rb, Elf-1, Rb, Rb, Elf-1, Rb, Rb, Elf-1, Rb, Rb Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein. The retinoblastoma gene product (Rb) is a nuclear phosphoprotein that regulates cell cycle progression. Elf-1 is a lymphoid-specific Ets transcription factor that regulates inducible gene expression during T cell activation. In this report, it is demonstrated that Elf-1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo. Elf-1 binds exclusively to the underphosphorylated form of Rb and fails to bind to Rb mutants derived from patients with retinoblastoma. Co-immunoprecipitation experiments demonstrated an association between Elf-1 and Rb in resting normal human T cells. After T cell activation, the phosphorylation of Rb results in the release of Elf-1, which is correlated temporally with the activation of Elf-1-mediated transcription. Overexpression of a phosphorylation-defective form of Rb inhibited Elf-1-dependent transcription during T cell activation. These results demonstrate that Rb interacts specifically with a lineage-restricted Ets transcription factor. This regulated interaction may be important for the coordination of lineage-specific effector functions such as lymphokine production with cell cycle progression in activated T cells.

[ "Regulation", "of", "the", "Ets", "-", "related", "transcription", "factor", "Elf-1", "by", "binding", "to", "the", "retinoblastoma", "protein", ".", "\n", "The", "retinoblastoma", "gene", "product", "(", "Rb", ")", "is", "a", "nuclear", "phosphoprotein", "that", "regulates", "cell", "cycle", "progression", ".", "Elf-1", "is", "a", "lymphoid", "-", "specific", "Ets", "transcription", "factor", "that", "regulates", "inducible", "gene", "expression", "during", "T", "cell", "activation", ".", "In", "this", "report", ",", "it", "is", "demonstrated", "that", "Elf-1", "contains", "a", "sequence", "motif", "that", "is", "highly", "related", "to", "the", "Rb", "binding", "sites", "of", "several", "viral", "oncoproteins", "and", "binds", "to", "the", "pocket", "region", "of", "Rb", "both", "in", "vitro", "and", "in", "vivo", ".", "Elf-1", "binds", "exclusively", "to", "the", "underphosphorylated", "form", "of", "Rb", "and", "fails", "to", "bind", "to", "Rb", "mutants", "derived", "from", "patients", "with", "retinoblastoma", ".", "Co", "-", "immunoprecipitation", "experiments", "demonstrated", "an", "association", "between", "Elf-1", "and", "Rb", "in", "resting", "normal", "human", "T", "cells", ".", "After", "T", "cell", "activation", ",", "the", "phosphorylation", "of", "Rb", "results", "in", "the", "release", "of", "Elf-1", ",", "which", "is", "correlated", "temporally", "with", "the", "activation", "of", "Elf-1-mediated", "transcription", ".", "Overexpression", "of", "a", "phosphorylation", "-", "defective", "form", "of", "Rb", "inhibited", "Elf-1-dependent", "transcription", "during", "T", "cell", "activation", ".", "These", "results", "demonstrate", "that", "Rb", "interacts", "specifically", "with", "a", "lineage", "-", "restricted", "Ets", "transcription", "factor", ".", "This", "regulated", "interaction", "may", "be", "important", "for", "the", "coordination", "of", "lineage", "-", "specific", "effector", "functions", "such", "as", "lymphokine", "production", "with", "cell", "cycle", "progression", "in", "activated", "T", "cells", "." ]

[ "Protein" ]

Elf-1, retinoblastoma protein, retinoblastoma, Rb, Elf-1, Elf-1, Rb, Rb, Elf-1, Rb, Rb, Elf-1, Rb, Rb, Elf-1, Rb, Rb

8493578_task2

Sentence: Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein. The retinoblastoma gene product (Rb) is a nuclear phosphoprotein that regulates cell cycle progression. Elf-1 is a lymphoid-specific Ets transcription factor that regulates inducible gene expression during T cell activation. In this report, it is demonstrated that Elf-1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo. Elf-1 binds exclusively to the underphosphorylated form of Rb and fails to bind to Rb mutants derived from patients with retinoblastoma. Co-immunoprecipitation experiments demonstrated an association between Elf-1 and Rb in resting normal human T cells. After T cell activation, the phosphorylation of Rb results in the release of Elf-1, which is correlated temporally with the activation of Elf-1-mediated transcription. Overexpression of a phosphorylation-defective form of Rb inhibited Elf-1-dependent transcription during T cell activation. These results demonstrate that Rb interacts specifically with a lineage-restricted Ets transcription factor. This regulated interaction may be important for the coordination of lineage-specific effector functions such as lymphokine production with cell cycle progression in activated T cells. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein. The retinoblastoma gene product (Rb) is a nuclear phosphoprotein that regulates cell cycle progression. Elf-1 is a lymphoid-specific Ets transcription factor that regulates inducible gene expression during T cell activation. In this report, it is demonstrated that Elf-1 contains a sequence motif that is highly related to the Rb binding sites of several viral oncoproteins and binds to the pocket region of Rb both in vitro and in vivo. Elf-1 binds exclusively to the underphosphorylated form of Rb and fails to bind to Rb mutants derived from patients with retinoblastoma. Co-immunoprecipitation experiments demonstrated an association between Elf-1 and Rb in resting normal human T cells. After T cell activation, the phosphorylation of Rb results in the release of Elf-1, which is correlated temporally with the activation of Elf-1-mediated transcription. Overexpression of a phosphorylation-defective form of Rb inhibited Elf-1-dependent transcription during T cell activation. These results demonstrate that Rb interacts specifically with a lineage-restricted Ets transcription factor. This regulated interaction may be important for the coordination of lineage-specific effector functions such as lymphokine production with cell cycle progression in activated T cells.

[ "Regulation", "of", "the", "Ets", "-", "related", "transcription", "factor", "Elf-1", "by", "binding", "to", "the", "retinoblastoma", "protein", ".", "\n", "The", "retinoblastoma", "gene", "product", "(", "Rb", ")", "is", "a", "nuclear", "phosphoprotein", "that", "regulates", "cell", "cycle", "progression", ".", "Elf-1", "is", "a", "lymphoid", "-", "specific", "Ets", "transcription", "factor", "that", "regulates", "inducible", "gene", "expression", "during", "T", "cell", "activation", ".", "In", "this", "report", ",", "it", "is", "demonstrated", "that", "Elf-1", "contains", "a", "sequence", "motif", "that", "is", "highly", "related", "to", "the", "Rb", "binding", "sites", "of", "several", "viral", "oncoproteins", "and", "binds", "to", "the", "pocket", "region", "of", "Rb", "both", "in", "vitro", "and", "in", "vivo", ".", "Elf-1", "binds", "exclusively", "to", "the", "underphosphorylated", "form", "of", "Rb", "and", "fails", "to", "bind", "to", "Rb", "mutants", "derived", "from", "patients", "with", "retinoblastoma", ".", "Co", "-", "immunoprecipitation", "experiments", "demonstrated", "an", "association", "between", "Elf-1", "and", "Rb", "in", "resting", "normal", "human", "T", "cells", ".", "After", "T", "cell", "activation", ",", "the", "phosphorylation", "of", "Rb", "results", "in", "the", "release", "of", "Elf-1", ",", "which", "is", "correlated", "temporally", "with", "the", "activation", "of", "Elf-1-mediated", "transcription", ".", "Overexpression", "of", "a", "phosphorylation", "-", "defective", "form", "of", "Rb", "inhibited", "Elf-1-dependent", "transcription", "during", "T", "cell", "activation", ".", "These", "results", "demonstrate", "that", "Rb", "interacts", "specifically", "with", "a", "lineage", "-", "restricted", "Ets", "transcription", "factor", ".", "This", "regulated", "interaction", "may", "be", "important", "for", "the", "coordination", "of", "lineage", "-", "specific", "effector", "functions", "such", "as", "lymphokine", "production", "with", "cell", "cycle", "progression", "in", "activated", "T", "cells", "." ]

[ "Protein" ]

human delta - globin gene promoter is a DNA_domain_or_region, primary adult erythroid cells is a cell_type

69735_task0

Sentence: Activation of the human delta-globin gene promoter in primary adult erythroid cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, DNA_domain_or_region

[ "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O" ]

Activation of the human delta-globin gene promoter in primary adult erythroid cells.

[ "Activation", "of", "the", "human", "delta", "-", "globin", "gene", "promoter", "in", "primary", "adult", "erythroid", "cells", "." ]

[ "DNA_domain_or_region", "cell_line", "cell_type", "protein_molecule", "polynucleotide" ]

human delta - globin gene promoter is a DNA_domain_or_region, primary adult erythroid cells is a cell_type

69735_task1

Sentence: Activation of the human delta-globin gene promoter in primary adult erythroid cells. Instructions: please typing these entity words according to sentence: human delta - globin gene promoter, primary adult erythroid cells Options: cell_type, DNA_domain_or_region

[ "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O" ]

Activation of the human delta-globin gene promoter in primary adult erythroid cells.

[ "Activation", "of", "the", "human", "delta", "-", "globin", "gene", "promoter", "in", "primary", "adult", "erythroid", "cells", "." ]

[ "DNA_domain_or_region", "cell_line", "cell_type", "protein_molecule", "polynucleotide" ]

human delta - globin gene promoter, primary adult erythroid cells

69735_task2

Sentence: Activation of the human delta-globin gene promoter in primary adult erythroid cells. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O" ]

Activation of the human delta-globin gene promoter in primary adult erythroid cells.

[ "Activation", "of", "the", "human", "delta", "-", "globin", "gene", "promoter", "in", "primary", "adult", "erythroid", "cells", "." ]

[ "DNA_domain_or_region", "cell_line", "cell_type", "protein_molecule", "polynucleotide" ]

Plattenepithelkarzinome is an umlsterm, Speicheldruesen is an umlsterm, Speicheldruesen is an umlsterm, Metastasen is an umlsterm, Haut is an umlsterm, Kopfhalsregion is an umlsterm, Plattenepithelmetaplasien is an umlsterm, Speicheldruesenkrankheiten is an umlsterm, nekrotisierende Sialometaplasie is an umlsterm, Speicheldruesentumoren is an umlsterm, Warthin - Tumor is an umlsterm, Speicheldruesen is an umlsterm, Speicheldruesen is an umlsterm, adenoide is an umlsterm, Akantholyse is an umlsterm, Karzinom is an umlsterm, Adenokarzinom is an umlsterm, Karzinom is an umlsterm, Karzinom is an umlsterm, Karzinoms is an umlsterm, schleimbildenden is an umlsterm, Becherzellen is an umlsterm, Prognose is an umlsterm, Therapie is an umlsterm

DerPathologe.80190201.ger.abstr_task0

Sentence: Primaere Plattenepithelkarzinome ( PEC ) der Speicheldruesen sind vorwiegend in den grossen Speicheldruesen lokalisiert und muessen von Metastasen extraglandulaerer PEC der Haut besonders der Kopfhalsregion abgegrenzt werden . Plattenepithelmetaplasien in nichttumoroesen Speicheldruesenkrankheiten ( z.B. nekrotisierende Sialometaplasie ) sowie in benignen oder malignen Speicheldruesentumoren ( z.B. metaplastischer Warthin-Tumor ) koennen PEC vortaeuschen . Ein weiteres differentialdiagnostisches Problem stellen Formvarianten des PEC dar , die ueberwiegend in den kleinen Speicheldruesen , dagegen fast nie in den grossen Speicheldruesen entwickelt sind . Hierzu gehoeren das seltene adenoide PEC mit pseudoglandulaeren Strukturen durch Akantholyse , das biphasische adenosquamoese Karzinom mit Differenzierung als PEC und Adenokarzinom , das basaloidsquamoese Karzinom mit biphasischem Aufbau als PEC und solides basaloides Karzinom ( analog dem soliden Typ des adenoid-zystischen Karzinoms ) und das niedrig-differenzierte Mukoepidermoidkarzinom ( Grad III ) mit biphasischem Aufbau aus undifferenzierten epidermoiden und intermediaeren Zellverbaenden sowie Einschluss kleiner Gruppen von schleimbildenden Becherzellen . Die differentialdiagnostischen Merkmale werden im Hinblick auf die Prognose und Therapie analysiert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]

Primaere Plattenepithelkarzinome ( PEC ) der Speicheldruesen sind vorwiegend in den grossen Speicheldruesen lokalisiert und muessen von Metastasen extraglandulaerer PEC der Haut besonders der Kopfhalsregion abgegrenzt werden . Plattenepithelmetaplasien in nichttumoroesen Speicheldruesenkrankheiten ( z.B. nekrotisierende Sialometaplasie ) sowie in benignen oder malignen Speicheldruesentumoren ( z.B. metaplastischer Warthin-Tumor ) koennen PEC vortaeuschen . Ein weiteres differentialdiagnostisches Problem stellen Formvarianten des PEC dar , die ueberwiegend in den kleinen Speicheldruesen , dagegen fast nie in den grossen Speicheldruesen entwickelt sind . Hierzu gehoeren das seltene adenoide PEC mit pseudoglandulaeren Strukturen durch Akantholyse , das biphasische adenosquamoese Karzinom mit Differenzierung als PEC und Adenokarzinom , das basaloidsquamoese Karzinom mit biphasischem Aufbau als PEC und solides basaloides Karzinom ( analog dem soliden Typ des adenoid-zystischen Karzinoms ) und das niedrig-differenzierte Mukoepidermoidkarzinom ( Grad III ) mit biphasischem Aufbau aus undifferenzierten epidermoiden und intermediaeren Zellverbaenden sowie Einschluss kleiner Gruppen von schleimbildenden Becherzellen . Die differentialdiagnostischen Merkmale werden im Hinblick auf die Prognose und Therapie analysiert .

[ "Primaere", "Plattenepithelkarzinome", "(", "PEC", ")", "der", "Speicheldruesen", "sind", "vorwiegend", "in", "den", "grossen", "Speicheldruesen", "lokalisiert", "und", "muessen", "von", "Metastasen", "extraglandulaerer", "PEC", "der", "Haut", "besonders", "der", "Kopfhalsregion", "abgegrenzt", "werden", ".", "Plattenepithelmetaplasien", "in", "nichttumoroesen", "Speicheldruesenkrankheiten", "(", "z.", "B.", "nekrotisierende", "Sialometaplasie", ")", "sowie", "in", "benignen", "oder", "malignen", "Speicheldruesentumoren", "(", "z.", "B.", "metaplastischer", "Warthin", "-", "Tumor", ")", "koennen", "PEC", "vortaeuschen", ".", "Ein", "weiteres", "differentialdiagnostisches", "Problem", "stellen", "Formvarianten", "des", "PEC", "dar", ",", "die", "ueberwiegend", "in", "den", "kleinen", "Speicheldruesen", ",", "dagegen", "fast", "nie", "in", "den", "grossen", "Speicheldruesen", "entwickelt", "sind", ".", "Hierzu", "gehoeren", "das", "seltene", "adenoide", "PEC", "mit", "pseudoglandulaeren", "Strukturen", "durch", "Akantholyse", ",", "das", "biphasische", "adenosquamoese", "Karzinom", "mit", "Differenzierung", "als", "PEC", "und", "Adenokarzinom", ",", "das", "basaloidsquamoese", "Karzinom", "mit", "biphasischem", "Aufbau", "als", "PEC", "und", "solides", "basaloides", "Karzinom", "(", "analog", "dem", "soliden", "Typ", "des", "adenoid", "-", "zystischen", "Karzinoms", ")", "und", "das", "niedrig", "-", "differenzierte", "Mukoepidermoidkarzinom", "(", "Grad", "III", ")", "mit", "biphasischem", "Aufbau", "aus", "undifferenzierten", "epidermoiden", "und", "intermediaeren", "Zellverbaenden", "sowie", "Einschluss", "kleiner", "Gruppen", "von", "schleimbildenden", "Becherzellen", ".", "Die", "differentialdiagnostischen", "Merkmale", "werden", "im", "Hinblick", "auf", "die", "Prognose", "und", "Therapie", "analysiert", "." ]

[ "umlsterm" ]

Plattenepithelkarzinome is an umlsterm, Speicheldruesen is an umlsterm, Speicheldruesen is an umlsterm, Metastasen is an umlsterm, Haut is an umlsterm, Kopfhalsregion is an umlsterm, Plattenepithelmetaplasien is an umlsterm, Speicheldruesenkrankheiten is an umlsterm, nekrotisierende Sialometaplasie is an umlsterm, Speicheldruesentumoren is an umlsterm, Warthin - Tumor is an umlsterm, Speicheldruesen is an umlsterm, Speicheldruesen is an umlsterm, adenoide is an umlsterm, Akantholyse is an umlsterm, Karzinom is an umlsterm, Adenokarzinom is an umlsterm, Karzinom is an umlsterm, Karzinom is an umlsterm, Karzinoms is an umlsterm, schleimbildenden is an umlsterm, Becherzellen is an umlsterm, Prognose is an umlsterm, Therapie is an umlsterm

DerPathologe.80190201.ger.abstr_task1

Sentence: Primaere Plattenepithelkarzinome ( PEC ) der Speicheldruesen sind vorwiegend in den grossen Speicheldruesen lokalisiert und muessen von Metastasen extraglandulaerer PEC der Haut besonders der Kopfhalsregion abgegrenzt werden . Plattenepithelmetaplasien in nichttumoroesen Speicheldruesenkrankheiten ( z.B. nekrotisierende Sialometaplasie ) sowie in benignen oder malignen Speicheldruesentumoren ( z.B. metaplastischer Warthin-Tumor ) koennen PEC vortaeuschen . Ein weiteres differentialdiagnostisches Problem stellen Formvarianten des PEC dar , die ueberwiegend in den kleinen Speicheldruesen , dagegen fast nie in den grossen Speicheldruesen entwickelt sind . Hierzu gehoeren das seltene adenoide PEC mit pseudoglandulaeren Strukturen durch Akantholyse , das biphasische adenosquamoese Karzinom mit Differenzierung als PEC und Adenokarzinom , das basaloidsquamoese Karzinom mit biphasischem Aufbau als PEC und solides basaloides Karzinom ( analog dem soliden Typ des adenoid-zystischen Karzinoms ) und das niedrig-differenzierte Mukoepidermoidkarzinom ( Grad III ) mit biphasischem Aufbau aus undifferenzierten epidermoiden und intermediaeren Zellverbaenden sowie Einschluss kleiner Gruppen von schleimbildenden Becherzellen . Die differentialdiagnostischen Merkmale werden im Hinblick auf die Prognose und Therapie analysiert . Instructions: please typing these entity words according to sentence: Plattenepithelkarzinome, Speicheldruesen, Speicheldruesen, Metastasen, Haut, Kopfhalsregion, Plattenepithelmetaplasien, Speicheldruesenkrankheiten, nekrotisierende Sialometaplasie, Speicheldruesentumoren, Warthin - Tumor, Speicheldruesen, Speicheldruesen, adenoide, Akantholyse, Karzinom, Adenokarzinom, Karzinom, Karzinom, Karzinoms, schleimbildenden, Becherzellen, Prognose, Therapie Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]

Primaere Plattenepithelkarzinome ( PEC ) der Speicheldruesen sind vorwiegend in den grossen Speicheldruesen lokalisiert und muessen von Metastasen extraglandulaerer PEC der Haut besonders der Kopfhalsregion abgegrenzt werden . Plattenepithelmetaplasien in nichttumoroesen Speicheldruesenkrankheiten ( z.B. nekrotisierende Sialometaplasie ) sowie in benignen oder malignen Speicheldruesentumoren ( z.B. metaplastischer Warthin-Tumor ) koennen PEC vortaeuschen . Ein weiteres differentialdiagnostisches Problem stellen Formvarianten des PEC dar , die ueberwiegend in den kleinen Speicheldruesen , dagegen fast nie in den grossen Speicheldruesen entwickelt sind . Hierzu gehoeren das seltene adenoide PEC mit pseudoglandulaeren Strukturen durch Akantholyse , das biphasische adenosquamoese Karzinom mit Differenzierung als PEC und Adenokarzinom , das basaloidsquamoese Karzinom mit biphasischem Aufbau als PEC und solides basaloides Karzinom ( analog dem soliden Typ des adenoid-zystischen Karzinoms ) und das niedrig-differenzierte Mukoepidermoidkarzinom ( Grad III ) mit biphasischem Aufbau aus undifferenzierten epidermoiden und intermediaeren Zellverbaenden sowie Einschluss kleiner Gruppen von schleimbildenden Becherzellen . Die differentialdiagnostischen Merkmale werden im Hinblick auf die Prognose und Therapie analysiert .

[ "Primaere", "Plattenepithelkarzinome", "(", "PEC", ")", "der", "Speicheldruesen", "sind", "vorwiegend", "in", "den", "grossen", "Speicheldruesen", "lokalisiert", "und", "muessen", "von", "Metastasen", "extraglandulaerer", "PEC", "der", "Haut", "besonders", "der", "Kopfhalsregion", "abgegrenzt", "werden", ".", "Plattenepithelmetaplasien", "in", "nichttumoroesen", "Speicheldruesenkrankheiten", "(", "z.", "B.", "nekrotisierende", "Sialometaplasie", ")", "sowie", "in", "benignen", "oder", "malignen", "Speicheldruesentumoren", "(", "z.", "B.", "metaplastischer", "Warthin", "-", "Tumor", ")", "koennen", "PEC", "vortaeuschen", ".", "Ein", "weiteres", "differentialdiagnostisches", "Problem", "stellen", "Formvarianten", "des", "PEC", "dar", ",", "die", "ueberwiegend", "in", "den", "kleinen", "Speicheldruesen", ",", "dagegen", "fast", "nie", "in", "den", "grossen", "Speicheldruesen", "entwickelt", "sind", ".", "Hierzu", "gehoeren", "das", "seltene", "adenoide", "PEC", "mit", "pseudoglandulaeren", "Strukturen", "durch", "Akantholyse", ",", "das", "biphasische", "adenosquamoese", "Karzinom", "mit", "Differenzierung", "als", "PEC", "und", "Adenokarzinom", ",", "das", "basaloidsquamoese", "Karzinom", "mit", "biphasischem", "Aufbau", "als", "PEC", "und", "solides", "basaloides", "Karzinom", "(", "analog", "dem", "soliden", "Typ", "des", "adenoid", "-", "zystischen", "Karzinoms", ")", "und", "das", "niedrig", "-", "differenzierte", "Mukoepidermoidkarzinom", "(", "Grad", "III", ")", "mit", "biphasischem", "Aufbau", "aus", "undifferenzierten", "epidermoiden", "und", "intermediaeren", "Zellverbaenden", "sowie", "Einschluss", "kleiner", "Gruppen", "von", "schleimbildenden", "Becherzellen", ".", "Die", "differentialdiagnostischen", "Merkmale", "werden", "im", "Hinblick", "auf", "die", "Prognose", "und", "Therapie", "analysiert", "." ]

[ "umlsterm" ]

Plattenepithelkarzinome, Speicheldruesen, Speicheldruesen, Metastasen, Haut, Kopfhalsregion, Plattenepithelmetaplasien, Speicheldruesenkrankheiten, nekrotisierende Sialometaplasie, Speicheldruesentumoren, Warthin - Tumor, Speicheldruesen, Speicheldruesen, adenoide, Akantholyse, Karzinom, Adenokarzinom, Karzinom, Karzinom, Karzinoms, schleimbildenden, Becherzellen, Prognose, Therapie

DerPathologe.80190201.ger.abstr_task2

Sentence: Primaere Plattenepithelkarzinome ( PEC ) der Speicheldruesen sind vorwiegend in den grossen Speicheldruesen lokalisiert und muessen von Metastasen extraglandulaerer PEC der Haut besonders der Kopfhalsregion abgegrenzt werden . Plattenepithelmetaplasien in nichttumoroesen Speicheldruesenkrankheiten ( z.B. nekrotisierende Sialometaplasie ) sowie in benignen oder malignen Speicheldruesentumoren ( z.B. metaplastischer Warthin-Tumor ) koennen PEC vortaeuschen . Ein weiteres differentialdiagnostisches Problem stellen Formvarianten des PEC dar , die ueberwiegend in den kleinen Speicheldruesen , dagegen fast nie in den grossen Speicheldruesen entwickelt sind . Hierzu gehoeren das seltene adenoide PEC mit pseudoglandulaeren Strukturen durch Akantholyse , das biphasische adenosquamoese Karzinom mit Differenzierung als PEC und Adenokarzinom , das basaloidsquamoese Karzinom mit biphasischem Aufbau als PEC und solides basaloides Karzinom ( analog dem soliden Typ des adenoid-zystischen Karzinoms ) und das niedrig-differenzierte Mukoepidermoidkarzinom ( Grad III ) mit biphasischem Aufbau aus undifferenzierten epidermoiden und intermediaeren Zellverbaenden sowie Einschluss kleiner Gruppen von schleimbildenden Becherzellen . Die differentialdiagnostischen Merkmale werden im Hinblick auf die Prognose und Therapie analysiert . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]

Primaere Plattenepithelkarzinome ( PEC ) der Speicheldruesen sind vorwiegend in den grossen Speicheldruesen lokalisiert und muessen von Metastasen extraglandulaerer PEC der Haut besonders der Kopfhalsregion abgegrenzt werden . Plattenepithelmetaplasien in nichttumoroesen Speicheldruesenkrankheiten ( z.B. nekrotisierende Sialometaplasie ) sowie in benignen oder malignen Speicheldruesentumoren ( z.B. metaplastischer Warthin-Tumor ) koennen PEC vortaeuschen . Ein weiteres differentialdiagnostisches Problem stellen Formvarianten des PEC dar , die ueberwiegend in den kleinen Speicheldruesen , dagegen fast nie in den grossen Speicheldruesen entwickelt sind . Hierzu gehoeren das seltene adenoide PEC mit pseudoglandulaeren Strukturen durch Akantholyse , das biphasische adenosquamoese Karzinom mit Differenzierung als PEC und Adenokarzinom , das basaloidsquamoese Karzinom mit biphasischem Aufbau als PEC und solides basaloides Karzinom ( analog dem soliden Typ des adenoid-zystischen Karzinoms ) und das niedrig-differenzierte Mukoepidermoidkarzinom ( Grad III ) mit biphasischem Aufbau aus undifferenzierten epidermoiden und intermediaeren Zellverbaenden sowie Einschluss kleiner Gruppen von schleimbildenden Becherzellen . Die differentialdiagnostischen Merkmale werden im Hinblick auf die Prognose und Therapie analysiert .

[ "Primaere", "Plattenepithelkarzinome", "(", "PEC", ")", "der", "Speicheldruesen", "sind", "vorwiegend", "in", "den", "grossen", "Speicheldruesen", "lokalisiert", "und", "muessen", "von", "Metastasen", "extraglandulaerer", "PEC", "der", "Haut", "besonders", "der", "Kopfhalsregion", "abgegrenzt", "werden", ".", "Plattenepithelmetaplasien", "in", "nichttumoroesen", "Speicheldruesenkrankheiten", "(", "z.", "B.", "nekrotisierende", "Sialometaplasie", ")", "sowie", "in", "benignen", "oder", "malignen", "Speicheldruesentumoren", "(", "z.", "B.", "metaplastischer", "Warthin", "-", "Tumor", ")", "koennen", "PEC", "vortaeuschen", ".", "Ein", "weiteres", "differentialdiagnostisches", "Problem", "stellen", "Formvarianten", "des", "PEC", "dar", ",", "die", "ueberwiegend", "in", "den", "kleinen", "Speicheldruesen", ",", "dagegen", "fast", "nie", "in", "den", "grossen", "Speicheldruesen", "entwickelt", "sind", ".", "Hierzu", "gehoeren", "das", "seltene", "adenoide", "PEC", "mit", "pseudoglandulaeren", "Strukturen", "durch", "Akantholyse", ",", "das", "biphasische", "adenosquamoese", "Karzinom", "mit", "Differenzierung", "als", "PEC", "und", "Adenokarzinom", ",", "das", "basaloidsquamoese", "Karzinom", "mit", "biphasischem", "Aufbau", "als", "PEC", "und", "solides", "basaloides", "Karzinom", "(", "analog", "dem", "soliden", "Typ", "des", "adenoid", "-", "zystischen", "Karzinoms", ")", "und", "das", "niedrig", "-", "differenzierte", "Mukoepidermoidkarzinom", "(", "Grad", "III", ")", "mit", "biphasischem", "Aufbau", "aus", "undifferenzierten", "epidermoiden", "und", "intermediaeren", "Zellverbaenden", "sowie", "Einschluss", "kleiner", "Gruppen", "von", "schleimbildenden", "Becherzellen", ".", "Die", "differentialdiagnostischen", "Merkmale", "werden", "im", "Hinblick", "auf", "die", "Prognose", "und", "Therapie", "analysiert", "." ]

[ "umlsterm" ]

PSEN1 is a Gene, PSEN2 is a Gene, BRCA1 is a Gene, BRCA2 is a Gene, DM1 is a Gene, HD is a Gene, EED is a Gene, CTNNA2 is a Gene, CALM1 is a Gene, CDH13 is a Gene, STMN2 is a Gene, CDH13 is a Gene

39_task0

Sentence: Intra- and interindividual epigenetic variation in human germ cells. Epigenetics represents a secondary inheritance system that has been poorly investigated in human biology. The objective of this study was to perform a comprehensive analysis of DNA methylation variation between and within the germlines of normal males. First, methylated cytosines were mapped using bisulphite modification-based sequencing in the promoter regions of the following disease genes: presenilins (PSEN1 and PSEN2), breast cancer (BRCA1 and BRCA2), myotonic dystrophy (DM1), and Huntington disease (HD). Major epigenetic variation was detected within samples, since the majority of sperm cells of the same individual exhibited unique DNA methylation profiles. In the interindividual analysis, 41 of 61 pairwise comparisons revealed distinct DNA methylation profiles (P=.036 to 6.8 x 10(-14)). Second, a microarray-based epigenetic profiling of the same sperm samples was performed using a 12,198-feature CpG island microarray. The microarray analysis has identified numerous DNA methylation-variable positions in the germ cell genome. The largest degree of variation was detected within the promoter CpG islands and pericentromeric satellites among the single-copy DNA fragments and repetitive elements, respectively. A number of genes, such as EED, CTNNA2, CALM1, CDH13, and STMN2, exhibited age-related DNA methylation changes. Finally, allele-specific methylation patterns in CDH13 were detected. This study provides evidence for significant epigenetic variability in human germ cells, which warrants further research to determine whether such epigenetic patterns can be efficiently transmitted across generations and what impact inherited epigenetic individuality may have on phenotypic outcomes in health and disease. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "B-Gene", "O", "B-Gene", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Intra- and interindividual epigenetic variation in human germ cells. Epigenetics represents a secondary inheritance system that has been poorly investigated in human biology. The objective of this study was to perform a comprehensive analysis of DNA methylation variation between and within the germlines of normal males. First, methylated cytosines were mapped using bisulphite modification-based sequencing in the promoter regions of the following disease genes: presenilins (PSEN1 and PSEN2), breast cancer (BRCA1 and BRCA2), myotonic dystrophy (DM1), and Huntington disease (HD). Major epigenetic variation was detected within samples, since the majority of sperm cells of the same individual exhibited unique DNA methylation profiles. In the interindividual analysis, 41 of 61 pairwise comparisons revealed distinct DNA methylation profiles (P=.036 to 6.8 x 10(-14)). Second, a microarray-based epigenetic profiling of the same sperm samples was performed using a 12,198-feature CpG island microarray. The microarray analysis has identified numerous DNA methylation-variable positions in the germ cell genome. The largest degree of variation was detected within the promoter CpG islands and pericentromeric satellites among the single-copy DNA fragments and repetitive elements, respectively. A number of genes, such as EED, CTNNA2, CALM1, CDH13, and STMN2, exhibited age-related DNA methylation changes. Finally, allele-specific methylation patterns in CDH13 were detected. This study provides evidence for significant epigenetic variability in human germ cells, which warrants further research to determine whether such epigenetic patterns can be efficiently transmitted across generations and what impact inherited epigenetic individuality may have on phenotypic outcomes in health and disease.

[ "Intra-", "and", "interindividual", "epigenetic", "variation", "in", "human", "germ", "cells", ".", "Epigenetics", "represents", "a", "secondary", "inheritance", "system", "that", "has", "been", "poorly", "investigated", "in", "human", "biology", ".", "The", "objective", "of", "this", "study", "was", "to", "perform", "a", "comprehensive", "analysis", "of", "DNA", "methylation", "variation", "between", "and", "within", "the", "germlines", "of", "normal", "males", ".", "First", ",", "methylated", "cytosines", "were", "mapped", "using", "bisulphite", "modification", "-", "based", "sequencing", "in", "the", "promoter", "regions", "of", "the", "following", "disease", "genes", ":", "presenilins", "(", "PSEN1", "and", "PSEN2", ")", ",", "breast", "cancer", "(", "BRCA1", "and", "BRCA2", ")", ",", "myotonic", "dystrophy", "(", "DM1", ")", ",", "and", "Huntington", "disease", "(", "HD", ")", ".", "Major", "epigenetic", "variation", "was", "detected", "within", "samples", ",", "since", "the", "majority", "of", "sperm", "cells", "of", "the", "same", "individual", "exhibited", "unique", "DNA", "methylation", "profiles", ".", "In", "the", "interindividual", "analysis", ",", "41", "of", "61", "pairwise", "comparisons", "revealed", "distinct", "DNA", "methylation", "profiles", "(", "P=.036", "to", "6.8", "x", "10(-14", ")", ")", ".", "Second", ",", "a", "microarray", "-", "based", "epigenetic", "profiling", "of", "the", "same", "sperm", "samples", "was", "performed", "using", "a", "12,198-feature", "CpG", "island", "microarray", ".", "The", "microarray", "analysis", "has", "identified", "numerous", "DNA", "methylation", "-", "variable", "positions", "in", "the", "germ", "cell", "genome", ".", "The", "largest", "degree", "of", "variation", "was", "detected", "within", "the", "promoter", "CpG", "islands", "and", "pericentromeric", "satellites", "among", "the", "single", "-", "copy", "DNA", "fragments", "and", "repetitive", "elements", ",", "respectively", ".", "A", "number", "of", "genes", ",", "such", "as", "EED", ",", "CTNNA2", ",", "CALM1", ",", "CDH13", ",", "and", "STMN2", ",", "exhibited", "age", "-", "related", "DNA", "methylation", "changes", ".", "Finally", ",", "allele", "-", "specific", "methylation", "patterns", "in", "CDH13", "were", "detected", ".", "This", "study", "provides", "evidence", "for", "significant", "epigenetic", "variability", "in", "human", "germ", "cells", ",", "which", "warrants", "further", "research", "to", "determine", "whether", "such", "epigenetic", "patterns", "can", "be", "efficiently", "transmitted", "across", "generations", "and", "what", "impact", "inherited", "epigenetic", "individuality", "may", "have", "on", "phenotypic", "outcomes", "in", "health", "and", "disease", ".", "\n" ]

[ "Gene" ]

PSEN1 is a Gene, PSEN2 is a Gene, BRCA1 is a Gene, BRCA2 is a Gene, DM1 is a Gene, HD is a Gene, EED is a Gene, CTNNA2 is a Gene, CALM1 is a Gene, CDH13 is a Gene, STMN2 is a Gene, CDH13 is a Gene

39_task1

Sentence: Intra- and interindividual epigenetic variation in human germ cells. Epigenetics represents a secondary inheritance system that has been poorly investigated in human biology. The objective of this study was to perform a comprehensive analysis of DNA methylation variation between and within the germlines of normal males. First, methylated cytosines were mapped using bisulphite modification-based sequencing in the promoter regions of the following disease genes: presenilins (PSEN1 and PSEN2), breast cancer (BRCA1 and BRCA2), myotonic dystrophy (DM1), and Huntington disease (HD). Major epigenetic variation was detected within samples, since the majority of sperm cells of the same individual exhibited unique DNA methylation profiles. In the interindividual analysis, 41 of 61 pairwise comparisons revealed distinct DNA methylation profiles (P=.036 to 6.8 x 10(-14)). Second, a microarray-based epigenetic profiling of the same sperm samples was performed using a 12,198-feature CpG island microarray. The microarray analysis has identified numerous DNA methylation-variable positions in the germ cell genome. The largest degree of variation was detected within the promoter CpG islands and pericentromeric satellites among the single-copy DNA fragments and repetitive elements, respectively. A number of genes, such as EED, CTNNA2, CALM1, CDH13, and STMN2, exhibited age-related DNA methylation changes. Finally, allele-specific methylation patterns in CDH13 were detected. This study provides evidence for significant epigenetic variability in human germ cells, which warrants further research to determine whether such epigenetic patterns can be efficiently transmitted across generations and what impact inherited epigenetic individuality may have on phenotypic outcomes in health and disease. Instructions: please typing these entity words according to sentence: PSEN1, PSEN2, BRCA1, BRCA2, DM1, HD, EED, CTNNA2, CALM1, CDH13, STMN2, CDH13 Options: Gene

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "B-Gene", "O", "B-Gene", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Intra- and interindividual epigenetic variation in human germ cells. Epigenetics represents a secondary inheritance system that has been poorly investigated in human biology. The objective of this study was to perform a comprehensive analysis of DNA methylation variation between and within the germlines of normal males. First, methylated cytosines were mapped using bisulphite modification-based sequencing in the promoter regions of the following disease genes: presenilins (PSEN1 and PSEN2), breast cancer (BRCA1 and BRCA2), myotonic dystrophy (DM1), and Huntington disease (HD). Major epigenetic variation was detected within samples, since the majority of sperm cells of the same individual exhibited unique DNA methylation profiles. In the interindividual analysis, 41 of 61 pairwise comparisons revealed distinct DNA methylation profiles (P=.036 to 6.8 x 10(-14)). Second, a microarray-based epigenetic profiling of the same sperm samples was performed using a 12,198-feature CpG island microarray. The microarray analysis has identified numerous DNA methylation-variable positions in the germ cell genome. The largest degree of variation was detected within the promoter CpG islands and pericentromeric satellites among the single-copy DNA fragments and repetitive elements, respectively. A number of genes, such as EED, CTNNA2, CALM1, CDH13, and STMN2, exhibited age-related DNA methylation changes. Finally, allele-specific methylation patterns in CDH13 were detected. This study provides evidence for significant epigenetic variability in human germ cells, which warrants further research to determine whether such epigenetic patterns can be efficiently transmitted across generations and what impact inherited epigenetic individuality may have on phenotypic outcomes in health and disease.

[ "Intra-", "and", "interindividual", "epigenetic", "variation", "in", "human", "germ", "cells", ".", "Epigenetics", "represents", "a", "secondary", "inheritance", "system", "that", "has", "been", "poorly", "investigated", "in", "human", "biology", ".", "The", "objective", "of", "this", "study", "was", "to", "perform", "a", "comprehensive", "analysis", "of", "DNA", "methylation", "variation", "between", "and", "within", "the", "germlines", "of", "normal", "males", ".", "First", ",", "methylated", "cytosines", "were", "mapped", "using", "bisulphite", "modification", "-", "based", "sequencing", "in", "the", "promoter", "regions", "of", "the", "following", "disease", "genes", ":", "presenilins", "(", "PSEN1", "and", "PSEN2", ")", ",", "breast", "cancer", "(", "BRCA1", "and", "BRCA2", ")", ",", "myotonic", "dystrophy", "(", "DM1", ")", ",", "and", "Huntington", "disease", "(", "HD", ")", ".", "Major", "epigenetic", "variation", "was", "detected", "within", "samples", ",", "since", "the", "majority", "of", "sperm", "cells", "of", "the", "same", "individual", "exhibited", "unique", "DNA", "methylation", "profiles", ".", "In", "the", "interindividual", "analysis", ",", "41", "of", "61", "pairwise", "comparisons", "revealed", "distinct", "DNA", "methylation", "profiles", "(", "P=.036", "to", "6.8", "x", "10(-14", ")", ")", ".", "Second", ",", "a", "microarray", "-", "based", "epigenetic", "profiling", "of", "the", "same", "sperm", "samples", "was", "performed", "using", "a", "12,198-feature", "CpG", "island", "microarray", ".", "The", "microarray", "analysis", "has", "identified", "numerous", "DNA", "methylation", "-", "variable", "positions", "in", "the", "germ", "cell", "genome", ".", "The", "largest", "degree", "of", "variation", "was", "detected", "within", "the", "promoter", "CpG", "islands", "and", "pericentromeric", "satellites", "among", "the", "single", "-", "copy", "DNA", "fragments", "and", "repetitive", "elements", ",", "respectively", ".", "A", "number", "of", "genes", ",", "such", "as", "EED", ",", "CTNNA2", ",", "CALM1", ",", "CDH13", ",", "and", "STMN2", ",", "exhibited", "age", "-", "related", "DNA", "methylation", "changes", ".", "Finally", ",", "allele", "-", "specific", "methylation", "patterns", "in", "CDH13", "were", "detected", ".", "This", "study", "provides", "evidence", "for", "significant", "epigenetic", "variability", "in", "human", "germ", "cells", ",", "which", "warrants", "further", "research", "to", "determine", "whether", "such", "epigenetic", "patterns", "can", "be", "efficiently", "transmitted", "across", "generations", "and", "what", "impact", "inherited", "epigenetic", "individuality", "may", "have", "on", "phenotypic", "outcomes", "in", "health", "and", "disease", ".", "\n" ]

[ "Gene" ]

PSEN1, PSEN2, BRCA1, BRCA2, DM1, HD, EED, CTNNA2, CALM1, CDH13, STMN2, CDH13

39_task2

Sentence: Intra- and interindividual epigenetic variation in human germ cells. Epigenetics represents a secondary inheritance system that has been poorly investigated in human biology. The objective of this study was to perform a comprehensive analysis of DNA methylation variation between and within the germlines of normal males. First, methylated cytosines were mapped using bisulphite modification-based sequencing in the promoter regions of the following disease genes: presenilins (PSEN1 and PSEN2), breast cancer (BRCA1 and BRCA2), myotonic dystrophy (DM1), and Huntington disease (HD). Major epigenetic variation was detected within samples, since the majority of sperm cells of the same individual exhibited unique DNA methylation profiles. In the interindividual analysis, 41 of 61 pairwise comparisons revealed distinct DNA methylation profiles (P=.036 to 6.8 x 10(-14)). Second, a microarray-based epigenetic profiling of the same sperm samples was performed using a 12,198-feature CpG island microarray. The microarray analysis has identified numerous DNA methylation-variable positions in the germ cell genome. The largest degree of variation was detected within the promoter CpG islands and pericentromeric satellites among the single-copy DNA fragments and repetitive elements, respectively. A number of genes, such as EED, CTNNA2, CALM1, CDH13, and STMN2, exhibited age-related DNA methylation changes. Finally, allele-specific methylation patterns in CDH13 were detected. This study provides evidence for significant epigenetic variability in human germ cells, which warrants further research to determine whether such epigenetic patterns can be efficiently transmitted across generations and what impact inherited epigenetic individuality may have on phenotypic outcomes in health and disease. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "B-Gene", "O", "B-Gene", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Intra- and interindividual epigenetic variation in human germ cells. Epigenetics represents a secondary inheritance system that has been poorly investigated in human biology. The objective of this study was to perform a comprehensive analysis of DNA methylation variation between and within the germlines of normal males. First, methylated cytosines were mapped using bisulphite modification-based sequencing in the promoter regions of the following disease genes: presenilins (PSEN1 and PSEN2), breast cancer (BRCA1 and BRCA2), myotonic dystrophy (DM1), and Huntington disease (HD). Major epigenetic variation was detected within samples, since the majority of sperm cells of the same individual exhibited unique DNA methylation profiles. In the interindividual analysis, 41 of 61 pairwise comparisons revealed distinct DNA methylation profiles (P=.036 to 6.8 x 10(-14)). Second, a microarray-based epigenetic profiling of the same sperm samples was performed using a 12,198-feature CpG island microarray. The microarray analysis has identified numerous DNA methylation-variable positions in the germ cell genome. The largest degree of variation was detected within the promoter CpG islands and pericentromeric satellites among the single-copy DNA fragments and repetitive elements, respectively. A number of genes, such as EED, CTNNA2, CALM1, CDH13, and STMN2, exhibited age-related DNA methylation changes. Finally, allele-specific methylation patterns in CDH13 were detected. This study provides evidence for significant epigenetic variability in human germ cells, which warrants further research to determine whether such epigenetic patterns can be efficiently transmitted across generations and what impact inherited epigenetic individuality may have on phenotypic outcomes in health and disease.

[ "Intra-", "and", "interindividual", "epigenetic", "variation", "in", "human", "germ", "cells", ".", "Epigenetics", "represents", "a", "secondary", "inheritance", "system", "that", "has", "been", "poorly", "investigated", "in", "human", "biology", ".", "The", "objective", "of", "this", "study", "was", "to", "perform", "a", "comprehensive", "analysis", "of", "DNA", "methylation", "variation", "between", "and", "within", "the", "germlines", "of", "normal", "males", ".", "First", ",", "methylated", "cytosines", "were", "mapped", "using", "bisulphite", "modification", "-", "based", "sequencing", "in", "the", "promoter", "regions", "of", "the", "following", "disease", "genes", ":", "presenilins", "(", "PSEN1", "and", "PSEN2", ")", ",", "breast", "cancer", "(", "BRCA1", "and", "BRCA2", ")", ",", "myotonic", "dystrophy", "(", "DM1", ")", ",", "and", "Huntington", "disease", "(", "HD", ")", ".", "Major", "epigenetic", "variation", "was", "detected", "within", "samples", ",", "since", "the", "majority", "of", "sperm", "cells", "of", "the", "same", "individual", "exhibited", "unique", "DNA", "methylation", "profiles", ".", "In", "the", "interindividual", "analysis", ",", "41", "of", "61", "pairwise", "comparisons", "revealed", "distinct", "DNA", "methylation", "profiles", "(", "P=.036", "to", "6.8", "x", "10(-14", ")", ")", ".", "Second", ",", "a", "microarray", "-", "based", "epigenetic", "profiling", "of", "the", "same", "sperm", "samples", "was", "performed", "using", "a", "12,198-feature", "CpG", "island", "microarray", ".", "The", "microarray", "analysis", "has", "identified", "numerous", "DNA", "methylation", "-", "variable", "positions", "in", "the", "germ", "cell", "genome", ".", "The", "largest", "degree", "of", "variation", "was", "detected", "within", "the", "promoter", "CpG", "islands", "and", "pericentromeric", "satellites", "among", "the", "single", "-", "copy", "DNA", "fragments", "and", "repetitive", "elements", ",", "respectively", ".", "A", "number", "of", "genes", ",", "such", "as", "EED", ",", "CTNNA2", ",", "CALM1", ",", "CDH13", ",", "and", "STMN2", ",", "exhibited", "age", "-", "related", "DNA", "methylation", "changes", ".", "Finally", ",", "allele", "-", "specific", "methylation", "patterns", "in", "CDH13", "were", "detected", ".", "This", "study", "provides", "evidence", "for", "significant", "epigenetic", "variability", "in", "human", "germ", "cells", ",", "which", "warrants", "further", "research", "to", "determine", "whether", "such", "epigenetic", "patterns", "can", "be", "efficiently", "transmitted", "across", "generations", "and", "what", "impact", "inherited", "epigenetic", "individuality", "may", "have", "on", "phenotypic", "outcomes", "in", "health", "and", "disease", ".", "\n" ]

[ "Gene" ]

actin is a Gene/protein/RNA, actin is a Gene/protein/RNA, cofilin is a Gene/protein/RNA, actin depolymerizing factor is a Gene/protein/RNA, profilin is a Gene/protein/RNA

284_task0

Sentence: Fluorographic analysis showed that the specific activity of soluble actin was two to three times that of its particulate form and that soluble actin, cofilin, actin depolymerizing factor, and profilin were transported at similar rates in slow component b of axonal flow. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fluorographic analysis showed that the specific activity of soluble actin was two to three times that of its particulate form and that soluble actin, cofilin, actin depolymerizing factor, and profilin were transported at similar rates in slow component b of axonal flow.

[ "Fluorographic", "analysis", "showed", "that", "the", "specific", "activity", "of", "soluble", "actin", "was", "two", "to", "three", "times", "that", "of", "its", "particulate", "form", "and", "that", "soluble", "actin", ",", "cofilin", ",", "actin", "depolymerizing", "factor", ",", "and", "profilin", "were", "transported", "at", "similar", "rates", "in", "slow", "component", "b", "of", "axonal", "flow", "." ]

[ "Gene/protein/RNA" ]

actin is a Gene/protein/RNA, actin is a Gene/protein/RNA, cofilin is a Gene/protein/RNA, actin depolymerizing factor is a Gene/protein/RNA, profilin is a Gene/protein/RNA

284_task1

Sentence: Fluorographic analysis showed that the specific activity of soluble actin was two to three times that of its particulate form and that soluble actin, cofilin, actin depolymerizing factor, and profilin were transported at similar rates in slow component b of axonal flow. Instructions: please typing these entity words according to sentence: actin, actin, cofilin, actin depolymerizing factor, profilin Options: Gene/protein/RNA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fluorographic analysis showed that the specific activity of soluble actin was two to three times that of its particulate form and that soluble actin, cofilin, actin depolymerizing factor, and profilin were transported at similar rates in slow component b of axonal flow.

[ "Fluorographic", "analysis", "showed", "that", "the", "specific", "activity", "of", "soluble", "actin", "was", "two", "to", "three", "times", "that", "of", "its", "particulate", "form", "and", "that", "soluble", "actin", ",", "cofilin", ",", "actin", "depolymerizing", "factor", ",", "and", "profilin", "were", "transported", "at", "similar", "rates", "in", "slow", "component", "b", "of", "axonal", "flow", "." ]

[ "Gene/protein/RNA" ]

actin, actin, cofilin, actin depolymerizing factor, profilin

284_task2

Sentence: Fluorographic analysis showed that the specific activity of soluble actin was two to three times that of its particulate form and that soluble actin, cofilin, actin depolymerizing factor, and profilin were transported at similar rates in slow component b of axonal flow. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fluorographic analysis showed that the specific activity of soluble actin was two to three times that of its particulate form and that soluble actin, cofilin, actin depolymerizing factor, and profilin were transported at similar rates in slow component b of axonal flow.

[ "Fluorographic", "analysis", "showed", "that", "the", "specific", "activity", "of", "soluble", "actin", "was", "two", "to", "three", "times", "that", "of", "its", "particulate", "form", "and", "that", "soluble", "actin", ",", "cofilin", ",", "actin", "depolymerizing", "factor", ",", "and", "profilin", "were", "transported", "at", "similar", "rates", "in", "slow", "component", "b", "of", "axonal", "flow", "." ]

[ "Gene/protein/RNA" ]

Beurteilung is an umlsterm, Therapie is an umlsterm

DerSchmerz.70110254.ger.abstr_task0

Sentence: Fragestellung : Zwei methodische Zugaenge der Veraenderungsmessung werden miteinander verglichen : der Prae-post-Vergleich der Merkmale und die subjektive Beurteilung der Veraenderung nach der Therapie . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Fragestellung : Zwei methodische Zugaenge der Veraenderungsmessung werden miteinander verglichen : der Prae-post-Vergleich der Merkmale und die subjektive Beurteilung der Veraenderung nach der Therapie .

[ "Fragestellung", ":", "Zwei", "methodische", "Zugaenge", "der", "Veraenderungsmessung", "werden", "miteinander", "verglichen", ":", "der", "Prae", "-", "post", "-", "Vergleich", "der", "Merkmale", "und", "die", "subjektive", "Beurteilung", "der", "Veraenderung", "nach", "der", "Therapie", "." ]

[ "umlsterm" ]

Beurteilung is an umlsterm, Therapie is an umlsterm

DerSchmerz.70110254.ger.abstr_task1

Sentence: Fragestellung : Zwei methodische Zugaenge der Veraenderungsmessung werden miteinander verglichen : der Prae-post-Vergleich der Merkmale und die subjektive Beurteilung der Veraenderung nach der Therapie . Instructions: please typing these entity words according to sentence: Beurteilung, Therapie Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Fragestellung : Zwei methodische Zugaenge der Veraenderungsmessung werden miteinander verglichen : der Prae-post-Vergleich der Merkmale und die subjektive Beurteilung der Veraenderung nach der Therapie .

[ "Fragestellung", ":", "Zwei", "methodische", "Zugaenge", "der", "Veraenderungsmessung", "werden", "miteinander", "verglichen", ":", "der", "Prae", "-", "post", "-", "Vergleich", "der", "Merkmale", "und", "die", "subjektive", "Beurteilung", "der", "Veraenderung", "nach", "der", "Therapie", "." ]

[ "umlsterm" ]

Beurteilung, Therapie

DerSchmerz.70110254.ger.abstr_task2

Sentence: Fragestellung : Zwei methodische Zugaenge der Veraenderungsmessung werden miteinander verglichen : der Prae-post-Vergleich der Merkmale und die subjektive Beurteilung der Veraenderung nach der Therapie . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Fragestellung : Zwei methodische Zugaenge der Veraenderungsmessung werden miteinander verglichen : der Prae-post-Vergleich der Merkmale und die subjektive Beurteilung der Veraenderung nach der Therapie .

[ "Fragestellung", ":", "Zwei", "methodische", "Zugaenge", "der", "Veraenderungsmessung", "werden", "miteinander", "verglichen", ":", "der", "Prae", "-", "post", "-", "Vergleich", "der", "Merkmale", "und", "die", "subjektive", "Beurteilung", "der", "Veraenderung", "nach", "der", "Therapie", "." ]

[ "umlsterm" ]

human immunodeficiency virus type 1 enhancer - binding proteins is a protein_family_or_group, human T - cell line is a cell_line, Jurkat is a cell_line

98025_task0

Sentence: Characterization of the human immunodeficiency virus type 1 enhancer-binding proteins from the human T-cell line Jurkat. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_family_or_group, cell_line

[ "O", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "B-cell_line", "O" ]

Characterization of the human immunodeficiency virus type 1 enhancer-binding proteins from the human T-cell line Jurkat.

[ "Characterization", "of", "the", "human", "immunodeficiency", "virus", "type", "1", "enhancer", "-", "binding", "proteins", "from", "the", "human", "T", "-", "cell", "line", "Jurkat", "." ]

[ "protein_family_or_group", "DNA_domain_or_region", "protein_subunit", "virus", "other_name", "protein_molecule", "cell_line", "atom", "polynucleotide" ]

human immunodeficiency virus type 1 enhancer - binding proteins is a protein_family_or_group, human T - cell line is a cell_line, Jurkat is a cell_line

98025_task1

Sentence: Characterization of the human immunodeficiency virus type 1 enhancer-binding proteins from the human T-cell line Jurkat. Instructions: please typing these entity words according to sentence: human immunodeficiency virus type 1 enhancer - binding proteins, human T - cell line, Jurkat Options: protein_family_or_group, cell_line

[ "O", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "B-cell_line", "O" ]

Characterization of the human immunodeficiency virus type 1 enhancer-binding proteins from the human T-cell line Jurkat.

[ "Characterization", "of", "the", "human", "immunodeficiency", "virus", "type", "1", "enhancer", "-", "binding", "proteins", "from", "the", "human", "T", "-", "cell", "line", "Jurkat", "." ]

[ "protein_family_or_group", "DNA_domain_or_region", "protein_subunit", "virus", "other_name", "protein_molecule", "cell_line", "atom", "polynucleotide" ]

human immunodeficiency virus type 1 enhancer - binding proteins, human T - cell line, Jurkat

98025_task2

Sentence: Characterization of the human immunodeficiency virus type 1 enhancer-binding proteins from the human T-cell line Jurkat. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "B-cell_line", "O" ]

Characterization of the human immunodeficiency virus type 1 enhancer-binding proteins from the human T-cell line Jurkat.

[ "Characterization", "of", "the", "human", "immunodeficiency", "virus", "type", "1", "enhancer", "-", "binding", "proteins", "from", "the", "human", "T", "-", "cell", "line", "Jurkat", "." ]

[ "protein_family_or_group", "DNA_domain_or_region", "protein_subunit", "virus", "other_name", "protein_molecule", "cell_line", "atom", "polynucleotide" ]

Speicheldruesen- is an umlsterm, Parotischirurgie is an umlsterm, Speicheldruesenerkrankungen is an umlsterm, Behandlung is an umlsterm, Speicheldruesenerkrankungen is an umlsterm, Referenzpathologie is an umlsterm, Speicheldruesenerkrankungen is an umlsterm, Sonographie is an umlsterm, Computertomogramm is an umlsterm, Kernspintomographie is an umlsterm, Literatur is an umlsterm, Speicheldruesen is an umlsterm, Therapie is an umlsterm, Parotischirurgie is an umlsterm, Tumorentitaeten is an umlsterm

MundKieferGesichtschirurgie.0004s401.ger.abstr_task0

Sentence: Nach einer ueber 26-jaehrigen Taetigkeit in der Speicheldruesen- und insbesondere in der Parotischirurgie sind folgende Aussagen zu erbringen : 1. Die Speicheldruesenerkrankungen sind extrem variabel und verlangen in der Behandlung einen grossen klinischen Erfahrungswert . 2. Die Bewertung der Speicheldruesenerkrankungen setzt eine hochkompetente pathologische Sekundanz und ein einschlaegiges Labor voraus . Die Forderungen nach einer Referenzpathologie muessen wie fuer viele Organe oder Organsysteme auch fuer die Speicheldruesenerkrankungen erneut und uneingeschraenkt erhoben werden . 3. Ein gewisser Wandel ist in den diagnostischen Massnahmen eingetreten . Die moderne Bildgebung zeigt eine wesentliche Verschiebung zugunsten der nichtinvasiven Sonographie und auch dem Computertomogramm mit und ohne Kontrastdarstellung sowie in zunehmendem Mass auch der Kernspintomographie . 4. Die Literatur zu den Erkrankungen der Speicheldruesen und ihrer Therapie ist kaum noch zu ueberblicken und bedauerlicherweise von ganz unterschiedlichen Bewertungsaspekten charakterisiert . Sie laesst in vielen Faellen vergleichende Diskussionen ueber bestimmte klinische und therapeutische Fragestellungen nur schwer zu . 5. Die Parotischirurgie verlangt ein klares Konzept hinsichtlich der verschiedenen Erkrankungen insbesondere der unterschiedlichen Tumorentitaeten . Die Darstellung und Praeparation des N. facialis von peripher und zentral muessen gleichermassen beherrscht werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Nach einer ueber 26-jaehrigen Taetigkeit in der Speicheldruesen- und insbesondere in der Parotischirurgie sind folgende Aussagen zu erbringen : 1. Die Speicheldruesenerkrankungen sind extrem variabel und verlangen in der Behandlung einen grossen klinischen Erfahrungswert . 2. Die Bewertung der Speicheldruesenerkrankungen setzt eine hochkompetente pathologische Sekundanz und ein einschlaegiges Labor voraus . Die Forderungen nach einer Referenzpathologie muessen wie fuer viele Organe oder Organsysteme auch fuer die Speicheldruesenerkrankungen erneut und uneingeschraenkt erhoben werden . 3. Ein gewisser Wandel ist in den diagnostischen Massnahmen eingetreten . Die moderne Bildgebung zeigt eine wesentliche Verschiebung zugunsten der nichtinvasiven Sonographie und auch dem Computertomogramm mit und ohne Kontrastdarstellung sowie in zunehmendem Mass auch der Kernspintomographie . 4. Die Literatur zu den Erkrankungen der Speicheldruesen und ihrer Therapie ist kaum noch zu ueberblicken und bedauerlicherweise von ganz unterschiedlichen Bewertungsaspekten charakterisiert . Sie laesst in vielen Faellen vergleichende Diskussionen ueber bestimmte klinische und therapeutische Fragestellungen nur schwer zu . 5. Die Parotischirurgie verlangt ein klares Konzept hinsichtlich der verschiedenen Erkrankungen insbesondere der unterschiedlichen Tumorentitaeten . Die Darstellung und Praeparation des N. facialis von peripher und zentral muessen gleichermassen beherrscht werden .

[ "Nach", "einer", "ueber", "26-jaehrigen", "Taetigkeit", "in", "der", "Speicheldruesen-", "und", "insbesondere", "in", "der", "Parotischirurgie", "sind", "folgende", "Aussagen", "zu", "erbringen", ":", "1", ".", "Die", "Speicheldruesenerkrankungen", "sind", "extrem", "variabel", "und", "verlangen", "in", "der", "Behandlung", "einen", "grossen", "klinischen", "Erfahrungswert", ".", "2", ".", "Die", "Bewertung", "der", "Speicheldruesenerkrankungen", "setzt", "eine", "hochkompetente", "pathologische", "Sekundanz", "und", "ein", "einschlaegiges", "Labor", "voraus", ".", "Die", "Forderungen", "nach", "einer", "Referenzpathologie", "muessen", "wie", "fuer", "viele", "Organe", "oder", "Organsysteme", "auch", "fuer", "die", "Speicheldruesenerkrankungen", "erneut", "und", "uneingeschraenkt", "erhoben", "werden", ".", "3", ".", "Ein", "gewisser", "Wandel", "ist", "in", "den", "diagnostischen", "Massnahmen", "eingetreten", ".", "Die", "moderne", "Bildgebung", "zeigt", "eine", "wesentliche", "Verschiebung", "zugunsten", "der", "nichtinvasiven", "Sonographie", "und", "auch", "dem", "Computertomogramm", "mit", "und", "ohne", "Kontrastdarstellung", "sowie", "in", "zunehmendem", "Mass", "auch", "der", "Kernspintomographie", ".", "4", ".", "Die", "Literatur", "zu", "den", "Erkrankungen", "der", "Speicheldruesen", "und", "ihrer", "Therapie", "ist", "kaum", "noch", "zu", "ueberblicken", "und", "bedauerlicherweise", "von", "ganz", "unterschiedlichen", "Bewertungsaspekten", "charakterisiert", ".", "Sie", "laesst", "in", "vielen", "Faellen", "vergleichende", "Diskussionen", "ueber", "bestimmte", "klinische", "und", "therapeutische", "Fragestellungen", "nur", "schwer", "zu", ".", "5", ".", "Die", "Parotischirurgie", "verlangt", "ein", "klares", "Konzept", "hinsichtlich", "der", "verschiedenen", "Erkrankungen", "insbesondere", "der", "unterschiedlichen", "Tumorentitaeten", ".", "Die", "Darstellung", "und", "Praeparation", "des", "N.", "facialis", "von", "peripher", "und", "zentral", "muessen", "gleichermassen", "beherrscht", "werden", "." ]

[ "umlsterm" ]

Speicheldruesen- is an umlsterm, Parotischirurgie is an umlsterm, Speicheldruesenerkrankungen is an umlsterm, Behandlung is an umlsterm, Speicheldruesenerkrankungen is an umlsterm, Referenzpathologie is an umlsterm, Speicheldruesenerkrankungen is an umlsterm, Sonographie is an umlsterm, Computertomogramm is an umlsterm, Kernspintomographie is an umlsterm, Literatur is an umlsterm, Speicheldruesen is an umlsterm, Therapie is an umlsterm, Parotischirurgie is an umlsterm, Tumorentitaeten is an umlsterm

MundKieferGesichtschirurgie.0004s401.ger.abstr_task1

Sentence: Nach einer ueber 26-jaehrigen Taetigkeit in der Speicheldruesen- und insbesondere in der Parotischirurgie sind folgende Aussagen zu erbringen : 1. Die Speicheldruesenerkrankungen sind extrem variabel und verlangen in der Behandlung einen grossen klinischen Erfahrungswert . 2. Die Bewertung der Speicheldruesenerkrankungen setzt eine hochkompetente pathologische Sekundanz und ein einschlaegiges Labor voraus . Die Forderungen nach einer Referenzpathologie muessen wie fuer viele Organe oder Organsysteme auch fuer die Speicheldruesenerkrankungen erneut und uneingeschraenkt erhoben werden . 3. Ein gewisser Wandel ist in den diagnostischen Massnahmen eingetreten . Die moderne Bildgebung zeigt eine wesentliche Verschiebung zugunsten der nichtinvasiven Sonographie und auch dem Computertomogramm mit und ohne Kontrastdarstellung sowie in zunehmendem Mass auch der Kernspintomographie . 4. Die Literatur zu den Erkrankungen der Speicheldruesen und ihrer Therapie ist kaum noch zu ueberblicken und bedauerlicherweise von ganz unterschiedlichen Bewertungsaspekten charakterisiert . Sie laesst in vielen Faellen vergleichende Diskussionen ueber bestimmte klinische und therapeutische Fragestellungen nur schwer zu . 5. Die Parotischirurgie verlangt ein klares Konzept hinsichtlich der verschiedenen Erkrankungen insbesondere der unterschiedlichen Tumorentitaeten . Die Darstellung und Praeparation des N. facialis von peripher und zentral muessen gleichermassen beherrscht werden . Instructions: please typing these entity words according to sentence: Speicheldruesen-, Parotischirurgie, Speicheldruesenerkrankungen, Behandlung, Speicheldruesenerkrankungen, Referenzpathologie, Speicheldruesenerkrankungen, Sonographie, Computertomogramm, Kernspintomographie, Literatur, Speicheldruesen, Therapie, Parotischirurgie, Tumorentitaeten Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Nach einer ueber 26-jaehrigen Taetigkeit in der Speicheldruesen- und insbesondere in der Parotischirurgie sind folgende Aussagen zu erbringen : 1. Die Speicheldruesenerkrankungen sind extrem variabel und verlangen in der Behandlung einen grossen klinischen Erfahrungswert . 2. Die Bewertung der Speicheldruesenerkrankungen setzt eine hochkompetente pathologische Sekundanz und ein einschlaegiges Labor voraus . Die Forderungen nach einer Referenzpathologie muessen wie fuer viele Organe oder Organsysteme auch fuer die Speicheldruesenerkrankungen erneut und uneingeschraenkt erhoben werden . 3. Ein gewisser Wandel ist in den diagnostischen Massnahmen eingetreten . Die moderne Bildgebung zeigt eine wesentliche Verschiebung zugunsten der nichtinvasiven Sonographie und auch dem Computertomogramm mit und ohne Kontrastdarstellung sowie in zunehmendem Mass auch der Kernspintomographie . 4. Die Literatur zu den Erkrankungen der Speicheldruesen und ihrer Therapie ist kaum noch zu ueberblicken und bedauerlicherweise von ganz unterschiedlichen Bewertungsaspekten charakterisiert . Sie laesst in vielen Faellen vergleichende Diskussionen ueber bestimmte klinische und therapeutische Fragestellungen nur schwer zu . 5. Die Parotischirurgie verlangt ein klares Konzept hinsichtlich der verschiedenen Erkrankungen insbesondere der unterschiedlichen Tumorentitaeten . Die Darstellung und Praeparation des N. facialis von peripher und zentral muessen gleichermassen beherrscht werden .

[ "Nach", "einer", "ueber", "26-jaehrigen", "Taetigkeit", "in", "der", "Speicheldruesen-", "und", "insbesondere", "in", "der", "Parotischirurgie", "sind", "folgende", "Aussagen", "zu", "erbringen", ":", "1", ".", "Die", "Speicheldruesenerkrankungen", "sind", "extrem", "variabel", "und", "verlangen", "in", "der", "Behandlung", "einen", "grossen", "klinischen", "Erfahrungswert", ".", "2", ".", "Die", "Bewertung", "der", "Speicheldruesenerkrankungen", "setzt", "eine", "hochkompetente", "pathologische", "Sekundanz", "und", "ein", "einschlaegiges", "Labor", "voraus", ".", "Die", "Forderungen", "nach", "einer", "Referenzpathologie", "muessen", "wie", "fuer", "viele", "Organe", "oder", "Organsysteme", "auch", "fuer", "die", "Speicheldruesenerkrankungen", "erneut", "und", "uneingeschraenkt", "erhoben", "werden", ".", "3", ".", "Ein", "gewisser", "Wandel", "ist", "in", "den", "diagnostischen", "Massnahmen", "eingetreten", ".", "Die", "moderne", "Bildgebung", "zeigt", "eine", "wesentliche", "Verschiebung", "zugunsten", "der", "nichtinvasiven", "Sonographie", "und", "auch", "dem", "Computertomogramm", "mit", "und", "ohne", "Kontrastdarstellung", "sowie", "in", "zunehmendem", "Mass", "auch", "der", "Kernspintomographie", ".", "4", ".", "Die", "Literatur", "zu", "den", "Erkrankungen", "der", "Speicheldruesen", "und", "ihrer", "Therapie", "ist", "kaum", "noch", "zu", "ueberblicken", "und", "bedauerlicherweise", "von", "ganz", "unterschiedlichen", "Bewertungsaspekten", "charakterisiert", ".", "Sie", "laesst", "in", "vielen", "Faellen", "vergleichende", "Diskussionen", "ueber", "bestimmte", "klinische", "und", "therapeutische", "Fragestellungen", "nur", "schwer", "zu", ".", "5", ".", "Die", "Parotischirurgie", "verlangt", "ein", "klares", "Konzept", "hinsichtlich", "der", "verschiedenen", "Erkrankungen", "insbesondere", "der", "unterschiedlichen", "Tumorentitaeten", ".", "Die", "Darstellung", "und", "Praeparation", "des", "N.", "facialis", "von", "peripher", "und", "zentral", "muessen", "gleichermassen", "beherrscht", "werden", "." ]

[ "umlsterm" ]

Speicheldruesen-, Parotischirurgie, Speicheldruesenerkrankungen, Behandlung, Speicheldruesenerkrankungen, Referenzpathologie, Speicheldruesenerkrankungen, Sonographie, Computertomogramm, Kernspintomographie, Literatur, Speicheldruesen, Therapie, Parotischirurgie, Tumorentitaeten

MundKieferGesichtschirurgie.0004s401.ger.abstr_task2

Sentence: Nach einer ueber 26-jaehrigen Taetigkeit in der Speicheldruesen- und insbesondere in der Parotischirurgie sind folgende Aussagen zu erbringen : 1. Die Speicheldruesenerkrankungen sind extrem variabel und verlangen in der Behandlung einen grossen klinischen Erfahrungswert . 2. Die Bewertung der Speicheldruesenerkrankungen setzt eine hochkompetente pathologische Sekundanz und ein einschlaegiges Labor voraus . Die Forderungen nach einer Referenzpathologie muessen wie fuer viele Organe oder Organsysteme auch fuer die Speicheldruesenerkrankungen erneut und uneingeschraenkt erhoben werden . 3. Ein gewisser Wandel ist in den diagnostischen Massnahmen eingetreten . Die moderne Bildgebung zeigt eine wesentliche Verschiebung zugunsten der nichtinvasiven Sonographie und auch dem Computertomogramm mit und ohne Kontrastdarstellung sowie in zunehmendem Mass auch der Kernspintomographie . 4. Die Literatur zu den Erkrankungen der Speicheldruesen und ihrer Therapie ist kaum noch zu ueberblicken und bedauerlicherweise von ganz unterschiedlichen Bewertungsaspekten charakterisiert . Sie laesst in vielen Faellen vergleichende Diskussionen ueber bestimmte klinische und therapeutische Fragestellungen nur schwer zu . 5. Die Parotischirurgie verlangt ein klares Konzept hinsichtlich der verschiedenen Erkrankungen insbesondere der unterschiedlichen Tumorentitaeten . Die Darstellung und Praeparation des N. facialis von peripher und zentral muessen gleichermassen beherrscht werden . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Nach einer ueber 26-jaehrigen Taetigkeit in der Speicheldruesen- und insbesondere in der Parotischirurgie sind folgende Aussagen zu erbringen : 1. Die Speicheldruesenerkrankungen sind extrem variabel und verlangen in der Behandlung einen grossen klinischen Erfahrungswert . 2. Die Bewertung der Speicheldruesenerkrankungen setzt eine hochkompetente pathologische Sekundanz und ein einschlaegiges Labor voraus . Die Forderungen nach einer Referenzpathologie muessen wie fuer viele Organe oder Organsysteme auch fuer die Speicheldruesenerkrankungen erneut und uneingeschraenkt erhoben werden . 3. Ein gewisser Wandel ist in den diagnostischen Massnahmen eingetreten . Die moderne Bildgebung zeigt eine wesentliche Verschiebung zugunsten der nichtinvasiven Sonographie und auch dem Computertomogramm mit und ohne Kontrastdarstellung sowie in zunehmendem Mass auch der Kernspintomographie . 4. Die Literatur zu den Erkrankungen der Speicheldruesen und ihrer Therapie ist kaum noch zu ueberblicken und bedauerlicherweise von ganz unterschiedlichen Bewertungsaspekten charakterisiert . Sie laesst in vielen Faellen vergleichende Diskussionen ueber bestimmte klinische und therapeutische Fragestellungen nur schwer zu . 5. Die Parotischirurgie verlangt ein klares Konzept hinsichtlich der verschiedenen Erkrankungen insbesondere der unterschiedlichen Tumorentitaeten . Die Darstellung und Praeparation des N. facialis von peripher und zentral muessen gleichermassen beherrscht werden .

[ "Nach", "einer", "ueber", "26-jaehrigen", "Taetigkeit", "in", "der", "Speicheldruesen-", "und", "insbesondere", "in", "der", "Parotischirurgie", "sind", "folgende", "Aussagen", "zu", "erbringen", ":", "1", ".", "Die", "Speicheldruesenerkrankungen", "sind", "extrem", "variabel", "und", "verlangen", "in", "der", "Behandlung", "einen", "grossen", "klinischen", "Erfahrungswert", ".", "2", ".", "Die", "Bewertung", "der", "Speicheldruesenerkrankungen", "setzt", "eine", "hochkompetente", "pathologische", "Sekundanz", "und", "ein", "einschlaegiges", "Labor", "voraus", ".", "Die", "Forderungen", "nach", "einer", "Referenzpathologie", "muessen", "wie", "fuer", "viele", "Organe", "oder", "Organsysteme", "auch", "fuer", "die", "Speicheldruesenerkrankungen", "erneut", "und", "uneingeschraenkt", "erhoben", "werden", ".", "3", ".", "Ein", "gewisser", "Wandel", "ist", "in", "den", "diagnostischen", "Massnahmen", "eingetreten", ".", "Die", "moderne", "Bildgebung", "zeigt", "eine", "wesentliche", "Verschiebung", "zugunsten", "der", "nichtinvasiven", "Sonographie", "und", "auch", "dem", "Computertomogramm", "mit", "und", "ohne", "Kontrastdarstellung", "sowie", "in", "zunehmendem", "Mass", "auch", "der", "Kernspintomographie", ".", "4", ".", "Die", "Literatur", "zu", "den", "Erkrankungen", "der", "Speicheldruesen", "und", "ihrer", "Therapie", "ist", "kaum", "noch", "zu", "ueberblicken", "und", "bedauerlicherweise", "von", "ganz", "unterschiedlichen", "Bewertungsaspekten", "charakterisiert", ".", "Sie", "laesst", "in", "vielen", "Faellen", "vergleichende", "Diskussionen", "ueber", "bestimmte", "klinische", "und", "therapeutische", "Fragestellungen", "nur", "schwer", "zu", ".", "5", ".", "Die", "Parotischirurgie", "verlangt", "ein", "klares", "Konzept", "hinsichtlich", "der", "verschiedenen", "Erkrankungen", "insbesondere", "der", "unterschiedlichen", "Tumorentitaeten", ".", "Die", "Darstellung", "und", "Praeparation", "des", "N.", "facialis", "von", "peripher", "und", "zentral", "muessen", "gleichermassen", "beherrscht", "werden", "." ]

[ "umlsterm" ]

Karzinoms is an umlsterm, pleomorphen Adenom is an umlsterm, Speicheldruesen is an umlsterm, Mundschleimhaut is an umlsterm, Tumor is an umlsterm, pleomorphes Adenom is an umlsterm, Speicheldruesen is an umlsterm, Karzinoms is an umlsterm, Rezidivtumor is an umlsterm, Tumoren is an umlsterm, Karzinom is an umlsterm, Speicheldruesen is an umlsterm, pleomorphen Adenoms is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Literatur is an umlsterm

HNO.80460066.ger.abstr_task0

Sentence: Es wird der seltene Verlauf der Entstehung eines myoepithelialen Karzinoms in einem pleomorphen Adenom der kleinen Speicheldruesen der Mundschleimhaut vorgestellt . Der im linken Mundwinkel angesiedelte Tumor zeigte primaer ein dominierendes pleomorphes Adenom der kleinen Speicheldruesen mit einem kleinen kapselnahen Areal eines myoepithelialen Karzinoms . Im Verlauf von 2 und 5 Jahren entwickelte sich im Bereich des linken Mundwinkels 2 malig ein erbsengrosser Rezidivtumor . Die Tumoren wurden grosszuegig exzidiert . Die histologische Aufarbeitung zeigte jeweils ein myoepitheliales Karzinom der kleinen Speicheldruesen , Anteile eines pleomorphen Adenoms liessen sich nicht mehr nachweisen . Die Klinik , Diagnostik , Therapie und histologischen Merkmale unter Beruecksichtigung der Literatur werden diskutiert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Es wird der seltene Verlauf der Entstehung eines myoepithelialen Karzinoms in einem pleomorphen Adenom der kleinen Speicheldruesen der Mundschleimhaut vorgestellt . Der im linken Mundwinkel angesiedelte Tumor zeigte primaer ein dominierendes pleomorphes Adenom der kleinen Speicheldruesen mit einem kleinen kapselnahen Areal eines myoepithelialen Karzinoms . Im Verlauf von 2 und 5 Jahren entwickelte sich im Bereich des linken Mundwinkels 2 malig ein erbsengrosser Rezidivtumor . Die Tumoren wurden grosszuegig exzidiert . Die histologische Aufarbeitung zeigte jeweils ein myoepitheliales Karzinom der kleinen Speicheldruesen , Anteile eines pleomorphen Adenoms liessen sich nicht mehr nachweisen . Die Klinik , Diagnostik , Therapie und histologischen Merkmale unter Beruecksichtigung der Literatur werden diskutiert .

[ "Es", "wird", "der", "seltene", "Verlauf", "der", "Entstehung", "eines", "myoepithelialen", "Karzinoms", "in", "einem", "pleomorphen", "Adenom", "der", "kleinen", "Speicheldruesen", "der", "Mundschleimhaut", "vorgestellt", ".", "Der", "im", "linken", "Mundwinkel", "angesiedelte", "Tumor", "zeigte", "primaer", "ein", "dominierendes", "pleomorphes", "Adenom", "der", "kleinen", "Speicheldruesen", "mit", "einem", "kleinen", "kapselnahen", "Areal", "eines", "myoepithelialen", "Karzinoms", ".", "Im", "Verlauf", "von", "2", "und", "5", "Jahren", "entwickelte", "sich", "im", "Bereich", "des", "linken", "Mundwinkels", "2", "malig", "ein", "erbsengrosser", "Rezidivtumor", ".", "Die", "Tumoren", "wurden", "grosszuegig", "exzidiert", ".", "Die", "histologische", "Aufarbeitung", "zeigte", "jeweils", "ein", "myoepitheliales", "Karzinom", "der", "kleinen", "Speicheldruesen", ",", "Anteile", "eines", "pleomorphen", "Adenoms", "liessen", "sich", "nicht", "mehr", "nachweisen", ".", "Die", "Klinik", ",", "Diagnostik", ",", "Therapie", "und", "histologischen", "Merkmale", "unter", "Beruecksichtigung", "der", "Literatur", "werden", "diskutiert", "." ]

[ "umlsterm" ]

Karzinoms is an umlsterm, pleomorphen Adenom is an umlsterm, Speicheldruesen is an umlsterm, Mundschleimhaut is an umlsterm, Tumor is an umlsterm, pleomorphes Adenom is an umlsterm, Speicheldruesen is an umlsterm, Karzinoms is an umlsterm, Rezidivtumor is an umlsterm, Tumoren is an umlsterm, Karzinom is an umlsterm, Speicheldruesen is an umlsterm, pleomorphen Adenoms is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Literatur is an umlsterm

HNO.80460066.ger.abstr_task1

Sentence: Es wird der seltene Verlauf der Entstehung eines myoepithelialen Karzinoms in einem pleomorphen Adenom der kleinen Speicheldruesen der Mundschleimhaut vorgestellt . Der im linken Mundwinkel angesiedelte Tumor zeigte primaer ein dominierendes pleomorphes Adenom der kleinen Speicheldruesen mit einem kleinen kapselnahen Areal eines myoepithelialen Karzinoms . Im Verlauf von 2 und 5 Jahren entwickelte sich im Bereich des linken Mundwinkels 2 malig ein erbsengrosser Rezidivtumor . Die Tumoren wurden grosszuegig exzidiert . Die histologische Aufarbeitung zeigte jeweils ein myoepitheliales Karzinom der kleinen Speicheldruesen , Anteile eines pleomorphen Adenoms liessen sich nicht mehr nachweisen . Die Klinik , Diagnostik , Therapie und histologischen Merkmale unter Beruecksichtigung der Literatur werden diskutiert . Instructions: please typing these entity words according to sentence: Karzinoms, pleomorphen Adenom, Speicheldruesen, Mundschleimhaut, Tumor, pleomorphes Adenom, Speicheldruesen, Karzinoms, Rezidivtumor, Tumoren, Karzinom, Speicheldruesen, pleomorphen Adenoms, Diagnostik, Therapie, Literatur Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Es wird der seltene Verlauf der Entstehung eines myoepithelialen Karzinoms in einem pleomorphen Adenom der kleinen Speicheldruesen der Mundschleimhaut vorgestellt . Der im linken Mundwinkel angesiedelte Tumor zeigte primaer ein dominierendes pleomorphes Adenom der kleinen Speicheldruesen mit einem kleinen kapselnahen Areal eines myoepithelialen Karzinoms . Im Verlauf von 2 und 5 Jahren entwickelte sich im Bereich des linken Mundwinkels 2 malig ein erbsengrosser Rezidivtumor . Die Tumoren wurden grosszuegig exzidiert . Die histologische Aufarbeitung zeigte jeweils ein myoepitheliales Karzinom der kleinen Speicheldruesen , Anteile eines pleomorphen Adenoms liessen sich nicht mehr nachweisen . Die Klinik , Diagnostik , Therapie und histologischen Merkmale unter Beruecksichtigung der Literatur werden diskutiert .

[ "Es", "wird", "der", "seltene", "Verlauf", "der", "Entstehung", "eines", "myoepithelialen", "Karzinoms", "in", "einem", "pleomorphen", "Adenom", "der", "kleinen", "Speicheldruesen", "der", "Mundschleimhaut", "vorgestellt", ".", "Der", "im", "linken", "Mundwinkel", "angesiedelte", "Tumor", "zeigte", "primaer", "ein", "dominierendes", "pleomorphes", "Adenom", "der", "kleinen", "Speicheldruesen", "mit", "einem", "kleinen", "kapselnahen", "Areal", "eines", "myoepithelialen", "Karzinoms", ".", "Im", "Verlauf", "von", "2", "und", "5", "Jahren", "entwickelte", "sich", "im", "Bereich", "des", "linken", "Mundwinkels", "2", "malig", "ein", "erbsengrosser", "Rezidivtumor", ".", "Die", "Tumoren", "wurden", "grosszuegig", "exzidiert", ".", "Die", "histologische", "Aufarbeitung", "zeigte", "jeweils", "ein", "myoepitheliales", "Karzinom", "der", "kleinen", "Speicheldruesen", ",", "Anteile", "eines", "pleomorphen", "Adenoms", "liessen", "sich", "nicht", "mehr", "nachweisen", ".", "Die", "Klinik", ",", "Diagnostik", ",", "Therapie", "und", "histologischen", "Merkmale", "unter", "Beruecksichtigung", "der", "Literatur", "werden", "diskutiert", "." ]

[ "umlsterm" ]

Karzinoms, pleomorphen Adenom, Speicheldruesen, Mundschleimhaut, Tumor, pleomorphes Adenom, Speicheldruesen, Karzinoms, Rezidivtumor, Tumoren, Karzinom, Speicheldruesen, pleomorphen Adenoms, Diagnostik, Therapie, Literatur

HNO.80460066.ger.abstr_task2

Sentence: Es wird der seltene Verlauf der Entstehung eines myoepithelialen Karzinoms in einem pleomorphen Adenom der kleinen Speicheldruesen der Mundschleimhaut vorgestellt . Der im linken Mundwinkel angesiedelte Tumor zeigte primaer ein dominierendes pleomorphes Adenom der kleinen Speicheldruesen mit einem kleinen kapselnahen Areal eines myoepithelialen Karzinoms . Im Verlauf von 2 und 5 Jahren entwickelte sich im Bereich des linken Mundwinkels 2 malig ein erbsengrosser Rezidivtumor . Die Tumoren wurden grosszuegig exzidiert . Die histologische Aufarbeitung zeigte jeweils ein myoepitheliales Karzinom der kleinen Speicheldruesen , Anteile eines pleomorphen Adenoms liessen sich nicht mehr nachweisen . Die Klinik , Diagnostik , Therapie und histologischen Merkmale unter Beruecksichtigung der Literatur werden diskutiert . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Es wird der seltene Verlauf der Entstehung eines myoepithelialen Karzinoms in einem pleomorphen Adenom der kleinen Speicheldruesen der Mundschleimhaut vorgestellt . Der im linken Mundwinkel angesiedelte Tumor zeigte primaer ein dominierendes pleomorphes Adenom der kleinen Speicheldruesen mit einem kleinen kapselnahen Areal eines myoepithelialen Karzinoms . Im Verlauf von 2 und 5 Jahren entwickelte sich im Bereich des linken Mundwinkels 2 malig ein erbsengrosser Rezidivtumor . Die Tumoren wurden grosszuegig exzidiert . Die histologische Aufarbeitung zeigte jeweils ein myoepitheliales Karzinom der kleinen Speicheldruesen , Anteile eines pleomorphen Adenoms liessen sich nicht mehr nachweisen . Die Klinik , Diagnostik , Therapie und histologischen Merkmale unter Beruecksichtigung der Literatur werden diskutiert .

[ "Es", "wird", "der", "seltene", "Verlauf", "der", "Entstehung", "eines", "myoepithelialen", "Karzinoms", "in", "einem", "pleomorphen", "Adenom", "der", "kleinen", "Speicheldruesen", "der", "Mundschleimhaut", "vorgestellt", ".", "Der", "im", "linken", "Mundwinkel", "angesiedelte", "Tumor", "zeigte", "primaer", "ein", "dominierendes", "pleomorphes", "Adenom", "der", "kleinen", "Speicheldruesen", "mit", "einem", "kleinen", "kapselnahen", "Areal", "eines", "myoepithelialen", "Karzinoms", ".", "Im", "Verlauf", "von", "2", "und", "5", "Jahren", "entwickelte", "sich", "im", "Bereich", "des", "linken", "Mundwinkels", "2", "malig", "ein", "erbsengrosser", "Rezidivtumor", ".", "Die", "Tumoren", "wurden", "grosszuegig", "exzidiert", ".", "Die", "histologische", "Aufarbeitung", "zeigte", "jeweils", "ein", "myoepitheliales", "Karzinom", "der", "kleinen", "Speicheldruesen", ",", "Anteile", "eines", "pleomorphen", "Adenoms", "liessen", "sich", "nicht", "mehr", "nachweisen", ".", "Die", "Klinik", ",", "Diagnostik", ",", "Therapie", "und", "histologischen", "Merkmale", "unter", "Beruecksichtigung", "der", "Literatur", "werden", "diskutiert", "." ]

[ "umlsterm" ]

M - CSF is a Gene_or_gene_product, MAPK is a Gene_or_gene_product, ERK is a Gene_or_gene_product, Sp1 is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, mononuclear phagocytes is a Cell, tumors is a Cancer, VEGF is a Gene_or_gene_product, endothelial cell is a Cell, blood vessel is a Multi-tissue_structure, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, human is a Organism, monocytes is a Cell, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, promoter is a DNA_domain_or_region, luciferase is a Gene_or_gene_product, HIF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, promoter is a DNA_domain_or_region, luciferase is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, MAPK is a Gene_or_gene_product, ERK is a Gene_or_gene_product, Sp1 is a Gene_or_gene_product, ERK is a Gene_or_gene_product, Sp1 is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, nuclear is a Cellular_component, Sp1 is a Gene_or_gene_product, ERK is a Gene_or_gene_product, Sp1 is a Gene_or_gene_product, binding sites is a DNA_domain_or_region, VEGF is a Gene_or_gene_product, promoter is a DNA_domain_or_region, ERK is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, promoter is a DNA_domain_or_region, M - CSF is a Gene_or_gene_product, human is a Organism, monocytes is a Cell, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, mononuclear phagocytes is a Cell, VEGF is a Gene_or_gene_product, VEGF antibody is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, blood vessel is a Multi-tissue_structure, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product

30_task0

Sentence: M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. BACKGROUND: M-CSF recruits mononuclear phagocytes which regulate processes such as angiogenesis and metastases in tumors. VEGF is a potent activator of angiogenesis as it promotes endothelial cell proliferation and new blood vessel formation. Previously, we reported that in vitro M-CSF induces the expression of biologically-active VEGF from human monocytes. METHODOLOGY AND RESULTS: In this study, we demonstrate the molecular mechanism of M-CSF-induced VEGF production. Using a construct containing the VEGF promoter linked to a luciferase reporter, we found that a mutation reducing HIF binding to the VEGF promoter had no significant effect on luciferase production induced by M-CSF stimulation. Further analysis revealed that M-CSF induced VEGF through the MAPK/ERK signaling pathway via the transcription factor, Sp1. Thus, inhibition of either ERK or Sp1 suppressed M-CSF-induced VEGF at the mRNA and protein level. M-CSF also induced the nuclear localization of Sp1, which was blocked by ERK inhibition. Finally, mutating the Sp1 binding sites within the VEGF promoter or inhibiting ERK decreased VEGF promoter activity in M-CSF-treated human monocytes. To evaluate the biological significance of M-CSF induced VEGF production, we used an in vivo angiogenesis model to illustrate the ability of M-CSF to recruit mononuclear phagocytes, increase VEGF levels, and enhance angiogenesis. Importantly, the addition of a neutralizing VEGF antibody abolished M-CSF-induced blood vessel formation. CONCLUSION: These data delineate an ERK- and Sp1-dependent mechanism of M-CSF induced VEGF production and demonstrate for the first time the ability of M-CSF to induce angiogenesis via VEGF in vivo. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene_or_gene_product, Cellular_component, Organism, DNA_domain_or_region, Cancer, Multi-tissue_structure, Cell

[ "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Organism", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Cellular_component", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Organism", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O" ]

M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. BACKGROUND: M-CSF recruits mononuclear phagocytes which regulate processes such as angiogenesis and metastases in tumors. VEGF is a potent activator of angiogenesis as it promotes endothelial cell proliferation and new blood vessel formation. Previously, we reported that in vitro M-CSF induces the expression of biologically-active VEGF from human monocytes. METHODOLOGY AND RESULTS: In this study, we demonstrate the molecular mechanism of M-CSF-induced VEGF production. Using a construct containing the VEGF promoter linked to a luciferase reporter, we found that a mutation reducing HIF binding to the VEGF promoter had no significant effect on luciferase production induced by M-CSF stimulation. Further analysis revealed that M-CSF induced VEGF through the MAPK/ERK signaling pathway via the transcription factor, Sp1. Thus, inhibition of either ERK or Sp1 suppressed M-CSF-induced VEGF at the mRNA and protein level. M-CSF also induced the nuclear localization of Sp1, which was blocked by ERK inhibition. Finally, mutating the Sp1 binding sites within the VEGF promoter or inhibiting ERK decreased VEGF promoter activity in M-CSF-treated human monocytes. To evaluate the biological significance of M-CSF induced VEGF production, we used an in vivo angiogenesis model to illustrate the ability of M-CSF to recruit mononuclear phagocytes, increase VEGF levels, and enhance angiogenesis. Importantly, the addition of a neutralizing VEGF antibody abolished M-CSF-induced blood vessel formation. CONCLUSION: These data delineate an ERK- and Sp1-dependent mechanism of M-CSF induced VEGF production and demonstrate for the first time the ability of M-CSF to induce angiogenesis via VEGF in vivo.

[ "M", "-", "CSF", "signals", "through", "the", "MAPK", "/", "ERK", "pathway", "via", "Sp1", "to", "induce", "VEGF", "production", "and", "induces", "angiogenesis", "in", "vivo", ".", "\n", "BACKGROUND", ":", "M", "-", "CSF", "recruits", "mononuclear", "phagocytes", "which", "regulate", "processes", "such", "as", "angiogenesis", "and", "metastases", "in", "tumors", ".", "VEGF", "is", "a", "potent", "activator", "of", "angiogenesis", "as", "it", "promotes", "endothelial", "cell", "proliferation", "and", "new", "blood", "vessel", "formation", ".", "Previously", ",", "we", "reported", "that", "in", "vitro", "M", "-", "CSF", "induces", "the", "expression", "of", "biologically", "-", "active", "VEGF", "from", "human", "monocytes", ".", "METHODOLOGY", "AND", "RESULTS", ":", "In", "this", "study", ",", "we", "demonstrate", "the", "molecular", "mechanism", "of", "M", "-", "CSF", "-", "induced", "VEGF", "production", ".", "Using", "a", "construct", "containing", "the", "VEGF", "promoter", "linked", "to", "a", "luciferase", "reporter", ",", "we", "found", "that", "a", "mutation", "reducing", "HIF", "binding", "to", "the", "VEGF", "promoter", "had", "no", "significant", "effect", "on", "luciferase", "production", "induced", "by", "M", "-", "CSF", "stimulation", ".", "Further", "analysis", "revealed", "that", "M", "-", "CSF", "induced", "VEGF", "through", "the", "MAPK", "/", "ERK", "signaling", "pathway", "via", "the", "transcription", "factor", ",", "Sp1", ".", "Thus", ",", "inhibition", "of", "either", "ERK", "or", "Sp1", "suppressed", "M", "-", "CSF", "-", "induced", "VEGF", "at", "the", "mRNA", "and", "protein", "level", ".", "M", "-", "CSF", "also", "induced", "the", "nuclear", "localization", "of", "Sp1", ",", "which", "was", "blocked", "by", "ERK", "inhibition", ".", "Finally", ",", "mutating", "the", "Sp1", "binding", "sites", "within", "the", "VEGF", "promoter", "or", "inhibiting", "ERK", "decreased", "VEGF", "promoter", "activity", "in", "M", "-", "CSF", "-", "treated", "human", "monocytes", ".", "To", "evaluate", "the", "biological", "significance", "of", "M", "-", "CSF", "induced", "VEGF", "production", ",", "we", "used", "an", "in", "vivo", "angiogenesis", "model", "to", "illustrate", "the", "ability", "of", "M", "-", "CSF", "to", "recruit", "mononuclear", "phagocytes", ",", "increase", "VEGF", "levels", ",", "and", "enhance", "angiogenesis", ".", "Importantly", ",", "the", "addition", "of", "a", "neutralizing", "VEGF", "antibody", "abolished", "M", "-", "CSF", "-", "induced", "blood", "vessel", "formation", ".", "CONCLUSION", ":", "These", "data", "delineate", "an", "ERK-", "and", "Sp1-dependent", "mechanism", "of", "M", "-", "CSF", "induced", "VEGF", "production", "and", "demonstrate", "for", "the", "first", "time", "the", "ability", "of", "M", "-", "CSF", "to", "induce", "angiogenesis", "via", "VEGF", "in", "vivo", ".", "\n" ]

[ "Cell", "Gene_or_gene_product", "DNA_domain_or_region", "Multi-tissue_structure", "Cellular_component", "Cancer", "Organism" ]

M - CSF is a Gene_or_gene_product, MAPK is a Gene_or_gene_product, ERK is a Gene_or_gene_product, Sp1 is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, mononuclear phagocytes is a Cell, tumors is a Cancer, VEGF is a Gene_or_gene_product, endothelial cell is a Cell, blood vessel is a Multi-tissue_structure, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, human is a Organism, monocytes is a Cell, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, promoter is a DNA_domain_or_region, luciferase is a Gene_or_gene_product, HIF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, promoter is a DNA_domain_or_region, luciferase is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, MAPK is a Gene_or_gene_product, ERK is a Gene_or_gene_product, Sp1 is a Gene_or_gene_product, ERK is a Gene_or_gene_product, Sp1 is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, nuclear is a Cellular_component, Sp1 is a Gene_or_gene_product, ERK is a Gene_or_gene_product, Sp1 is a Gene_or_gene_product, binding sites is a DNA_domain_or_region, VEGF is a Gene_or_gene_product, promoter is a DNA_domain_or_region, ERK is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, promoter is a DNA_domain_or_region, M - CSF is a Gene_or_gene_product, human is a Organism, monocytes is a Cell, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, mononuclear phagocytes is a Cell, VEGF is a Gene_or_gene_product, VEGF antibody is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, blood vessel is a Multi-tissue_structure, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, M - CSF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product

30_task1

Sentence: M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. BACKGROUND: M-CSF recruits mononuclear phagocytes which regulate processes such as angiogenesis and metastases in tumors. VEGF is a potent activator of angiogenesis as it promotes endothelial cell proliferation and new blood vessel formation. Previously, we reported that in vitro M-CSF induces the expression of biologically-active VEGF from human monocytes. METHODOLOGY AND RESULTS: In this study, we demonstrate the molecular mechanism of M-CSF-induced VEGF production. Using a construct containing the VEGF promoter linked to a luciferase reporter, we found that a mutation reducing HIF binding to the VEGF promoter had no significant effect on luciferase production induced by M-CSF stimulation. Further analysis revealed that M-CSF induced VEGF through the MAPK/ERK signaling pathway via the transcription factor, Sp1. Thus, inhibition of either ERK or Sp1 suppressed M-CSF-induced VEGF at the mRNA and protein level. M-CSF also induced the nuclear localization of Sp1, which was blocked by ERK inhibition. Finally, mutating the Sp1 binding sites within the VEGF promoter or inhibiting ERK decreased VEGF promoter activity in M-CSF-treated human monocytes. To evaluate the biological significance of M-CSF induced VEGF production, we used an in vivo angiogenesis model to illustrate the ability of M-CSF to recruit mononuclear phagocytes, increase VEGF levels, and enhance angiogenesis. Importantly, the addition of a neutralizing VEGF antibody abolished M-CSF-induced blood vessel formation. CONCLUSION: These data delineate an ERK- and Sp1-dependent mechanism of M-CSF induced VEGF production and demonstrate for the first time the ability of M-CSF to induce angiogenesis via VEGF in vivo. Instructions: please typing these entity words according to sentence: M - CSF, MAPK, ERK, Sp1, VEGF, M - CSF, mononuclear phagocytes, tumors, VEGF, endothelial cell, blood vessel, M - CSF, VEGF, human, monocytes, M - CSF, VEGF, VEGF, promoter, luciferase, HIF, VEGF, promoter, luciferase, M - CSF, M - CSF, VEGF, MAPK, ERK, Sp1, ERK, Sp1, M - CSF, VEGF, M - CSF, nuclear, Sp1, ERK, Sp1, binding sites, VEGF, promoter, ERK, VEGF, promoter, M - CSF, human, monocytes, M - CSF, VEGF, M - CSF, mononuclear phagocytes, VEGF, VEGF antibody, M - CSF, blood vessel, M - CSF, VEGF, M - CSF, VEGF Options: Gene_or_gene_product, Cellular_component, Organism, DNA_domain_or_region, Cancer, Multi-tissue_structure, Cell

[ "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Organism", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Cellular_component", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Organism", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O" ]

M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. BACKGROUND: M-CSF recruits mononuclear phagocytes which regulate processes such as angiogenesis and metastases in tumors. VEGF is a potent activator of angiogenesis as it promotes endothelial cell proliferation and new blood vessel formation. Previously, we reported that in vitro M-CSF induces the expression of biologically-active VEGF from human monocytes. METHODOLOGY AND RESULTS: In this study, we demonstrate the molecular mechanism of M-CSF-induced VEGF production. Using a construct containing the VEGF promoter linked to a luciferase reporter, we found that a mutation reducing HIF binding to the VEGF promoter had no significant effect on luciferase production induced by M-CSF stimulation. Further analysis revealed that M-CSF induced VEGF through the MAPK/ERK signaling pathway via the transcription factor, Sp1. Thus, inhibition of either ERK or Sp1 suppressed M-CSF-induced VEGF at the mRNA and protein level. M-CSF also induced the nuclear localization of Sp1, which was blocked by ERK inhibition. Finally, mutating the Sp1 binding sites within the VEGF promoter or inhibiting ERK decreased VEGF promoter activity in M-CSF-treated human monocytes. To evaluate the biological significance of M-CSF induced VEGF production, we used an in vivo angiogenesis model to illustrate the ability of M-CSF to recruit mononuclear phagocytes, increase VEGF levels, and enhance angiogenesis. Importantly, the addition of a neutralizing VEGF antibody abolished M-CSF-induced blood vessel formation. CONCLUSION: These data delineate an ERK- and Sp1-dependent mechanism of M-CSF induced VEGF production and demonstrate for the first time the ability of M-CSF to induce angiogenesis via VEGF in vivo.

[ "M", "-", "CSF", "signals", "through", "the", "MAPK", "/", "ERK", "pathway", "via", "Sp1", "to", "induce", "VEGF", "production", "and", "induces", "angiogenesis", "in", "vivo", ".", "\n", "BACKGROUND", ":", "M", "-", "CSF", "recruits", "mononuclear", "phagocytes", "which", "regulate", "processes", "such", "as", "angiogenesis", "and", "metastases", "in", "tumors", ".", "VEGF", "is", "a", "potent", "activator", "of", "angiogenesis", "as", "it", "promotes", "endothelial", "cell", "proliferation", "and", "new", "blood", "vessel", "formation", ".", "Previously", ",", "we", "reported", "that", "in", "vitro", "M", "-", "CSF", "induces", "the", "expression", "of", "biologically", "-", "active", "VEGF", "from", "human", "monocytes", ".", "METHODOLOGY", "AND", "RESULTS", ":", "In", "this", "study", ",", "we", "demonstrate", "the", "molecular", "mechanism", "of", "M", "-", "CSF", "-", "induced", "VEGF", "production", ".", "Using", "a", "construct", "containing", "the", "VEGF", "promoter", "linked", "to", "a", "luciferase", "reporter", ",", "we", "found", "that", "a", "mutation", "reducing", "HIF", "binding", "to", "the", "VEGF", "promoter", "had", "no", "significant", "effect", "on", "luciferase", "production", "induced", "by", "M", "-", "CSF", "stimulation", ".", "Further", "analysis", "revealed", "that", "M", "-", "CSF", "induced", "VEGF", "through", "the", "MAPK", "/", "ERK", "signaling", "pathway", "via", "the", "transcription", "factor", ",", "Sp1", ".", "Thus", ",", "inhibition", "of", "either", "ERK", "or", "Sp1", "suppressed", "M", "-", "CSF", "-", "induced", "VEGF", "at", "the", "mRNA", "and", "protein", "level", ".", "M", "-", "CSF", "also", "induced", "the", "nuclear", "localization", "of", "Sp1", ",", "which", "was", "blocked", "by", "ERK", "inhibition", ".", "Finally", ",", "mutating", "the", "Sp1", "binding", "sites", "within", "the", "VEGF", "promoter", "or", "inhibiting", "ERK", "decreased", "VEGF", "promoter", "activity", "in", "M", "-", "CSF", "-", "treated", "human", "monocytes", ".", "To", "evaluate", "the", "biological", "significance", "of", "M", "-", "CSF", "induced", "VEGF", "production", ",", "we", "used", "an", "in", "vivo", "angiogenesis", "model", "to", "illustrate", "the", "ability", "of", "M", "-", "CSF", "to", "recruit", "mononuclear", "phagocytes", ",", "increase", "VEGF", "levels", ",", "and", "enhance", "angiogenesis", ".", "Importantly", ",", "the", "addition", "of", "a", "neutralizing", "VEGF", "antibody", "abolished", "M", "-", "CSF", "-", "induced", "blood", "vessel", "formation", ".", "CONCLUSION", ":", "These", "data", "delineate", "an", "ERK-", "and", "Sp1-dependent", "mechanism", "of", "M", "-", "CSF", "induced", "VEGF", "production", "and", "demonstrate", "for", "the", "first", "time", "the", "ability", "of", "M", "-", "CSF", "to", "induce", "angiogenesis", "via", "VEGF", "in", "vivo", ".", "\n" ]

[ "Cell", "Gene_or_gene_product", "DNA_domain_or_region", "Multi-tissue_structure", "Cellular_component", "Cancer", "Organism" ]

M - CSF, MAPK, ERK, Sp1, VEGF, M - CSF, mononuclear phagocytes, tumors, VEGF, endothelial cell, blood vessel, M - CSF, VEGF, human, monocytes, M - CSF, VEGF, VEGF, promoter, luciferase, HIF, VEGF, promoter, luciferase, M - CSF, M - CSF, VEGF, MAPK, ERK, Sp1, ERK, Sp1, M - CSF, VEGF, M - CSF, nuclear, Sp1, ERK, Sp1, binding sites, VEGF, promoter, ERK, VEGF, promoter, M - CSF, human, monocytes, M - CSF, VEGF, M - CSF, mononuclear phagocytes, VEGF, VEGF antibody, M - CSF, blood vessel, M - CSF, VEGF, M - CSF, VEGF

30_task2

Sentence: M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. BACKGROUND: M-CSF recruits mononuclear phagocytes which regulate processes such as angiogenesis and metastases in tumors. VEGF is a potent activator of angiogenesis as it promotes endothelial cell proliferation and new blood vessel formation. Previously, we reported that in vitro M-CSF induces the expression of biologically-active VEGF from human monocytes. METHODOLOGY AND RESULTS: In this study, we demonstrate the molecular mechanism of M-CSF-induced VEGF production. Using a construct containing the VEGF promoter linked to a luciferase reporter, we found that a mutation reducing HIF binding to the VEGF promoter had no significant effect on luciferase production induced by M-CSF stimulation. Further analysis revealed that M-CSF induced VEGF through the MAPK/ERK signaling pathway via the transcription factor, Sp1. Thus, inhibition of either ERK or Sp1 suppressed M-CSF-induced VEGF at the mRNA and protein level. M-CSF also induced the nuclear localization of Sp1, which was blocked by ERK inhibition. Finally, mutating the Sp1 binding sites within the VEGF promoter or inhibiting ERK decreased VEGF promoter activity in M-CSF-treated human monocytes. To evaluate the biological significance of M-CSF induced VEGF production, we used an in vivo angiogenesis model to illustrate the ability of M-CSF to recruit mononuclear phagocytes, increase VEGF levels, and enhance angiogenesis. Importantly, the addition of a neutralizing VEGF antibody abolished M-CSF-induced blood vessel formation. CONCLUSION: These data delineate an ERK- and Sp1-dependent mechanism of M-CSF induced VEGF production and demonstrate for the first time the ability of M-CSF to induce angiogenesis via VEGF in vivo. Instructions: please extract entity words from the input sentence

[ "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Organism", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Cellular_component", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Organism", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O" ]

M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. BACKGROUND: M-CSF recruits mononuclear phagocytes which regulate processes such as angiogenesis and metastases in tumors. VEGF is a potent activator of angiogenesis as it promotes endothelial cell proliferation and new blood vessel formation. Previously, we reported that in vitro M-CSF induces the expression of biologically-active VEGF from human monocytes. METHODOLOGY AND RESULTS: In this study, we demonstrate the molecular mechanism of M-CSF-induced VEGF production. Using a construct containing the VEGF promoter linked to a luciferase reporter, we found that a mutation reducing HIF binding to the VEGF promoter had no significant effect on luciferase production induced by M-CSF stimulation. Further analysis revealed that M-CSF induced VEGF through the MAPK/ERK signaling pathway via the transcription factor, Sp1. Thus, inhibition of either ERK or Sp1 suppressed M-CSF-induced VEGF at the mRNA and protein level. M-CSF also induced the nuclear localization of Sp1, which was blocked by ERK inhibition. Finally, mutating the Sp1 binding sites within the VEGF promoter or inhibiting ERK decreased VEGF promoter activity in M-CSF-treated human monocytes. To evaluate the biological significance of M-CSF induced VEGF production, we used an in vivo angiogenesis model to illustrate the ability of M-CSF to recruit mononuclear phagocytes, increase VEGF levels, and enhance angiogenesis. Importantly, the addition of a neutralizing VEGF antibody abolished M-CSF-induced blood vessel formation. CONCLUSION: These data delineate an ERK- and Sp1-dependent mechanism of M-CSF induced VEGF production and demonstrate for the first time the ability of M-CSF to induce angiogenesis via VEGF in vivo.

[ "M", "-", "CSF", "signals", "through", "the", "MAPK", "/", "ERK", "pathway", "via", "Sp1", "to", "induce", "VEGF", "production", "and", "induces", "angiogenesis", "in", "vivo", ".", "\n", "BACKGROUND", ":", "M", "-", "CSF", "recruits", "mononuclear", "phagocytes", "which", "regulate", "processes", "such", "as", "angiogenesis", "and", "metastases", "in", "tumors", ".", "VEGF", "is", "a", "potent", "activator", "of", "angiogenesis", "as", "it", "promotes", "endothelial", "cell", "proliferation", "and", "new", "blood", "vessel", "formation", ".", "Previously", ",", "we", "reported", "that", "in", "vitro", "M", "-", "CSF", "induces", "the", "expression", "of", "biologically", "-", "active", "VEGF", "from", "human", "monocytes", ".", "METHODOLOGY", "AND", "RESULTS", ":", "In", "this", "study", ",", "we", "demonstrate", "the", "molecular", "mechanism", "of", "M", "-", "CSF", "-", "induced", "VEGF", "production", ".", "Using", "a", "construct", "containing", "the", "VEGF", "promoter", "linked", "to", "a", "luciferase", "reporter", ",", "we", "found", "that", "a", "mutation", "reducing", "HIF", "binding", "to", "the", "VEGF", "promoter", "had", "no", "significant", "effect", "on", "luciferase", "production", "induced", "by", "M", "-", "CSF", "stimulation", ".", "Further", "analysis", "revealed", "that", "M", "-", "CSF", "induced", "VEGF", "through", "the", "MAPK", "/", "ERK", "signaling", "pathway", "via", "the", "transcription", "factor", ",", "Sp1", ".", "Thus", ",", "inhibition", "of", "either", "ERK", "or", "Sp1", "suppressed", "M", "-", "CSF", "-", "induced", "VEGF", "at", "the", "mRNA", "and", "protein", "level", ".", "M", "-", "CSF", "also", "induced", "the", "nuclear", "localization", "of", "Sp1", ",", "which", "was", "blocked", "by", "ERK", "inhibition", ".", "Finally", ",", "mutating", "the", "Sp1", "binding", "sites", "within", "the", "VEGF", "promoter", "or", "inhibiting", "ERK", "decreased", "VEGF", "promoter", "activity", "in", "M", "-", "CSF", "-", "treated", "human", "monocytes", ".", "To", "evaluate", "the", "biological", "significance", "of", "M", "-", "CSF", "induced", "VEGF", "production", ",", "we", "used", "an", "in", "vivo", "angiogenesis", "model", "to", "illustrate", "the", "ability", "of", "M", "-", "CSF", "to", "recruit", "mononuclear", "phagocytes", ",", "increase", "VEGF", "levels", ",", "and", "enhance", "angiogenesis", ".", "Importantly", ",", "the", "addition", "of", "a", "neutralizing", "VEGF", "antibody", "abolished", "M", "-", "CSF", "-", "induced", "blood", "vessel", "formation", ".", "CONCLUSION", ":", "These", "data", "delineate", "an", "ERK-", "and", "Sp1-dependent", "mechanism", "of", "M", "-", "CSF", "induced", "VEGF", "production", "and", "demonstrate", "for", "the", "first", "time", "the", "ability", "of", "M", "-", "CSF", "to", "induce", "angiogenesis", "via", "VEGF", "in", "vivo", ".", "\n" ]

[ "Cell", "Gene_or_gene_product", "DNA_domain_or_region", "Multi-tissue_structure", "Cellular_component", "Cancer", "Organism" ]

LMP1 is a Protein, LMP1 is a Protein, IL4 is a Protein, LMP1 is a Protein, LMP1 is a Protein, CD19 is a Protein, LMP1 is a Protein, IL4 is a Protein, LMP1 is a Protein, IL4 is a Protein, LMP1 is a Protein

60_task0

Sentence: LMP1 Promotes B Cell Survival and Proliferation In Vitro (A) MTS assay of splenocytes from WT and LMP1 transgenic mice. Splenocytes were cultured in the presence (grey bars) or absence (black bars) of IL4 for 3 d. The results are the mean +/- SEM of triplicate samples averaged from multiple mice where "n" the number of mice analyzed is as follows: n = 2 for WT lymphocytes and WT lymphomas, n = 11 for LMP1 transgenic lymphocytes, and n = 13 for LMP1 transgenic lymphomas. (B) EMA exclusion of CD19+ gated splenocytes from WT and LMP1 transgenic mice showing percentage of viable B cells cultured with (white bars) or without (black bars) IL4 for 2 d. (C) Flow cytometry analysis for incorporated BrdU in WT and LMP1 transgenic lymphoma cells cultured with or without IL4 for 2 d. Shown are the results from WT lymphoma 1 and LMP1 transgenic lymphoma 2. Percentages of cells in each quadrant are shown. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

LMP1 Promotes B Cell Survival and Proliferation In Vitro (A) MTS assay of splenocytes from WT and LMP1 transgenic mice. Splenocytes were cultured in the presence (grey bars) or absence (black bars) of IL4 for 3 d. The results are the mean +/- SEM of triplicate samples averaged from multiple mice where "n" the number of mice analyzed is as follows: n = 2 for WT lymphocytes and WT lymphomas, n = 11 for LMP1 transgenic lymphocytes, and n = 13 for LMP1 transgenic lymphomas. (B) EMA exclusion of CD19+ gated splenocytes from WT and LMP1 transgenic mice showing percentage of viable B cells cultured with (white bars) or without (black bars) IL4 for 2 d. (C) Flow cytometry analysis for incorporated BrdU in WT and LMP1 transgenic lymphoma cells cultured with or without IL4 for 2 d. Shown are the results from WT lymphoma 1 and LMP1 transgenic lymphoma 2. Percentages of cells in each quadrant are shown.

[ "LMP1", "Promotes", "B", "Cell", "Survival", "and", "Proliferation", "In", "Vitro", "\n", "(", "A", ")", "MTS", "assay", "of", "splenocytes", "from", "WT", "and", "LMP1", "transgenic", "mice", ".", "Splenocytes", "were", "cultured", "in", "the", "presence", "(", "grey", "bars", ")", "or", "absence", "(", "black", "bars", ")", "of", "IL4", "for", "3", "d.", "The", "results", "are", "the", "mean", "+", "/-", "SEM", "of", "triplicate", "samples", "averaged", "from", "multiple", "mice", "where", "\"", "n", "\"", "the", "number", "of", "mice", "analyzed", "is", "as", "follows", ":", "n", "=", "2", "for", "WT", "lymphocytes", "and", "WT", "lymphomas", ",", "n", "=", "11", "for", "LMP1", "transgenic", "lymphocytes", ",", "and", "n", "=", "13", "for", "LMP1", "transgenic", "lymphomas", ".", "\n", "(", "B", ")", "EMA", "exclusion", "of", "CD19", "+", "gated", "splenocytes", "from", "WT", "and", "LMP1", "transgenic", "mice", "showing", "percentage", "of", "viable", "B", "cells", "cultured", "with", "(", "white", "bars", ")", "or", "without", "(", "black", "bars", ")", "IL4", "for", "2", "d.", "\n", "(", "C", ")", "Flow", "cytometry", "analysis", "for", "incorporated", "BrdU", "in", "WT", "and", "LMP1", "transgenic", "lymphoma", "cells", "cultured", "with", "or", "without", "IL4", "for", "2", "d.", "Shown", "are", "the", "results", "from", "WT", "lymphoma", "1", "and", "LMP1", "transgenic", "lymphoma", "2", ".", "Percentages", "of", "cells", "in", "each", "quadrant", "are", "shown", ".", "\n" ]

[ "Protein" ]

LMP1 is a Protein, LMP1 is a Protein, IL4 is a Protein, LMP1 is a Protein, LMP1 is a Protein, CD19 is a Protein, LMP1 is a Protein, IL4 is a Protein, LMP1 is a Protein, IL4 is a Protein, LMP1 is a Protein

60_task1

Sentence: LMP1 Promotes B Cell Survival and Proliferation In Vitro (A) MTS assay of splenocytes from WT and LMP1 transgenic mice. Splenocytes were cultured in the presence (grey bars) or absence (black bars) of IL4 for 3 d. The results are the mean +/- SEM of triplicate samples averaged from multiple mice where "n" the number of mice analyzed is as follows: n = 2 for WT lymphocytes and WT lymphomas, n = 11 for LMP1 transgenic lymphocytes, and n = 13 for LMP1 transgenic lymphomas. (B) EMA exclusion of CD19+ gated splenocytes from WT and LMP1 transgenic mice showing percentage of viable B cells cultured with (white bars) or without (black bars) IL4 for 2 d. (C) Flow cytometry analysis for incorporated BrdU in WT and LMP1 transgenic lymphoma cells cultured with or without IL4 for 2 d. Shown are the results from WT lymphoma 1 and LMP1 transgenic lymphoma 2. Percentages of cells in each quadrant are shown. Instructions: please typing these entity words according to sentence: LMP1, LMP1, IL4, LMP1, LMP1, CD19, LMP1, IL4, LMP1, IL4, LMP1 Options: Protein

[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

LMP1 Promotes B Cell Survival and Proliferation In Vitro (A) MTS assay of splenocytes from WT and LMP1 transgenic mice. Splenocytes were cultured in the presence (grey bars) or absence (black bars) of IL4 for 3 d. The results are the mean +/- SEM of triplicate samples averaged from multiple mice where "n" the number of mice analyzed is as follows: n = 2 for WT lymphocytes and WT lymphomas, n = 11 for LMP1 transgenic lymphocytes, and n = 13 for LMP1 transgenic lymphomas. (B) EMA exclusion of CD19+ gated splenocytes from WT and LMP1 transgenic mice showing percentage of viable B cells cultured with (white bars) or without (black bars) IL4 for 2 d. (C) Flow cytometry analysis for incorporated BrdU in WT and LMP1 transgenic lymphoma cells cultured with or without IL4 for 2 d. Shown are the results from WT lymphoma 1 and LMP1 transgenic lymphoma 2. Percentages of cells in each quadrant are shown.

[ "LMP1", "Promotes", "B", "Cell", "Survival", "and", "Proliferation", "In", "Vitro", "\n", "(", "A", ")", "MTS", "assay", "of", "splenocytes", "from", "WT", "and", "LMP1", "transgenic", "mice", ".", "Splenocytes", "were", "cultured", "in", "the", "presence", "(", "grey", "bars", ")", "or", "absence", "(", "black", "bars", ")", "of", "IL4", "for", "3", "d.", "The", "results", "are", "the", "mean", "+", "/-", "SEM", "of", "triplicate", "samples", "averaged", "from", "multiple", "mice", "where", "\"", "n", "\"", "the", "number", "of", "mice", "analyzed", "is", "as", "follows", ":", "n", "=", "2", "for", "WT", "lymphocytes", "and", "WT", "lymphomas", ",", "n", "=", "11", "for", "LMP1", "transgenic", "lymphocytes", ",", "and", "n", "=", "13", "for", "LMP1", "transgenic", "lymphomas", ".", "\n", "(", "B", ")", "EMA", "exclusion", "of", "CD19", "+", "gated", "splenocytes", "from", "WT", "and", "LMP1", "transgenic", "mice", "showing", "percentage", "of", "viable", "B", "cells", "cultured", "with", "(", "white", "bars", ")", "or", "without", "(", "black", "bars", ")", "IL4", "for", "2", "d.", "\n", "(", "C", ")", "Flow", "cytometry", "analysis", "for", "incorporated", "BrdU", "in", "WT", "and", "LMP1", "transgenic", "lymphoma", "cells", "cultured", "with", "or", "without", "IL4", "for", "2", "d.", "Shown", "are", "the", "results", "from", "WT", "lymphoma", "1", "and", "LMP1", "transgenic", "lymphoma", "2", ".", "Percentages", "of", "cells", "in", "each", "quadrant", "are", "shown", ".", "\n" ]

[ "Protein" ]

LMP1, LMP1, IL4, LMP1, LMP1, CD19, LMP1, IL4, LMP1, IL4, LMP1

60_task2

Sentence: LMP1 Promotes B Cell Survival and Proliferation In Vitro (A) MTS assay of splenocytes from WT and LMP1 transgenic mice. Splenocytes were cultured in the presence (grey bars) or absence (black bars) of IL4 for 3 d. The results are the mean +/- SEM of triplicate samples averaged from multiple mice where "n" the number of mice analyzed is as follows: n = 2 for WT lymphocytes and WT lymphomas, n = 11 for LMP1 transgenic lymphocytes, and n = 13 for LMP1 transgenic lymphomas. (B) EMA exclusion of CD19+ gated splenocytes from WT and LMP1 transgenic mice showing percentage of viable B cells cultured with (white bars) or without (black bars) IL4 for 2 d. (C) Flow cytometry analysis for incorporated BrdU in WT and LMP1 transgenic lymphoma cells cultured with or without IL4 for 2 d. Shown are the results from WT lymphoma 1 and LMP1 transgenic lymphoma 2. Percentages of cells in each quadrant are shown. Instructions: please extract entity words from the input sentence

[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

LMP1 Promotes B Cell Survival and Proliferation In Vitro (A) MTS assay of splenocytes from WT and LMP1 transgenic mice. Splenocytes were cultured in the presence (grey bars) or absence (black bars) of IL4 for 3 d. The results are the mean +/- SEM of triplicate samples averaged from multiple mice where "n" the number of mice analyzed is as follows: n = 2 for WT lymphocytes and WT lymphomas, n = 11 for LMP1 transgenic lymphocytes, and n = 13 for LMP1 transgenic lymphomas. (B) EMA exclusion of CD19+ gated splenocytes from WT and LMP1 transgenic mice showing percentage of viable B cells cultured with (white bars) or without (black bars) IL4 for 2 d. (C) Flow cytometry analysis for incorporated BrdU in WT and LMP1 transgenic lymphoma cells cultured with or without IL4 for 2 d. Shown are the results from WT lymphoma 1 and LMP1 transgenic lymphoma 2. Percentages of cells in each quadrant are shown.

[ "LMP1", "Promotes", "B", "Cell", "Survival", "and", "Proliferation", "In", "Vitro", "\n", "(", "A", ")", "MTS", "assay", "of", "splenocytes", "from", "WT", "and", "LMP1", "transgenic", "mice", ".", "Splenocytes", "were", "cultured", "in", "the", "presence", "(", "grey", "bars", ")", "or", "absence", "(", "black", "bars", ")", "of", "IL4", "for", "3", "d.", "The", "results", "are", "the", "mean", "+", "/-", "SEM", "of", "triplicate", "samples", "averaged", "from", "multiple", "mice", "where", "\"", "n", "\"", "the", "number", "of", "mice", "analyzed", "is", "as", "follows", ":", "n", "=", "2", "for", "WT", "lymphocytes", "and", "WT", "lymphomas", ",", "n", "=", "11", "for", "LMP1", "transgenic", "lymphocytes", ",", "and", "n", "=", "13", "for", "LMP1", "transgenic", "lymphomas", ".", "\n", "(", "B", ")", "EMA", "exclusion", "of", "CD19", "+", "gated", "splenocytes", "from", "WT", "and", "LMP1", "transgenic", "mice", "showing", "percentage", "of", "viable", "B", "cells", "cultured", "with", "(", "white", "bars", ")", "or", "without", "(", "black", "bars", ")", "IL4", "for", "2", "d.", "\n", "(", "C", ")", "Flow", "cytometry", "analysis", "for", "incorporated", "BrdU", "in", "WT", "and", "LMP1", "transgenic", "lymphoma", "cells", "cultured", "with", "or", "without", "IL4", "for", "2", "d.", "Shown", "are", "the", "results", "from", "WT", "lymphoma", "1", "and", "LMP1", "transgenic", "lymphoma", "2", ".", "Percentages", "of", "cells", "in", "each", "quadrant", "are", "shown", ".", "\n" ]

[ "Protein" ]

polyethylene glycol is a compound, Na2SO4 is a compound, pectinase is a protein, pectinase is a protein

DS.d535_task0

Sentence: Concentrations of polyethylene glycol 1000 and Na2SO4 were selected as independent variables to evaluate their impact on parameters of partitioning in aqueous two-phase system--the partition coefficient of pectinase, purification factor and pectinase yield. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "B-compound", "I-compound", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein", "O", "O" ]

Concentrations of polyethylene glycol 1000 and Na2SO4 were selected as independent variables to evaluate their impact on parameters of partitioning in aqueous two-phase system--the partition coefficient of pectinase, purification factor and pectinase yield.

[ "Concentrations", "of", "polyethylene", "glycol", "1000", "and", "Na2SO4", "were", "selected", "as", "independent", "variables", "to", "evaluate", "their", "impact", "on", "parameters", "of", "partitioning", "in", "aqueous", "two", "-", "phase", "system", "--", "the", "partition", "coefficient", "of", "pectinase", ",", "purification", "factor", "and", "pectinase", "yield", "." ]

[ "compound", "protein" ]

polyethylene glycol is a compound, Na2SO4 is a compound, pectinase is a protein, pectinase is a protein

DS.d535_task1

Sentence: Concentrations of polyethylene glycol 1000 and Na2SO4 were selected as independent variables to evaluate their impact on parameters of partitioning in aqueous two-phase system--the partition coefficient of pectinase, purification factor and pectinase yield. Instructions: please typing these entity words according to sentence: polyethylene glycol, Na2SO4, pectinase, pectinase Options: compound, protein

[ "O", "O", "B-compound", "I-compound", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein", "O", "O" ]

Concentrations of polyethylene glycol 1000 and Na2SO4 were selected as independent variables to evaluate their impact on parameters of partitioning in aqueous two-phase system--the partition coefficient of pectinase, purification factor and pectinase yield.

[ "Concentrations", "of", "polyethylene", "glycol", "1000", "and", "Na2SO4", "were", "selected", "as", "independent", "variables", "to", "evaluate", "their", "impact", "on", "parameters", "of", "partitioning", "in", "aqueous", "two", "-", "phase", "system", "--", "the", "partition", "coefficient", "of", "pectinase", ",", "purification", "factor", "and", "pectinase", "yield", "." ]

[ "compound", "protein" ]

polyethylene glycol, Na2SO4, pectinase, pectinase

DS.d535_task2

Sentence: Concentrations of polyethylene glycol 1000 and Na2SO4 were selected as independent variables to evaluate their impact on parameters of partitioning in aqueous two-phase system--the partition coefficient of pectinase, purification factor and pectinase yield. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-compound", "I-compound", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-protein", "O", "O" ]

Concentrations of polyethylene glycol 1000 and Na2SO4 were selected as independent variables to evaluate their impact on parameters of partitioning in aqueous two-phase system--the partition coefficient of pectinase, purification factor and pectinase yield.

[ "Concentrations", "of", "polyethylene", "glycol", "1000", "and", "Na2SO4", "were", "selected", "as", "independent", "variables", "to", "evaluate", "their", "impact", "on", "parameters", "of", "partitioning", "in", "aqueous", "two", "-", "phase", "system", "--", "the", "partition", "coefficient", "of", "pectinase", ",", "purification", "factor", "and", "pectinase", "yield", "." ]

[ "compound", "protein" ]

vasopressin is a CHEMICAL, oxytocin is a CHEMICAL, V1a is a GENE-Y, V1b is a GENE-Y, V2 is a GENE-Y, OT receptors is a GENE-Y

18655903_task0

Sentence: Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O" ]

Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.

[ "Peptide", "and", "non", "-", "peptide", "agonists", "and", "antagonists", "for", "the", "vasopressin", "and", "oxytocin", "V1a", ",", "V1b", ",", "V2", "and", "OT", "receptors", ":", "research", "tools", "and", "potential", "therapeutic", "agents", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

vasopressin is a CHEMICAL, oxytocin is a CHEMICAL, V1a is a GENE-Y, V1b is a GENE-Y, V2 is a GENE-Y, OT receptors is a GENE-Y

18655903_task1

Sentence: Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Instructions: please typing these entity words according to sentence: vasopressin, oxytocin, V1a, V1b, V2, OT receptors Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O" ]

Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.

[ "Peptide", "and", "non", "-", "peptide", "agonists", "and", "antagonists", "for", "the", "vasopressin", "and", "oxytocin", "V1a", ",", "V1b", ",", "V2", "and", "OT", "receptors", ":", "research", "tools", "and", "potential", "therapeutic", "agents", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

vasopressin, oxytocin, V1a, V1b, V2, OT receptors

18655903_task2

Sentence: Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O" ]

Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.

[ "Peptide", "and", "non", "-", "peptide", "agonists", "and", "antagonists", "for", "the", "vasopressin", "and", "oxytocin", "V1a", ",", "V1b", ",", "V2", "and", "OT", "receptors", ":", "research", "tools", "and", "potential", "therapeutic", "agents", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

huGATA-3 transcription is an other_name, GATA regulatory elements is a DNA_domain_or_region, HIV-1 long terminal repeat is a DNA_domain_or_region, surface plasmon resonance is an other_name

54173_task0

Sentence: Analysis of interactions between huGATA-3 transcription factor and three GATA regulatory elements of HIV-1 long terminal repeat, by surface plasmon resonance. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region, other_name

[ "O", "O", "O", "O", "B-other_name", "I-other_name", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]

Analysis of interactions between huGATA-3 transcription factor and three GATA regulatory elements of HIV-1 long terminal repeat, by surface plasmon resonance.

[ "Analysis", "of", "interactions", "between", "huGATA-3", "transcription", "factor", "and", "three", "GATA", "regulatory", "elements", "of", "HIV-1", "long", "terminal", "repeat", ",", "by", "surface", "plasmon", "resonance", "." ]

[ "DNA_domain_or_region", "other_name", "protein_molecule", "protein_family_or_group", "(AND DNA_domain_or_region DNA_domain_or_region DNA_domain_or_region)", "cell_component", "virus", "" ]

huGATA-3 transcription is an other_name, GATA regulatory elements is a DNA_domain_or_region, HIV-1 long terminal repeat is a DNA_domain_or_region, surface plasmon resonance is an other_name

54173_task1

Sentence: Analysis of interactions between huGATA-3 transcription factor and three GATA regulatory elements of HIV-1 long terminal repeat, by surface plasmon resonance. Instructions: please typing these entity words according to sentence: huGATA-3 transcription, GATA regulatory elements, HIV-1 long terminal repeat, surface plasmon resonance Options: DNA_domain_or_region, other_name

[ "O", "O", "O", "O", "B-other_name", "I-other_name", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]

Analysis of interactions between huGATA-3 transcription factor and three GATA regulatory elements of HIV-1 long terminal repeat, by surface plasmon resonance.

[ "Analysis", "of", "interactions", "between", "huGATA-3", "transcription", "factor", "and", "three", "GATA", "regulatory", "elements", "of", "HIV-1", "long", "terminal", "repeat", ",", "by", "surface", "plasmon", "resonance", "." ]

[ "DNA_domain_or_region", "other_name", "protein_molecule", "protein_family_or_group", "(AND DNA_domain_or_region DNA_domain_or_region DNA_domain_or_region)", "cell_component", "virus", "" ]

huGATA-3 transcription, GATA regulatory elements, HIV-1 long terminal repeat, surface plasmon resonance

54173_task2

Sentence: Analysis of interactions between huGATA-3 transcription factor and three GATA regulatory elements of HIV-1 long terminal repeat, by surface plasmon resonance. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-other_name", "I-other_name", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]

Analysis of interactions between huGATA-3 transcription factor and three GATA regulatory elements of HIV-1 long terminal repeat, by surface plasmon resonance.

[ "Analysis", "of", "interactions", "between", "huGATA-3", "transcription", "factor", "and", "three", "GATA", "regulatory", "elements", "of", "HIV-1", "long", "terminal", "repeat", ",", "by", "surface", "plasmon", "resonance", "." ]

[ "DNA_domain_or_region", "other_name", "protein_molecule", "protein_family_or_group", "(AND DNA_domain_or_region DNA_domain_or_region DNA_domain_or_region)", "cell_component", "virus", "" ]

interleukin-2 receptor alpha chain expression is an other_name, nuclear factor.kappa B activation is an other_name, protein kinase C is a protein_molecule, T lymphocytes is a cell_type, tumor necrosis factor alpha is a protein_molecule

11994_task0

Sentence: Regulation of interleukin-2 receptor alpha chain expression and nuclear factor.kappa B activation by protein kinase C in T lymphocytes. Autocrine role of tumor necrosis factor alpha. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, protein_molecule, other_name

[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_type", "I-cell_type", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]

Regulation of interleukin-2 receptor alpha chain expression and nuclear factor.kappa B activation by protein kinase C in T lymphocytes. Autocrine role of tumor necrosis factor alpha.

[ "Regulation", "of", "interleukin-2", "receptor", "alpha", "chain", "expression", "and", "nuclear", "factor.kappa", "B", "activation", "by", "protein", "kinase", "C", "in", "T", "lymphocytes", ".", "Autocrine", "role", "of", "tumor", "necrosis", "factor", "alpha", "." ]

[ "other_name", "protein_molecule", "protein_subunit", "DNA_domain_or_region", "cell_component", "cell_type", "protein_family_or_group", "other_organic_compound", "protein_complex" ]

interleukin-2 receptor alpha chain expression is an other_name, nuclear factor.kappa B activation is an other_name, protein kinase C is a protein_molecule, T lymphocytes is a cell_type, tumor necrosis factor alpha is a protein_molecule

11994_task1

Sentence: Regulation of interleukin-2 receptor alpha chain expression and nuclear factor.kappa B activation by protein kinase C in T lymphocytes. Autocrine role of tumor necrosis factor alpha. Instructions: please typing these entity words according to sentence: interleukin-2 receptor alpha chain expression, nuclear factor.kappa B activation, protein kinase C, T lymphocytes, tumor necrosis factor alpha Options: cell_type, protein_molecule, other_name

[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_type", "I-cell_type", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]

Regulation of interleukin-2 receptor alpha chain expression and nuclear factor.kappa B activation by protein kinase C in T lymphocytes. Autocrine role of tumor necrosis factor alpha.

[ "Regulation", "of", "interleukin-2", "receptor", "alpha", "chain", "expression", "and", "nuclear", "factor.kappa", "B", "activation", "by", "protein", "kinase", "C", "in", "T", "lymphocytes", ".", "Autocrine", "role", "of", "tumor", "necrosis", "factor", "alpha", "." ]

[ "other_name", "protein_molecule", "protein_subunit", "DNA_domain_or_region", "cell_component", "cell_type", "protein_family_or_group", "other_organic_compound", "protein_complex" ]

interleukin-2 receptor alpha chain expression, nuclear factor.kappa B activation, protein kinase C, T lymphocytes, tumor necrosis factor alpha

11994_task2

Sentence: Regulation of interleukin-2 receptor alpha chain expression and nuclear factor.kappa B activation by protein kinase C in T lymphocytes. Autocrine role of tumor necrosis factor alpha. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-cell_type", "I-cell_type", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]

Regulation of interleukin-2 receptor alpha chain expression and nuclear factor.kappa B activation by protein kinase C in T lymphocytes. Autocrine role of tumor necrosis factor alpha.

[ "Regulation", "of", "interleukin-2", "receptor", "alpha", "chain", "expression", "and", "nuclear", "factor.kappa", "B", "activation", "by", "protein", "kinase", "C", "in", "T", "lymphocytes", ".", "Autocrine", "role", "of", "tumor", "necrosis", "factor", "alpha", "." ]

[ "other_name", "protein_molecule", "protein_subunit", "DNA_domain_or_region", "cell_component", "cell_type", "protein_family_or_group", "other_organic_compound", "protein_complex" ]

Sicherheit is an umlsterm, Sumatriptan is an umlsterm, Akuttherapie is an umlsterm, Clusterkopfschmerzen is an umlsterm, Patienten is an umlsterm, Clusterkopfschmerz is an umlsterm, Patienten is an umlsterm, Sumatriptan is an umlsterm, Dokumentation is an umlsterm, Patienten is an umlsterm, Schmerzkalenders is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Injektion is an umlsterm, Schmerzfreiheit is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Sumatriptan is an umlsterm, Akuttherapie is an umlsterm, Kontraindikationen is an umlsterm

DerNervenarzt.80690320.ger.abstr_task0

Sentence: Die Wirksamkeit , Sicherheit und Vertraeglichkeit von Sumatriptan s.c. in der Akuttherapie von Clusterkopfschmerzen wurde in einer offenen multizentrischen Studie in einem Untersuchungszeitraum von bis zu einem Jahr ueberprueft . Hieran nahmen von Dezember 1992 bis Oktober 1993 52 Patienten mit episodischem ( 71% und chronischem ( 29% ) Clusterkopfschmerz ) teil . Die Patienten konnten waehrend der Studie Clusterattacken selbstaendig und ausserhalb der Klinik mit 6 mg Sumatriptan behandeln . Die Dokumentation der entsprechenden Zielparameter wurde von den Patienten mit Hilfe eines Schmerzkalenders durchgefuehrt . Insgesamt wurden 2031 Attacken ausgewertet . Eine erfolgreiche Therapie trat bei 88% aller Attacken ein , 57% der Patienten waren innerhalb 15 min nach der Injektion komplett schmerzfrei . Schmerzfreiheit innerhalb von 15 min in ueber 90% aller behandelten Attacken wurde von 42% der Patienten erreicht . Ein Nachlassen der Therapierfolgsrate im Behandlungszeitraum trat nicht ein . Wegen mangelnder Wirksamkeit oder unerwuenschter Ereignisse wurde die Studie von 10% der Patienten abgebrochen . Ueber unerwuenschte Ereignisse berichteten 62% der Patienten , davon wurden 3,8% als schwerwiegend eingestuft . Sumatriptan s.c. stellt in der Akuttherapie des Clusterkopschmerzes ein zuverlaessiges , schnell wirksames und bei Beachtung von Kontraindikationen sicheres und gut vertraegliches Therapeutikum dar . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Die Wirksamkeit , Sicherheit und Vertraeglichkeit von Sumatriptan s.c. in der Akuttherapie von Clusterkopfschmerzen wurde in einer offenen multizentrischen Studie in einem Untersuchungszeitraum von bis zu einem Jahr ueberprueft . Hieran nahmen von Dezember 1992 bis Oktober 1993 52 Patienten mit episodischem ( 71% und chronischem ( 29% ) Clusterkopfschmerz ) teil . Die Patienten konnten waehrend der Studie Clusterattacken selbstaendig und ausserhalb der Klinik mit 6 mg Sumatriptan behandeln . Die Dokumentation der entsprechenden Zielparameter wurde von den Patienten mit Hilfe eines Schmerzkalenders durchgefuehrt . Insgesamt wurden 2031 Attacken ausgewertet . Eine erfolgreiche Therapie trat bei 88% aller Attacken ein , 57% der Patienten waren innerhalb 15 min nach der Injektion komplett schmerzfrei . Schmerzfreiheit innerhalb von 15 min in ueber 90% aller behandelten Attacken wurde von 42% der Patienten erreicht . Ein Nachlassen der Therapierfolgsrate im Behandlungszeitraum trat nicht ein . Wegen mangelnder Wirksamkeit oder unerwuenschter Ereignisse wurde die Studie von 10% der Patienten abgebrochen . Ueber unerwuenschte Ereignisse berichteten 62% der Patienten , davon wurden 3,8% als schwerwiegend eingestuft . Sumatriptan s.c. stellt in der Akuttherapie des Clusterkopschmerzes ein zuverlaessiges , schnell wirksames und bei Beachtung von Kontraindikationen sicheres und gut vertraegliches Therapeutikum dar .

[ "Die", "Wirksamkeit", ",", "Sicherheit", "und", "Vertraeglichkeit", "von", "Sumatriptan", "s.c", ".", "in", "der", "Akuttherapie", "von", "Clusterkopfschmerzen", "wurde", "in", "einer", "offenen", "multizentrischen", "Studie", "in", "einem", "Untersuchungszeitraum", "von", "bis", "zu", "einem", "Jahr", "ueberprueft", ".", "Hieran", "nahmen", "von", "Dezember", "1992", "bis", "Oktober", "1993", "52", "Patienten", "mit", "episodischem", "(", "71", "%", "und", "chronischem", "(", "29", "%", ")", "Clusterkopfschmerz", ")", "teil", ".", "Die", "Patienten", "konnten", "waehrend", "der", "Studie", "Clusterattacken", "selbstaendig", "und", "ausserhalb", "der", "Klinik", "mit", "6", "mg", "Sumatriptan", "behandeln", ".", "Die", "Dokumentation", "der", "entsprechenden", "Zielparameter", "wurde", "von", "den", "Patienten", "mit", "Hilfe", "eines", "Schmerzkalenders", "durchgefuehrt", ".", "Insgesamt", "wurden", "2031", "Attacken", "ausgewertet", ".", "Eine", "erfolgreiche", "Therapie", "trat", "bei", "88", "%", "aller", "Attacken", "ein", ",", "57", "%", "der", "Patienten", "waren", "innerhalb", "15", "min", "nach", "der", "Injektion", "komplett", "schmerzfrei", ".", "Schmerzfreiheit", "innerhalb", "von", "15", "min", "in", "ueber", "90", "%", "aller", "behandelten", "Attacken", "wurde", "von", "42", "%", "der", "Patienten", "erreicht", ".", "Ein", "Nachlassen", "der", "Therapierfolgsrate", "im", "Behandlungszeitraum", "trat", "nicht", "ein", ".", "Wegen", "mangelnder", "Wirksamkeit", "oder", "unerwuenschter", "Ereignisse", "wurde", "die", "Studie", "von", "10", "%", "der", "Patienten", "abgebrochen", ".", "Ueber", "unerwuenschte", "Ereignisse", "berichteten", "62", "%", "der", "Patienten", ",", "davon", "wurden", "3,8", "%", "als", "schwerwiegend", "eingestuft", ".", "Sumatriptan", "s.c", ".", "stellt", "in", "der", "Akuttherapie", "des", "Clusterkopschmerzes", "ein", "zuverlaessiges", ",", "schnell", "wirksames", "und", "bei", "Beachtung", "von", "Kontraindikationen", "sicheres", "und", "gut", "vertraegliches", "Therapeutikum", "dar", "." ]

[ "umlsterm" ]

Sicherheit is an umlsterm, Sumatriptan is an umlsterm, Akuttherapie is an umlsterm, Clusterkopfschmerzen is an umlsterm, Patienten is an umlsterm, Clusterkopfschmerz is an umlsterm, Patienten is an umlsterm, Sumatriptan is an umlsterm, Dokumentation is an umlsterm, Patienten is an umlsterm, Schmerzkalenders is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Injektion is an umlsterm, Schmerzfreiheit is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Sumatriptan is an umlsterm, Akuttherapie is an umlsterm, Kontraindikationen is an umlsterm

DerNervenarzt.80690320.ger.abstr_task1

Sentence: Die Wirksamkeit , Sicherheit und Vertraeglichkeit von Sumatriptan s.c. in der Akuttherapie von Clusterkopfschmerzen wurde in einer offenen multizentrischen Studie in einem Untersuchungszeitraum von bis zu einem Jahr ueberprueft . Hieran nahmen von Dezember 1992 bis Oktober 1993 52 Patienten mit episodischem ( 71% und chronischem ( 29% ) Clusterkopfschmerz ) teil . Die Patienten konnten waehrend der Studie Clusterattacken selbstaendig und ausserhalb der Klinik mit 6 mg Sumatriptan behandeln . Die Dokumentation der entsprechenden Zielparameter wurde von den Patienten mit Hilfe eines Schmerzkalenders durchgefuehrt . Insgesamt wurden 2031 Attacken ausgewertet . Eine erfolgreiche Therapie trat bei 88% aller Attacken ein , 57% der Patienten waren innerhalb 15 min nach der Injektion komplett schmerzfrei . Schmerzfreiheit innerhalb von 15 min in ueber 90% aller behandelten Attacken wurde von 42% der Patienten erreicht . Ein Nachlassen der Therapierfolgsrate im Behandlungszeitraum trat nicht ein . Wegen mangelnder Wirksamkeit oder unerwuenschter Ereignisse wurde die Studie von 10% der Patienten abgebrochen . Ueber unerwuenschte Ereignisse berichteten 62% der Patienten , davon wurden 3,8% als schwerwiegend eingestuft . Sumatriptan s.c. stellt in der Akuttherapie des Clusterkopschmerzes ein zuverlaessiges , schnell wirksames und bei Beachtung von Kontraindikationen sicheres und gut vertraegliches Therapeutikum dar . Instructions: please typing these entity words according to sentence: Sicherheit, Sumatriptan, Akuttherapie, Clusterkopfschmerzen, Patienten, Clusterkopfschmerz, Patienten, Sumatriptan, Dokumentation, Patienten, Schmerzkalenders, Therapie, Patienten, Injektion, Schmerzfreiheit, Patienten, Patienten, Patienten, Sumatriptan, Akuttherapie, Kontraindikationen Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Die Wirksamkeit , Sicherheit und Vertraeglichkeit von Sumatriptan s.c. in der Akuttherapie von Clusterkopfschmerzen wurde in einer offenen multizentrischen Studie in einem Untersuchungszeitraum von bis zu einem Jahr ueberprueft . Hieran nahmen von Dezember 1992 bis Oktober 1993 52 Patienten mit episodischem ( 71% und chronischem ( 29% ) Clusterkopfschmerz ) teil . Die Patienten konnten waehrend der Studie Clusterattacken selbstaendig und ausserhalb der Klinik mit 6 mg Sumatriptan behandeln . Die Dokumentation der entsprechenden Zielparameter wurde von den Patienten mit Hilfe eines Schmerzkalenders durchgefuehrt . Insgesamt wurden 2031 Attacken ausgewertet . Eine erfolgreiche Therapie trat bei 88% aller Attacken ein , 57% der Patienten waren innerhalb 15 min nach der Injektion komplett schmerzfrei . Schmerzfreiheit innerhalb von 15 min in ueber 90% aller behandelten Attacken wurde von 42% der Patienten erreicht . Ein Nachlassen der Therapierfolgsrate im Behandlungszeitraum trat nicht ein . Wegen mangelnder Wirksamkeit oder unerwuenschter Ereignisse wurde die Studie von 10% der Patienten abgebrochen . Ueber unerwuenschte Ereignisse berichteten 62% der Patienten , davon wurden 3,8% als schwerwiegend eingestuft . Sumatriptan s.c. stellt in der Akuttherapie des Clusterkopschmerzes ein zuverlaessiges , schnell wirksames und bei Beachtung von Kontraindikationen sicheres und gut vertraegliches Therapeutikum dar .

[ "Die", "Wirksamkeit", ",", "Sicherheit", "und", "Vertraeglichkeit", "von", "Sumatriptan", "s.c", ".", "in", "der", "Akuttherapie", "von", "Clusterkopfschmerzen", "wurde", "in", "einer", "offenen", "multizentrischen", "Studie", "in", "einem", "Untersuchungszeitraum", "von", "bis", "zu", "einem", "Jahr", "ueberprueft", ".", "Hieran", "nahmen", "von", "Dezember", "1992", "bis", "Oktober", "1993", "52", "Patienten", "mit", "episodischem", "(", "71", "%", "und", "chronischem", "(", "29", "%", ")", "Clusterkopfschmerz", ")", "teil", ".", "Die", "Patienten", "konnten", "waehrend", "der", "Studie", "Clusterattacken", "selbstaendig", "und", "ausserhalb", "der", "Klinik", "mit", "6", "mg", "Sumatriptan", "behandeln", ".", "Die", "Dokumentation", "der", "entsprechenden", "Zielparameter", "wurde", "von", "den", "Patienten", "mit", "Hilfe", "eines", "Schmerzkalenders", "durchgefuehrt", ".", "Insgesamt", "wurden", "2031", "Attacken", "ausgewertet", ".", "Eine", "erfolgreiche", "Therapie", "trat", "bei", "88", "%", "aller", "Attacken", "ein", ",", "57", "%", "der", "Patienten", "waren", "innerhalb", "15", "min", "nach", "der", "Injektion", "komplett", "schmerzfrei", ".", "Schmerzfreiheit", "innerhalb", "von", "15", "min", "in", "ueber", "90", "%", "aller", "behandelten", "Attacken", "wurde", "von", "42", "%", "der", "Patienten", "erreicht", ".", "Ein", "Nachlassen", "der", "Therapierfolgsrate", "im", "Behandlungszeitraum", "trat", "nicht", "ein", ".", "Wegen", "mangelnder", "Wirksamkeit", "oder", "unerwuenschter", "Ereignisse", "wurde", "die", "Studie", "von", "10", "%", "der", "Patienten", "abgebrochen", ".", "Ueber", "unerwuenschte", "Ereignisse", "berichteten", "62", "%", "der", "Patienten", ",", "davon", "wurden", "3,8", "%", "als", "schwerwiegend", "eingestuft", ".", "Sumatriptan", "s.c", ".", "stellt", "in", "der", "Akuttherapie", "des", "Clusterkopschmerzes", "ein", "zuverlaessiges", ",", "schnell", "wirksames", "und", "bei", "Beachtung", "von", "Kontraindikationen", "sicheres", "und", "gut", "vertraegliches", "Therapeutikum", "dar", "." ]

[ "umlsterm" ]

Sicherheit, Sumatriptan, Akuttherapie, Clusterkopfschmerzen, Patienten, Clusterkopfschmerz, Patienten, Sumatriptan, Dokumentation, Patienten, Schmerzkalenders, Therapie, Patienten, Injektion, Schmerzfreiheit, Patienten, Patienten, Patienten, Sumatriptan, Akuttherapie, Kontraindikationen

DerNervenarzt.80690320.ger.abstr_task2

Sentence: Die Wirksamkeit , Sicherheit und Vertraeglichkeit von Sumatriptan s.c. in der Akuttherapie von Clusterkopfschmerzen wurde in einer offenen multizentrischen Studie in einem Untersuchungszeitraum von bis zu einem Jahr ueberprueft . Hieran nahmen von Dezember 1992 bis Oktober 1993 52 Patienten mit episodischem ( 71% und chronischem ( 29% ) Clusterkopfschmerz ) teil . Die Patienten konnten waehrend der Studie Clusterattacken selbstaendig und ausserhalb der Klinik mit 6 mg Sumatriptan behandeln . Die Dokumentation der entsprechenden Zielparameter wurde von den Patienten mit Hilfe eines Schmerzkalenders durchgefuehrt . Insgesamt wurden 2031 Attacken ausgewertet . Eine erfolgreiche Therapie trat bei 88% aller Attacken ein , 57% der Patienten waren innerhalb 15 min nach der Injektion komplett schmerzfrei . Schmerzfreiheit innerhalb von 15 min in ueber 90% aller behandelten Attacken wurde von 42% der Patienten erreicht . Ein Nachlassen der Therapierfolgsrate im Behandlungszeitraum trat nicht ein . Wegen mangelnder Wirksamkeit oder unerwuenschter Ereignisse wurde die Studie von 10% der Patienten abgebrochen . Ueber unerwuenschte Ereignisse berichteten 62% der Patienten , davon wurden 3,8% als schwerwiegend eingestuft . Sumatriptan s.c. stellt in der Akuttherapie des Clusterkopschmerzes ein zuverlaessiges , schnell wirksames und bei Beachtung von Kontraindikationen sicheres und gut vertraegliches Therapeutikum dar . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Die Wirksamkeit , Sicherheit und Vertraeglichkeit von Sumatriptan s.c. in der Akuttherapie von Clusterkopfschmerzen wurde in einer offenen multizentrischen Studie in einem Untersuchungszeitraum von bis zu einem Jahr ueberprueft . Hieran nahmen von Dezember 1992 bis Oktober 1993 52 Patienten mit episodischem ( 71% und chronischem ( 29% ) Clusterkopfschmerz ) teil . Die Patienten konnten waehrend der Studie Clusterattacken selbstaendig und ausserhalb der Klinik mit 6 mg Sumatriptan behandeln . Die Dokumentation der entsprechenden Zielparameter wurde von den Patienten mit Hilfe eines Schmerzkalenders durchgefuehrt . Insgesamt wurden 2031 Attacken ausgewertet . Eine erfolgreiche Therapie trat bei 88% aller Attacken ein , 57% der Patienten waren innerhalb 15 min nach der Injektion komplett schmerzfrei . Schmerzfreiheit innerhalb von 15 min in ueber 90% aller behandelten Attacken wurde von 42% der Patienten erreicht . Ein Nachlassen der Therapierfolgsrate im Behandlungszeitraum trat nicht ein . Wegen mangelnder Wirksamkeit oder unerwuenschter Ereignisse wurde die Studie von 10% der Patienten abgebrochen . Ueber unerwuenschte Ereignisse berichteten 62% der Patienten , davon wurden 3,8% als schwerwiegend eingestuft . Sumatriptan s.c. stellt in der Akuttherapie des Clusterkopschmerzes ein zuverlaessiges , schnell wirksames und bei Beachtung von Kontraindikationen sicheres und gut vertraegliches Therapeutikum dar .

[ "Die", "Wirksamkeit", ",", "Sicherheit", "und", "Vertraeglichkeit", "von", "Sumatriptan", "s.c", ".", "in", "der", "Akuttherapie", "von", "Clusterkopfschmerzen", "wurde", "in", "einer", "offenen", "multizentrischen", "Studie", "in", "einem", "Untersuchungszeitraum", "von", "bis", "zu", "einem", "Jahr", "ueberprueft", ".", "Hieran", "nahmen", "von", "Dezember", "1992", "bis", "Oktober", "1993", "52", "Patienten", "mit", "episodischem", "(", "71", "%", "und", "chronischem", "(", "29", "%", ")", "Clusterkopfschmerz", ")", "teil", ".", "Die", "Patienten", "konnten", "waehrend", "der", "Studie", "Clusterattacken", "selbstaendig", "und", "ausserhalb", "der", "Klinik", "mit", "6", "mg", "Sumatriptan", "behandeln", ".", "Die", "Dokumentation", "der", "entsprechenden", "Zielparameter", "wurde", "von", "den", "Patienten", "mit", "Hilfe", "eines", "Schmerzkalenders", "durchgefuehrt", ".", "Insgesamt", "wurden", "2031", "Attacken", "ausgewertet", ".", "Eine", "erfolgreiche", "Therapie", "trat", "bei", "88", "%", "aller", "Attacken", "ein", ",", "57", "%", "der", "Patienten", "waren", "innerhalb", "15", "min", "nach", "der", "Injektion", "komplett", "schmerzfrei", ".", "Schmerzfreiheit", "innerhalb", "von", "15", "min", "in", "ueber", "90", "%", "aller", "behandelten", "Attacken", "wurde", "von", "42", "%", "der", "Patienten", "erreicht", ".", "Ein", "Nachlassen", "der", "Therapierfolgsrate", "im", "Behandlungszeitraum", "trat", "nicht", "ein", ".", "Wegen", "mangelnder", "Wirksamkeit", "oder", "unerwuenschter", "Ereignisse", "wurde", "die", "Studie", "von", "10", "%", "der", "Patienten", "abgebrochen", ".", "Ueber", "unerwuenschte", "Ereignisse", "berichteten", "62", "%", "der", "Patienten", ",", "davon", "wurden", "3,8", "%", "als", "schwerwiegend", "eingestuft", ".", "Sumatriptan", "s.c", ".", "stellt", "in", "der", "Akuttherapie", "des", "Clusterkopschmerzes", "ein", "zuverlaessiges", ",", "schnell", "wirksames", "und", "bei", "Beachtung", "von", "Kontraindikationen", "sicheres", "und", "gut", "vertraegliches", "Therapeutikum", "dar", "." ]

[ "umlsterm" ]

Diagnostik is an umlsterm, Wahrnehmungsstoerungen is an umlsterm, Grundschulkindern is an umlsterm, Kindern is an umlsterm, Arbeit is an umlsterm, Analyse is an umlsterm, Testleistungen is an umlsterm

HNO.80460753.ger.abstr_task0

Sentence: Der dichotische Diskriminationstest nach Uttenweiler leistet einen wertvollen Beitrag in der Diagnostik auditiver Wahrnehmungsstoerungen . Er ist in der Lage , Defizite bei der Kontrastierung und Abgrenzung von beidohrig aufgenommenen Schallsignalen verlaesslich aufzudecken , wie eine eigene Untersuchung an normalhoerigen Grundschulkindern und Kindern mit auditiver Wahrnehmungsstoerung aufzeigte . Bisher war der interindividuelle Vergleich von Testergebnissen nur in begrenztem Umfang moeglich , da die bisherige Testdurchfuehrung ein Anheben des Schallpegels vorsah , wenn die Worte nicht vollstaendig verstanden wurden . Ein weiteres Problem ergab sich daraus , dass unterschiedliche dichotische Hoerfaehigkeiten ein gleiches Testergebnis erbrachten . In dieser Arbeit wird eine alternative Form der Durchfuehrung und Auswertung vorgestellt , welche einen direkten interindividuellen Vergleich der Testergebnisse erlaubt . Es entfaellt die Anhebung der Schallpegels auch wenn die Worte nicht vollstaendig verstanden wurden , da die Ueberpruefung mit einem konstanten mittleren Schallpegel erfolgt . Zusaetzlich wurde ein Punktsystem eingefuehrt , welches eine quantitative Analyse der Testleistungen ermoeglicht . Das neue Bewertungsschema wird an konkreten Beispielen vorgestellt und erlaeutert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Der dichotische Diskriminationstest nach Uttenweiler leistet einen wertvollen Beitrag in der Diagnostik auditiver Wahrnehmungsstoerungen . Er ist in der Lage , Defizite bei der Kontrastierung und Abgrenzung von beidohrig aufgenommenen Schallsignalen verlaesslich aufzudecken , wie eine eigene Untersuchung an normalhoerigen Grundschulkindern und Kindern mit auditiver Wahrnehmungsstoerung aufzeigte . Bisher war der interindividuelle Vergleich von Testergebnissen nur in begrenztem Umfang moeglich , da die bisherige Testdurchfuehrung ein Anheben des Schallpegels vorsah , wenn die Worte nicht vollstaendig verstanden wurden . Ein weiteres Problem ergab sich daraus , dass unterschiedliche dichotische Hoerfaehigkeiten ein gleiches Testergebnis erbrachten . In dieser Arbeit wird eine alternative Form der Durchfuehrung und Auswertung vorgestellt , welche einen direkten interindividuellen Vergleich der Testergebnisse erlaubt . Es entfaellt die Anhebung der Schallpegels auch wenn die Worte nicht vollstaendig verstanden wurden , da die Ueberpruefung mit einem konstanten mittleren Schallpegel erfolgt . Zusaetzlich wurde ein Punktsystem eingefuehrt , welches eine quantitative Analyse der Testleistungen ermoeglicht . Das neue Bewertungsschema wird an konkreten Beispielen vorgestellt und erlaeutert .

[ "Der", "dichotische", "Diskriminationstest", "nach", "Uttenweiler", "leistet", "einen", "wertvollen", "Beitrag", "in", "der", "Diagnostik", "auditiver", "Wahrnehmungsstoerungen", ".", "Er", "ist", "in", "der", "Lage", ",", "Defizite", "bei", "der", "Kontrastierung", "und", "Abgrenzung", "von", "beidohrig", "aufgenommenen", "Schallsignalen", "verlaesslich", "aufzudecken", ",", "wie", "eine", "eigene", "Untersuchung", "an", "normalhoerigen", "Grundschulkindern", "und", "Kindern", "mit", "auditiver", "Wahrnehmungsstoerung", "aufzeigte", ".", "Bisher", "war", "der", "interindividuelle", "Vergleich", "von", "Testergebnissen", "nur", "in", "begrenztem", "Umfang", "moeglich", ",", "da", "die", "bisherige", "Testdurchfuehrung", "ein", "Anheben", "des", "Schallpegels", "vorsah", ",", "wenn", "die", "Worte", "nicht", "vollstaendig", "verstanden", "wurden", ".", "Ein", "weiteres", "Problem", "ergab", "sich", "daraus", ",", "dass", "unterschiedliche", "dichotische", "Hoerfaehigkeiten", "ein", "gleiches", "Testergebnis", "erbrachten", ".", "In", "dieser", "Arbeit", "wird", "eine", "alternative", "Form", "der", "Durchfuehrung", "und", "Auswertung", "vorgestellt", ",", "welche", "einen", "direkten", "interindividuellen", "Vergleich", "der", "Testergebnisse", "erlaubt", ".", "Es", "entfaellt", "die", "Anhebung", "der", "Schallpegels", "auch", "wenn", "die", "Worte", "nicht", "vollstaendig", "verstanden", "wurden", ",", "da", "die", "Ueberpruefung", "mit", "einem", "konstanten", "mittleren", "Schallpegel", "erfolgt", ".", "Zusaetzlich", "wurde", "ein", "Punktsystem", "eingefuehrt", ",", "welches", "eine", "quantitative", "Analyse", "der", "Testleistungen", "ermoeglicht", ".", "Das", "neue", "Bewertungsschema", "wird", "an", "konkreten", "Beispielen", "vorgestellt", "und", "erlaeutert", "." ]

[ "umlsterm" ]

Diagnostik is an umlsterm, Wahrnehmungsstoerungen is an umlsterm, Grundschulkindern is an umlsterm, Kindern is an umlsterm, Arbeit is an umlsterm, Analyse is an umlsterm, Testleistungen is an umlsterm

HNO.80460753.ger.abstr_task1

Sentence: Der dichotische Diskriminationstest nach Uttenweiler leistet einen wertvollen Beitrag in der Diagnostik auditiver Wahrnehmungsstoerungen . Er ist in der Lage , Defizite bei der Kontrastierung und Abgrenzung von beidohrig aufgenommenen Schallsignalen verlaesslich aufzudecken , wie eine eigene Untersuchung an normalhoerigen Grundschulkindern und Kindern mit auditiver Wahrnehmungsstoerung aufzeigte . Bisher war der interindividuelle Vergleich von Testergebnissen nur in begrenztem Umfang moeglich , da die bisherige Testdurchfuehrung ein Anheben des Schallpegels vorsah , wenn die Worte nicht vollstaendig verstanden wurden . Ein weiteres Problem ergab sich daraus , dass unterschiedliche dichotische Hoerfaehigkeiten ein gleiches Testergebnis erbrachten . In dieser Arbeit wird eine alternative Form der Durchfuehrung und Auswertung vorgestellt , welche einen direkten interindividuellen Vergleich der Testergebnisse erlaubt . Es entfaellt die Anhebung der Schallpegels auch wenn die Worte nicht vollstaendig verstanden wurden , da die Ueberpruefung mit einem konstanten mittleren Schallpegel erfolgt . Zusaetzlich wurde ein Punktsystem eingefuehrt , welches eine quantitative Analyse der Testleistungen ermoeglicht . Das neue Bewertungsschema wird an konkreten Beispielen vorgestellt und erlaeutert . Instructions: please typing these entity words according to sentence: Diagnostik, Wahrnehmungsstoerungen, Grundschulkindern, Kindern, Arbeit, Analyse, Testleistungen Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Der dichotische Diskriminationstest nach Uttenweiler leistet einen wertvollen Beitrag in der Diagnostik auditiver Wahrnehmungsstoerungen . Er ist in der Lage , Defizite bei der Kontrastierung und Abgrenzung von beidohrig aufgenommenen Schallsignalen verlaesslich aufzudecken , wie eine eigene Untersuchung an normalhoerigen Grundschulkindern und Kindern mit auditiver Wahrnehmungsstoerung aufzeigte . Bisher war der interindividuelle Vergleich von Testergebnissen nur in begrenztem Umfang moeglich , da die bisherige Testdurchfuehrung ein Anheben des Schallpegels vorsah , wenn die Worte nicht vollstaendig verstanden wurden . Ein weiteres Problem ergab sich daraus , dass unterschiedliche dichotische Hoerfaehigkeiten ein gleiches Testergebnis erbrachten . In dieser Arbeit wird eine alternative Form der Durchfuehrung und Auswertung vorgestellt , welche einen direkten interindividuellen Vergleich der Testergebnisse erlaubt . Es entfaellt die Anhebung der Schallpegels auch wenn die Worte nicht vollstaendig verstanden wurden , da die Ueberpruefung mit einem konstanten mittleren Schallpegel erfolgt . Zusaetzlich wurde ein Punktsystem eingefuehrt , welches eine quantitative Analyse der Testleistungen ermoeglicht . Das neue Bewertungsschema wird an konkreten Beispielen vorgestellt und erlaeutert .

[ "Der", "dichotische", "Diskriminationstest", "nach", "Uttenweiler", "leistet", "einen", "wertvollen", "Beitrag", "in", "der", "Diagnostik", "auditiver", "Wahrnehmungsstoerungen", ".", "Er", "ist", "in", "der", "Lage", ",", "Defizite", "bei", "der", "Kontrastierung", "und", "Abgrenzung", "von", "beidohrig", "aufgenommenen", "Schallsignalen", "verlaesslich", "aufzudecken", ",", "wie", "eine", "eigene", "Untersuchung", "an", "normalhoerigen", "Grundschulkindern", "und", "Kindern", "mit", "auditiver", "Wahrnehmungsstoerung", "aufzeigte", ".", "Bisher", "war", "der", "interindividuelle", "Vergleich", "von", "Testergebnissen", "nur", "in", "begrenztem", "Umfang", "moeglich", ",", "da", "die", "bisherige", "Testdurchfuehrung", "ein", "Anheben", "des", "Schallpegels", "vorsah", ",", "wenn", "die", "Worte", "nicht", "vollstaendig", "verstanden", "wurden", ".", "Ein", "weiteres", "Problem", "ergab", "sich", "daraus", ",", "dass", "unterschiedliche", "dichotische", "Hoerfaehigkeiten", "ein", "gleiches", "Testergebnis", "erbrachten", ".", "In", "dieser", "Arbeit", "wird", "eine", "alternative", "Form", "der", "Durchfuehrung", "und", "Auswertung", "vorgestellt", ",", "welche", "einen", "direkten", "interindividuellen", "Vergleich", "der", "Testergebnisse", "erlaubt", ".", "Es", "entfaellt", "die", "Anhebung", "der", "Schallpegels", "auch", "wenn", "die", "Worte", "nicht", "vollstaendig", "verstanden", "wurden", ",", "da", "die", "Ueberpruefung", "mit", "einem", "konstanten", "mittleren", "Schallpegel", "erfolgt", ".", "Zusaetzlich", "wurde", "ein", "Punktsystem", "eingefuehrt", ",", "welches", "eine", "quantitative", "Analyse", "der", "Testleistungen", "ermoeglicht", ".", "Das", "neue", "Bewertungsschema", "wird", "an", "konkreten", "Beispielen", "vorgestellt", "und", "erlaeutert", "." ]

[ "umlsterm" ]

Diagnostik, Wahrnehmungsstoerungen, Grundschulkindern, Kindern, Arbeit, Analyse, Testleistungen

HNO.80460753.ger.abstr_task2

Sentence: Der dichotische Diskriminationstest nach Uttenweiler leistet einen wertvollen Beitrag in der Diagnostik auditiver Wahrnehmungsstoerungen . Er ist in der Lage , Defizite bei der Kontrastierung und Abgrenzung von beidohrig aufgenommenen Schallsignalen verlaesslich aufzudecken , wie eine eigene Untersuchung an normalhoerigen Grundschulkindern und Kindern mit auditiver Wahrnehmungsstoerung aufzeigte . Bisher war der interindividuelle Vergleich von Testergebnissen nur in begrenztem Umfang moeglich , da die bisherige Testdurchfuehrung ein Anheben des Schallpegels vorsah , wenn die Worte nicht vollstaendig verstanden wurden . Ein weiteres Problem ergab sich daraus , dass unterschiedliche dichotische Hoerfaehigkeiten ein gleiches Testergebnis erbrachten . In dieser Arbeit wird eine alternative Form der Durchfuehrung und Auswertung vorgestellt , welche einen direkten interindividuellen Vergleich der Testergebnisse erlaubt . Es entfaellt die Anhebung der Schallpegels auch wenn die Worte nicht vollstaendig verstanden wurden , da die Ueberpruefung mit einem konstanten mittleren Schallpegel erfolgt . Zusaetzlich wurde ein Punktsystem eingefuehrt , welches eine quantitative Analyse der Testleistungen ermoeglicht . Das neue Bewertungsschema wird an konkreten Beispielen vorgestellt und erlaeutert . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Der dichotische Diskriminationstest nach Uttenweiler leistet einen wertvollen Beitrag in der Diagnostik auditiver Wahrnehmungsstoerungen . Er ist in der Lage , Defizite bei der Kontrastierung und Abgrenzung von beidohrig aufgenommenen Schallsignalen verlaesslich aufzudecken , wie eine eigene Untersuchung an normalhoerigen Grundschulkindern und Kindern mit auditiver Wahrnehmungsstoerung aufzeigte . Bisher war der interindividuelle Vergleich von Testergebnissen nur in begrenztem Umfang moeglich , da die bisherige Testdurchfuehrung ein Anheben des Schallpegels vorsah , wenn die Worte nicht vollstaendig verstanden wurden . Ein weiteres Problem ergab sich daraus , dass unterschiedliche dichotische Hoerfaehigkeiten ein gleiches Testergebnis erbrachten . In dieser Arbeit wird eine alternative Form der Durchfuehrung und Auswertung vorgestellt , welche einen direkten interindividuellen Vergleich der Testergebnisse erlaubt . Es entfaellt die Anhebung der Schallpegels auch wenn die Worte nicht vollstaendig verstanden wurden , da die Ueberpruefung mit einem konstanten mittleren Schallpegel erfolgt . Zusaetzlich wurde ein Punktsystem eingefuehrt , welches eine quantitative Analyse der Testleistungen ermoeglicht . Das neue Bewertungsschema wird an konkreten Beispielen vorgestellt und erlaeutert .

[ "Der", "dichotische", "Diskriminationstest", "nach", "Uttenweiler", "leistet", "einen", "wertvollen", "Beitrag", "in", "der", "Diagnostik", "auditiver", "Wahrnehmungsstoerungen", ".", "Er", "ist", "in", "der", "Lage", ",", "Defizite", "bei", "der", "Kontrastierung", "und", "Abgrenzung", "von", "beidohrig", "aufgenommenen", "Schallsignalen", "verlaesslich", "aufzudecken", ",", "wie", "eine", "eigene", "Untersuchung", "an", "normalhoerigen", "Grundschulkindern", "und", "Kindern", "mit", "auditiver", "Wahrnehmungsstoerung", "aufzeigte", ".", "Bisher", "war", "der", "interindividuelle", "Vergleich", "von", "Testergebnissen", "nur", "in", "begrenztem", "Umfang", "moeglich", ",", "da", "die", "bisherige", "Testdurchfuehrung", "ein", "Anheben", "des", "Schallpegels", "vorsah", ",", "wenn", "die", "Worte", "nicht", "vollstaendig", "verstanden", "wurden", ".", "Ein", "weiteres", "Problem", "ergab", "sich", "daraus", ",", "dass", "unterschiedliche", "dichotische", "Hoerfaehigkeiten", "ein", "gleiches", "Testergebnis", "erbrachten", ".", "In", "dieser", "Arbeit", "wird", "eine", "alternative", "Form", "der", "Durchfuehrung", "und", "Auswertung", "vorgestellt", ",", "welche", "einen", "direkten", "interindividuellen", "Vergleich", "der", "Testergebnisse", "erlaubt", ".", "Es", "entfaellt", "die", "Anhebung", "der", "Schallpegels", "auch", "wenn", "die", "Worte", "nicht", "vollstaendig", "verstanden", "wurden", ",", "da", "die", "Ueberpruefung", "mit", "einem", "konstanten", "mittleren", "Schallpegel", "erfolgt", ".", "Zusaetzlich", "wurde", "ein", "Punktsystem", "eingefuehrt", ",", "welches", "eine", "quantitative", "Analyse", "der", "Testleistungen", "ermoeglicht", ".", "Das", "neue", "Bewertungsschema", "wird", "an", "konkreten", "Beispielen", "vorgestellt", "und", "erlaeutert", "." ]

[ "umlsterm" ]

hormone - refractory prostate cancer is a Cancer, HRPC is a Cancer, Hormone - refractory prostate cancer is a Cancer, HRPC is a Cancer, prostate is a Organ, HRPC is a Cancer, cell is a Cell, HRPC is a Cancer, HRPC is a Cancer

PMID-15723619_task0

Sentence: Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC). Hormone-refractory prostate cancer (HRPC) is an inevitable evolution of prostate carcinogenesis, through which the normal dependence on hormones for growth and survival is bypassed. Although advances in terms of symptoms palliation and quality of life improvement have been addressed with current treatment options, innovative approaches are needed to improve survival rates. A thorough understanding of HRPC-associated molecular pathways and mechanisms of resistance are a prerequisite for novel potential therapeutic interventions. Preclinical and early clinical studies are ongoing to evaluate new therapies that target specific molecular entities. Agents under development include growth factor receptor inhibitors, small molecules targeting signal transduction pathways, apoptosis and cell-cycle regulators, angiogenesis and metastasis inhibitors, differentiation agents, telomerase inactivators, and epigenetic therapeutics. Incorporation of these agents into existing treatment regimens will guide us in the development of a multidisciplinary treatment strategy of HRPC. This article critically reviews published data on new biological agents that are being tested in HRPC clinical trials, highlights ongoing research and considers the future perspectives of this new class of agents. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cancer, Organ, Cell

[ "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC). Hormone-refractory prostate cancer (HRPC) is an inevitable evolution of prostate carcinogenesis, through which the normal dependence on hormones for growth and survival is bypassed. Although advances in terms of symptoms palliation and quality of life improvement have been addressed with current treatment options, innovative approaches are needed to improve survival rates. A thorough understanding of HRPC-associated molecular pathways and mechanisms of resistance are a prerequisite for novel potential therapeutic interventions. Preclinical and early clinical studies are ongoing to evaluate new therapies that target specific molecular entities. Agents under development include growth factor receptor inhibitors, small molecules targeting signal transduction pathways, apoptosis and cell-cycle regulators, angiogenesis and metastasis inhibitors, differentiation agents, telomerase inactivators, and epigenetic therapeutics. Incorporation of these agents into existing treatment regimens will guide us in the development of a multidisciplinary treatment strategy of HRPC. This article critically reviews published data on new biological agents that are being tested in HRPC clinical trials, highlights ongoing research and considers the future perspectives of this new class of agents.

[ "Novel", "biological", "agents", "for", "the", "treatment", "of", "hormone", "-", "refractory", "prostate", "cancer", "(", "HRPC", ")", ".", "\n", "Hormone", "-", "refractory", "prostate", "cancer", "(", "HRPC", ")", "is", "an", "inevitable", "evolution", "of", "prostate", "carcinogenesis", ",", "through", "which", "the", "normal", "dependence", "on", "hormones", "for", "growth", "and", "survival", "is", "bypassed", ".", "Although", "advances", "in", "terms", "of", "symptoms", "palliation", "and", "quality", "of", "life", "improvement", "have", "been", "addressed", "with", "current", "treatment", "options", ",", "innovative", "approaches", "are", "needed", "to", "improve", "survival", "rates", ".", "A", "thorough", "understanding", "of", "HRPC", "-", "associated", "molecular", "pathways", "and", "mechanisms", "of", "resistance", "are", "a", "prerequisite", "for", "novel", "potential", "therapeutic", "interventions", ".", "Preclinical", "and", "early", "clinical", "studies", "are", "ongoing", "to", "evaluate", "new", "therapies", "that", "target", "specific", "molecular", "entities", ".", "Agents", "under", "development", "include", "growth", "factor", "receptor", "inhibitors", ",", "small", "molecules", "targeting", "signal", "transduction", "pathways", ",", "apoptosis", "and", "cell", "-", "cycle", "regulators", ",", "angiogenesis", "and", "metastasis", "inhibitors", ",", "differentiation", "agents", ",", "telomerase", "inactivators", ",", "and", "epigenetic", "therapeutics", ".", "Incorporation", "of", "these", "agents", "into", "existing", "treatment", "regimens", "will", "guide", "us", "in", "the", "development", "of", "a", "multidisciplinary", "treatment", "strategy", "of", "HRPC", ".", "This", "article", "critically", "reviews", "published", "data", "on", "new", "biological", "agents", "that", "are", "being", "tested", "in", "HRPC", "clinical", "trials", ",", "highlights", "ongoing", "research", "and", "considers", "the", "future", "perspectives", "of", "this", "new", "class", "of", "agents", ".", "\n" ]

[ "Cancer", "Organ", "Cell" ]

hormone - refractory prostate cancer is a Cancer, HRPC is a Cancer, Hormone - refractory prostate cancer is a Cancer, HRPC is a Cancer, prostate is a Organ, HRPC is a Cancer, cell is a Cell, HRPC is a Cancer, HRPC is a Cancer

PMID-15723619_task1

Sentence: Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC). Hormone-refractory prostate cancer (HRPC) is an inevitable evolution of prostate carcinogenesis, through which the normal dependence on hormones for growth and survival is bypassed. Although advances in terms of symptoms palliation and quality of life improvement have been addressed with current treatment options, innovative approaches are needed to improve survival rates. A thorough understanding of HRPC-associated molecular pathways and mechanisms of resistance are a prerequisite for novel potential therapeutic interventions. Preclinical and early clinical studies are ongoing to evaluate new therapies that target specific molecular entities. Agents under development include growth factor receptor inhibitors, small molecules targeting signal transduction pathways, apoptosis and cell-cycle regulators, angiogenesis and metastasis inhibitors, differentiation agents, telomerase inactivators, and epigenetic therapeutics. Incorporation of these agents into existing treatment regimens will guide us in the development of a multidisciplinary treatment strategy of HRPC. This article critically reviews published data on new biological agents that are being tested in HRPC clinical trials, highlights ongoing research and considers the future perspectives of this new class of agents. Instructions: please typing these entity words according to sentence: hormone - refractory prostate cancer, HRPC, Hormone - refractory prostate cancer, HRPC, prostate, HRPC, cell, HRPC, HRPC Options: Cancer, Organ, Cell

[ "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC). Hormone-refractory prostate cancer (HRPC) is an inevitable evolution of prostate carcinogenesis, through which the normal dependence on hormones for growth and survival is bypassed. Although advances in terms of symptoms palliation and quality of life improvement have been addressed with current treatment options, innovative approaches are needed to improve survival rates. A thorough understanding of HRPC-associated molecular pathways and mechanisms of resistance are a prerequisite for novel potential therapeutic interventions. Preclinical and early clinical studies are ongoing to evaluate new therapies that target specific molecular entities. Agents under development include growth factor receptor inhibitors, small molecules targeting signal transduction pathways, apoptosis and cell-cycle regulators, angiogenesis and metastasis inhibitors, differentiation agents, telomerase inactivators, and epigenetic therapeutics. Incorporation of these agents into existing treatment regimens will guide us in the development of a multidisciplinary treatment strategy of HRPC. This article critically reviews published data on new biological agents that are being tested in HRPC clinical trials, highlights ongoing research and considers the future perspectives of this new class of agents.

[ "Novel", "biological", "agents", "for", "the", "treatment", "of", "hormone", "-", "refractory", "prostate", "cancer", "(", "HRPC", ")", ".", "\n", "Hormone", "-", "refractory", "prostate", "cancer", "(", "HRPC", ")", "is", "an", "inevitable", "evolution", "of", "prostate", "carcinogenesis", ",", "through", "which", "the", "normal", "dependence", "on", "hormones", "for", "growth", "and", "survival", "is", "bypassed", ".", "Although", "advances", "in", "terms", "of", "symptoms", "palliation", "and", "quality", "of", "life", "improvement", "have", "been", "addressed", "with", "current", "treatment", "options", ",", "innovative", "approaches", "are", "needed", "to", "improve", "survival", "rates", ".", "A", "thorough", "understanding", "of", "HRPC", "-", "associated", "molecular", "pathways", "and", "mechanisms", "of", "resistance", "are", "a", "prerequisite", "for", "novel", "potential", "therapeutic", "interventions", ".", "Preclinical", "and", "early", "clinical", "studies", "are", "ongoing", "to", "evaluate", "new", "therapies", "that", "target", "specific", "molecular", "entities", ".", "Agents", "under", "development", "include", "growth", "factor", "receptor", "inhibitors", ",", "small", "molecules", "targeting", "signal", "transduction", "pathways", ",", "apoptosis", "and", "cell", "-", "cycle", "regulators", ",", "angiogenesis", "and", "metastasis", "inhibitors", ",", "differentiation", "agents", ",", "telomerase", "inactivators", ",", "and", "epigenetic", "therapeutics", ".", "Incorporation", "of", "these", "agents", "into", "existing", "treatment", "regimens", "will", "guide", "us", "in", "the", "development", "of", "a", "multidisciplinary", "treatment", "strategy", "of", "HRPC", ".", "This", "article", "critically", "reviews", "published", "data", "on", "new", "biological", "agents", "that", "are", "being", "tested", "in", "HRPC", "clinical", "trials", ",", "highlights", "ongoing", "research", "and", "considers", "the", "future", "perspectives", "of", "this", "new", "class", "of", "agents", ".", "\n" ]

[ "Cancer", "Organ", "Cell" ]

hormone - refractory prostate cancer, HRPC, Hormone - refractory prostate cancer, HRPC, prostate, HRPC, cell, HRPC, HRPC

PMID-15723619_task2

Sentence: Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC). Hormone-refractory prostate cancer (HRPC) is an inevitable evolution of prostate carcinogenesis, through which the normal dependence on hormones for growth and survival is bypassed. Although advances in terms of symptoms palliation and quality of life improvement have been addressed with current treatment options, innovative approaches are needed to improve survival rates. A thorough understanding of HRPC-associated molecular pathways and mechanisms of resistance are a prerequisite for novel potential therapeutic interventions. Preclinical and early clinical studies are ongoing to evaluate new therapies that target specific molecular entities. Agents under development include growth factor receptor inhibitors, small molecules targeting signal transduction pathways, apoptosis and cell-cycle regulators, angiogenesis and metastasis inhibitors, differentiation agents, telomerase inactivators, and epigenetic therapeutics. Incorporation of these agents into existing treatment regimens will guide us in the development of a multidisciplinary treatment strategy of HRPC. This article critically reviews published data on new biological agents that are being tested in HRPC clinical trials, highlights ongoing research and considers the future perspectives of this new class of agents. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC). Hormone-refractory prostate cancer (HRPC) is an inevitable evolution of prostate carcinogenesis, through which the normal dependence on hormones for growth and survival is bypassed. Although advances in terms of symptoms palliation and quality of life improvement have been addressed with current treatment options, innovative approaches are needed to improve survival rates. A thorough understanding of HRPC-associated molecular pathways and mechanisms of resistance are a prerequisite for novel potential therapeutic interventions. Preclinical and early clinical studies are ongoing to evaluate new therapies that target specific molecular entities. Agents under development include growth factor receptor inhibitors, small molecules targeting signal transduction pathways, apoptosis and cell-cycle regulators, angiogenesis and metastasis inhibitors, differentiation agents, telomerase inactivators, and epigenetic therapeutics. Incorporation of these agents into existing treatment regimens will guide us in the development of a multidisciplinary treatment strategy of HRPC. This article critically reviews published data on new biological agents that are being tested in HRPC clinical trials, highlights ongoing research and considers the future perspectives of this new class of agents.

[ "Novel", "biological", "agents", "for", "the", "treatment", "of", "hormone", "-", "refractory", "prostate", "cancer", "(", "HRPC", ")", ".", "\n", "Hormone", "-", "refractory", "prostate", "cancer", "(", "HRPC", ")", "is", "an", "inevitable", "evolution", "of", "prostate", "carcinogenesis", ",", "through", "which", "the", "normal", "dependence", "on", "hormones", "for", "growth", "and", "survival", "is", "bypassed", ".", "Although", "advances", "in", "terms", "of", "symptoms", "palliation", "and", "quality", "of", "life", "improvement", "have", "been", "addressed", "with", "current", "treatment", "options", ",", "innovative", "approaches", "are", "needed", "to", "improve", "survival", "rates", ".", "A", "thorough", "understanding", "of", "HRPC", "-", "associated", "molecular", "pathways", "and", "mechanisms", "of", "resistance", "are", "a", "prerequisite", "for", "novel", "potential", "therapeutic", "interventions", ".", "Preclinical", "and", "early", "clinical", "studies", "are", "ongoing", "to", "evaluate", "new", "therapies", "that", "target", "specific", "molecular", "entities", ".", "Agents", "under", "development", "include", "growth", "factor", "receptor", "inhibitors", ",", "small", "molecules", "targeting", "signal", "transduction", "pathways", ",", "apoptosis", "and", "cell", "-", "cycle", "regulators", ",", "angiogenesis", "and", "metastasis", "inhibitors", ",", "differentiation", "agents", ",", "telomerase", "inactivators", ",", "and", "epigenetic", "therapeutics", ".", "Incorporation", "of", "these", "agents", "into", "existing", "treatment", "regimens", "will", "guide", "us", "in", "the", "development", "of", "a", "multidisciplinary", "treatment", "strategy", "of", "HRPC", ".", "This", "article", "critically", "reviews", "published", "data", "on", "new", "biological", "agents", "that", "are", "being", "tested", "in", "HRPC", "clinical", "trials", ",", "highlights", "ongoing", "research", "and", "considers", "the", "future", "perspectives", "of", "this", "new", "class", "of", "agents", ".", "\n" ]

[ "Cancer", "Organ", "Cell" ]

carcinoma ductal pobremente diferenciado is a MORFOLOGIA_NEOPLASIA, carcinoma inflamatorio is a MORFOLOGIA_NEOPLASIA, carcinoma inflamatorio is a MORFOLOGIA_NEOPLASIA, fibroadenoma is a MORFOLOGIA_NEOPLASIA, carcinoma intraductal sólido de alto grado is a MORFOLOGIA_NEOPLASIA, tumor phyllodes , histológicamente benigno is a MORFOLOGIA_NEOPLASIA, Carcinoma ductal inflamatorio is a MORFOLOGIA_NEOPLASIA, pT4cN1M0 is a MORFOLOGIA_NEOPLASIA, Tumor phyllodes benigno is a MORFOLOGIA_NEOPLASIA, carcinoma intraductal sólido de alto grado is a MORFOLOGIA_NEOPLASIA, carcinoma ductal inflamatorio is a MORFOLOGIA_NEOPLASIA, pT4cN1M0 is a MORFOLOGIA_NEOPLASIA, carcinoma ductal infiltrante is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, carcinoma intraductal de alto grado is a MORFOLOGIA_NEOPLASIA, tumor phyllodes benigno is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA

991_task0

Sentence: Anamnesis Paciente mujer de 45 años de edad, sin antecedentes médico-quirúrgicos importantes, fumadora de 1 paquete de cigarrillos al día desde los 20 años de edad y sin antecedentes familiares oncológicos, que consultó por dolor en la mama izquierda, asociado a enrojecimiento y edema cutáneo, que inicialmente fue manejado como una mastitis con cloxacilina, sin mejoría clínica. Ante la refractariedad al tratamiento antibiótico, se decidió realizar biopsia cutánea. Exploración física A la exploración destaca una mama izquierda dura y nodular, con engrosamiento cutáneo acompañado de piel de naranja y eritema generalizado; en la axila ipsilateral se palpan adenopatías de unos 2 cm, duras y móviles. En la mama derecha se palpa un nódulo en el cuadrante inferoexterno móvil de 2 cm aproximadamente, sin palparse adenopatías a nivel axilar. Pruebas complementarias » Punch de piel de mama izquierda: cilindros cutáneos con múltiples émbolos linfáticos de carcinoma ductal pobremente diferenciado (carcinoma inflamatorio), con receptores hormonales negativos, Her-2 no amplificado y Ki-67 del 40%. » Resonancia de mamas: captación difusa de mama izquierda con edema y engrosamiento de la piel concordante con el diagnóstico histológico de carcinoma inflamatorio (BRADS6), asociado a adenopatías axilares sospechosas. En la mama derecha lesiones con distorsión del parénquima en el cuadrante superoexterno y probable fibroadenoma en el cuadrante ínfero externo. » BAG de mama derecha: CSE, carcinoma intraductal sólido de alto grado. CIE, tumor phyllodes, histológicamente benigno. » Se realiza estudio de extensión con TC y gammagrafía ósea, que son negativos. Diagnóstico Carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB). Tumor phyllodes benigno de mama derecha, asociado a carcinoma intraductal sólido de alto grado. Tratamiento Con el diagnóstico de carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB), inicia tratamiento de quimioterapia con intención neoadyuvante, con taxol semanal (80 mg/m2) por 12 ciclos, con neurotoxicidad grado 2 como evento adverso importante, seguido de cuatro ciclos de FEC (5-FU 600 mg/m2 + epirrubicina 90 mg/m2 + ciclofosfamida 600 mg/m2). Tras finalizar la neoadyuvancia, es intervenida quirúrgicamente con mastectomía bilateral y linfadenectomía axilar izquierda, con resultados de anatomía patológica de: » Mastectomía izquierda: persistencia postneoadyuvancia de carcinoma ductal infiltrante en toda la mama en forma de agregados dispersos (el mayor de 2,5 mm), con invasión tumoral linfática en el parénquima mamario y en la dermis del huso de piel incluido. Con un grado de regresión tumoral por quimioterapia neoadyuvante de al menos el 50% (categoría R1) y afectación de 3 de los 9 ganglios linfáticos aislados de la linfadenectomía axilar.Estadio tumoral AJCC/UICC, 7ª edición: ypT4d N1a. » Mastectomía derecha: alteraciones estromales compatibles con la administración de quimioterapia neoadyuvante. Estadio tumoral AJCC/UICC, 7ª edición: pT0 Nx. En la pieza de mastectomía derecha no se identifica lecho tumoral ni carcinoma intraductal de alto grado ni infiltrante, aunque sí se observan zonas con patrón fibroadenomatoide que pueden explicar el diagnóstico previo de tumor phyllodes benigno. Comparando la morfología de las lesiones observadas en la pieza de mastectomía con las biopsias iniciales de la BAG se evidencia que las imágenes de la pieza quirúrgica podrían ser compatibles con una extensión tumoral residual a los lobulillos que sería lo que, finalmente, queda del tumor original tras la quimioterapia neoadyuvante. Tras el tratamiento quirúrgico, la paciente recibe tratamiento de radioterapia sobre la pared torácica izquierda y áreas ganglionares supraclaviculares, interpectorales, infraclaviculares y niveles ganglionares axilares I a III con una dosis total de 50 Gy, con sobreimpresión de 10 Gy adicionales sobre el área de la pared torácica izquierda. Evolución Actualmente la paciente se encuentra realizando revisiones periódicas sin incidencias. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Paciente mujer de 45 años de edad, sin antecedentes médico-quirúrgicos importantes, fumadora de 1 paquete de cigarrillos al día desde los 20 años de edad y sin antecedentes familiares oncológicos, que consultó por dolor en la mama izquierda, asociado a enrojecimiento y edema cutáneo, que inicialmente fue manejado como una mastitis con cloxacilina, sin mejoría clínica. Ante la refractariedad al tratamiento antibiótico, se decidió realizar biopsia cutánea. Exploración física A la exploración destaca una mama izquierda dura y nodular, con engrosamiento cutáneo acompañado de piel de naranja y eritema generalizado; en la axila ipsilateral se palpan adenopatías de unos 2 cm, duras y móviles. En la mama derecha se palpa un nódulo en el cuadrante inferoexterno móvil de 2 cm aproximadamente, sin palparse adenopatías a nivel axilar. Pruebas complementarias » Punch de piel de mama izquierda: cilindros cutáneos con múltiples émbolos linfáticos de carcinoma ductal pobremente diferenciado (carcinoma inflamatorio), con receptores hormonales negativos, Her-2 no amplificado y Ki-67 del 40%. » Resonancia de mamas: captación difusa de mama izquierda con edema y engrosamiento de la piel concordante con el diagnóstico histológico de carcinoma inflamatorio (BRADS6), asociado a adenopatías axilares sospechosas. En la mama derecha lesiones con distorsión del parénquima en el cuadrante superoexterno y probable fibroadenoma en el cuadrante ínfero externo. » BAG de mama derecha: CSE, carcinoma intraductal sólido de alto grado. CIE, tumor phyllodes, histológicamente benigno. » Se realiza estudio de extensión con TC y gammagrafía ósea, que son negativos. Diagnóstico Carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB). Tumor phyllodes benigno de mama derecha, asociado a carcinoma intraductal sólido de alto grado. Tratamiento Con el diagnóstico de carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB), inicia tratamiento de quimioterapia con intención neoadyuvante, con taxol semanal (80 mg/m2) por 12 ciclos, con neurotoxicidad grado 2 como evento adverso importante, seguido de cuatro ciclos de FEC (5-FU 600 mg/m2 + epirrubicina 90 mg/m2 + ciclofosfamida 600 mg/m2). Tras finalizar la neoadyuvancia, es intervenida quirúrgicamente con mastectomía bilateral y linfadenectomía axilar izquierda, con resultados de anatomía patológica de: » Mastectomía izquierda: persistencia postneoadyuvancia de carcinoma ductal infiltrante en toda la mama en forma de agregados dispersos (el mayor de 2,5 mm), con invasión tumoral linfática en el parénquima mamario y en la dermis del huso de piel incluido. Con un grado de regresión tumoral por quimioterapia neoadyuvante de al menos el 50% (categoría R1) y afectación de 3 de los 9 ganglios linfáticos aislados de la linfadenectomía axilar.Estadio tumoral AJCC/UICC, 7ª edición: ypT4d N1a. » Mastectomía derecha: alteraciones estromales compatibles con la administración de quimioterapia neoadyuvante. Estadio tumoral AJCC/UICC, 7ª edición: pT0 Nx. En la pieza de mastectomía derecha no se identifica lecho tumoral ni carcinoma intraductal de alto grado ni infiltrante, aunque sí se observan zonas con patrón fibroadenomatoide que pueden explicar el diagnóstico previo de tumor phyllodes benigno. Comparando la morfología de las lesiones observadas en la pieza de mastectomía con las biopsias iniciales de la BAG se evidencia que las imágenes de la pieza quirúrgica podrían ser compatibles con una extensión tumoral residual a los lobulillos que sería lo que, finalmente, queda del tumor original tras la quimioterapia neoadyuvante. Tras el tratamiento quirúrgico, la paciente recibe tratamiento de radioterapia sobre la pared torácica izquierda y áreas ganglionares supraclaviculares, interpectorales, infraclaviculares y niveles ganglionares axilares I a III con una dosis total de 50 Gy, con sobreimpresión de 10 Gy adicionales sobre el área de la pared torácica izquierda. Evolución Actualmente la paciente se encuentra realizando revisiones periódicas sin incidencias.

[ "Anamnesis", "\n", "Paciente", "mujer", "de", "45", "años", "de", "edad", ",", "sin", "antecedentes", "médico", "-", "quirúrgicos", "importantes", ",", "fumadora", "de", "1", "paquete", "de", "cigarrillos", "al", "día", "desde", "los", "20", "años", "de", "edad", "y", "sin", "antecedentes", "familiares", "oncológicos", ",", "que", "consultó", "por", "dolor", "en", "la", "mama", "izquierda", ",", "asociado", "a", "enrojecimiento", "y", "edema", "cutáneo", ",", "que", "inicialmente", "fue", "manejado", "como", "una", "mastitis", "con", "cloxacilina", ",", "sin", "mejoría", "clínica", ".", "Ante", "la", "refractariedad", "al", "tratamiento", "antibiótico", ",", "se", "decidió", "realizar", "biopsia", "cutánea", ".", "\n\n", "Exploración", "física", "\n", "A", "la", "exploración", "destaca", "una", "mama", "izquierda", "dura", "y", "nodular", ",", "con", "engrosamiento", "cutáneo", "acompañado", "de", "piel", "de", "naranja", "y", "eritema", "generalizado", ";", "en", "la", "axila", "ipsilateral", "se", "palpan", "adenopatías", "de", "unos", "2", "cm", ",", "duras", "y", "móviles", ".", "En", "la", "mama", "derecha", "se", "palpa", "un", "nódulo", "en", "el", "cuadrante", "inferoexterno", "móvil", "de", "2", "cm", "aproximadamente", ",", "sin", "palparse", "adenopatías", "a", "nivel", "axilar", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "Punch", "de", "piel", "de", "mama", "izquierda", ":", "cilindros", "cutáneos", "con", "múltiples", "émbolos", "linfáticos", "de", "carcinoma", "ductal", "pobremente", "diferenciado", "(", "carcinoma", "inflamatorio", ")", ",", "con", "receptores", "hormonales", "negativos", ",", "Her-2", "no", "amplificado", "y", "Ki-67", "del", "40", "%", ".", "\n", "»", "Resonancia", "de", "mamas", ":", "captación", "difusa", "de", "mama", "izquierda", "con", "edema", "y", "engrosamiento", "de", "la", "piel", "concordante", "con", "el", "diagnóstico", "histológico", "de", "carcinoma", "inflamatorio", "(", "BRADS6", ")", ",", "asociado", "a", "adenopatías", "axilares", "sospechosas", ".", "En", "la", "mama", "derecha", "lesiones", "con", "distorsión", "del", "parénquima", "en", "el", "cuadrante", "superoexterno", "y", "probable", "fibroadenoma", "en", "el", "cuadrante", "ínfero", "externo", ".", "\n", "»", "BAG", "de", "mama", "derecha", ":", "CSE", ",", "carcinoma", "intraductal", "sólido", "de", "alto", "grado", ".", "CIE", ",", "tumor", "phyllodes", ",", "histológicamente", "benigno", ".", "\n", "»", "Se", "realiza", "estudio", "de", "extensión", "con", "TC", "y", "gammagrafía", "ósea", ",", "que", "son", "negativos", ".", "\n\n", "Diagnóstico", "\n", "Carcinoma", "ductal", "inflamatorio", "de", "mama", "izquierda", "pT4cN1M0", "(", "estadio", "IIIB", ")", ".", "\n\n", "Tumor", "phyllodes", "benigno", "de", "mama", "derecha", ",", "asociado", "a", "carcinoma", "intraductal", "sólido", "de", "alto", "grado", ".", "\n\n", "Tratamiento", "\n", "Con", "el", "diagnóstico", "de", "carcinoma", "ductal", "inflamatorio", "de", "mama", "izquierda", "pT4cN1M0", "(", "estadio", "IIIB", ")", ",", "inicia", "tratamiento", "de", "quimioterapia", "con", "intención", "neoadyuvante", ",", "con", "taxol", "semanal", "(", "80", "mg", "/", "m2", ")", "por", "12", "ciclos", ",", "con", "neurotoxicidad", "grado", "2", "como", "evento", "adverso", "importante", ",", "seguido", "de", "cuatro", "ciclos", "de", "FEC", "(", "5-FU", "600", "mg", "/", "m2", "+", "epirrubicina", "90", "mg", "/", "m2", "+", "ciclofosfamida", "600", "mg", "/", "m2", ")", ".", "\n\n", "Tras", "finalizar", "la", "neoadyuvancia", ",", "es", "intervenida", "quirúrgicamente", "con", "mastectomía", "bilateral", "y", "linfadenectomía", "axilar", "izquierda", ",", "con", "resultados", "de", "anatomía", "patológica", "de", ":", "\n", "»", "Mastectomía", "izquierda", ":", "persistencia", "postneoadyuvancia", "de", "carcinoma", "ductal", "infiltrante", "en", "toda", "la", "mama", "en", "forma", "de", "agregados", "dispersos", "(", "el", "mayor", "de", "2,5", "mm", ")", ",", "con", "invasión", "tumoral", "linfática", "en", "el", "parénquima", "mamario", "y", "en", "la", "dermis", "del", "huso", "de", "piel", "incluido", ".", "Con", "un", "grado", "de", "regresión", "tumoral", "por", "quimioterapia", "neoadyuvante", "de", "al", "menos", "el", "50", "%", "(", "categoría", "R1", ")", "y", "afectación", "de", "3", "de", "los", "9", "ganglios", "linfáticos", "aislados", "de", "la", "linfadenectomía", "axilar", ".", "Estadio", "tumoral", "AJCC", "/", "UICC", ",", "7ª", "edición", ":", "ypT4d", "N1a", ".", "\n", "»", "Mastectomía", "derecha", ":", "alteraciones", "estromales", "compatibles", "con", "la", "administración", "de", "quimioterapia", "neoadyuvante", ".", "Estadio", "tumoral", "AJCC", "/", "UICC", ",", "7ª", "edición", ":", "pT0", "Nx", ".", "En", "la", "pieza", "de", "mastectomía", "derecha", "no", "se", "identifica", "lecho", "tumoral", "ni", "carcinoma", "intraductal", "de", "alto", "grado", "ni", "infiltrante", ",", "aunque", "sí", "se", "observan", "zonas", "con", "patrón", "fibroadenomatoide", "que", "pueden", "explicar", "el", "diagnóstico", "previo", "de", "tumor", "phyllodes", "benigno", ".", "Comparando", "la", "morfología", "de", "las", "lesiones", "observadas", "en", "la", "pieza", "de", "mastectomía", "con", "las", "biopsias", "iniciales", "de", "la", "BAG", "se", "evidencia", "que", "las", "imágenes", "de", "la", "pieza", "quirúrgica", "podrían", "ser", "compatibles", "con", "una", "extensión", "tumoral", "residual", "a", "los", "lobulillos", "que", "sería", "lo", "que", ",", "finalmente", ",", "queda", "del", "tumor", "original", "tras", "la", "quimioterapia", "neoadyuvante", ".", "\n", "Tras", "el", "tratamiento", "quirúrgico", ",", "la", "paciente", "recibe", "tratamiento", "de", "radioterapia", "sobre", "la", "pared", "torácica", "izquierda", "y", "áreas", "ganglionares", "supraclaviculares", ",", "interpectorales", ",", "infraclaviculares", "y", "niveles", "ganglionares", "axilares", "I", "a", "III", "con", "una", "dosis", "total", "de", "50", "Gy", ",", "con", "sobreimpresión", "de", "10", "Gy", "adicionales", "sobre", "el", "área", "de", "la", "pared", "torácica", "izquierda", ".", "\n\n", "Evolución", "\n", "Actualmente", "la", "paciente", "se", "encuentra", "realizando", "revisiones", "periódicas", "sin", "incidencias", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

carcinoma ductal pobremente diferenciado is a MORFOLOGIA_NEOPLASIA, carcinoma inflamatorio is a MORFOLOGIA_NEOPLASIA, carcinoma inflamatorio is a MORFOLOGIA_NEOPLASIA, fibroadenoma is a MORFOLOGIA_NEOPLASIA, carcinoma intraductal sólido de alto grado is a MORFOLOGIA_NEOPLASIA, tumor phyllodes , histológicamente benigno is a MORFOLOGIA_NEOPLASIA, Carcinoma ductal inflamatorio is a MORFOLOGIA_NEOPLASIA, pT4cN1M0 is a MORFOLOGIA_NEOPLASIA, Tumor phyllodes benigno is a MORFOLOGIA_NEOPLASIA, carcinoma intraductal sólido de alto grado is a MORFOLOGIA_NEOPLASIA, carcinoma ductal inflamatorio is a MORFOLOGIA_NEOPLASIA, pT4cN1M0 is a MORFOLOGIA_NEOPLASIA, carcinoma ductal infiltrante is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, carcinoma intraductal de alto grado is a MORFOLOGIA_NEOPLASIA, tumor phyllodes benigno is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA

991_task1

Sentence: Anamnesis Paciente mujer de 45 años de edad, sin antecedentes médico-quirúrgicos importantes, fumadora de 1 paquete de cigarrillos al día desde los 20 años de edad y sin antecedentes familiares oncológicos, que consultó por dolor en la mama izquierda, asociado a enrojecimiento y edema cutáneo, que inicialmente fue manejado como una mastitis con cloxacilina, sin mejoría clínica. Ante la refractariedad al tratamiento antibiótico, se decidió realizar biopsia cutánea. Exploración física A la exploración destaca una mama izquierda dura y nodular, con engrosamiento cutáneo acompañado de piel de naranja y eritema generalizado; en la axila ipsilateral se palpan adenopatías de unos 2 cm, duras y móviles. En la mama derecha se palpa un nódulo en el cuadrante inferoexterno móvil de 2 cm aproximadamente, sin palparse adenopatías a nivel axilar. Pruebas complementarias » Punch de piel de mama izquierda: cilindros cutáneos con múltiples émbolos linfáticos de carcinoma ductal pobremente diferenciado (carcinoma inflamatorio), con receptores hormonales negativos, Her-2 no amplificado y Ki-67 del 40%. » Resonancia de mamas: captación difusa de mama izquierda con edema y engrosamiento de la piel concordante con el diagnóstico histológico de carcinoma inflamatorio (BRADS6), asociado a adenopatías axilares sospechosas. En la mama derecha lesiones con distorsión del parénquima en el cuadrante superoexterno y probable fibroadenoma en el cuadrante ínfero externo. » BAG de mama derecha: CSE, carcinoma intraductal sólido de alto grado. CIE, tumor phyllodes, histológicamente benigno. » Se realiza estudio de extensión con TC y gammagrafía ósea, que son negativos. Diagnóstico Carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB). Tumor phyllodes benigno de mama derecha, asociado a carcinoma intraductal sólido de alto grado. Tratamiento Con el diagnóstico de carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB), inicia tratamiento de quimioterapia con intención neoadyuvante, con taxol semanal (80 mg/m2) por 12 ciclos, con neurotoxicidad grado 2 como evento adverso importante, seguido de cuatro ciclos de FEC (5-FU 600 mg/m2 + epirrubicina 90 mg/m2 + ciclofosfamida 600 mg/m2). Tras finalizar la neoadyuvancia, es intervenida quirúrgicamente con mastectomía bilateral y linfadenectomía axilar izquierda, con resultados de anatomía patológica de: » Mastectomía izquierda: persistencia postneoadyuvancia de carcinoma ductal infiltrante en toda la mama en forma de agregados dispersos (el mayor de 2,5 mm), con invasión tumoral linfática en el parénquima mamario y en la dermis del huso de piel incluido. Con un grado de regresión tumoral por quimioterapia neoadyuvante de al menos el 50% (categoría R1) y afectación de 3 de los 9 ganglios linfáticos aislados de la linfadenectomía axilar.Estadio tumoral AJCC/UICC, 7ª edición: ypT4d N1a. » Mastectomía derecha: alteraciones estromales compatibles con la administración de quimioterapia neoadyuvante. Estadio tumoral AJCC/UICC, 7ª edición: pT0 Nx. En la pieza de mastectomía derecha no se identifica lecho tumoral ni carcinoma intraductal de alto grado ni infiltrante, aunque sí se observan zonas con patrón fibroadenomatoide que pueden explicar el diagnóstico previo de tumor phyllodes benigno. Comparando la morfología de las lesiones observadas en la pieza de mastectomía con las biopsias iniciales de la BAG se evidencia que las imágenes de la pieza quirúrgica podrían ser compatibles con una extensión tumoral residual a los lobulillos que sería lo que, finalmente, queda del tumor original tras la quimioterapia neoadyuvante. Tras el tratamiento quirúrgico, la paciente recibe tratamiento de radioterapia sobre la pared torácica izquierda y áreas ganglionares supraclaviculares, interpectorales, infraclaviculares y niveles ganglionares axilares I a III con una dosis total de 50 Gy, con sobreimpresión de 10 Gy adicionales sobre el área de la pared torácica izquierda. Evolución Actualmente la paciente se encuentra realizando revisiones periódicas sin incidencias. Instructions: please typing these entity words according to sentence: carcinoma ductal pobremente diferenciado, carcinoma inflamatorio, carcinoma inflamatorio, fibroadenoma, carcinoma intraductal sólido de alto grado, tumor phyllodes , histológicamente benigno, Carcinoma ductal inflamatorio, pT4cN1M0, Tumor phyllodes benigno, carcinoma intraductal sólido de alto grado, carcinoma ductal inflamatorio, pT4cN1M0, carcinoma ductal infiltrante, tumoral, tumoral, tumoral, tumoral, tumoral, carcinoma intraductal de alto grado, tumor phyllodes benigno, tumoral, tumor Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Paciente mujer de 45 años de edad, sin antecedentes médico-quirúrgicos importantes, fumadora de 1 paquete de cigarrillos al día desde los 20 años de edad y sin antecedentes familiares oncológicos, que consultó por dolor en la mama izquierda, asociado a enrojecimiento y edema cutáneo, que inicialmente fue manejado como una mastitis con cloxacilina, sin mejoría clínica. Ante la refractariedad al tratamiento antibiótico, se decidió realizar biopsia cutánea. Exploración física A la exploración destaca una mama izquierda dura y nodular, con engrosamiento cutáneo acompañado de piel de naranja y eritema generalizado; en la axila ipsilateral se palpan adenopatías de unos 2 cm, duras y móviles. En la mama derecha se palpa un nódulo en el cuadrante inferoexterno móvil de 2 cm aproximadamente, sin palparse adenopatías a nivel axilar. Pruebas complementarias » Punch de piel de mama izquierda: cilindros cutáneos con múltiples émbolos linfáticos de carcinoma ductal pobremente diferenciado (carcinoma inflamatorio), con receptores hormonales negativos, Her-2 no amplificado y Ki-67 del 40%. » Resonancia de mamas: captación difusa de mama izquierda con edema y engrosamiento de la piel concordante con el diagnóstico histológico de carcinoma inflamatorio (BRADS6), asociado a adenopatías axilares sospechosas. En la mama derecha lesiones con distorsión del parénquima en el cuadrante superoexterno y probable fibroadenoma en el cuadrante ínfero externo. » BAG de mama derecha: CSE, carcinoma intraductal sólido de alto grado. CIE, tumor phyllodes, histológicamente benigno. » Se realiza estudio de extensión con TC y gammagrafía ósea, que son negativos. Diagnóstico Carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB). Tumor phyllodes benigno de mama derecha, asociado a carcinoma intraductal sólido de alto grado. Tratamiento Con el diagnóstico de carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB), inicia tratamiento de quimioterapia con intención neoadyuvante, con taxol semanal (80 mg/m2) por 12 ciclos, con neurotoxicidad grado 2 como evento adverso importante, seguido de cuatro ciclos de FEC (5-FU 600 mg/m2 + epirrubicina 90 mg/m2 + ciclofosfamida 600 mg/m2). Tras finalizar la neoadyuvancia, es intervenida quirúrgicamente con mastectomía bilateral y linfadenectomía axilar izquierda, con resultados de anatomía patológica de: » Mastectomía izquierda: persistencia postneoadyuvancia de carcinoma ductal infiltrante en toda la mama en forma de agregados dispersos (el mayor de 2,5 mm), con invasión tumoral linfática en el parénquima mamario y en la dermis del huso de piel incluido. Con un grado de regresión tumoral por quimioterapia neoadyuvante de al menos el 50% (categoría R1) y afectación de 3 de los 9 ganglios linfáticos aislados de la linfadenectomía axilar.Estadio tumoral AJCC/UICC, 7ª edición: ypT4d N1a. » Mastectomía derecha: alteraciones estromales compatibles con la administración de quimioterapia neoadyuvante. Estadio tumoral AJCC/UICC, 7ª edición: pT0 Nx. En la pieza de mastectomía derecha no se identifica lecho tumoral ni carcinoma intraductal de alto grado ni infiltrante, aunque sí se observan zonas con patrón fibroadenomatoide que pueden explicar el diagnóstico previo de tumor phyllodes benigno. Comparando la morfología de las lesiones observadas en la pieza de mastectomía con las biopsias iniciales de la BAG se evidencia que las imágenes de la pieza quirúrgica podrían ser compatibles con una extensión tumoral residual a los lobulillos que sería lo que, finalmente, queda del tumor original tras la quimioterapia neoadyuvante. Tras el tratamiento quirúrgico, la paciente recibe tratamiento de radioterapia sobre la pared torácica izquierda y áreas ganglionares supraclaviculares, interpectorales, infraclaviculares y niveles ganglionares axilares I a III con una dosis total de 50 Gy, con sobreimpresión de 10 Gy adicionales sobre el área de la pared torácica izquierda. Evolución Actualmente la paciente se encuentra realizando revisiones periódicas sin incidencias.

[ "Anamnesis", "\n", "Paciente", "mujer", "de", "45", "años", "de", "edad", ",", "sin", "antecedentes", "médico", "-", "quirúrgicos", "importantes", ",", "fumadora", "de", "1", "paquete", "de", "cigarrillos", "al", "día", "desde", "los", "20", "años", "de", "edad", "y", "sin", "antecedentes", "familiares", "oncológicos", ",", "que", "consultó", "por", "dolor", "en", "la", "mama", "izquierda", ",", "asociado", "a", "enrojecimiento", "y", "edema", "cutáneo", ",", "que", "inicialmente", "fue", "manejado", "como", "una", "mastitis", "con", "cloxacilina", ",", "sin", "mejoría", "clínica", ".", "Ante", "la", "refractariedad", "al", "tratamiento", "antibiótico", ",", "se", "decidió", "realizar", "biopsia", "cutánea", ".", "\n\n", "Exploración", "física", "\n", "A", "la", "exploración", "destaca", "una", "mama", "izquierda", "dura", "y", "nodular", ",", "con", "engrosamiento", "cutáneo", "acompañado", "de", "piel", "de", "naranja", "y", "eritema", "generalizado", ";", "en", "la", "axila", "ipsilateral", "se", "palpan", "adenopatías", "de", "unos", "2", "cm", ",", "duras", "y", "móviles", ".", "En", "la", "mama", "derecha", "se", "palpa", "un", "nódulo", "en", "el", "cuadrante", "inferoexterno", "móvil", "de", "2", "cm", "aproximadamente", ",", "sin", "palparse", "adenopatías", "a", "nivel", "axilar", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "Punch", "de", "piel", "de", "mama", "izquierda", ":", "cilindros", "cutáneos", "con", "múltiples", "émbolos", "linfáticos", "de", "carcinoma", "ductal", "pobremente", "diferenciado", "(", "carcinoma", "inflamatorio", ")", ",", "con", "receptores", "hormonales", "negativos", ",", "Her-2", "no", "amplificado", "y", "Ki-67", "del", "40", "%", ".", "\n", "»", "Resonancia", "de", "mamas", ":", "captación", "difusa", "de", "mama", "izquierda", "con", "edema", "y", "engrosamiento", "de", "la", "piel", "concordante", "con", "el", "diagnóstico", "histológico", "de", "carcinoma", "inflamatorio", "(", "BRADS6", ")", ",", "asociado", "a", "adenopatías", "axilares", "sospechosas", ".", "En", "la", "mama", "derecha", "lesiones", "con", "distorsión", "del", "parénquima", "en", "el", "cuadrante", "superoexterno", "y", "probable", "fibroadenoma", "en", "el", "cuadrante", "ínfero", "externo", ".", "\n", "»", "BAG", "de", "mama", "derecha", ":", "CSE", ",", "carcinoma", "intraductal", "sólido", "de", "alto", "grado", ".", "CIE", ",", "tumor", "phyllodes", ",", "histológicamente", "benigno", ".", "\n", "»", "Se", "realiza", "estudio", "de", "extensión", "con", "TC", "y", "gammagrafía", "ósea", ",", "que", "son", "negativos", ".", "\n\n", "Diagnóstico", "\n", "Carcinoma", "ductal", "inflamatorio", "de", "mama", "izquierda", "pT4cN1M0", "(", "estadio", "IIIB", ")", ".", "\n\n", "Tumor", "phyllodes", "benigno", "de", "mama", "derecha", ",", "asociado", "a", "carcinoma", "intraductal", "sólido", "de", "alto", "grado", ".", "\n\n", "Tratamiento", "\n", "Con", "el", "diagnóstico", "de", "carcinoma", "ductal", "inflamatorio", "de", "mama", "izquierda", "pT4cN1M0", "(", "estadio", "IIIB", ")", ",", "inicia", "tratamiento", "de", "quimioterapia", "con", "intención", "neoadyuvante", ",", "con", "taxol", "semanal", "(", "80", "mg", "/", "m2", ")", "por", "12", "ciclos", ",", "con", "neurotoxicidad", "grado", "2", "como", "evento", "adverso", "importante", ",", "seguido", "de", "cuatro", "ciclos", "de", "FEC", "(", "5-FU", "600", "mg", "/", "m2", "+", "epirrubicina", "90", "mg", "/", "m2", "+", "ciclofosfamida", "600", "mg", "/", "m2", ")", ".", "\n\n", "Tras", "finalizar", "la", "neoadyuvancia", ",", "es", "intervenida", "quirúrgicamente", "con", "mastectomía", "bilateral", "y", "linfadenectomía", "axilar", "izquierda", ",", "con", "resultados", "de", "anatomía", "patológica", "de", ":", "\n", "»", "Mastectomía", "izquierda", ":", "persistencia", "postneoadyuvancia", "de", "carcinoma", "ductal", "infiltrante", "en", "toda", "la", "mama", "en", "forma", "de", "agregados", "dispersos", "(", "el", "mayor", "de", "2,5", "mm", ")", ",", "con", "invasión", "tumoral", "linfática", "en", "el", "parénquima", "mamario", "y", "en", "la", "dermis", "del", "huso", "de", "piel", "incluido", ".", "Con", "un", "grado", "de", "regresión", "tumoral", "por", "quimioterapia", "neoadyuvante", "de", "al", "menos", "el", "50", "%", "(", "categoría", "R1", ")", "y", "afectación", "de", "3", "de", "los", "9", "ganglios", "linfáticos", "aislados", "de", "la", "linfadenectomía", "axilar", ".", "Estadio", "tumoral", "AJCC", "/", "UICC", ",", "7ª", "edición", ":", "ypT4d", "N1a", ".", "\n", "»", "Mastectomía", "derecha", ":", "alteraciones", "estromales", "compatibles", "con", "la", "administración", "de", "quimioterapia", "neoadyuvante", ".", "Estadio", "tumoral", "AJCC", "/", "UICC", ",", "7ª", "edición", ":", "pT0", "Nx", ".", "En", "la", "pieza", "de", "mastectomía", "derecha", "no", "se", "identifica", "lecho", "tumoral", "ni", "carcinoma", "intraductal", "de", "alto", "grado", "ni", "infiltrante", ",", "aunque", "sí", "se", "observan", "zonas", "con", "patrón", "fibroadenomatoide", "que", "pueden", "explicar", "el", "diagnóstico", "previo", "de", "tumor", "phyllodes", "benigno", ".", "Comparando", "la", "morfología", "de", "las", "lesiones", "observadas", "en", "la", "pieza", "de", "mastectomía", "con", "las", "biopsias", "iniciales", "de", "la", "BAG", "se", "evidencia", "que", "las", "imágenes", "de", "la", "pieza", "quirúrgica", "podrían", "ser", "compatibles", "con", "una", "extensión", "tumoral", "residual", "a", "los", "lobulillos", "que", "sería", "lo", "que", ",", "finalmente", ",", "queda", "del", "tumor", "original", "tras", "la", "quimioterapia", "neoadyuvante", ".", "\n", "Tras", "el", "tratamiento", "quirúrgico", ",", "la", "paciente", "recibe", "tratamiento", "de", "radioterapia", "sobre", "la", "pared", "torácica", "izquierda", "y", "áreas", "ganglionares", "supraclaviculares", ",", "interpectorales", ",", "infraclaviculares", "y", "niveles", "ganglionares", "axilares", "I", "a", "III", "con", "una", "dosis", "total", "de", "50", "Gy", ",", "con", "sobreimpresión", "de", "10", "Gy", "adicionales", "sobre", "el", "área", "de", "la", "pared", "torácica", "izquierda", ".", "\n\n", "Evolución", "\n", "Actualmente", "la", "paciente", "se", "encuentra", "realizando", "revisiones", "periódicas", "sin", "incidencias", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

carcinoma ductal pobremente diferenciado, carcinoma inflamatorio, carcinoma inflamatorio, fibroadenoma, carcinoma intraductal sólido de alto grado, tumor phyllodes , histológicamente benigno, Carcinoma ductal inflamatorio, pT4cN1M0, Tumor phyllodes benigno, carcinoma intraductal sólido de alto grado, carcinoma ductal inflamatorio, pT4cN1M0, carcinoma ductal infiltrante, tumoral, tumoral, tumoral, tumoral, tumoral, carcinoma intraductal de alto grado, tumor phyllodes benigno, tumoral, tumor

991_task2

Sentence: Anamnesis Paciente mujer de 45 años de edad, sin antecedentes médico-quirúrgicos importantes, fumadora de 1 paquete de cigarrillos al día desde los 20 años de edad y sin antecedentes familiares oncológicos, que consultó por dolor en la mama izquierda, asociado a enrojecimiento y edema cutáneo, que inicialmente fue manejado como una mastitis con cloxacilina, sin mejoría clínica. Ante la refractariedad al tratamiento antibiótico, se decidió realizar biopsia cutánea. Exploración física A la exploración destaca una mama izquierda dura y nodular, con engrosamiento cutáneo acompañado de piel de naranja y eritema generalizado; en la axila ipsilateral se palpan adenopatías de unos 2 cm, duras y móviles. En la mama derecha se palpa un nódulo en el cuadrante inferoexterno móvil de 2 cm aproximadamente, sin palparse adenopatías a nivel axilar. Pruebas complementarias » Punch de piel de mama izquierda: cilindros cutáneos con múltiples émbolos linfáticos de carcinoma ductal pobremente diferenciado (carcinoma inflamatorio), con receptores hormonales negativos, Her-2 no amplificado y Ki-67 del 40%. » Resonancia de mamas: captación difusa de mama izquierda con edema y engrosamiento de la piel concordante con el diagnóstico histológico de carcinoma inflamatorio (BRADS6), asociado a adenopatías axilares sospechosas. En la mama derecha lesiones con distorsión del parénquima en el cuadrante superoexterno y probable fibroadenoma en el cuadrante ínfero externo. » BAG de mama derecha: CSE, carcinoma intraductal sólido de alto grado. CIE, tumor phyllodes, histológicamente benigno. » Se realiza estudio de extensión con TC y gammagrafía ósea, que son negativos. Diagnóstico Carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB). Tumor phyllodes benigno de mama derecha, asociado a carcinoma intraductal sólido de alto grado. Tratamiento Con el diagnóstico de carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB), inicia tratamiento de quimioterapia con intención neoadyuvante, con taxol semanal (80 mg/m2) por 12 ciclos, con neurotoxicidad grado 2 como evento adverso importante, seguido de cuatro ciclos de FEC (5-FU 600 mg/m2 + epirrubicina 90 mg/m2 + ciclofosfamida 600 mg/m2). Tras finalizar la neoadyuvancia, es intervenida quirúrgicamente con mastectomía bilateral y linfadenectomía axilar izquierda, con resultados de anatomía patológica de: » Mastectomía izquierda: persistencia postneoadyuvancia de carcinoma ductal infiltrante en toda la mama en forma de agregados dispersos (el mayor de 2,5 mm), con invasión tumoral linfática en el parénquima mamario y en la dermis del huso de piel incluido. Con un grado de regresión tumoral por quimioterapia neoadyuvante de al menos el 50% (categoría R1) y afectación de 3 de los 9 ganglios linfáticos aislados de la linfadenectomía axilar.Estadio tumoral AJCC/UICC, 7ª edición: ypT4d N1a. » Mastectomía derecha: alteraciones estromales compatibles con la administración de quimioterapia neoadyuvante. Estadio tumoral AJCC/UICC, 7ª edición: pT0 Nx. En la pieza de mastectomía derecha no se identifica lecho tumoral ni carcinoma intraductal de alto grado ni infiltrante, aunque sí se observan zonas con patrón fibroadenomatoide que pueden explicar el diagnóstico previo de tumor phyllodes benigno. Comparando la morfología de las lesiones observadas en la pieza de mastectomía con las biopsias iniciales de la BAG se evidencia que las imágenes de la pieza quirúrgica podrían ser compatibles con una extensión tumoral residual a los lobulillos que sería lo que, finalmente, queda del tumor original tras la quimioterapia neoadyuvante. Tras el tratamiento quirúrgico, la paciente recibe tratamiento de radioterapia sobre la pared torácica izquierda y áreas ganglionares supraclaviculares, interpectorales, infraclaviculares y niveles ganglionares axilares I a III con una dosis total de 50 Gy, con sobreimpresión de 10 Gy adicionales sobre el área de la pared torácica izquierda. Evolución Actualmente la paciente se encuentra realizando revisiones periódicas sin incidencias. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Paciente mujer de 45 años de edad, sin antecedentes médico-quirúrgicos importantes, fumadora de 1 paquete de cigarrillos al día desde los 20 años de edad y sin antecedentes familiares oncológicos, que consultó por dolor en la mama izquierda, asociado a enrojecimiento y edema cutáneo, que inicialmente fue manejado como una mastitis con cloxacilina, sin mejoría clínica. Ante la refractariedad al tratamiento antibiótico, se decidió realizar biopsia cutánea. Exploración física A la exploración destaca una mama izquierda dura y nodular, con engrosamiento cutáneo acompañado de piel de naranja y eritema generalizado; en la axila ipsilateral se palpan adenopatías de unos 2 cm, duras y móviles. En la mama derecha se palpa un nódulo en el cuadrante inferoexterno móvil de 2 cm aproximadamente, sin palparse adenopatías a nivel axilar. Pruebas complementarias » Punch de piel de mama izquierda: cilindros cutáneos con múltiples émbolos linfáticos de carcinoma ductal pobremente diferenciado (carcinoma inflamatorio), con receptores hormonales negativos, Her-2 no amplificado y Ki-67 del 40%. » Resonancia de mamas: captación difusa de mama izquierda con edema y engrosamiento de la piel concordante con el diagnóstico histológico de carcinoma inflamatorio (BRADS6), asociado a adenopatías axilares sospechosas. En la mama derecha lesiones con distorsión del parénquima en el cuadrante superoexterno y probable fibroadenoma en el cuadrante ínfero externo. » BAG de mama derecha: CSE, carcinoma intraductal sólido de alto grado. CIE, tumor phyllodes, histológicamente benigno. » Se realiza estudio de extensión con TC y gammagrafía ósea, que son negativos. Diagnóstico Carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB). Tumor phyllodes benigno de mama derecha, asociado a carcinoma intraductal sólido de alto grado. Tratamiento Con el diagnóstico de carcinoma ductal inflamatorio de mama izquierda pT4cN1M0 (estadio IIIB), inicia tratamiento de quimioterapia con intención neoadyuvante, con taxol semanal (80 mg/m2) por 12 ciclos, con neurotoxicidad grado 2 como evento adverso importante, seguido de cuatro ciclos de FEC (5-FU 600 mg/m2 + epirrubicina 90 mg/m2 + ciclofosfamida 600 mg/m2). Tras finalizar la neoadyuvancia, es intervenida quirúrgicamente con mastectomía bilateral y linfadenectomía axilar izquierda, con resultados de anatomía patológica de: » Mastectomía izquierda: persistencia postneoadyuvancia de carcinoma ductal infiltrante en toda la mama en forma de agregados dispersos (el mayor de 2,5 mm), con invasión tumoral linfática en el parénquima mamario y en la dermis del huso de piel incluido. Con un grado de regresión tumoral por quimioterapia neoadyuvante de al menos el 50% (categoría R1) y afectación de 3 de los 9 ganglios linfáticos aislados de la linfadenectomía axilar.Estadio tumoral AJCC/UICC, 7ª edición: ypT4d N1a. » Mastectomía derecha: alteraciones estromales compatibles con la administración de quimioterapia neoadyuvante. Estadio tumoral AJCC/UICC, 7ª edición: pT0 Nx. En la pieza de mastectomía derecha no se identifica lecho tumoral ni carcinoma intraductal de alto grado ni infiltrante, aunque sí se observan zonas con patrón fibroadenomatoide que pueden explicar el diagnóstico previo de tumor phyllodes benigno. Comparando la morfología de las lesiones observadas en la pieza de mastectomía con las biopsias iniciales de la BAG se evidencia que las imágenes de la pieza quirúrgica podrían ser compatibles con una extensión tumoral residual a los lobulillos que sería lo que, finalmente, queda del tumor original tras la quimioterapia neoadyuvante. Tras el tratamiento quirúrgico, la paciente recibe tratamiento de radioterapia sobre la pared torácica izquierda y áreas ganglionares supraclaviculares, interpectorales, infraclaviculares y niveles ganglionares axilares I a III con una dosis total de 50 Gy, con sobreimpresión de 10 Gy adicionales sobre el área de la pared torácica izquierda. Evolución Actualmente la paciente se encuentra realizando revisiones periódicas sin incidencias.

[ "Anamnesis", "\n", "Paciente", "mujer", "de", "45", "años", "de", "edad", ",", "sin", "antecedentes", "médico", "-", "quirúrgicos", "importantes", ",", "fumadora", "de", "1", "paquete", "de", "cigarrillos", "al", "día", "desde", "los", "20", "años", "de", "edad", "y", "sin", "antecedentes", "familiares", "oncológicos", ",", "que", "consultó", "por", "dolor", "en", "la", "mama", "izquierda", ",", "asociado", "a", "enrojecimiento", "y", "edema", "cutáneo", ",", "que", "inicialmente", "fue", "manejado", "como", "una", "mastitis", "con", "cloxacilina", ",", "sin", "mejoría", "clínica", ".", "Ante", "la", "refractariedad", "al", "tratamiento", "antibiótico", ",", "se", "decidió", "realizar", "biopsia", "cutánea", ".", "\n\n", "Exploración", "física", "\n", "A", "la", "exploración", "destaca", "una", "mama", "izquierda", "dura", "y", "nodular", ",", "con", "engrosamiento", "cutáneo", "acompañado", "de", "piel", "de", "naranja", "y", "eritema", "generalizado", ";", "en", "la", "axila", "ipsilateral", "se", "palpan", "adenopatías", "de", "unos", "2", "cm", ",", "duras", "y", "móviles", ".", "En", "la", "mama", "derecha", "se", "palpa", "un", "nódulo", "en", "el", "cuadrante", "inferoexterno", "móvil", "de", "2", "cm", "aproximadamente", ",", "sin", "palparse", "adenopatías", "a", "nivel", "axilar", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "Punch", "de", "piel", "de", "mama", "izquierda", ":", "cilindros", "cutáneos", "con", "múltiples", "émbolos", "linfáticos", "de", "carcinoma", "ductal", "pobremente", "diferenciado", "(", "carcinoma", "inflamatorio", ")", ",", "con", "receptores", "hormonales", "negativos", ",", "Her-2", "no", "amplificado", "y", "Ki-67", "del", "40", "%", ".", "\n", "»", "Resonancia", "de", "mamas", ":", "captación", "difusa", "de", "mama", "izquierda", "con", "edema", "y", "engrosamiento", "de", "la", "piel", "concordante", "con", "el", "diagnóstico", "histológico", "de", "carcinoma", "inflamatorio", "(", "BRADS6", ")", ",", "asociado", "a", "adenopatías", "axilares", "sospechosas", ".", "En", "la", "mama", "derecha", "lesiones", "con", "distorsión", "del", "parénquima", "en", "el", "cuadrante", "superoexterno", "y", "probable", "fibroadenoma", "en", "el", "cuadrante", "ínfero", "externo", ".", "\n", "»", "BAG", "de", "mama", "derecha", ":", "CSE", ",", "carcinoma", "intraductal", "sólido", "de", "alto", "grado", ".", "CIE", ",", "tumor", "phyllodes", ",", "histológicamente", "benigno", ".", "\n", "»", "Se", "realiza", "estudio", "de", "extensión", "con", "TC", "y", "gammagrafía", "ósea", ",", "que", "son", "negativos", ".", "\n\n", "Diagnóstico", "\n", "Carcinoma", "ductal", "inflamatorio", "de", "mama", "izquierda", "pT4cN1M0", "(", "estadio", "IIIB", ")", ".", "\n\n", "Tumor", "phyllodes", "benigno", "de", "mama", "derecha", ",", "asociado", "a", "carcinoma", "intraductal", "sólido", "de", "alto", "grado", ".", "\n\n", "Tratamiento", "\n", "Con", "el", "diagnóstico", "de", "carcinoma", "ductal", "inflamatorio", "de", "mama", "izquierda", "pT4cN1M0", "(", "estadio", "IIIB", ")", ",", "inicia", "tratamiento", "de", "quimioterapia", "con", "intención", "neoadyuvante", ",", "con", "taxol", "semanal", "(", "80", "mg", "/", "m2", ")", "por", "12", "ciclos", ",", "con", "neurotoxicidad", "grado", "2", "como", "evento", "adverso", "importante", ",", "seguido", "de", "cuatro", "ciclos", "de", "FEC", "(", "5-FU", "600", "mg", "/", "m2", "+", "epirrubicina", "90", "mg", "/", "m2", "+", "ciclofosfamida", "600", "mg", "/", "m2", ")", ".", "\n\n", "Tras", "finalizar", "la", "neoadyuvancia", ",", "es", "intervenida", "quirúrgicamente", "con", "mastectomía", "bilateral", "y", "linfadenectomía", "axilar", "izquierda", ",", "con", "resultados", "de", "anatomía", "patológica", "de", ":", "\n", "»", "Mastectomía", "izquierda", ":", "persistencia", "postneoadyuvancia", "de", "carcinoma", "ductal", "infiltrante", "en", "toda", "la", "mama", "en", "forma", "de", "agregados", "dispersos", "(", "el", "mayor", "de", "2,5", "mm", ")", ",", "con", "invasión", "tumoral", "linfática", "en", "el", "parénquima", "mamario", "y", "en", "la", "dermis", "del", "huso", "de", "piel", "incluido", ".", "Con", "un", "grado", "de", "regresión", "tumoral", "por", "quimioterapia", "neoadyuvante", "de", "al", "menos", "el", "50", "%", "(", "categoría", "R1", ")", "y", "afectación", "de", "3", "de", "los", "9", "ganglios", "linfáticos", "aislados", "de", "la", "linfadenectomía", "axilar", ".", "Estadio", "tumoral", "AJCC", "/", "UICC", ",", "7ª", "edición", ":", "ypT4d", "N1a", ".", "\n", "»", "Mastectomía", "derecha", ":", "alteraciones", "estromales", "compatibles", "con", "la", "administración", "de", "quimioterapia", "neoadyuvante", ".", "Estadio", "tumoral", "AJCC", "/", "UICC", ",", "7ª", "edición", ":", "pT0", "Nx", ".", "En", "la", "pieza", "de", "mastectomía", "derecha", "no", "se", "identifica", "lecho", "tumoral", "ni", "carcinoma", "intraductal", "de", "alto", "grado", "ni", "infiltrante", ",", "aunque", "sí", "se", "observan", "zonas", "con", "patrón", "fibroadenomatoide", "que", "pueden", "explicar", "el", "diagnóstico", "previo", "de", "tumor", "phyllodes", "benigno", ".", "Comparando", "la", "morfología", "de", "las", "lesiones", "observadas", "en", "la", "pieza", "de", "mastectomía", "con", "las", "biopsias", "iniciales", "de", "la", "BAG", "se", "evidencia", "que", "las", "imágenes", "de", "la", "pieza", "quirúrgica", "podrían", "ser", "compatibles", "con", "una", "extensión", "tumoral", "residual", "a", "los", "lobulillos", "que", "sería", "lo", "que", ",", "finalmente", ",", "queda", "del", "tumor", "original", "tras", "la", "quimioterapia", "neoadyuvante", ".", "\n", "Tras", "el", "tratamiento", "quirúrgico", ",", "la", "paciente", "recibe", "tratamiento", "de", "radioterapia", "sobre", "la", "pared", "torácica", "izquierda", "y", "áreas", "ganglionares", "supraclaviculares", ",", "interpectorales", ",", "infraclaviculares", "y", "niveles", "ganglionares", "axilares", "I", "a", "III", "con", "una", "dosis", "total", "de", "50", "Gy", ",", "con", "sobreimpresión", "de", "10", "Gy", "adicionales", "sobre", "el", "área", "de", "la", "pared", "torácica", "izquierda", ".", "\n\n", "Evolución", "\n", "Actualmente", "la", "paciente", "se", "encuentra", "realizando", "revisiones", "periódicas", "sin", "incidencias", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

Lck is a Protein, Lck is a Protein, L - selectin is a Protein, ICAM-3 is a Protein, H - CAM is a Protein

9175835_task0

Sentence: Tap: a novel cellular protein that interacts with tip of herpesvirus saimiri and induces lymphocyte aggregation. Tip of herpesvirus saimiri associates with Lck and down-regulates Lck-mediated activation. We identified a novel cellular Tip-associated protein (Tap) by a yeast two-hybrid screen. Tap associated with Tip following transient expression in COS-1 cells and stable expression in human Jurkat-T cells. Expression of Tip and Tap in Jurkat-T cells induced dramatic cell aggregation. Aggregation was likely caused by the up-regulated surface expression of adhesion molecules including integrin alpha, L-selectin, ICAM-3, and H-CAM. Furthermore, NF-kappaB transcriptional factor of aggregated cells had approximately 40-fold higher activity than that of parental cells. Thus, Tap is likely to be an important cellular mediator of Tip function in T cell transformation by herpesvirus saimiri. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Tap: a novel cellular protein that interacts with tip of herpesvirus saimiri and induces lymphocyte aggregation. Tip of herpesvirus saimiri associates with Lck and down-regulates Lck-mediated activation. We identified a novel cellular Tip-associated protein (Tap) by a yeast two-hybrid screen. Tap associated with Tip following transient expression in COS-1 cells and stable expression in human Jurkat-T cells. Expression of Tip and Tap in Jurkat-T cells induced dramatic cell aggregation. Aggregation was likely caused by the up-regulated surface expression of adhesion molecules including integrin alpha, L-selectin, ICAM-3, and H-CAM. Furthermore, NF-kappaB transcriptional factor of aggregated cells had approximately 40-fold higher activity than that of parental cells. Thus, Tap is likely to be an important cellular mediator of Tip function in T cell transformation by herpesvirus saimiri.

[ "Tap", ":", "a", "novel", "cellular", "protein", "that", "interacts", "with", "tip", "of", "herpesvirus", "saimiri", "and", "induces", "lymphocyte", "aggregation", ".", "\n", "Tip", "of", "herpesvirus", "saimiri", "associates", "with", "Lck", "and", "down", "-", "regulates", "Lck", "-", "mediated", "activation", ".", "We", "identified", "a", "novel", "cellular", "Tip", "-", "associated", "protein", "(", "Tap", ")", "by", "a", "yeast", "two", "-", "hybrid", "screen", ".", "Tap", "associated", "with", "Tip", "following", "transient", "expression", "in", "COS-1", "cells", "and", "stable", "expression", "in", "human", "Jurkat", "-", "T", "cells", ".", "Expression", "of", "Tip", "and", "Tap", "in", "Jurkat", "-", "T", "cells", "induced", "dramatic", "cell", "aggregation", ".", "Aggregation", "was", "likely", "caused", "by", "the", "up", "-", "regulated", "surface", "expression", "of", "adhesion", "molecules", "including", "integrin", "alpha", ",", "L", "-", "selectin", ",", "ICAM-3", ",", "and", "H", "-", "CAM", ".", "Furthermore", ",", "NF", "-", "kappaB", "transcriptional", "factor", "of", "aggregated", "cells", "had", "approximately", "40-fold", "higher", "activity", "than", "that", "of", "parental", "cells", ".", "Thus", ",", "Tap", "is", "likely", "to", "be", "an", "important", "cellular", "mediator", "of", "Tip", "function", "in", "T", "cell", "transformation", "by", "herpesvirus", "saimiri", "." ]

[ "Protein" ]

Lck is a Protein, Lck is a Protein, L - selectin is a Protein, ICAM-3 is a Protein, H - CAM is a Protein

9175835_task1

Sentence: Tap: a novel cellular protein that interacts with tip of herpesvirus saimiri and induces lymphocyte aggregation. Tip of herpesvirus saimiri associates with Lck and down-regulates Lck-mediated activation. We identified a novel cellular Tip-associated protein (Tap) by a yeast two-hybrid screen. Tap associated with Tip following transient expression in COS-1 cells and stable expression in human Jurkat-T cells. Expression of Tip and Tap in Jurkat-T cells induced dramatic cell aggregation. Aggregation was likely caused by the up-regulated surface expression of adhesion molecules including integrin alpha, L-selectin, ICAM-3, and H-CAM. Furthermore, NF-kappaB transcriptional factor of aggregated cells had approximately 40-fold higher activity than that of parental cells. Thus, Tap is likely to be an important cellular mediator of Tip function in T cell transformation by herpesvirus saimiri. Instructions: please typing these entity words according to sentence: Lck, Lck, L - selectin, ICAM-3, H - CAM Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Tap: a novel cellular protein that interacts with tip of herpesvirus saimiri and induces lymphocyte aggregation. Tip of herpesvirus saimiri associates with Lck and down-regulates Lck-mediated activation. We identified a novel cellular Tip-associated protein (Tap) by a yeast two-hybrid screen. Tap associated with Tip following transient expression in COS-1 cells and stable expression in human Jurkat-T cells. Expression of Tip and Tap in Jurkat-T cells induced dramatic cell aggregation. Aggregation was likely caused by the up-regulated surface expression of adhesion molecules including integrin alpha, L-selectin, ICAM-3, and H-CAM. Furthermore, NF-kappaB transcriptional factor of aggregated cells had approximately 40-fold higher activity than that of parental cells. Thus, Tap is likely to be an important cellular mediator of Tip function in T cell transformation by herpesvirus saimiri.

[ "Tap", ":", "a", "novel", "cellular", "protein", "that", "interacts", "with", "tip", "of", "herpesvirus", "saimiri", "and", "induces", "lymphocyte", "aggregation", ".", "\n", "Tip", "of", "herpesvirus", "saimiri", "associates", "with", "Lck", "and", "down", "-", "regulates", "Lck", "-", "mediated", "activation", ".", "We", "identified", "a", "novel", "cellular", "Tip", "-", "associated", "protein", "(", "Tap", ")", "by", "a", "yeast", "two", "-", "hybrid", "screen", ".", "Tap", "associated", "with", "Tip", "following", "transient", "expression", "in", "COS-1", "cells", "and", "stable", "expression", "in", "human", "Jurkat", "-", "T", "cells", ".", "Expression", "of", "Tip", "and", "Tap", "in", "Jurkat", "-", "T", "cells", "induced", "dramatic", "cell", "aggregation", ".", "Aggregation", "was", "likely", "caused", "by", "the", "up", "-", "regulated", "surface", "expression", "of", "adhesion", "molecules", "including", "integrin", "alpha", ",", "L", "-", "selectin", ",", "ICAM-3", ",", "and", "H", "-", "CAM", ".", "Furthermore", ",", "NF", "-", "kappaB", "transcriptional", "factor", "of", "aggregated", "cells", "had", "approximately", "40-fold", "higher", "activity", "than", "that", "of", "parental", "cells", ".", "Thus", ",", "Tap", "is", "likely", "to", "be", "an", "important", "cellular", "mediator", "of", "Tip", "function", "in", "T", "cell", "transformation", "by", "herpesvirus", "saimiri", "." ]

[ "Protein" ]

Lck, Lck, L - selectin, ICAM-3, H - CAM

9175835_task2

Sentence: Tap: a novel cellular protein that interacts with tip of herpesvirus saimiri and induces lymphocyte aggregation. Tip of herpesvirus saimiri associates with Lck and down-regulates Lck-mediated activation. We identified a novel cellular Tip-associated protein (Tap) by a yeast two-hybrid screen. Tap associated with Tip following transient expression in COS-1 cells and stable expression in human Jurkat-T cells. Expression of Tip and Tap in Jurkat-T cells induced dramatic cell aggregation. Aggregation was likely caused by the up-regulated surface expression of adhesion molecules including integrin alpha, L-selectin, ICAM-3, and H-CAM. Furthermore, NF-kappaB transcriptional factor of aggregated cells had approximately 40-fold higher activity than that of parental cells. Thus, Tap is likely to be an important cellular mediator of Tip function in T cell transformation by herpesvirus saimiri. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Tap: a novel cellular protein that interacts with tip of herpesvirus saimiri and induces lymphocyte aggregation. Tip of herpesvirus saimiri associates with Lck and down-regulates Lck-mediated activation. We identified a novel cellular Tip-associated protein (Tap) by a yeast two-hybrid screen. Tap associated with Tip following transient expression in COS-1 cells and stable expression in human Jurkat-T cells. Expression of Tip and Tap in Jurkat-T cells induced dramatic cell aggregation. Aggregation was likely caused by the up-regulated surface expression of adhesion molecules including integrin alpha, L-selectin, ICAM-3, and H-CAM. Furthermore, NF-kappaB transcriptional factor of aggregated cells had approximately 40-fold higher activity than that of parental cells. Thus, Tap is likely to be an important cellular mediator of Tip function in T cell transformation by herpesvirus saimiri.

[ "Tap", ":", "a", "novel", "cellular", "protein", "that", "interacts", "with", "tip", "of", "herpesvirus", "saimiri", "and", "induces", "lymphocyte", "aggregation", ".", "\n", "Tip", "of", "herpesvirus", "saimiri", "associates", "with", "Lck", "and", "down", "-", "regulates", "Lck", "-", "mediated", "activation", ".", "We", "identified", "a", "novel", "cellular", "Tip", "-", "associated", "protein", "(", "Tap", ")", "by", "a", "yeast", "two", "-", "hybrid", "screen", ".", "Tap", "associated", "with", "Tip", "following", "transient", "expression", "in", "COS-1", "cells", "and", "stable", "expression", "in", "human", "Jurkat", "-", "T", "cells", ".", "Expression", "of", "Tip", "and", "Tap", "in", "Jurkat", "-", "T", "cells", "induced", "dramatic", "cell", "aggregation", ".", "Aggregation", "was", "likely", "caused", "by", "the", "up", "-", "regulated", "surface", "expression", "of", "adhesion", "molecules", "including", "integrin", "alpha", ",", "L", "-", "selectin", ",", "ICAM-3", ",", "and", "H", "-", "CAM", ".", "Furthermore", ",", "NF", "-", "kappaB", "transcriptional", "factor", "of", "aggregated", "cells", "had", "approximately", "40-fold", "higher", "activity", "than", "that", "of", "parental", "cells", ".", "Thus", ",", "Tap", "is", "likely", "to", "be", "an", "important", "cellular", "mediator", "of", "Tip", "function", "in", "T", "cell", "transformation", "by", "herpesvirus", "saimiri", "." ]

[ "Protein" ]

beta - catenin is a Individual_protein, beta - catenin is a Gene/protein/RNA, alpha - catenin is a Individual_protein, beta - catenin is a Gene/protein/RNA

184_task0

Sentence: Full-length beta-catenin, beta-catenin mutant proteins with NH2-terminal deletions before (deltaN90) or after (deltaN131, deltaN151) the alpha-catenin binding site, or a mutant beta-catenin with a COOH-terminal deletion (delta C) were expressed in MDCK cells under the control of the tetracycline-repressible transactivator. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA, Individual_protein

[ "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Full-length beta-catenin, beta-catenin mutant proteins with NH2-terminal deletions before (deltaN90) or after (deltaN131, deltaN151) the alpha-catenin binding site, or a mutant beta-catenin with a COOH-terminal deletion (delta C) were expressed in MDCK cells under the control of the tetracycline-repressible transactivator.

[ "Full", "-", "length", "beta", "-", "catenin", ",", "beta", "-", "catenin", "mutant", "proteins", "with", "NH2-terminal", "deletions", "before", "(", "deltaN90", ")", "or", "after", "(", "deltaN131", ",", "deltaN151", ")", "the", "alpha", "-", "catenin", "binding", "site", ",", "or", "a", "mutant", "beta", "-", "catenin", "with", "a", "COOH", "-", "terminal", "deletion", "(", "delta", "C", ")", "were", "expressed", "in", "MDCK", "cells", "under", "the", "control", "of", "the", "tetracycline", "-", "repressible", "transactivator", "." ]

[ "Individual_protein", "Gene/protein/RNA" ]

beta - catenin is a Individual_protein, beta - catenin is a Gene/protein/RNA, alpha - catenin is a Individual_protein, beta - catenin is a Gene/protein/RNA

184_task1

Sentence: Full-length beta-catenin, beta-catenin mutant proteins with NH2-terminal deletions before (deltaN90) or after (deltaN131, deltaN151) the alpha-catenin binding site, or a mutant beta-catenin with a COOH-terminal deletion (delta C) were expressed in MDCK cells under the control of the tetracycline-repressible transactivator. Instructions: please typing these entity words according to sentence: beta - catenin, beta - catenin, alpha - catenin, beta - catenin Options: Gene/protein/RNA, Individual_protein

[ "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Full-length beta-catenin, beta-catenin mutant proteins with NH2-terminal deletions before (deltaN90) or after (deltaN131, deltaN151) the alpha-catenin binding site, or a mutant beta-catenin with a COOH-terminal deletion (delta C) were expressed in MDCK cells under the control of the tetracycline-repressible transactivator.

[ "Full", "-", "length", "beta", "-", "catenin", ",", "beta", "-", "catenin", "mutant", "proteins", "with", "NH2-terminal", "deletions", "before", "(", "deltaN90", ")", "or", "after", "(", "deltaN131", ",", "deltaN151", ")", "the", "alpha", "-", "catenin", "binding", "site", ",", "or", "a", "mutant", "beta", "-", "catenin", "with", "a", "COOH", "-", "terminal", "deletion", "(", "delta", "C", ")", "were", "expressed", "in", "MDCK", "cells", "under", "the", "control", "of", "the", "tetracycline", "-", "repressible", "transactivator", "." ]

[ "Individual_protein", "Gene/protein/RNA" ]

beta - catenin, beta - catenin, alpha - catenin, beta - catenin

184_task2

Sentence: Full-length beta-catenin, beta-catenin mutant proteins with NH2-terminal deletions before (deltaN90) or after (deltaN131, deltaN151) the alpha-catenin binding site, or a mutant beta-catenin with a COOH-terminal deletion (delta C) were expressed in MDCK cells under the control of the tetracycline-repressible transactivator. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Full-length beta-catenin, beta-catenin mutant proteins with NH2-terminal deletions before (deltaN90) or after (deltaN131, deltaN151) the alpha-catenin binding site, or a mutant beta-catenin with a COOH-terminal deletion (delta C) were expressed in MDCK cells under the control of the tetracycline-repressible transactivator.

[ "Full", "-", "length", "beta", "-", "catenin", ",", "beta", "-", "catenin", "mutant", "proteins", "with", "NH2-terminal", "deletions", "before", "(", "deltaN90", ")", "or", "after", "(", "deltaN131", ",", "deltaN151", ")", "the", "alpha", "-", "catenin", "binding", "site", ",", "or", "a", "mutant", "beta", "-", "catenin", "with", "a", "COOH", "-", "terminal", "deletion", "(", "delta", "C", ")", "were", "expressed", "in", "MDCK", "cells", "under", "the", "control", "of", "the", "tetracycline", "-", "repressible", "transactivator", "." ]

[ "Individual_protein", "Gene/protein/RNA" ]

direct is an umlsterm, mammography is an umlsterm, radiography is an umlsterm, clinical study is an umlsterm, direct is an umlsterm, mammograms is an umlsterm, Methods is an umlsterm, survey is an umlsterm, mammograms is an umlsterm, spot is an umlsterm, direct is an umlsterm, mammography is an umlsterm, radiograms is an umlsterm, patients is an umlsterm, diagnostic is an umlsterm, value is an umlsterm, survey is an umlsterm, mammograms is an umlsterm, direct is an umlsterm, technique is an umlsterm, radiograms is an umlsterm, breast is an umlsterm, identification is an umlsterm, Spot is an umlsterm, techniques is an umlsterm, evaluation is an umlsterm, diagnostic is an umlsterm, procedures is an umlsterm, direct is an umlsterm, technique is an umlsterm, radiography is an umlsterm, mammography is an umlsterm, overall is an umlsterm, diagnostic is an umlsterm, value is an umlsterm, direct is an umlsterm, survey is an umlsterm, mammograms is an umlsterm, mammograms is an umlsterm, spot is an umlsterm

DerRadiologe.70370597.eng.abstr_task0

Sentence: Introduction : The combination of direct magnification mammography and computed radiography provides an improvement in spatial resolution of storage phosphor-based digital systems . A clinical study comparing conventional and digital direct magnification mammograms was performed . Methods : 100 survey mammograms in 1.5- or 1.7-fold magnification and 50 4-fold spot magnification views were obtained with a prototype direct magnification mammography system and a storage phosphor-based digital system . An intraindividual comparison of these with previous conventional radiograms of the same patients was carried out . Results : The diagnostic value of digital survey mammograms using the direct magnification technique is comparable to that of conventional radiograms of the breast , especially with regard to the identification of microcalcifications and lesions and the clinical consequences . Spot magnification views performed with this combination of techniques allowed improvement in the evaluation of microcalcifications . In 15 % of cases , diagnostic procedures were adjusted accordingly . Conclusion : The combination of the direct magnification technique with digital storage phosphor radiography systems allows the performance of digital mammography by improving the overall spatial resolution . The diagnostic value of digital direct magnification survey mammograms was comparable to that of conventional mammograms . Digital 4-fold spot magnification views improved visualisation of the morphologic aspects of microcalcifications . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Introduction : The combination of direct magnification mammography and computed radiography provides an improvement in spatial resolution of storage phosphor-based digital systems . A clinical study comparing conventional and digital direct magnification mammograms was performed . Methods : 100 survey mammograms in 1.5- or 1.7-fold magnification and 50 4-fold spot magnification views were obtained with a prototype direct magnification mammography system and a storage phosphor-based digital system . An intraindividual comparison of these with previous conventional radiograms of the same patients was carried out . Results : The diagnostic value of digital survey mammograms using the direct magnification technique is comparable to that of conventional radiograms of the breast , especially with regard to the identification of microcalcifications and lesions and the clinical consequences . Spot magnification views performed with this combination of techniques allowed improvement in the evaluation of microcalcifications . In 15 % of cases , diagnostic procedures were adjusted accordingly . Conclusion : The combination of the direct magnification technique with digital storage phosphor radiography systems allows the performance of digital mammography by improving the overall spatial resolution . The diagnostic value of digital direct magnification survey mammograms was comparable to that of conventional mammograms . Digital 4-fold spot magnification views improved visualisation of the morphologic aspects of microcalcifications .

[ "Introduction", ":", "The", "combination", "of", "direct", "magnification", "mammography", "and", "computed", "radiography", "provides", "an", "improvement", "in", "spatial", "resolution", "of", "storage", "phosphor", "-", "based", "digital", "systems", ".", "A", "clinical", "study", "comparing", "conventional", "and", "digital", "direct", "magnification", "mammograms", "was", "performed", ".", "Methods", ":", "100", "survey", "mammograms", "in", "1.5-", "or", "1.7-fold", "magnification", "and", "50", "4-fold", "spot", "magnification", "views", "were", "obtained", "with", "a", "prototype", "direct", "magnification", "mammography", "system", "and", "a", "storage", "phosphor", "-", "based", "digital", "system", ".", "An", "intraindividual", "comparison", "of", "these", "with", "previous", "conventional", "radiograms", "of", "the", "same", "patients", "was", "carried", "out", ".", "Results", ":", "The", "diagnostic", "value", "of", "digital", "survey", "mammograms", "using", "the", "direct", "magnification", "technique", "is", "comparable", "to", "that", "of", "conventional", "radiograms", "of", "the", "breast", ",", "especially", "with", "regard", "to", "the", "identification", "of", "microcalcifications", "and", "lesions", "and", "the", "clinical", "consequences", ".", "Spot", "magnification", "views", "performed", "with", "this", "combination", "of", "techniques", "allowed", "improvement", "in", "the", "evaluation", "of", "microcalcifications", ".", "In", "15", "%", "of", "cases", ",", "diagnostic", "procedures", "were", "adjusted", "accordingly", ".", "Conclusion", ":", "The", "combination", "of", "the", "direct", "magnification", "technique", "with", "digital", "storage", "phosphor", "radiography", "systems", "allows", "the", "performance", "of", "digital", "mammography", "by", "improving", "the", "overall", "spatial", "resolution", ".", "The", "diagnostic", "value", "of", "digital", "direct", "magnification", "survey", "mammograms", "was", "comparable", "to", "that", "of", "conventional", "mammograms", ".", "Digital", "4-fold", "spot", "magnification", "views", "improved", "visualisation", "of", "the", "morphologic", "aspects", "of", "microcalcifications", "." ]

[ "umlsterm" ]

direct is an umlsterm, mammography is an umlsterm, radiography is an umlsterm, clinical study is an umlsterm, direct is an umlsterm, mammograms is an umlsterm, Methods is an umlsterm, survey is an umlsterm, mammograms is an umlsterm, spot is an umlsterm, direct is an umlsterm, mammography is an umlsterm, radiograms is an umlsterm, patients is an umlsterm, diagnostic is an umlsterm, value is an umlsterm, survey is an umlsterm, mammograms is an umlsterm, direct is an umlsterm, technique is an umlsterm, radiograms is an umlsterm, breast is an umlsterm, identification is an umlsterm, Spot is an umlsterm, techniques is an umlsterm, evaluation is an umlsterm, diagnostic is an umlsterm, procedures is an umlsterm, direct is an umlsterm, technique is an umlsterm, radiography is an umlsterm, mammography is an umlsterm, overall is an umlsterm, diagnostic is an umlsterm, value is an umlsterm, direct is an umlsterm, survey is an umlsterm, mammograms is an umlsterm, mammograms is an umlsterm, spot is an umlsterm

DerRadiologe.70370597.eng.abstr_task1

Sentence: Introduction : The combination of direct magnification mammography and computed radiography provides an improvement in spatial resolution of storage phosphor-based digital systems . A clinical study comparing conventional and digital direct magnification mammograms was performed . Methods : 100 survey mammograms in 1.5- or 1.7-fold magnification and 50 4-fold spot magnification views were obtained with a prototype direct magnification mammography system and a storage phosphor-based digital system . An intraindividual comparison of these with previous conventional radiograms of the same patients was carried out . Results : The diagnostic value of digital survey mammograms using the direct magnification technique is comparable to that of conventional radiograms of the breast , especially with regard to the identification of microcalcifications and lesions and the clinical consequences . Spot magnification views performed with this combination of techniques allowed improvement in the evaluation of microcalcifications . In 15 % of cases , diagnostic procedures were adjusted accordingly . Conclusion : The combination of the direct magnification technique with digital storage phosphor radiography systems allows the performance of digital mammography by improving the overall spatial resolution . The diagnostic value of digital direct magnification survey mammograms was comparable to that of conventional mammograms . Digital 4-fold spot magnification views improved visualisation of the morphologic aspects of microcalcifications . Instructions: please typing these entity words according to sentence: direct, mammography, radiography, clinical study, direct, mammograms, Methods, survey, mammograms, spot, direct, mammography, radiograms, patients, diagnostic, value, survey, mammograms, direct, technique, radiograms, breast, identification, Spot, techniques, evaluation, diagnostic, procedures, direct, technique, radiography, mammography, overall, diagnostic, value, direct, survey, mammograms, mammograms, spot Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Introduction : The combination of direct magnification mammography and computed radiography provides an improvement in spatial resolution of storage phosphor-based digital systems . A clinical study comparing conventional and digital direct magnification mammograms was performed . Methods : 100 survey mammograms in 1.5- or 1.7-fold magnification and 50 4-fold spot magnification views were obtained with a prototype direct magnification mammography system and a storage phosphor-based digital system . An intraindividual comparison of these with previous conventional radiograms of the same patients was carried out . Results : The diagnostic value of digital survey mammograms using the direct magnification technique is comparable to that of conventional radiograms of the breast , especially with regard to the identification of microcalcifications and lesions and the clinical consequences . Spot magnification views performed with this combination of techniques allowed improvement in the evaluation of microcalcifications . In 15 % of cases , diagnostic procedures were adjusted accordingly . Conclusion : The combination of the direct magnification technique with digital storage phosphor radiography systems allows the performance of digital mammography by improving the overall spatial resolution . The diagnostic value of digital direct magnification survey mammograms was comparable to that of conventional mammograms . Digital 4-fold spot magnification views improved visualisation of the morphologic aspects of microcalcifications .

[ "Introduction", ":", "The", "combination", "of", "direct", "magnification", "mammography", "and", "computed", "radiography", "provides", "an", "improvement", "in", "spatial", "resolution", "of", "storage", "phosphor", "-", "based", "digital", "systems", ".", "A", "clinical", "study", "comparing", "conventional", "and", "digital", "direct", "magnification", "mammograms", "was", "performed", ".", "Methods", ":", "100", "survey", "mammograms", "in", "1.5-", "or", "1.7-fold", "magnification", "and", "50", "4-fold", "spot", "magnification", "views", "were", "obtained", "with", "a", "prototype", "direct", "magnification", "mammography", "system", "and", "a", "storage", "phosphor", "-", "based", "digital", "system", ".", "An", "intraindividual", "comparison", "of", "these", "with", "previous", "conventional", "radiograms", "of", "the", "same", "patients", "was", "carried", "out", ".", "Results", ":", "The", "diagnostic", "value", "of", "digital", "survey", "mammograms", "using", "the", "direct", "magnification", "technique", "is", "comparable", "to", "that", "of", "conventional", "radiograms", "of", "the", "breast", ",", "especially", "with", "regard", "to", "the", "identification", "of", "microcalcifications", "and", "lesions", "and", "the", "clinical", "consequences", ".", "Spot", "magnification", "views", "performed", "with", "this", "combination", "of", "techniques", "allowed", "improvement", "in", "the", "evaluation", "of", "microcalcifications", ".", "In", "15", "%", "of", "cases", ",", "diagnostic", "procedures", "were", "adjusted", "accordingly", ".", "Conclusion", ":", "The", "combination", "of", "the", "direct", "magnification", "technique", "with", "digital", "storage", "phosphor", "radiography", "systems", "allows", "the", "performance", "of", "digital", "mammography", "by", "improving", "the", "overall", "spatial", "resolution", ".", "The", "diagnostic", "value", "of", "digital", "direct", "magnification", "survey", "mammograms", "was", "comparable", "to", "that", "of", "conventional", "mammograms", ".", "Digital", "4-fold", "spot", "magnification", "views", "improved", "visualisation", "of", "the", "morphologic", "aspects", "of", "microcalcifications", "." ]

[ "umlsterm" ]

direct, mammography, radiography, clinical study, direct, mammograms, Methods, survey, mammograms, spot, direct, mammography, radiograms, patients, diagnostic, value, survey, mammograms, direct, technique, radiograms, breast, identification, Spot, techniques, evaluation, diagnostic, procedures, direct, technique, radiography, mammography, overall, diagnostic, value, direct, survey, mammograms, mammograms, spot

DerRadiologe.70370597.eng.abstr_task2

Sentence: Introduction : The combination of direct magnification mammography and computed radiography provides an improvement in spatial resolution of storage phosphor-based digital systems . A clinical study comparing conventional and digital direct magnification mammograms was performed . Methods : 100 survey mammograms in 1.5- or 1.7-fold magnification and 50 4-fold spot magnification views were obtained with a prototype direct magnification mammography system and a storage phosphor-based digital system . An intraindividual comparison of these with previous conventional radiograms of the same patients was carried out . Results : The diagnostic value of digital survey mammograms using the direct magnification technique is comparable to that of conventional radiograms of the breast , especially with regard to the identification of microcalcifications and lesions and the clinical consequences . Spot magnification views performed with this combination of techniques allowed improvement in the evaluation of microcalcifications . In 15 % of cases , diagnostic procedures were adjusted accordingly . Conclusion : The combination of the direct magnification technique with digital storage phosphor radiography systems allows the performance of digital mammography by improving the overall spatial resolution . The diagnostic value of digital direct magnification survey mammograms was comparable to that of conventional mammograms . Digital 4-fold spot magnification views improved visualisation of the morphologic aspects of microcalcifications . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Introduction : The combination of direct magnification mammography and computed radiography provides an improvement in spatial resolution of storage phosphor-based digital systems . A clinical study comparing conventional and digital direct magnification mammograms was performed . Methods : 100 survey mammograms in 1.5- or 1.7-fold magnification and 50 4-fold spot magnification views were obtained with a prototype direct magnification mammography system and a storage phosphor-based digital system . An intraindividual comparison of these with previous conventional radiograms of the same patients was carried out . Results : The diagnostic value of digital survey mammograms using the direct magnification technique is comparable to that of conventional radiograms of the breast , especially with regard to the identification of microcalcifications and lesions and the clinical consequences . Spot magnification views performed with this combination of techniques allowed improvement in the evaluation of microcalcifications . In 15 % of cases , diagnostic procedures were adjusted accordingly . Conclusion : The combination of the direct magnification technique with digital storage phosphor radiography systems allows the performance of digital mammography by improving the overall spatial resolution . The diagnostic value of digital direct magnification survey mammograms was comparable to that of conventional mammograms . Digital 4-fold spot magnification views improved visualisation of the morphologic aspects of microcalcifications .

[ "Introduction", ":", "The", "combination", "of", "direct", "magnification", "mammography", "and", "computed", "radiography", "provides", "an", "improvement", "in", "spatial", "resolution", "of", "storage", "phosphor", "-", "based", "digital", "systems", ".", "A", "clinical", "study", "comparing", "conventional", "and", "digital", "direct", "magnification", "mammograms", "was", "performed", ".", "Methods", ":", "100", "survey", "mammograms", "in", "1.5-", "or", "1.7-fold", "magnification", "and", "50", "4-fold", "spot", "magnification", "views", "were", "obtained", "with", "a", "prototype", "direct", "magnification", "mammography", "system", "and", "a", "storage", "phosphor", "-", "based", "digital", "system", ".", "An", "intraindividual", "comparison", "of", "these", "with", "previous", "conventional", "radiograms", "of", "the", "same", "patients", "was", "carried", "out", ".", "Results", ":", "The", "diagnostic", "value", "of", "digital", "survey", "mammograms", "using", "the", "direct", "magnification", "technique", "is", "comparable", "to", "that", "of", "conventional", "radiograms", "of", "the", "breast", ",", "especially", "with", "regard", "to", "the", "identification", "of", "microcalcifications", "and", "lesions", "and", "the", "clinical", "consequences", ".", "Spot", "magnification", "views", "performed", "with", "this", "combination", "of", "techniques", "allowed", "improvement", "in", "the", "evaluation", "of", "microcalcifications", ".", "In", "15", "%", "of", "cases", ",", "diagnostic", "procedures", "were", "adjusted", "accordingly", ".", "Conclusion", ":", "The", "combination", "of", "the", "direct", "magnification", "technique", "with", "digital", "storage", "phosphor", "radiography", "systems", "allows", "the", "performance", "of", "digital", "mammography", "by", "improving", "the", "overall", "spatial", "resolution", ".", "The", "diagnostic", "value", "of", "digital", "direct", "magnification", "survey", "mammograms", "was", "comparable", "to", "that", "of", "conventional", "mammograms", ".", "Digital", "4-fold", "spot", "magnification", "views", "improved", "visualisation", "of", "the", "morphologic", "aspects", "of", "microcalcifications", "." ]

[ "umlsterm" ]

Orexin - A is a GENE-Y, glucose is a CHEMICAL, brain - derived neurotrophic factor is a GENE-Y

23117790_task0

Sentence: Orexin-A suppresses postischemic glucose intolerance and neuronal damage through hypothalamic brain-derived neurotrophic factor. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]

Orexin-A suppresses postischemic glucose intolerance and neuronal damage through hypothalamic brain-derived neurotrophic factor.

[ "Orexin", "-", "A", "suppresses", "postischemic", "glucose", "intolerance", "and", "neuronal", "damage", "through", "hypothalamic", "brain", "-", "derived", "neurotrophic", "factor", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

Orexin - A is a GENE-Y, glucose is a CHEMICAL, brain - derived neurotrophic factor is a GENE-Y

23117790_task1

Sentence: Orexin-A suppresses postischemic glucose intolerance and neuronal damage through hypothalamic brain-derived neurotrophic factor. Instructions: please typing these entity words according to sentence: Orexin - A, glucose, brain - derived neurotrophic factor Options: GENE-Y, CHEMICAL

[ "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]

Orexin-A suppresses postischemic glucose intolerance and neuronal damage through hypothalamic brain-derived neurotrophic factor.

[ "Orexin", "-", "A", "suppresses", "postischemic", "glucose", "intolerance", "and", "neuronal", "damage", "through", "hypothalamic", "brain", "-", "derived", "neurotrophic", "factor", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

Orexin - A, glucose, brain - derived neurotrophic factor

23117790_task2

Sentence: Orexin-A suppresses postischemic glucose intolerance and neuronal damage through hypothalamic brain-derived neurotrophic factor. Instructions: please extract entity words from the input sentence

[ "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]

Orexin-A suppresses postischemic glucose intolerance and neuronal damage through hypothalamic brain-derived neurotrophic factor.

[ "Orexin", "-", "A", "suppresses", "postischemic", "glucose", "intolerance", "and", "neuronal", "damage", "through", "hypothalamic", "brain", "-", "derived", "neurotrophic", "factor", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

fractures is an umlsterm, injuries is an umlsterm, diagnosis is an umlsterm, therapy is an umlsterm, anatomic is an umlsterm, tissues is an umlsterm, treatment is an umlsterm, standard is an umlsterm, Maryland is an umlsterm, operation is an umlsterm, variation is an umlsterm, skin is an umlsterm, fractures is an umlsterm, surgical is an umlsterm, Maryland is an umlsterm, universal is an umlsterm

DerOrthopaede.70260384.eng.abstr_task0

Sentence: Acetabular fractures are severe injuries . Making a diagnosis and deciding on therapy are difficult because of the complexity of the anatomic structure and because of the soft tissues . Choosing the most suitable approach is the most important problem when deciding on the operative treatment . Besides standard approaches ( Kocher/Langenbeck , ilioinguinal and extended iliofemoral ) , the " Maryland approach " has been established in the last few years . Modifying the steps of preparation , it is possible to begin the operation with a Kocher/Langenbeck approach ( with variation on where the skin incision is made ) and to extend the approach step by step to achieve optimal exposure . Here we describe the results of acetabular fractures treated between 1989 and 1994 ( n = 159 ) in our clinic related to the surgical approach . The " modified Maryland approach " as used in our clinic , starts with exposure of the dorsal column , offering the possibility of a universal exposure . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Acetabular fractures are severe injuries . Making a diagnosis and deciding on therapy are difficult because of the complexity of the anatomic structure and because of the soft tissues . Choosing the most suitable approach is the most important problem when deciding on the operative treatment . Besides standard approaches ( Kocher/Langenbeck , ilioinguinal and extended iliofemoral ) , the " Maryland approach " has been established in the last few years . Modifying the steps of preparation , it is possible to begin the operation with a Kocher/Langenbeck approach ( with variation on where the skin incision is made ) and to extend the approach step by step to achieve optimal exposure . Here we describe the results of acetabular fractures treated between 1989 and 1994 ( n = 159 ) in our clinic related to the surgical approach . The " modified Maryland approach " as used in our clinic , starts with exposure of the dorsal column , offering the possibility of a universal exposure .

[ "Acetabular", "fractures", "are", "severe", "injuries", ".", "Making", "a", "diagnosis", "and", "deciding", "on", "therapy", "are", "difficult", "because", "of", "the", "complexity", "of", "the", "anatomic", "structure", "and", "because", "of", "the", "soft", "tissues", ".", "Choosing", "the", "most", "suitable", "approach", "is", "the", "most", "important", "problem", "when", "deciding", "on", "the", "operative", "treatment", ".", "Besides", "standard", "approaches", "(", "Kocher", "/", "Langenbeck", ",", "ilioinguinal", "and", "extended", "iliofemoral", ")", ",", "the", "\"", "Maryland", "approach", "\"", "has", "been", "established", "in", "the", "last", "few", "years", ".", "Modifying", "the", "steps", "of", "preparation", ",", "it", "is", "possible", "to", "begin", "the", "operation", "with", "a", "Kocher", "/", "Langenbeck", "approach", "(", "with", "variation", "on", "where", "the", "skin", "incision", "is", "made", ")", "and", "to", "extend", "the", "approach", "step", "by", "step", "to", "achieve", "optimal", "exposure", ".", "Here", "we", "describe", "the", "results", "of", "acetabular", "fractures", "treated", "between", "1989", "and", "1994", "(", "n", "=", "159", ")", "in", "our", "clinic", "related", "to", "the", "surgical", "approach", ".", "The", "\"", "modified", "Maryland", "approach", "\"", "as", "used", "in", "our", "clinic", ",", "starts", "with", "exposure", "of", "the", "dorsal", "column", ",", "offering", "the", "possibility", "of", "a", "universal", "exposure", "." ]

[ "umlsterm" ]

fractures is an umlsterm, injuries is an umlsterm, diagnosis is an umlsterm, therapy is an umlsterm, anatomic is an umlsterm, tissues is an umlsterm, treatment is an umlsterm, standard is an umlsterm, Maryland is an umlsterm, operation is an umlsterm, variation is an umlsterm, skin is an umlsterm, fractures is an umlsterm, surgical is an umlsterm, Maryland is an umlsterm, universal is an umlsterm

DerOrthopaede.70260384.eng.abstr_task1

Sentence: Acetabular fractures are severe injuries . Making a diagnosis and deciding on therapy are difficult because of the complexity of the anatomic structure and because of the soft tissues . Choosing the most suitable approach is the most important problem when deciding on the operative treatment . Besides standard approaches ( Kocher/Langenbeck , ilioinguinal and extended iliofemoral ) , the " Maryland approach " has been established in the last few years . Modifying the steps of preparation , it is possible to begin the operation with a Kocher/Langenbeck approach ( with variation on where the skin incision is made ) and to extend the approach step by step to achieve optimal exposure . Here we describe the results of acetabular fractures treated between 1989 and 1994 ( n = 159 ) in our clinic related to the surgical approach . The " modified Maryland approach " as used in our clinic , starts with exposure of the dorsal column , offering the possibility of a universal exposure . Instructions: please typing these entity words according to sentence: fractures, injuries, diagnosis, therapy, anatomic, tissues, treatment, standard, Maryland, operation, variation, skin, fractures, surgical, Maryland, universal Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Acetabular fractures are severe injuries . Making a diagnosis and deciding on therapy are difficult because of the complexity of the anatomic structure and because of the soft tissues . Choosing the most suitable approach is the most important problem when deciding on the operative treatment . Besides standard approaches ( Kocher/Langenbeck , ilioinguinal and extended iliofemoral ) , the " Maryland approach " has been established in the last few years . Modifying the steps of preparation , it is possible to begin the operation with a Kocher/Langenbeck approach ( with variation on where the skin incision is made ) and to extend the approach step by step to achieve optimal exposure . Here we describe the results of acetabular fractures treated between 1989 and 1994 ( n = 159 ) in our clinic related to the surgical approach . The " modified Maryland approach " as used in our clinic , starts with exposure of the dorsal column , offering the possibility of a universal exposure .

[ "Acetabular", "fractures", "are", "severe", "injuries", ".", "Making", "a", "diagnosis", "and", "deciding", "on", "therapy", "are", "difficult", "because", "of", "the", "complexity", "of", "the", "anatomic", "structure", "and", "because", "of", "the", "soft", "tissues", ".", "Choosing", "the", "most", "suitable", "approach", "is", "the", "most", "important", "problem", "when", "deciding", "on", "the", "operative", "treatment", ".", "Besides", "standard", "approaches", "(", "Kocher", "/", "Langenbeck", ",", "ilioinguinal", "and", "extended", "iliofemoral", ")", ",", "the", "\"", "Maryland", "approach", "\"", "has", "been", "established", "in", "the", "last", "few", "years", ".", "Modifying", "the", "steps", "of", "preparation", ",", "it", "is", "possible", "to", "begin", "the", "operation", "with", "a", "Kocher", "/", "Langenbeck", "approach", "(", "with", "variation", "on", "where", "the", "skin", "incision", "is", "made", ")", "and", "to", "extend", "the", "approach", "step", "by", "step", "to", "achieve", "optimal", "exposure", ".", "Here", "we", "describe", "the", "results", "of", "acetabular", "fractures", "treated", "between", "1989", "and", "1994", "(", "n", "=", "159", ")", "in", "our", "clinic", "related", "to", "the", "surgical", "approach", ".", "The", "\"", "modified", "Maryland", "approach", "\"", "as", "used", "in", "our", "clinic", ",", "starts", "with", "exposure", "of", "the", "dorsal", "column", ",", "offering", "the", "possibility", "of", "a", "universal", "exposure", "." ]

[ "umlsterm" ]

fractures, injuries, diagnosis, therapy, anatomic, tissues, treatment, standard, Maryland, operation, variation, skin, fractures, surgical, Maryland, universal

DerOrthopaede.70260384.eng.abstr_task2

Sentence: Acetabular fractures are severe injuries . Making a diagnosis and deciding on therapy are difficult because of the complexity of the anatomic structure and because of the soft tissues . Choosing the most suitable approach is the most important problem when deciding on the operative treatment . Besides standard approaches ( Kocher/Langenbeck , ilioinguinal and extended iliofemoral ) , the " Maryland approach " has been established in the last few years . Modifying the steps of preparation , it is possible to begin the operation with a Kocher/Langenbeck approach ( with variation on where the skin incision is made ) and to extend the approach step by step to achieve optimal exposure . Here we describe the results of acetabular fractures treated between 1989 and 1994 ( n = 159 ) in our clinic related to the surgical approach . The " modified Maryland approach " as used in our clinic , starts with exposure of the dorsal column , offering the possibility of a universal exposure . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Acetabular fractures are severe injuries . Making a diagnosis and deciding on therapy are difficult because of the complexity of the anatomic structure and because of the soft tissues . Choosing the most suitable approach is the most important problem when deciding on the operative treatment . Besides standard approaches ( Kocher/Langenbeck , ilioinguinal and extended iliofemoral ) , the " Maryland approach " has been established in the last few years . Modifying the steps of preparation , it is possible to begin the operation with a Kocher/Langenbeck approach ( with variation on where the skin incision is made ) and to extend the approach step by step to achieve optimal exposure . Here we describe the results of acetabular fractures treated between 1989 and 1994 ( n = 159 ) in our clinic related to the surgical approach . The " modified Maryland approach " as used in our clinic , starts with exposure of the dorsal column , offering the possibility of a universal exposure .

[ "Acetabular", "fractures", "are", "severe", "injuries", ".", "Making", "a", "diagnosis", "and", "deciding", "on", "therapy", "are", "difficult", "because", "of", "the", "complexity", "of", "the", "anatomic", "structure", "and", "because", "of", "the", "soft", "tissues", ".", "Choosing", "the", "most", "suitable", "approach", "is", "the", "most", "important", "problem", "when", "deciding", "on", "the", "operative", "treatment", ".", "Besides", "standard", "approaches", "(", "Kocher", "/", "Langenbeck", ",", "ilioinguinal", "and", "extended", "iliofemoral", ")", ",", "the", "\"", "Maryland", "approach", "\"", "has", "been", "established", "in", "the", "last", "few", "years", ".", "Modifying", "the", "steps", "of", "preparation", ",", "it", "is", "possible", "to", "begin", "the", "operation", "with", "a", "Kocher", "/", "Langenbeck", "approach", "(", "with", "variation", "on", "where", "the", "skin", "incision", "is", "made", ")", "and", "to", "extend", "the", "approach", "step", "by", "step", "to", "achieve", "optimal", "exposure", ".", "Here", "we", "describe", "the", "results", "of", "acetabular", "fractures", "treated", "between", "1989", "and", "1994", "(", "n", "=", "159", ")", "in", "our", "clinic", "related", "to", "the", "surgical", "approach", ".", "The", "\"", "modified", "Maryland", "approach", "\"", "as", "used", "in", "our", "clinic", ",", "starts", "with", "exposure", "of", "the", "dorsal", "column", ",", "offering", "the", "possibility", "of", "a", "universal", "exposure", "." ]

[ "umlsterm" ]

CHB is a Condition, NAs is a Drug, more than 12 months . is a Temporal, Hepatitis B e antigen is a Measurement, anti - HBeAg is a Measurement, positive is a Value, Hepatitis B surface antigen is a Measurement, HBsAg is a Measurement, positive is a Value, Hepatitis B virus DNA is a Measurement

NCT02745704_inc_task0

Sentence: CHB patients who had received NAs for more than 12 months. Hepatitis B e antigen (HBeAg)-negative and anti-HBeAg positive. Hepatitis B surface antigen (HBsAg) positive and <1500 IU/mL. Hepatitis B virus DNA not detectable(Roche Cobas). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Value, Measurement, Drug

[ "B-Condition", "O", "O", "O", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Measurement", "O", "B-Value", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "O", "O", "O" ]

CHB patients who had received NAs for more than 12 months. Hepatitis B e antigen (HBeAg)-negative and anti-HBeAg positive. Hepatitis B surface antigen (HBsAg) positive and <1500 IU/mL. Hepatitis B virus DNA not detectable(Roche Cobas).

[ "CHB", "patients", "who", "had", "received", "NAs", "for", "more", "than", "12", "months", ".", "\n", "Hepatitis", "B", "e", "antigen", "(", "HBeAg)-negative", "and", "anti", "-", "HBeAg", "positive", ".", "\n", "Hepatitis", "B", "surface", "antigen", "(", "HBsAg", ")", "positive", "and", "<", "1500", "IU", "/", "mL.", "\n", "Hepatitis", "B", "virus", "DNA", "not", "detectable(Roche", "Cobas", ")", ".", "\n" ]

[ "Measurement", "Temporal", "Value", "Condition", "Drug" ]

CHB is a Condition, NAs is a Drug, more than 12 months . is a Temporal, Hepatitis B e antigen is a Measurement, anti - HBeAg is a Measurement, positive is a Value, Hepatitis B surface antigen is a Measurement, HBsAg is a Measurement, positive is a Value, Hepatitis B virus DNA is a Measurement

NCT02745704_inc_task1

Sentence: CHB patients who had received NAs for more than 12 months. Hepatitis B e antigen (HBeAg)-negative and anti-HBeAg positive. Hepatitis B surface antigen (HBsAg) positive and <1500 IU/mL. Hepatitis B virus DNA not detectable(Roche Cobas). Instructions: please typing these entity words according to sentence: CHB, NAs, more than 12 months ., Hepatitis B e antigen, anti - HBeAg, positive, Hepatitis B surface antigen, HBsAg, positive, Hepatitis B virus DNA Options: Temporal, Condition, Value, Measurement, Drug

[ "B-Condition", "O", "O", "O", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Measurement", "O", "B-Value", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "O", "O", "O" ]

CHB patients who had received NAs for more than 12 months. Hepatitis B e antigen (HBeAg)-negative and anti-HBeAg positive. Hepatitis B surface antigen (HBsAg) positive and <1500 IU/mL. Hepatitis B virus DNA not detectable(Roche Cobas).

[ "CHB", "patients", "who", "had", "received", "NAs", "for", "more", "than", "12", "months", ".", "\n", "Hepatitis", "B", "e", "antigen", "(", "HBeAg)-negative", "and", "anti", "-", "HBeAg", "positive", ".", "\n", "Hepatitis", "B", "surface", "antigen", "(", "HBsAg", ")", "positive", "and", "<", "1500", "IU", "/", "mL.", "\n", "Hepatitis", "B", "virus", "DNA", "not", "detectable(Roche", "Cobas", ")", ".", "\n" ]

[ "Measurement", "Temporal", "Value", "Condition", "Drug" ]

CHB, NAs, more than 12 months ., Hepatitis B e antigen, anti - HBeAg, positive, Hepatitis B surface antigen, HBsAg, positive, Hepatitis B virus DNA

NCT02745704_inc_task2

Sentence: CHB patients who had received NAs for more than 12 months. Hepatitis B e antigen (HBeAg)-negative and anti-HBeAg positive. Hepatitis B surface antigen (HBsAg) positive and <1500 IU/mL. Hepatitis B virus DNA not detectable(Roche Cobas). Instructions: please extract entity words from the input sentence

[ "B-Condition", "O", "O", "O", "O", "B-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Measurement", "O", "B-Value", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "O", "O", "O" ]

CHB patients who had received NAs for more than 12 months. Hepatitis B e antigen (HBeAg)-negative and anti-HBeAg positive. Hepatitis B surface antigen (HBsAg) positive and <1500 IU/mL. Hepatitis B virus DNA not detectable(Roche Cobas).

[ "CHB", "patients", "who", "had", "received", "NAs", "for", "more", "than", "12", "months", ".", "\n", "Hepatitis", "B", "e", "antigen", "(", "HBeAg)-negative", "and", "anti", "-", "HBeAg", "positive", ".", "\n", "Hepatitis", "B", "surface", "antigen", "(", "HBsAg", ")", "positive", "and", "<", "1500", "IU", "/", "mL.", "\n", "Hepatitis", "B", "virus", "DNA", "not", "detectable(Roche", "Cobas", ")", ".", "\n" ]

[ "Measurement", "Temporal", "Value", "Condition", "Drug" ]

FHL1 is a Gene, EMD is a Gene, LMNA is a Gene, FHL1 is a Gene, EMD- is a Gene, LMNA is a Gene, FHL1 is a Gene, FHL1 is a Gene, FHL1 is a Gene, FHL1 is a Gene, FHL1 is a Gene

406_task0

Sentence: Mutations of the FHL1 gene cause Emery-Dreifuss muscular dystrophy. Emery-Dreifuss muscular dystrophy (EDMD) is a rare disorder characterized by early joint contractures, muscular dystrophy, and cardiac involvement with conduction defects and arrhythmias. So far, only 35% of EDMD cases are genetically elucidated and associated with EMD or LMNA gene mutations, suggesting the existence of additional major genes. By whole-genome scan, we identified linkage to the Xq26.3 locus containing the FHL1 gene in three informative families belonging to our EMD- and LMNA-negative cohort. Analysis of the FHL1 gene identified seven mutations, in the distal exons of FHL1 in these families, three additional families, and one isolated case, which differently affect the three FHL1 protein isoforms: two missense mutations affecting highly conserved cysteines, one abolishing the termination codon, and four out-of-frame insertions or deletions. The predominant phenotype was characterized by myopathy with scapulo-peroneal and/or axial distribution, as well as joint contractures, and associated with a peculiar cardiac disease characterized by conduction defects, arrhythmias, and hypertrophic cardiomyopathy in all index cases of the seven families. Heterozygous female carriers were either asymptomatic or had cardiac disease and/or mild myopathy. Interestingly, four of the FHL1-mutated male relatives had isolated cardiac disease, and an overt hypertrophic cardiomyopathy was present in two. Expression and functional studies demonstrated that the FHL1 proteins were severely reduced in all tested patients and that this was associated with a severe delay in myotube formation in the two patients for whom myoblasts were available. In conclusion, FHL1 should be considered as a gene associated with the X-linked EDMD phenotype, as well as with hypertrophic cardiomyopathy. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene

[ "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mutations of the FHL1 gene cause Emery-Dreifuss muscular dystrophy. Emery-Dreifuss muscular dystrophy (EDMD) is a rare disorder characterized by early joint contractures, muscular dystrophy, and cardiac involvement with conduction defects and arrhythmias. So far, only 35% of EDMD cases are genetically elucidated and associated with EMD or LMNA gene mutations, suggesting the existence of additional major genes. By whole-genome scan, we identified linkage to the Xq26.3 locus containing the FHL1 gene in three informative families belonging to our EMD- and LMNA-negative cohort. Analysis of the FHL1 gene identified seven mutations, in the distal exons of FHL1 in these families, three additional families, and one isolated case, which differently affect the three FHL1 protein isoforms: two missense mutations affecting highly conserved cysteines, one abolishing the termination codon, and four out-of-frame insertions or deletions. The predominant phenotype was characterized by myopathy with scapulo-peroneal and/or axial distribution, as well as joint contractures, and associated with a peculiar cardiac disease characterized by conduction defects, arrhythmias, and hypertrophic cardiomyopathy in all index cases of the seven families. Heterozygous female carriers were either asymptomatic or had cardiac disease and/or mild myopathy. Interestingly, four of the FHL1-mutated male relatives had isolated cardiac disease, and an overt hypertrophic cardiomyopathy was present in two. Expression and functional studies demonstrated that the FHL1 proteins were severely reduced in all tested patients and that this was associated with a severe delay in myotube formation in the two patients for whom myoblasts were available. In conclusion, FHL1 should be considered as a gene associated with the X-linked EDMD phenotype, as well as with hypertrophic cardiomyopathy.

[ "Mutations", "of", "the", "FHL1", "gene", "cause", "Emery", "-", "Dreifuss", "muscular", "dystrophy", ".", "Emery", "-", "Dreifuss", "muscular", "dystrophy", "(", "EDMD", ")", "is", "a", "rare", "disorder", "characterized", "by", "early", "joint", "contractures", ",", "muscular", "dystrophy", ",", "and", "cardiac", "involvement", "with", "conduction", "defects", "and", "arrhythmias", ".", "So", "far", ",", "only", "35", "%", "of", "EDMD", "cases", "are", "genetically", "elucidated", "and", "associated", "with", "EMD", "or", "LMNA", "gene", "mutations", ",", "suggesting", "the", "existence", "of", "additional", "major", "genes", ".", "By", "whole", "-", "genome", "scan", ",", "we", "identified", "linkage", "to", "the", "Xq26.3", "locus", "containing", "the", "FHL1", "gene", "in", "three", "informative", "families", "belonging", "to", "our", "EMD-", "and", "LMNA", "-", "negative", "cohort", ".", "Analysis", "of", "the", "FHL1", "gene", "identified", "seven", "mutations", ",", "in", "the", "distal", "exons", "of", "FHL1", "in", "these", "families", ",", "three", "additional", "families", ",", "and", "one", "isolated", "case", ",", "which", "differently", "affect", "the", "three", "FHL1", "protein", "isoforms", ":", "two", "missense", "mutations", "affecting", "highly", "conserved", "cysteines", ",", "one", "abolishing", "the", "termination", "codon", ",", "and", "four", "out", "-", "of", "-", "frame", "insertions", "or", "deletions", ".", "The", "predominant", "phenotype", "was", "characterized", "by", "myopathy", "with", "scapulo", "-", "peroneal", "and", "/", "or", "axial", "distribution", ",", "as", "well", "as", "joint", "contractures", ",", "and", "associated", "with", "a", "peculiar", "cardiac", "disease", "characterized", "by", "conduction", "defects", ",", "arrhythmias", ",", "and", "hypertrophic", "cardiomyopathy", "in", "all", "index", "cases", "of", "the", "seven", "families", ".", "Heterozygous", "female", "carriers", "were", "either", "asymptomatic", "or", "had", "cardiac", "disease", "and", "/", "or", "mild", "myopathy", ".", "Interestingly", ",", "four", "of", "the", "FHL1-mutated", "male", "relatives", "had", "isolated", "cardiac", "disease", ",", "and", "an", "overt", "hypertrophic", "cardiomyopathy", "was", "present", "in", "two", ".", "Expression", "and", "functional", "studies", "demonstrated", "that", "the", "FHL1", "proteins", "were", "severely", "reduced", "in", "all", "tested", "patients", "and", "that", "this", "was", "associated", "with", "a", "severe", "delay", "in", "myotube", "formation", "in", "the", "two", "patients", "for", "whom", "myoblasts", "were", "available", ".", "In", "conclusion", ",", "FHL1", "should", "be", "considered", "as", "a", "gene", "associated", "with", "the", "X", "-", "linked", "EDMD", "phenotype", ",", "as", "well", "as", "with", "hypertrophic", "cardiomyopathy", ".", "\n" ]

[ "Gene" ]